

## CURRICULUM VITAE

**January 2026**

**Joseph C. Cappelleri, Ph.D., M.P.H., M.S.**

*Office:*

Pfizer Inc  
445 Eastern Point Road  
Groton, CT 06340

E-mail: [joseph.c.cappelleri@pfizer.com](mailto:joseph.c.cappelleri@pfizer.com)

LinkedIn: [Joe Cappelleri LinkedIn](#)

### **EDUCATION**

#### **Graduate**

1993 M.P.H. (Epidemiology), Harvard University, Cambridge, MA (GPA=3.9)  
1991 Ph.D. (Psychometrics), Cornell University, Ithaca, NY (GPA=4.0)  
1986 M.S. (Statistics), City University of New York (Baruch College), NY (GPA=3.8)

#### **Undergraduate**

1984 B.B.A. (Economics & Finance), City University of New York (Baruch College), NY (GPA=3.8)

### **WORK EXPERIENCE**

Pfizer Inc, Biostatistics, Statistical Research and Data Science Center, New York, NY

5/17	-	Present	Executive Director, Statistical Scientist, Head of Health Economics and Outcomes Research (HEOR) Statistics
4/16	-	4/17	Senior Director, Statistical Scientist, Statistics Group Lead
8/08	-	3/16	Senior Director, Statistical Scientist, Statistics Lead
1/04	-	7/08	Director, Statistical Scientist
12/02	-	12/03	Senior Associate Director, Statistical Scientist
2/00	-	11/02	Associate Director II, Statistical Scientist
2/98	-	1/00	Associate Director I, Statistical Scientist
6/96	-	1/98	Senior Coordinator, Statistical Scientist

- Support the operating plans across therapeutic areas by providing scientific, methodologic, and strategic leadership and collaboration – on internal reports, regulatory documents, publications, presentations, workshops, design, analysis, and interpretation of results – in health services & outcomes research across all phases of patient-centric drug development and also manage several colleagues.

07/2014 – present Adjunct Professor of Biostatistics

Department of Biostatistics, Brown University, Providence, RI

- Deliver seminars to students on career opportunities, comparative effectiveness research, patient-centered outcomes research; collaborate with faculty on educational initiatives

11/2007 – present Adjunct Professor of Statistics

8/2003 – 9/2007 Adjunct Associate Professor of Statistics

Department of Statistics, University of Connecticut, Storrs, CT

- Teach semester-long graduate course on epidemiology (and, on one occasion, on longitudinal analysis) as well as advise students

8/2007 – present      Adjunct Professor of Medicine

## Department of Medicine

Tufts University School of Medicine, Boston, MA

4/2004 – 7/2007 Adjunct Associate Professor of Medicine

## Department of Medicine

Tufts University School of School, Boston, MA

7/1996 – 3/2004      Adjunct Assistant Professor of Medicine

## Department of Medicine

## Tufts University School

elaborate with faculty, supervise students, lecture

Research Associate, Instructor, Assistant Professor of Medicine, New England Medical Center (now Tufts Medical Center) and Tufts University School of Medicine, Boston, MA.

New England Medical Center (now Tufts Medical Center) and Tufts University School of Medicine, Department of Medicine, Division of

University School of Medicine, Department of Medicine, Division of Clinical Care Research, Boston, MA

elaborated on development and management.

- Collaborated on development and management of the Real-Time Meta-Analysis System -- a systematic approach and computer software to organize, display, and utilize data from randomized control trials to perform meta-analysis efficiently -- for pharmaceuticals agents that cover antibiotic usage, hypertension, congestive heart failure, and AIDS
- Collaborated on meta-analyses to evaluate the efficacy and safety of drugs for infectious (including AIDS), cardiovascular, and cerebrovascular diseases
- Collaborated on statistical and methodological issues in meta-analysis

- Presented lectures on meta-analysis to post-doctoral fellows

2/1992 - 9/1992	Post-Doctoral Fellow and Research Associate, Technology Assessment Group, Harvard School of Public Health, Boston, MA
	<ul style="list-style-type: none"> <li>• Prepared a meta-analysis on the relative efficacy and safety of different aspirin dosages on vascular events</li> </ul>
1/1990 - 9/1991	<p>Research Support Specialist National Data Archive on Child Abuse &amp; Neglect, Cornell University, Ithaca, NY</p> <ul style="list-style-type: none"> <li>• Provided statistical and technical support on the Second National Incidence and Prevalence Study of Child Abuse &amp; Neglect</li> <li>• Worked with complex survey data analyzed with the programs WESVAR WESREG, and WESLOG; used large data tapes, SAS, and the VM/MVS and VM/CMS computer operating system</li> </ul>

### **ACCOLADES (Selective)**

2020-2025	Listed among the world's top 2% scientists (according to Standard University and Elsevier)
2025	Applied Public Health Statistics Section Achievement (Industry) Award from the American Public Health Association
2024	Key contributor and recipient of the Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award from the American Statistical Association for "The Setting International Standards in Analyzing Patient Reported Outcome and Quality of Life Data – Innovative Medicines Initiative"
	<i>Citation:</i> In recognition of an exemplary collaboration resulting in international guidelines for the design, analysis, and interpretation of patient-reported outcome data.
2024	Placed in top 0.5% of all scholars worldwide based on strong publication record, the impact of work, and the notable quality of scholarly contributions (Source: ScholarGPS)\
2020-2024	Listed among the top 2% most-cited and influential scientists and researchers in the world, according to Stanford University and Elsevier.

2023	Elected recipient of the Long-Term Excellence Award from the Health Policy Statistics Section of the American Statistical Association (HPSS Long-Term Excellence Award)
2023	Citeline award finalist (CVS-Pfizer) for research on COVID-19 (excellence in use of real-world evidence)
2021	Lifetime Achievement Award (Avedis Donabedian) from ISPOR - The Professional Society for Health Economics and Outcomes Research (also known as the International Society for Pharmacoeconomics and Outcomes Research).
2012-present	Consistently ranked, weekly, as among the most read and cited author from Pfizer Inc (Source: ResearchGate) – and noted as a most prolific author in history of Pfizer and the pharmaceutical industry based on the number and impact of publications (Sources: Web of Science and Scopus)
2012-present	Elected member of the Society for Research Synthesis Methodology
2017-2019	Acknowledged for excellence in teaching, University of Connecticut, Storrs
2018	Featured in “Human Ecology,” Spring 2018, magazine of the College of Human Ecology, Cornell University
2018	Recipient of the Craig A. Saxton Clinical Development Excellence Award, Pfizer’s highest and most prestigious accolade: “Sharing Expertise with Colleagues, and the World: The most prolific author in Pfizer history puts the patient’s voice in development, and personally and professionally ‘pays it forward’ by sharing his expertise and encouragement with colleagues.”
2018	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for consulting on the development and validation of patient-reported medication adherence instrument
2018	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for delivering in-depth critical training to Field Medical Directors on crisaborole data related to pruritus

2018	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for exceptional work on two pruritus manuscripts of critical importance to advancing the scientific narrative of crisaborole
2017	Recipient of External Collaboration Team Award for outstanding medical collaboration with an external customer and of corresponding W.E. Upjohn Award from Pfizer Inc.
2017	Featured in cover story in “Legacy Matters,” Fall 2017, Harvard T.H. Chan School of Public Health Newsletter for Sophisticated Donors
2017	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for being integral to the crisaborole pruritus dossier team, reducing completion time for global and US regulatory submissions, and elevating the science on the validation of pruritus measurement
2017	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for customer focus in preparing two internal grants in support of innovation in oncology
2017	Recipient of W.E. Upjohn Prizes Award from Pfizer Inc. for the evaluation of particular diagnostic screening tool to estimate the prevalence of alopecia areata in an epidemiology study
2016	Earned Meritorious Contributor Award for outstanding contributions as short course instructor for “Patient-Reported Outcomes: Measurement, Implementation and Interpretation” at the Duke-Industry Statistics Symposium
2015	Identified as a top reviewer for Quality of Life Research
2015	Selected as Baruch College Alumnus of the Month and featured in alumni spotlight
2015	Recognized by ResearchGate as consistently being the most viewed researcher from Pfizer Inc., with thousands of new publication views and downloads.
2015	Recipient of two W.E. Upjohn Prizes Award from Pfizer Inc. for critical collaborative and statistical input to pain portfolio projects, for economic impact of Humana step edit therapy on Lyrica, and

	for demonstrating exceptional performance and leader behaviors on a daily basis.
2014	Coauthored articles ranked as the first (Jansen et al. 2011; 14:417-428) and third (Hoaglin et al. 2011; 14:429-437) most frequently cited articles in the history of Value in Health.
2013	Earned Individual Performance Award at Pfizer for prolific and influential publications.
2013	Earned Individual Performance Award at Pfizer for presentation on meta-analysis
2012	Earned three Individual Performance Awards at Pfizer for collaboration
2012	Featured in interview on “The Leaders Among Us,” disseminated globally within Pfizer Inc. (lead story in internal news communication)
2011-2012	Listed in “Who’s Who in Medicine and Healthcare”
2011-present	Elected Fellow of the American Statistical Association in recognition for prominent contributions to the development and psychometric evaluation of patient-reported outcomes; for influential contributions to the methodology and applications of meta-analysis; for outstanding contributions to regression-discontinuity (cutoff-based) designs; and for significant service to the statistical and medical professions
	<i>Citation:</i> For prominent contributions to the development and psychometric evaluation of patient-reported outcomes; for influential contributions to the methodology and applications of meta-analysis; for outstanding contributions to regression-discontinuity (cutoff-based) designs; and for significant service to the statistical and medical professions.
2011	Coauthored presentation “Current trends in the surgical management of Dupuytren’s disease in Europe: An analysis of patient charts” that won the Jacques Duparc Award at the 12 <sup>th</sup> Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Copenhagen, Denmark, June 1-4

2011	Earned Individual Performance Award at Pfizer for helping to lead network meta-analysis on renal cell carcinoma
2011	Earned Individual Performance Award at Pfizer for teaching a series of seminars on interpretation and responder analysis of patient-reported outcomes
2010	Coauthored article (Logman et al. Current Medical Research and Opinion. 2010; 26:1565-1578) was the journal's top 10 accessed and top 10 cited paper for 2010
2010	Earned Individual Performance Award at Pfizer for continued efforts to promote the scholarship of statistics internally and externally, for many influential publications, and for commitment to statistical excellence
2010	Earned Individual Performance Award at Pfizer for preparing and delivering a highly informative workshop on PROC MIXED (SAS) to statisticians
2010	Earned Individual Performance Award at Pfizer for exceptional scholarship, performance, and leadership -- internally and externally
2009	Elected to Think Science Now 100, a group that includes 100 of Pfizer's most inspiring science and medical professionals, and authorized to serve as a Science Ambassador for Pfizer
2009	Earned Individual Performance Award at Pfizer for bringing new insights into the clinical relevance of Peak VO2 (oxygen consumption) as an endpoint in children with pulmonary arterial disease –exemplary leadership on the development, execution, analysis, and finalization on the Peak VO2 validation—that attests to Pfizer's ability to move science forward beyond its own assets
2009	Earned Individual Performance Award at Pfizer for exceptional performance and leader behaviors on a daily basis in support of Celebrex
2009	Earned Individual Performance Award at Pfizer for demonstrating the Pfizer values of innovation, quality, teamwork with

publications in 2008: “Your ability to work together with many colleagues exemplifies leadership and focus on customers.”

2008 Identified as a top reviewer (based on influence and quality of reviews) for Quality of Life Research.

2008 Earned the highest possible performance rating at Pfizer (unprecedented)

2008 Recognized for scholarship on communication strategies for patients with erectile dysfunction: article featured as part of continuing medical education credit in newsletter Primary Issue (volume 10, issue 3, 2008)

2008 Nominated for both the W.E. Upjohn award and the Pfizer Achievement Award

2008 Awarded Excellence in Clinical Research by Pfizer Inc., Global Research and Development, for coauthoring one of the most influential Pfizer publications for excellence in clinical sciences (Journal of Sexual Medicine 2007; 4:1626-1634)

2008 Certified Concepts Systems Facilitator

2007 Scored highest in performance (perfect score) among statisticians at Pfizer

2007 Selected as a lecturer in the Pfizer-sponsored Brown University Science Ambassador Program

2007 Shared with team members the Prix Galien prize for Best Pharmaceutical Agent for Chantix/Champtix for smoking cessation (this prize is often referred to as the Nobel Prize for the pharmaceutical industry)

2007 Coauthored article (Allison et al. 1999; 156:1686-1696) ranked as the fifth most cited article ever in the American Journal of Psychiatry

2007 Recognized for exceptional psychometric validation on patient-reported outcomes (including the Erection Hardness Scale) in erectile dysfunction (Pfizer Inc.)

2007	Recognized for outstanding psychometric validation on patient-reported outcomes in obesity (Pfizer Inc.)
2007	Interviewed in <i>Doctor's Guide to the Internet</i> article "Sunitinib (Sutent) Improves Quality of Life over Interferon-Alfa in Kidney Cancer" based on conference presentation
2006	Interviewed in Pfizer Press Release on "New Data Suggest Pfizer's Varenicline Reduces Craving and Withdrawal Symptoms Associated with Quitting Smoking and Decreases Satisfaction and Reward from Smoking" for delivering conference presentations
2006	Interviewed in Blackwell Publishing Press Release on "Erection Pill Associated with Normalization of Relationships and Self-Esteem in Men with Erectile Dysfunction" as lead author on journal article
2006	Recognized for leadership, support, and leadership for the Hierarchical and Survival Models Workshops at Pfizer Inc.
2004-2005	Awarded Research Fellow, Center for Healthcare & Insurance Studies, University of Connecticut, Storrs, CT
2005	Coauthored article (Rosenstock et al. <i>Diabetes Care</i> . 2004; 27:1318-1323). Selected for the Yearbook of Endocrinology 2005 that brings together abstracts of articles that reported the year's breakthrough developments in endocrinology (In: Mazzaferri EL, ed. <i>Yearbook of Endocrinology</i> 2005. Philadelphia, PA: Elsevier)
2005	Recognized for leadership, support, and teamwork for the Applied Longitudinal Analysis Workshops at Pfizer Inc.
2005	Recognized for leadership and team building for presenting 5-hour workshop on meta-analysis to Outcomes Research Group at Pfizer Inc.
2005	Statistical and methodological contributions in developing and validating an instrument for early onset for patients with generalized anxiety disorder (Pfizer Inc.)

2004	Recognized for leadership in and teaching of Item Response Theory Seminar Series to colleagues in Outcomes Research at Pfizer Inc.
2004	Recognized for regulatory support of Femhrt (Pfizer Inc.)
2004	Recognized for analysis and strategy in support of Celebrex (Pfizer Inc.)
2003	Recognized for tireless efforts, enthusiasm, and productive collaborations in support of Outcomes Research at Pfizer Inc.
2003	Recognized for psychometric analyses of data on smoking cessation (Pfizer Inc.)
2002	Recognized for leadership, teamwork, and contributions to support Femhrt skin aging program and Zoloft (Pfizer Inc.)
2001	Interviewed in book “Viagra: The remarkable story of the discovery and launch” (by Larry Katzenstein, New York: Medical Information Press, 61-62)
2001	Recognized for outstanding performance in teaching Modern Psychometric Workshop and Clinical Significance Workshop (Pfizer Inc.)
2001	Recognized for excellence in overall statistical support to Outcomes Research (Pfizer Inc.)
2001	Recognized for teamwork and leadership in support of biometrics support to Ann Arbor’s Outcomes Research development (Pfizer Inc.)
2001	Recognized for major contributions in Phases 2 and 3 of the inhaled insulin program (Pfizer Inc.)
1995	Earned Special and Scientific Staff, Tufts University
1995	Interviewed in Boston Globe (May 1) on risk and benefit of aspirin doses
1991	Awarded Cancer Epidemiology Fellowship, Harvard University

1990	Earned Phi Kappa Phi, Cornell University Chapter
1986	Earned Rosenkranz-Goldstein Award for Excellence in Statistics
1984	Earned Magna Cum Laude
1984	Earned Baruch Alumni Scholarship
1983	Earned Beta Gamma Sigma

## **PROFESSIONAL AFFILIATIONS**

- American Statistical Association
- International Society for Pharmacoeconomics and Outcomes Research
- International Society for Quality of Life Research
- International Chinese Statistical Association
- Drug Information Association (1997-2007, 2017-)
- Toastmasters (Thames River; 2009-2010)
- Statisticians in Pharmaceutical Industry (affiliated member, 2010-2011)
- Pharmaceutical Research and Manufacturers of America (1998-2005)
- Society for Clinical Trials (1993-2007)
- Society for Medical Decision Making (1993-2007)

## **SEMESTER-LONG COURSES TAUGHT**

- Instructor on the graduate statistics course “Introduction to Epidemiology” at the University of Connecticut, Storrs (spring 2004 semester, spring 2005 semester, spring 2007 semester, fall 2009 semester, fall 2012 semester, fall 2013 semester, fall 2015-2025 semester)
- Instructor on the graduate statistics course “Applied Longitudinal Analysis” to students at the University of Connecticut, Storrs (spring 2006 semesters)
- Instructor on undergraduate statistics course “Introduction to Business Statistics” at Baruch College, New York, NY (spring 1987 and summer 1987)
- Teaching assistant on “Measurement in Program Evaluation & Research” (fall 1988 to Cornell graduate students)
- Teaching assistant on “Program Evaluation & Research Design” (spring 1989 to Cornell graduate students)
- Teaching assistant on “Statistics and the World We Live In” (spring 1988 to Cornell undergraduates)

## FORMER RESEARCH SUPPORT

**Contract:** University of Illinois at Chicago  
National Research and Training Center on Psychiatric Disability

**Amount:** \$53,000

**Period:** 9/1995 - 6/1996

**Role:** Statistical Consultant

**Grant Title:** Comparative Outcomes of Ambulatory Pharmaceutical Agents

**Funding Agency:** Agency for Health Care Policy and Research

**Amount:** \$1.2 million

**Period:** 3/1993 - 3/1996

**Role:** Co-Investigator

## EDITORIAL ACTIVITY

2014-	Editorial Board, Features Editor on Historical Reviews, and Associate Editor, Research Synthesis Methods
2022-	Editorial Board - Statistical Advisor, Reviewer, Health and Quality of Life Outcomes
2012-2025	Editorial Advisory Board and Reviewer, Therapeutic Innovation & Regulatory Science
2004-2025	International Advisory Board Member (2022-25) and Reviewer, Quality of Life Research
2024-2025	Reviewer, Statistics in Biopharmaceutical Research
2015-25	Reviewer, Value in Health
2000, 2003,	Reviewer, Journal of Clinical Epidemiology
2017-19, 2024-2025	
2024	Reviewer, The Lancet Regional Health – Europe
2024	Reviewer, Journal of Allergy and Clinical Immunology: Global
1998-2002, 2004,	Reviewer, JAMA - Journal of the American Medical Association
2006, 2009-12,	
2016, 2024	
2023-2024	Reviewer, Chance
2023-2024	Associate Editor, Journal of Biopharmaceutical Statistics
2017-18, 2020-24	Reviewer, Journal of Patient-Reported Outcomes
2023	Reviewer, European Journal of Cancer
2015-2019, 2022-23	Reviewer, Journal of Sexual Medicine
2020, 2022-2023	Reviewer, JAMA Network Open
2021	Reviewer, The Patient – Patient-Centered Outcomes Research
2015, 2021	Reviewer, Psychological Methods
2017-18, 2021	Reviewer, Health and Quality of Life Outcomes

2008, 2014-21	Reviewer, Statistics in Medicine
2020-2021	Reviewer, Urology
2020	Reviewer, Journal of Rheumatology
2019-20	Reviewer, Value in Health Regional Issues
2019	Reviewer, Amstat News
2018-2019	Guest Editor, Health Services and Outcomes Research Methodology
2018-2019	Reviewer, Health Services and Outcomes Research Methodology
2018	Reviewer, JAMA Cardiology
2018	Reviewer, BMC Cancer
2018	Reviewer, Medical Care
2017-18	Reviewer, Statistical Methods in Medical Research
2001-04,	Reviewer, Obesity
2006-07, 2010-11	
2015-17	
2016	Reviewer, International Journal of Obesity
2016	Reviewer, BMJ Open
2015-2016	Editorial Board, Expert Review of Quality of Life in Cancer Care
2015	Reviewer, Clinical Pharmacology & Therapeutics
2015	Reviewer, The American Journal of Clinical Nutrition
2008, 2010-12	Reviewer, Health Services and Outcomes Research Methodology
2015, 2018	
2013, 2015	Reviewer, Journal of Clinical Psychopharmacology
2010, 2015	Reviewer, Clinical Therapeutics
2014	Reviewer, James Lind Library
2009-10, 2014	Reviewer, Nicotine & Tobacco Research
2012, 2014	Reviewer, Agency for Healthcare Research and Quality
2013	Reviewer, Sexual Medicine
2013	Reviewer, American Journal of Evaluation
2012-13	Reviewer, Cancer
2011-13	Reviewer, Research Synthesis Methods
2005, 2006, 2009,	Reviewer, Clinical Trials
2013	
2012	Reviewer, Journal of Comparative Effectiveness Research
1998-2012	Editorial Board and Reviewer, Drug Information Journal
2005-11	Editorial Board and Reviewer, Asian Journal of Andrology
2010-11	Reviewer, Journal of General Internal Medicine
2010-11	Reviewer, Health Affairs
2008, 2011	Judge, Science Unbound Foundation Best Paper Awards
2011	Reviewer, Biopharmaceutical Report
2010	Reviewer, International Journal of Epidemiology
2010	Reviewer, Behavioral Sleep Medicine
2010	Reviewer, Addictive Behaviors

2010	Reviewer, Journal of Clinical Psychology
2010	Reviewer, book chapter on moderation and mediation in Design and Analysis of Quality of Life Studies in Clinical Trials (second edition; Diane Fairclough: Boca Raton, Florida, 2010)
2009	Reviewer, Introduction to Systematic Reviews and Meta-Analysis -- International Society for Pharmaceutical and Outcomes Research, Distance Learning Module 1
2009	Reviewer, Systematic Review and Meta-Analysis: Applications -- International Society for Pharmaceutical and Outcomes Research, Distance Learning Module 2
2009	Reviewer, American Journal of Managed Care
2009	Reviewer, Radiotherapy and Oncology
2008-09	Reviewer, Applied Psychological Measurement
2001-02, 2004-07,	Reviewer, Medical Care
2009	
2008	Reviewer, Journal of Educational and Behavioral Statistics
2008	Reviewer, Annals of Internal Medicine
2008	Reviewer, Statistics and Its Interface
2008	Reviewer, Preventive Medicine
2006-08	Reviewer and Consultant, National Evaluation of Early Reading First, "No Child Left Behind" (U.S. Department of Education)
1994, 2000-03, 2005-06, 2008	Reviewer, Diabetes Care
2004-08	Reviewer, International Journal of Impotence Research
2006-07	Reviewer, Pharmaceutical Statistics
2007	Reviewer, Biomed Central (BMC) Health Services Research
2006	Reviewer, Drug and Alcohol Dependence
2006	Reviewer, Dose Findings in Drug Development (Naitee Ting, editor; New York, NY: Springer-Verlag, 2006)
2004	Reviewer, Applied Longitudinal Analysis (Garrett M Fitzmaurice, Nan M Laird, James H Ware; New York, NY: John Wiley, 2004)
2003-04	Reviewer, Asian Journal of Andrology
1996-2003	Editorial Board, Clinical Research and Regulatory Affairs
2003	Reviewer, Journal of Consulting and Clinical Psychology
2001	Contributor, "Instrument Responsiveness," ISPOR Lexicon, 2 <sup>nd</sup> edition
2000	Reviewer, Evaluation & the Health Professions
2000	Reviewer, Journal of Statistical Planning and Inference
1999	Reviewer, Journal of Clinical Oncology
1996	Reviewer, Journal of Thoracic and Cardiovascular Surgery
1995	Reviewer, Drug and Therapeutics Bulletin

## BIBLIOGRAPHY (Google Scholar: citations = 36,109; h-index = 77; i10-index = 318)

### Google Scholar - Joseph C. Cappelleri

#### Published Manuscripts

Deodhar A, Maculaitis MC, Kopenhafer L, Beusterien K, Ling Y-Li, Hauber B, Cappelleri JC, Yndestad A, Phillips LR, Zayed M. Patients' perspectives regarding ankylosing spondylitis treatment administration features: evidence from qualitative interviews and a multinational quantitative preference survey. *Rheumatology and Therapy*. In press.

Gokhale M, Chan PK, Jiang W, Levin R, Cappelleri JC, Noxon-Wood V, Yu, A, Okunev I. Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: A real-world evidence study. *Leukemia and Lymphoma*. In press.

Le H, Coulter J, Culver K, Cappelleri JC, Rifi N, Lu H, Quaife M, Meginnis K, Fernandez GS, Vaghela S, Hauber B, Stinchcombe TE. Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States. *Lung Cancer* 2026; 211:108850.

<https://doi.org/10.1016/j.lungcan.2025.108850>.

Strober J, Ishigaki K, Posner N, Cappelleri JC, Xiao S, Talaga A, Brunner S, Dukacz S, Iqbal H, Chatterton E, Morton E, Weatherby S, de Courcy J. Caregiver burden in Duchenne muscular dystrophy in Europe, Japan, and the United States – a real-world study. *BMC Neurology*. In press.

Jiang Z, Liu J, He W, Cappelleri JC, Roychoudhury S, Chen Y, Chu H. The hazards of using hazard ratios from proportional hazard model in indirect treatment comparisons. *Research Synthesis Methods*. In press.

Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC. Symptom alleviation/resolution and returns to usual health/activities in immunocompromised adults with COVID-19 treated with nirmatrelvir-ritonavir: Results from the EPIC-IC trial. *Infectious Diseases and Therapy*. In press.

Nyberg L, Halfvarson J, Söderling J, Olén O, Strid H, Hedin C, Jónsdóttir S, Hjortswang H, Jäghult S, Cappelleri JC, Henrohn D, Seddighzadeh M, Marsal J, Grip O for the SWIBREG ODEN study group. Prospective observational study of tofacitinib in ulcerative colitis – Analysis of clinical data, fatigue and health related quality of life during the induction phase. *Therapeutic Advances in Gastroenterology*. 2025. In press.

McCarthy M, Cappelleri JC, Byrom B, Doll H, Di J, Demanuele C, Buenconsejo J, Coon CD. Considerations and approaches to establishing estimates of meaningful change for digital endpoints in drug development. *Therapeutic Innovation & Regulatory Science*. 2025. In press.

Lu H, Gould T, Colavecchia C, Coulter J, Wilcox LJ, Cappelleri JC, Christopher SA, Sohn A, Hauber B, Vargas AAG, Dunn N, Chowdary P, Whitty JA. Patient and caregiver preferences for long-term prophylactic treatment of bleeds in hemophilia: A discrete-choice experiment. *Haemophilia*. 2025. In press. <https://doi.org/10.1111/hae.70172>.

Chen X, Thompson J, Yao Z, Cappelleri JC, Amponsah J, Mukherjee R, Hu J. Explainable AI predicting Alzheimer's disease with latent multimodal deep neural networks. *Journal of Biopharmaceutical Statistics*. 2025. In press.

<https://www.tandfonline.com/doi/full/10.1080/10543406.2025.2511194><https://doi.org/10.1080/10543406.2025.2511194>.

Fernandez MA, Brady BL, Evans KA, Sidhu GS, Cislo P, Ernst FR, Cappelleri JC, Chaudhary MA, Drabo EF, Mokgokong R. Comparison of work productivity losses in the United States between employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir. *Journal of Medical Economics*. 2025; 28:2198-2215.

<https://doi.org/10.1080/13696998.2025.2601454>.

Tripathy D, Blum JL, McCune S, Pluard T, Anderson D, Johnston A, Montelongo MZ, Zhang Z, Cappelleri JC, Gauthier E, Rocque GB. Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS. *Future Oncology*. 2025; 21:3359-3376.

<https://doi.org/10.1080/14796694.2025.2570468>.

Roth JA, D'Amico PG, Cappelleri JC, Donckels EA, Yu A, Okunev I, Petrilla A, Purcell S, Ma J, Russell A. Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population. *Future Oncology* 2025; 21:3811-3820.

<https://doi.org/10.1080/14796694.2025.2587568>.

Flood E, Clarke N, King-Kallimanis B, Musoro J, Eremenco S, Ward C, Cappelleri JC, Nolte S. Defining score interpretation thresholds for clinical outcome assessments: a review of terminology and reporting recommendations. *Journal of Patient-Reported Outcomes*. 2025; 9:137. <https://doi.org/10.1186/s41687-025-00966-2>.

Amdal CD, Falk RS, Ahu Alanya A, Schlichting M, Roychoudhury S, Bhatnagar V, Wintner LM, Regnault A, Ingelgård I, Coens C, le Cessi S, Holzner B, Chang J, Taphoorn M, Cislo P, Giesinger JM, Cappelleri JC, Pawar V, ten Seldam S, Papadopoulos EJ, Calvert MJ, Joseph KL, Bottomley A, Griebsch I, Arraras JI, Astrup GL, Basch E, Belančić A, Brundage M, Campbell A, Rantell KR, Cocks K, Cherny N, Eremenco S, Ferrer M, Fiero MH, Gerlinger C, Goetghebeur

E, Grouven U, Lauer A, Aiyebusi OL, Machingura A, Mizusawa J, Molenberghs G, Petersen MAa, Reijneveld J, Ringash J, Rumpold G, Rutherford C, Quinten C, Sail K, Sasseville M, Sauerbrei W, Schiel A, Smith AW, Snyder C, Velikova G, Wang XS, Bjordal K, Pe M on behalf of the SISAQOL-IMI Consortium. SISAQOL-IMI consensus-based guidelines to design, analyse, interpret and present patient-reported outcomes in cancer clinical trials. *The Lancet Oncology*. 2025; 26:e683-93. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(25\)00520-0/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00520-0/fulltext).

Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gautier E, Wang Y, Montelongo MZ, Cappelleri JC, Chen C, Karaturi MS, Tripathy D. Enhancing the interpretation of real-world quality of life in patients with HR+/HER2- advanced breast cancer enrolled in the POLARIS study. *The Oncologist*. 2025; 30(10). <https://doi.org/10.1093/oncolo/ovaf281>.

Chaudhary MA, Chu H, Cappelleri JC. Evaluating uncertainties in health economic models: A review and guide. *Applied Stochastic Models in Business and Industry*. 2025; 41:e70044. <https://doi.org/10.1002/asmb.70044>.

Chandler D, Abramoff B, Bramson C, Cappelleri JC, Chohan A, Harrington M, Jamal H, Lusk J, Mazar I, Paredes R, Tatlock S, Ustianowski A, Weinsten E, Mokgokong R. Development and content validation of the Long COVID/ post-acute sequelae of COVID-19 (PASC) patient-reported outcome (PRO) instrument. *Journal of Patient-Reported Outcomes*. 2025; 9:105. <https://doi.org/10.1186/s41687-025-00942-w>.

Ren J, Bushmakin A, Cislo P, Abraham L, Cappelleri JC, Dworkin R, Farrar JT. Meaningful within-patient change for clinical outcome assessments: Model-based approach versus cumulative distribution functions. *Journal of Biopharmaceutical Statistics*. 2025; 35:826-838. <https://doi.org/10.1080/10543406.2023.2281575>.

Cappelleri JC, Cislo PR. Analysis of clinically meaningful change on patient-reported outcomes: Renewed insights about covariate adjustment. *Journal of Biopharmaceutical Statistics*. 2025; 35:812-825. <https://doi.org/10.1080/10543406.2023.2237115>.

Hu J, Kerdabadi M, Mei X, Cappelleri J, Barohn R, Yao Z. Recurrent neural networks and attention scores for personalized prediction and interpretation of patient-reported outcomes. *Journal of Biopharmaceutical Statistics*. 2025; 35:933-943. <https://doi.org/10.1080/10543406.2025.2469884>.

Sun X, DeShazo JP, Anatale-Tardiff L, Di Fusco M, Allen KE, Porter TM, Coetzer H, Lopez SMC, Puzniak L, Cappelleri JC. Latent class analysis of post-acute sequelae of SARS-CoV-2 infection. *Journal of Biopharmaceutical Statistics*. 2025; 35:902-917. <https://doi.org/10.1080/10543406.2024.2424844>

Kortüm M, Theurich S, Farrell J, Jackson G, Cook G, Cappelleri JC, Ashman O, Neff-Baro S, Gauthier A, Jewitt-Rigondza K, Sidhom A, Chaudhary A, Scheid C. Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data. *BMC Cancer*. 2025; 25:1288.

<https://doi.org/10.1186/s12885-025-14724-6>.

Fahrbach K, Cichewicz A, Chu H, Di Fusco M, Burnett H, Kin-Fajive Moroduoluwa, Mendoza CF, Cappelleri JC. Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: A systematic literature review and network meta-analysis. *Expert Review of Vaccines*. 2025; 24:416-432. <https://doi.org/10.1080/14760584.2025.2505754>.

Pe M, Voltz-Girolt C, Bell J, Bhatnagar V, Bogaerts J, Booth C, Burgos JG, Cappelleri JC. Coens C, Demolis P, Enzmann H, Giesinger J, Gilber A, Groenvold M, Kluetz P, Piccinin C, Postmus D, Quinten C, Ryll B, Sasseville M, Schlichting M, Schuerer H, Schiel A, Shaw JW, Smith AW, Tezuka S, Torre C, van der Graff WTA, Wieseler B, Wittenbecher F, Reijneveld J, Mol P. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop. *The Lancet Oncology*. 2025; 26:687-690. [https://doi.org/10.1016/S1470-2045\(25\)00150-0](https://doi.org/10.1016/S1470-2045(25)00150-0).

Jiang Z, Liu J, Alemayehu D, Cappelleri JC, Abrahami D, Chen Y, Chu H. A critical assessment of matching-adjusted indirect comparisons in relation to target populations. *Research Synthesis Methods*. 2025; 17:319-333. <https://doi.org/10.1017/rsm.2025.10>.

Li L, Lin L, Cappelleri JC, Chu H, Chen Y. ZIBGLMM: Zero-inflated bivariate generalized linear mixed model for meta-analysis with double-zero-event studies. *Research Synthesis Methods*. 2025; 16:251-271. <https://doi.org/10.1017/rsm.2024.4>.

King AL, Vasilj T, Cooper D, Vera E, Berhanu S, Johnson M, Locke C, McIver B, Basch Cappelleri JC, Dueck A, Gilbert MR, Jones L, Li Yuelin, Minasian LM, Reeve BB, Armstrong TS, Mendoza T. Prevalence of toxicities including symptomatic adverse events (SAEs) related to novel oncological therapies: A scoping review. *JNCI Cancer Spectrum*. 2025; 9(3), pka036. <https://doi.org/10.1093/jncics/pkaf036>.

Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. Matching-adjusted indirect comparison of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma: Updated results. *Journal of Blood Medicine*. 2025; 16:233-239.

Flora DR, Byrd R, Platt D, Hlavacek P, Goldman EH, Cappelleri JC, Kennedy CT, LeBlanc TW. Multiple myeloma experiences and preferences: a mixed methods study of patients and care partners in the United States. *Patient Preference and Adherence*. 2025; 19:963-979. <https://doi.org/10.2147/PPA.S491263>.

Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: An updated matching-adjusted indirect comparison. *Journal of Comparative Effectiveness Research*. 2025; e240236.

<https://becarispublishing.com/doi/10.57264/cer-2024-0236>

Jairath V, Raine T, Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, Hur P, Bartolome. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: Systematic literature review and Bayesian network meta-analysis. *Journal of Comparative Effectiveness Research*. 2025; e240225. <https://doi.org/10.57264/cer-2024-0225>.

Jairath V, Raine T, Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, Hur P, Bartolome L. Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis. *Journal of Comparative Effectiveness Research*. 2025; 240193. <https://doi.org/10.57264/cer-2024-0193>.

Thomassen D, Roychoudhury S, Amdal CD, Reynders D, Musoro JZ, Sauerbrei W, Goetghebeur, le Cessie S, on behalf of SISAQOL-IM Work Package 3. Handling missing values in patient-reported outcome data in the presence of intercurrent events. *BMC Medical Research Methodology*. 2025; 25:56. <https://doi.org/10.1186/s12874-025-02510-8>.

Machingura A, Coens C, Pe M, Alanya A, Regnault A, Mazerolle F, Bunod L, Cappelleri JC, Fiero MH, Ingelgård A, Oosting SF, Gilbert A, Catalan CF, Reksten TR, Rantell KR, Herold R, Schlichting M. Methodological work and use of Patient-Reported Outcomes data in randomised controlled trials (RCTs) in cancer: Literature reviews on current practices and guidelines. Zenodo. January 27, 2025. <https://doi.org/10.5281/zenodo.14749434>.

Silverberg JI, Anderson P, Cappelleri JC, Piercy J, Levenberg ME, Myers DE, Gerber RA. Burden of mild and moderate atopic dermatitis in adults: Results from a real-world study in the United States. *Archives of Dermatological Research*. 2025; 317:556. <https://doi.org/10.1007/s00403-025-03910-y>.

Mei X, Cappelleri JC, Hu J. Bayesian item response theory to estimate power in clinical trials with patient-reported outcomes as endpoints. *Quality of Life Research*. 2025; 34:1113-1124. <https://doi.org/10.1007/s11136-024-03874-y>.

Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D. Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy:

EORTC QLQ-C30 results from POLARIS. *Breast Cancer Research and Treatment*. 2025; 209:613-627. <https://doi.org/10.1007/s10549-024-07524-2>.

Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Cella D. Improvement of fatigue in patients with ankylosing spondylitis receiving tofacitinib: Analyses of a Phase 3 randomized controlled trial. *Rheumatology and Therapy*. 2025; 12:85-98. <https://doi.org/10.1007/s40744-024-00727-5>.

Ma J, Ren J, Cappelleri JC. Patient-reported outcome measure and its application in patients with stroke. *Stroke & Vascular Neurology*. 2025; 10:e003166. doi:10.1136/svn-2024-003166.

Thomassen D, Roychoudhury S, Amdal CD, Reynders D, Musoro JZ, Sauerbrei W, Goetghebeur E, le Cessie, on behalf of SISAQOL-IMI Work Package 3. The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials. *BMC Medical Research Methodology*. 2024; 24:290. <https://doi.org/10.1186/s12874-024-02408-x>.

Assaf AR, Sidhu GS, Soni A, Cappelleri JC, Draica F, Herbert C, Arham I, Bader M, Jimenez C, Bois M, Silvester E, Meservey J, Eng V, Nelson M, Cai Y, Nangarlia A, Tian Z, Liu Y, Watt SJ. Cross-sectional survey of factors contributing to COVID-19 testing hesitancy among US adults at risk of severe outcomes from COVID-19. *Infectious Diseases and Therapy*. 2024; 13:1683-1701. <https://doi.org/10.1007/s40121-024-01001-5>.

Ernani V, Liu D, Peng Y, Guo Q, Hopps M, Cappelleri JC, Gupta R, Chen J, de Andrade M, Yi ES, Yang P. Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity. *Heliyon*. 2024; 10:e28285. <https://doi.org/10.1016/j.heliyon.2024.e28285>.

Coulter J, Whichello C, Heidenreich S, Hauber B, Micheals-Igbokwe C, Cappelleri JC, Peyrani P, Presa JV, Venkatraman M, Schley K. From qualitative research to quantitative preference elicitation: An example in invasive meningococcal disease. *The Patient - Patient-Centered Outcomes Research*. 2024; 17:319-333. <https://doi.org/10.1007/s40271-024-00677-8>.

Wang Z, Liu Y-L, Chen Y, Siegel L, Cappelleri JC, Chu H. Double-negative results matter: A re-evaluation of sensitivities for detecting SARS-CoV-2 infection using saliva versus nasopharyngeal swabs. *American Journal of Epidemiology*. 2024; 193:548-560. <https://doi.org/10.1093/aje/kwad212>.

Sellers K, Bhattacharyya A, Cappelleri J, Rao A, Batcher M, Bellamy Sc, Holt G, Price K, Zhong W, Pierson S. Committee works to recognize excellence beyond statistics, data science communities. *Amstat News*. November 2024; 5. [https://magazine.amstat.org/wp-content/uploads/2024/10/AmstatNovember2024\\_Web.pdf](https://magazine.amstat.org/wp-content/uploads/2024/10/AmstatNovember2024_Web.pdf)

Sun X, Di Fusco M, Lupton LL, Yehoshua A, Alvarez MB, Allen KE, Puzniak L, Lopez SMC, Cappelleri JC. Predictors of long COVID among symptomatic US adults testing positive for SARS-CoV-2 at a national retail pharmacy. *Healthcare* 2024; 12:2321.

<https://doi.org/10.3390/healthcare12232321>.

Incerti D, Morris A, Cappelleri JC, Merla V, Posner N, Goldman DP, Lakdawalla DN. A new frontier in health economics and outcomes research: Generalizing clinical trial outcomes to real-world settings. *Value & Outcomes Spotlight* 2024; 10:27-31.

[ISPOR - A New Frontier in Health Economics and Outcomes Research: Generalizing Clinical Trial Outcomes to Real-World Settings](#).

Di Fusco M, Cappelleri JC, Yehoshua A, Craig Thomas KJ, Alvarez MB, Allen KE, Porter TM, Lopez SMC, Puzniak L, Sun X. Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy. *Journal of Patient-Reported Outcomes*. 2024; 8:122.

<https://doi.org/10.1186/s41687-024-00797-7>.

Draelos ZD, Bushmakin AG, Ghosh P, Xenakis J, Cappelleri JC. Validation of the Peak Pruritus-Numerical Rating Scale in patients with chronic plaque psoriasis: results from a Phase 2 study. *International Journal of Dermatology*. 2024; 63:e375-e382. <https://doi.org/10.1111/ijd.17428>.

Mease PJ, Papademetriou E, Potluri R, Agarwal E, Cappelleri JC, Ling Y-L. Adherence, persistence, healthcare resource use, and costs in tofacitinib-treated patients with psoriatic arthritis: Data from two United States claims databases. *Advances in Therapy*. 2024; 41:2850-34867. <https://doi.org/10.1007/s12325-024-02904-y>.

Kopenhafer L, Thompson A, Chang J, Sikirica S, Masters ET, Cappelleri JC, Peck EY, Maculaitis MC. Patient experience and unmet needs in high-risk non-muscle invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey. *Urologic Oncology: Seminars and Original Investigations*. 2024; 42:70.e1-70.e10.

<https://doi.org/10.1016/j.urolonc.2024.01.013>.

Samjoo I, Hall A, Chen C, Nguyen B-N, Bartlett M, Smith ML, Harbeck N, Cappelleri JC, Karuturi M, Makari D, Arruda LS, Sandin R, Hanson K, Doan J. A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. *Journal of Comparative Effectiveness Research*. 2024; 13:24011.

<https://becarispublishing.com/doi/10.57264/cer-2024-0111>.

Schley K, Whichello C, Hauber B, Krucien N, Cappelleri JC, Peyrani P, Presa JV, Coulter J, Heidenreich S. Preferences of US adolescents and parents for vaccination against invasive meningococcal disease. *Vaccine*. 2024; 42:126264.

<https://doi.org/10.1016/j.vaccine.2024.126264>

Vietri J, Maculaitis MC, Cappelleri JC, Yu H, Kopenhafer L, Beusterien K. Preferences for a *Clostridoides difficile* vaccine among adults in the United States. *Vaccine*. 2024; 42:126261. <https://doi.org/10.1016/j.vaccine.2024.126261>.

Eder L, Richette P, Coates LC, Azevedo VF, Cappelleri JC, Johnson P, Hoang M, Moser J, Kessouri M. Gender differences in perceptions of psoriatic arthritis disease impact, management, and physician interactions: Results from a global patient survey. *Rheumatology and Therapy*. 2024; 11:1115-1134. **Error! Hyperlink reference not valid.** <https://doi.org/10.1007/s40744-024-00678-x>.

Jiang Z, Cappelleri JC, Gamalo M, Chen Y, Thomas N, Chu H. A comprehensive review and shiny application on the matching-adjusted indirect comparison (MAIC). *Research Synthesis Methods*. 2024; 15:671-686. <http://doi.org/10.1002/jrsm.1709>.

Maculaitis MC, Hauber B, Beusterien KM, Will O, Kopenhafer L, Law AW, Vietri JT, Cappelleri JC, Coulter JR, Pugh S, Shea KM. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States. *Human Vaccines & Immunotherapeutics*. 2024; 26:2358566. <https://doi.org/10.1080/21645515.2024.2358566>.

Navarro-Compán V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Rammaoui J. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofakinitinib: a post hoc analysis. *Arthritis Research & Therapy*. 2024; 26:105. <https://doi.org/10.1186/s13075-024-03313-w>.

Beusterien JM, Law AW, Maculaitis MC, Will O, Kopenhafer L, Olsen P, Hauber B, Vietri J, Cappelleri JC, Coulter JR, Shea KM. Healthcare providers' and pregnant people's preferences for a preventive to protect infants from serious illness due to respiratory syncytial virus. *Vaccines*. 2024; 12:560. <https://doi.org/10.3390/vaccines12050560>.

Mol I, Hu Ya, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart Z, Hlavacek P. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. *Leukemia and Lymphoma*. 2024; 65:660-668. <https://doi.org/10.1080/10428194.2024.2313628>.

Schnitzer TJ, Conaghan PG, Berenbaum F, Abraham L, Cappelleri JC, Bushmakin AG, Viktrup L, Yang R, Brown MT. Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomized clinical trials in osteoarthritis. *Advances in Rheumatology*. 2024; 64:31. <https://doi.org/10.1186/s42358-024-00358-y>.

Magrey M, Wei JC-C, Yndestad A, Bushmakin A, Cappelleri JC, Oluwaseyi D, Deodhar A. Relationships of work productivity and activity impairment with patient-reported outcomes in ankylosing spondylitis: Results from two trials. *Arthritis Care & Research*. 2024; 76:359-365. <https://doi.org/10.1002/acr.25267>.

Yosipovitch G, Gooderham MJ, Ständer S, Fonacier L, Szepietowski JC, Deleuran M, Girolomoni G, Su JC, Bushmakin AG, Cappelleri JC, Feeney C, Chan G, Thorpe AJ, Valdez H, Biswas P, Rojo R, DiBonaventura M, Myers DE. Interpreting the relationship among itch, sleep, and work productivity in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE MONO-2. *American Journal of Clinical Dermatology*. 2024; 25:127-138. <https://doi.org/10.1007/s40257-023-00810-7>.

Feldman SR, Thyssen JP, Boeri M, Gerber R, Neary MP, Cha A, Hauber B, Cappelleri JC, Xenakis J, Leach C, Zeichner J. Adult, adolescent, and caregiver preferences for attributes of topical treatments for mild-to-moderate atopic dermatitis: a discrete-choice experiment. *Journal of Dermatological Treatment*. 2024; 35:2304020. <https://doi.org/10.1080/09546634.2024.2304020>.

Di Fusco M, Sun X, Allen Ke, Yehoshua A, Berk A, Alvarez MB, Porter TM, Ren J, Puzniak :, Lopez SMC, Cappelleri JC. Effectiveness of BNT162b2 BA.4/5 bivalent COVID-19 vaccine against long COVID symptoms: A US nationwide study. *Vaccines*. 2024; 12:183. <https://doi.org/10.3390/vaccines12020183>.

AlHarbi O, Farsakh Abu N, Al-Awadhi S, Al-Taweel T, Mikhail I, Batwa F, Bedran K, Balkan D, Gunay LM, Cappelleri JC, Boeri M, Leach C, Habjoka S, Mosli M. Patient preferences for ulcerative colitis treatment in the Middle East region: A discrete-choice experiment. *Gastro Hep Advances*. 2024; 3:190-200. <https://doi.org/10.1016/j.gastha.2023.10.002>.

von Kobyletzki LB, Henrohn D, Ballardini N, Neary MP, Ortsäter G, Dun AR, Geale K, Lindberg I, Theodosiou G, Neregård P, De Geer A, Cha A, Cappelleri JC, Thyssen JP. Comorbidities in childhood atopic dermatitis: A population-based study. *Journal of the European Academy of Dermatology and Venereology*. 2024; 38:354-364. <https://doi.org/10.1111/jdv.19569>.

Thyssen JP, Henrohn D, Neary MP, Geale K, Dun AR, Ortsäter G, Lindberg I, De Geer A, Neregård P, Cha A. Comorbidity burden in adult atopic dermatitis: A population-based study. *JEADV Clinical Practice*. 2024; 3:128-141. <https://doi.org/10.1002/jvc2.303>.

Mols I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma. *Current Medical Research and Opinion*. 2024; 40:199-207. **Error! Hyperlink reference not valid.** <https://doi.org/10.1080/03007995.2023.2277850>.

Chu H, Lin K, Xang Z, Wang Z, Chen Y, Cappelleri JC. A review and comparison of arm-based vs. contrast-based network meta-analysis for binary outcomes – Understanding their differences and limitations. *WIREs Computational Statistics*. 2024; 16:e1639. <https://doi.org/10.1002/wics.1639>.

Peipert JD, Chang J, Li S, di Pietro A, Cislo P, Cappelleri JC, Cella D. Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBISI-18) in patients with advanced urothelial cancer. *Cancer*. 2024; 130:31-40. <https://doi.org/10.1002/cncr.35025>.

Karuturi MS, Cappelleri JC, Blum JL, Patel K, Telivala B, McCune S, Cuevas JD, Lakhapal S, Montelongo MZ, Wang Y, Tripathy D, Rocque GB. Measures of functional status in geriatric patients treated with palbociclib for advanced breast cancer. *Journal of Geriatric Oncology*. 2024; 15:101670. <https://doi.org/10.1016/j.jgo.2023.101670>.

Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen, Cuevas J, Lakhapal S, Montelongo MZ, Zhang Z, Cappelleri JC, Wang Y, Tripathy D. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study. *Breast Cancer Research and Treatment*. 2024; 203:463-475. <https://doi.org/10.1007/s10549-023-07145-1>.

Dubinsky M, Rice A, Yarlas A, Hur P, Cappelleri JC, Kulisek N, Fahrny A, Bushmakin A, Biedermann L. Systematic literature review: Ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators. *Inflammatory Bowel Diseases*. 2024; 30:2115-2126. <https://doi.org/10.1093/ibd/izad282>

Ren J, Ma J, Cappelleri JC. Appropriateness of conducting and reporting random-effects meta-analysis in oncology: A research brief. *Research Synthesis Methods*. 2024; 15:326-331. <https://doi.org/10.1002/jrsm.1702>.

Wang Z, Liu Y-L, Chen Y, Siegel L, Cappelleri JC, Chu H. Double-negative results matter: A re-evaluation of sensitivities for detecting SARS-CoV-2 infection using saliva versus nasopharyngeal swabs. *American Journal of Epidemiology*. 2024; 193:548-560. <https://doi.org/10.1093/aje/kwad212>.

Peyrin-Biroulet L, Yläne K, Sipes A, Segovia M, Gardiner S, Cappelleri JC, Mulvey A, Panaccione R. The impact of the COVID-19 pandemic on patients with ulcerative colitis: Results from a global ulcerative colitis narrative patient survey. *Advances in Therapy*. 2024; 41:59-617. <https://doi.org/10.1007/s12325-023-02673-0>.

Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Alvarez MB, Puzniak L, Tabak YP, Cappelleri JC. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during

Omicron. Journal of Patient-Reported Outcomes. 2023; 7:77. <https://doi.org/10.1186/s41687-023-00616-5>.

Mukherjee K, Gunsoy NB, Kristy RM, Cappelleri JC, Roydhouse J, Stephenson JJ, Vanness DJ, Ramachandran S, Onwudiwe N, Pentakota SR, Karcher H, Di Tanna GL. Handling missing data in health economics and outcomes research (HEOR) – A systematic review and practical recommendations. *Pharmacoeconomics*. 2023; 41:1589-1601. <https://doi.org/10.1007/s40273-023-01297-0>.

Mc Carthy M, Burrows K, Griffiths P, Black PM, Demanuele C, Karlsson N, Buenconsejo J, Patel N, Chen W-H, Cappelleri JC. From meaningful outcomes to meaningful change thresholds – the path to progress for establishing digital endpoints. *Therapeutic Innovation & Regulatory Science*. 2023; 57:629-645. <https://doi.org/10.1007/s43441-023-00502-8>.

Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli S, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. *Clinical Genitourinary Cancer*. 2023; 21:459-466. <https://doi.org/10.1016/j.clgc.2023.03.011>.

Odufalu F-D, Dubinsky MC, Peyrin-Biroulet L, Yläne K, Sipes A, Cappelleri JC, Russo LJ, Segovia M, Gardiner S, Johnson EP, Mulvey A, Panaccione R. Healthcare disparities, social determinants of health, and emotional impacts in patients with ulcerative colitis: Results from a global ulcerative colitis narrative patient survey. *Inflammatory Bowel Diseases*. 2023; 29:1681-1692. <https://doi.org/10.1093/ibd/izad102>.

Kristensen LK, Navarro-Compán V, Magrey M, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Taylor PC. Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis. *Rheumatology and Therapy*. 2023; 10:1073-1087. <https://doi.org/10.1007/s40744-023-00570-0>.

Patel P, Macdonald J, Boobalan J, Marsden M, Rizzi R, Zenon M, Ren J, Chu H, Cappelleri JC, Roychoudhury S, O'Brien J, Izaki-Lee K, Boyce D. Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162bs mRNA COVID-19 vaccine: A retrospective study. *Frontiers in Medicine*. 2023; 10:1275815. <https://doi.org/10.3389/fmed.2023.1275817>.

Di Fusco M, Xun Z, Anatale-Tardiff L, Yehoshua A, Coetzer H, Alvarez MB, Allen KE, Porter TM, Puzniak L, Lopez SMC, Cappelleri JC. Impact of bivalent BA.4/5 BNT162b2 COVID-19 vaccine on acute symptoms, quality of life, work productivity and activity levels among

symptomatic US adults testing positive for SARS-CoV-2 at a national retail pharmacy. *Vaccines*. 2023; 11:1169. <https://doi.org/10.3390/vaccines11111669>.

McErlane F, Boeri M, Bussberg C, Cappelleri JC, Germino R, Stockert L, Vass C, Huber A. Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: A discrete-choice experiment. *Pediatric Rheumatology*. 2023; 21:129. <https://doi.org/10.1186/s12969-023-00906-8>.

Di Fusco M, Cappelleri JC, Anatale-Tardiff L, Coetzer H, Yehoshua A, Alvarez MB, Allen KE, Porter TM, Puzniak, Cha-Silva A, Lopes SMC, Sun X. Impact of COVID-19 infection on health-related quality of life, work productivity and activity impairment by symptom-based long COVID status and age in the US. *Healthcare*. 2023; 11:2790. <https://doi.org/10.3390/healthcare11202790>.

Gascon GM, Wallman KK, Ravula S, Cappelleri JC, Lee J, Lum K, Nagaraja CH, Paul S, Roy D, Wu E. DSLA 2023: Facing the dangers of data illiteracy. *Significance*. 2023; 20:26-29.  
<https://academic.oup.com/jrssig/article/20/5/26/7296072>  
<https://academic.oup.com/jrssig/article/20/5/26/7296072>  
<https://academic.oup.com/jrssig/article/20/5/26/7296072>  
<https://academic.oup.com/jrssig/article/20/5/26/7296072>.

Sun X, Di Fusco M, Puzniak L, Coetzer H, Zamparo JM, Tabak YP, Cappelleri JC. Assessment of retrospective collection of EQ-5D-5L in a US COVID-19 population. *Health and Quality of Life Outcomes*. 2023; 21:103. <https://doi.org/10.1186/s12955-023-02187-x>.

Daniele P, Mamolo C, Cappelleri JC, Bell T, Neuhof A, Tremblay G, Musat M, Forsythe A. Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. *Future Oncology*. 2023; 19:463-471.  
<https://doi.org/10.2217/fon-2022-0932>.

Lamerato L, Shah V, Abraham L, Cappelleri JC, DeLor B, Ellsworth SR, Hegeman-Dingle R, Park PW. Impact of Electronic Chronic Pain Questions on patient-reported outcomes and healthcare utilization, and attitudes towards eCPQ use among patients and physicians: prospective pragmatic study in a US general practice setting. *Frontiers in Medicine*. 2023; 10:933975. <https://doi.org/10.3389/fmed.2023.933975>.

Pe M, Ahu A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck R, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Cessie S le, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A, on behalf of SISAQOL-IMI Consortium. Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer

Clinical Trials - Innovative Medicines Initiative (SISAQOL-IMI): Stakeholder Views, Objectives, and Procedures. *The Lancet Oncology*. 2023; 24:e270-e283. [https://doi.org/10.1016/S1470-2045\(23\)00157-2](https://doi.org/10.1016/S1470-2045(23)00157-2).

Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, Cessie S le; on behalf of SISAQOL-IMI Work Package 3. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice. *The Lancet Oncology*. 2023; 24:e197-e206. [https://doi.org/10.1016/S1470-2045\(23\)00110-9](https://doi.org/10.1016/S1470-2045(23)00110-9).

Crawford R, Sikirica S, Morrison R, Cappelleri JC, Russell-Smith A, Shah R, Chadwick H, Doward L. The patient experience of acute lymphoblastic leukemia and its treatment: A social media review. *JMIR Cancer*. 2023; 9:e39852. doi:10.2196/39852.

Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J. Opioids for osteoarthritis: Cross-sectional survey of patient perspectives and satisfaction. *Journal of Clinical Medicine*. 2023; 12:2733. <https://doi.org/10.3390/jcm12072733>.

Abraham L, Dworkin RH, Turk DC, Markman JD, Williams DA, Bushmakin AG, Hall JA, Semel DC, Cappelleri JC, Yang R. Examining the relationships among treatment, pain, and physical function in patients with osteoarthritis: A mediation-modeling approach. *The Clinical Journal of Pain*. 2023; 39:159-165.

Dubinsky MC, Armuzzi A, Gecse KB, Ullman T, Bushmakin AG, DiBonaventura M, Cappelleri JC, Connelly SB, Woolcott JC, Salese L. Improvements in disease activity partially mediates the effect of tofacitinib treatment on generic and disease-specific health-related quality of life in patients with ulcerative colitis: data from the OCTAVE program. *Digestive Diseases*. 2023; 41:604-614. <https://doi.org/10.1159/000528788>.

Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J. Opioid prescribing for osteoarthritis pain: cross-sectional survey among primary care physicians, rheumatologists, and orthopaedic surgeons. *Journal of Clinical Medicine*. 2023; 12:589. <https://doi.org/10.3390/jcm12020589>.

Heeg B, Verhoek A, Tremblay G, Harari O, Soltanifar M, Chu H, Roychoudhury S, Cappelleri J, Ouwens M. Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. *Journal of Comparative Effectiveness Research*. 2023; 12:e220159. <https://doi.org/10.2217/cer-2022-0159>.

Harari O, Soltanifar M, Cappelleri JC, Verhoek A, Ouwens M, Daly C, Heeg B. Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analyses. *Research Synthesis Methods*. 2023; 14:211-233. <https://onlinelibrary.wiley.com/doi/10.1002/jrsm.1608>.

Ren J, Cislo P, Cappelleri JC, Hlavacek P, DiBonaventura M. Comparing G-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: A simulation study. *BMC Medical Research Methodology*. 2023; 23:18. <https://doi.org/10.1186/s12874-023-01835-6>.

Armuzzi A, Hart A, Cappelleri JC, Mammar N, Hur P, Hoskins B, Hennessy F, Milligan G, Dignass A. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. *BMC Gastroenterology*. 2023; 23:17. <https://doi.org/10.1186/s12876-023-02640-7>.

Rickles NM, Mulrooney M, Sobieraj D, Hernandez AV, Manzey LL, Gouveia-Pisano JA, Townsend KA, Luder H, Cappelleri JC, Possidente CJ. A systematic review of primary care-focused, self-reported medication adherence tools. *Journal of the American Pharmacists Association*. 2023; 63:477-490. <https://doi.org/10.1016/j.japh.2022.09.007>.

Conaghan P, Abraham L, Viktrup L, Cappelleri JC, Beck C, Bushmakin AG, Berry M, Jackson J. Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data. *Scandinavian Journal of Rheumatology*. 2023; 52:353-363. <https://doi.org/10.1080/03009742.2022.2058168>.

Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J. Disease activity and health-related quality of life relationships with work productivity in patients with ulcerative colitis in OCTAVE Induction 1&2 and OCTAVE Sustain. *Journal of Crohn's and Colitis*. 2023; 17:513-523. <https://doi.org/10.1093/ecco-jcc/jjac161>.

Daniele P, Mamolo C, Cappelleri JC, Bell T, Neuhof A, Tremblay G, Musat M, Forsythe A. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. *PLoS One*. 2022; 17:e0267979. <https://doi.org/10.1371/journal.pone.0267979>.

Heeg B, Garcia A, van Beekhuizen S, Verhoek A, van Oostrum I, Roychoudhury S, Cappelleri JC, Postma MJ, Ouwens MJNM. Novel and existing flexible survival methods for network meta-analyses. *Journal of Comparative Effectiveness Research*. 2022; 11:1121-1133. <https://doi.org/10.2217/cer-2022-0044>.

Wu, JJ, Lafeuille M-H, Emond B, Fakih I, Duh Sheng M, Cappelleri JC, Yin N, Feeney C, Myers DE, DiBonaventura M. Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: A claims database analysis. *Advances in Therapy*. 2022; 39:4157-4168. <https://doi.org/10.1007/s12325-022-02197-z>.

Boeri M, Hauber B, Cappelleri JC. Considerations around coding the membership probability function in latent class analysis: Renewed insights. *PharmacoEconomics*. 2022; 40:653-661. <https://doi.org/10.1007/s40273-022-01155-5>.

Fukui N, Conaghan PG, Togo K, Ebata N, Abraham L, Jackson J, Berry M, Cappelleri JC, Pandit H. Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: Results of a real-world study. *BMC Musculoskeletal Diseases*. 2022; 23:1065. <https://doi.org/10.1186/s12891-022-05954-x>.

Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, Cappelleri JC, Navarro-Compán V. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. *Journal of Patient-Reported Outcomes*. 2022; 6:100. <https://jpro.springeropen.com/articles/10.1186/s41687-022-00508-0>.

Navarro-Compán V, Cheng-Chung Wei J, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. *RMD Open*. 2022; 8:e002253. doi:10.1136/rmdopen-2022-002253.

<https://rmdopen.bmjjournals.org/content/8/2/e002253>  
Richette P, Coates LC, Azevedo VF, Cappelleri JC, Moser J, Queiro-Silva R, Fallon L, Kessouri M. Patient perception of medical care for psoriatic arthritis in North American and Europe: Results from a patient survey. *Rheumatology and Therapy*. 2022; 9:823-838

Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Puzniak L, Alvarez MB, Tabak YP, Cappelleri JC. Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: Quality of life, symptoms and work productivity among US adult outpatients. *Journal of Patient-Reported Outcomes*. 2022; 6:123. <https://doi.org/10.1186/s41687-022-00528-w>. (Finalist in the 2023 Citeline Awards for Excellence in Use of Real-World Evidence, partnership with CVS Health Clinical Trials Services.)

Ortsäter G, De Geer A, Dun AR, Geale K, Lindberg I, Thyssen JP, von Kobyletzki LB, Metsini A, Henrohn D, Neregård P, Cha A, Cappelleri JC, Romero W, Neary MP. Societal economic burden and determinants of costs for atopic dermatitis. *JEADV Clinical Practice*. 2022; 1:326-343. <https://doi.org/10.1002/jvc2.74>.

Deitelzweig S, Bergrath E, Di Fusco M, Kang A, Savone M, Cappelleri JC, Russ C, Betts M,

Cichewicz A, Schaible K, Tarpey J, Fahrbach K. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: A systematic review and network meta-analysis. Future Cardiology. 2022; 18:393-405. <https://doi.org/10.2217/fca-2021-0120>.

Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. Journal of Dermatological Treatment. 2022; 33:2614-2620. <https://doi.org/10.1080/09546634.2022.2060924>.

Schnitzer TJ, Robinson RL, Tive L, Cappelleri JC, Bushmakin AG, Jackson J, Berry M, Barlow S, Walker C, Viktrup L. Factors associated with physician-reported treatment status of patients with osteoarthritis pain. BMC Musculoskeletal Disorders. 2022; 23:498. <https://doi.org/10.1186/s12891-022-05414-6>.

Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterology. 2022; 22:177. <https://doi.org/10.1186/s12876-022-02215-y>.

Groff M, Tremblay G, Iadeluca L, Daniele P, Wilner K, Wiltshire R, Bartoleme L, Usari I, Cappelleri JC, Cambridge DR. Effectiveness of crizotinib versus entrectinib in ROS1+ non-small cell lung cancer using clinical and real-world data. Future Oncology. 2022; 18:2063-2074. <https://www.futuremedicine.com/doi/10.2217/fon-2021-1102>.

Russell-Smith TA, Gurskyte L, Muresan B, Mamolo CM, Gezin A, Hashim M, Cappelleri JC, Heeg B. The efficacy of therapies approved for treating relapsed/refractory acute myeloid leukemia not eligible for intensive therapy: A systematic literature review. Future Oncology. 2022; 18:2029-2039. <https://www.futuremedicine.com/doi/10.2217/fon-2021-1355>.

Hunter DL, Schnitzer TJ, Hall J, Semel D, Davignon I, Cappelleri JC, Bushmakin AB, Abraham L. Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab. Osteoarthritis & Cartilage Open. 2022; 4:100294. <https://doi.org/10.1016/j.ocarto.2022.100294>.

Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Research & Therapy. 2022; 24:40. <https://doi.org/10.1186/s13075-022-02721-0>.

Ortsäter G, De Geer A, Geale K, Dun AR, Lindberg I, Thyssen JP, von Kobyletzki L, Ballardini N, Henrohn D, Neregård P, Cha A, Cappelleri JC, Neary MP. Validation of patient identification

algorithms for atopic dermatitis using healthcare databases. *Dermatology and Therapy*. 2022; 12:545-559. <https://doi.org/10.1007/s13555-021-00670-1>.

Robinson RL, Schnitzer TJ, Barlow S, Berry M, Bushmakin AG, Cappelleri JC, Tive L, Jackson J, Jackson J, Viktrup L. Satisfaction with medications prescribed for osteoarthritis: A cross-sectional survey of patients and their physicians in the United States. *Pain and Therapy*. 2022; 11:191-208. <https://link.springer.com/article/10.1007/s40122-021-00350-0>.

Di J, Demanuele C, Kettermann A, Karahanoglu FI, Cappelleri JC, Potter A, Bury D, Cedarbaum JM, Byron B. Considerations to address missing data when deriving clinical trial endpoints from digital health technologies. *Contemporary Clinical Trials*. 2022; 113:106661. <https://doi.org/10.1016/j.cct.2021.106661>.

Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L. WOMAC meaningful within-patient change: Results from three studies of tanezumab in patients with moderate-to-severe osteoarthritis of the hip or knee. *The Journal of Rheumatology*. 2022; 49:615-621. <https://www.jrheum.org/content/49/6/615>.

Walsh D, Boeri M, Abraham L, Atkinson J, Bushmakin AG, Cappelleri JC, Hauber B, Klein K, Russo L, Viktrup L, Turk D. Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. *European Journal of Pain*. 2022; 26:648-667. <https://doi.org/10.1002/ejp.1892>.

von Kobyletzki L, Natalia Ballardini N, Henrohn D, Neary MP, Ortsäter G, Geale K, Dun AR, Lindberg I, De Geer A, Neregård P, Cha A, Cappelleri JC, Romero W, Thyssen JP. Care pathways in atopic dermatitis: a retrospective population-based cohort. *Journal of the European Academy of Dermatology & Venereology*. 2022; 36:1456-1466. <https://doi.org/10.1111/jdv.18185>.

Thom H, Cheng V, Keeney E, Neary MP, Eccleston A, Zang C, Cappelleri JC, Cha A, Thyssen JP. Matching-adjusted indirect comparison of crisaborole ointment 2% vs. topical calcineurin inhibitors in the treatment of patients with mild-to-moderate atopic dermatitis. *Dermatology and Therapy*. 2022; 12:185-194. <https://doi.org/10.1007/s13555-021-00646-1>.

Perrot S, Doane MJ, Jaffe DH, Dragon E, Abraham L, Viktrup L, Bushmakin AG, Cappelleri JC, Conaghan PG. Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries. *Pain Practice*. 2022; 22:359-371. <https://onlinelibrary.wiley.com/doi/10.1111/papr.13093>.

Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, DiBonaventura M. Quantifying patient preferences for systematic atopic dermatitis treatments using a discrete-choice experiment.

Journal of Dermatological Treatment. 2022; 33:1449-1458.  
<https://doi.org/10.1080/09546634.2020.1832185>.

Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. *Journal of Dermatological Treatment*. 2022; 33:2225-2233. Online open access.

Salt E, Wiggins A, Lohr K, Crofford L, Studts J, Nowell B, Cappelleri JC, Rayens MK. The development and validation of a Patient-Perceived Methotrexate Intolerance Scale (PPMIS) for use in adult rheumatoid arthritis patients. *Musculoskeletal Care*. 2022; 20:529-540.  
<https://doi.org/10.1002/msc.1606>.

Egeberg A, Anderson P, Piercy J, Massey L, Cappelleri JC, Encinas GA, Feeney C, DiBonaventura M. Symptom burden of patients with moderate-to-severe atopic dermatitis. *European Journal of Dermatology*. 2021; 31:752-758.

Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in studies of crisaborole for atopic dermatitis. *Dermatology and Therapy*. 2021; 11:845-853.

Tremblay G, Daniele P, Bell T, Chan G, Brown A, Cappelleri JC. Comparative effectiveness of glasdegib vs. venetoclax combined with low-dose cytarabine in acute myeloid leukemia. *Journal of Comparative Effectiveness Research*. 2021; 10:603-612.

Dubinsky MC, Watanabe K, Molander P, Peyrin-Biroult L, Rubin M, Melmed GY, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Connor, on behalf of The Global UC Narrative Survey Panel. Ulcerative colitis narrative global survey findings: The impact of living with ulcerative colitis – a patients' and physicians' view. *Inflammatory Bowel Diseases*. 2021; 27:1747-1755.

Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with ulcerative colitis in Japan: Biologic persistence and healthcare resource use. *Inflammatory Intestinal Disease*. 2021; 6:16-198.  
<https://doi.org/10.1159/000519123>.

Coates LC, Azevedo VF, Cappelleri JC, Moser J, Eder L, Richette P, Weng M-Y, Queiro Silva R, Garg A, Majjhoo A, Griffiths CEM, Young P, Howland S. Exploring the quality of communication between patients with psoriatic arthritis and physicians: Results of a global online survey. *Rheumatology and Therapy*. 2021; 8:1741-1758.  
<https://link.springer.com/article/10.1007/s40744-021-00367-z>.

Simpson EL, Wolleberg A, Bissonnette R, Silverberg JI, Papcharalambous J, Zhu L, Zhang W, Beebe JS, Vincent M, Peeva E, Bushmakin AG, Cappelleri JC, Chen L, Sikirica V, Xenakis J. Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: Results from a Phase 2b study with oral Janus kinase selective inhibitor abrocitinib. *Dermatitis*. 2021; 32:S54-S61.

Taylor PC, Bushmakin A, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Itch as major mediator of effect of tofacitinib in health-related quality of life in psoriatic arthritis: A mediation analysis. *Journal of Clinical Medicine*. 2021; 10(18):4081. <https://doi.org/10.3390/jcm10184081>.

Korotaeva T, Dina O, Holdsworth E, Fallon L, Milligan G, Meakin S, Wang L, Vasilescu R, Cappelleri JC, Deodhar A. Investigating diagnosis, treatment and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: A real-world study. *Clinical Rheumatology*. 2021; 40:4915-4926. <https://doi.org/10.1007/s10067-021-05864-8>.

Trigg A, Kelly M, Iadeluca L, Chang J, Moreno-Koehler A, Yaworsky A, Krohe M, Rider A, Cappelleri JC, Cella D, Cocks K. Reliability, validity, and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18). *Future Oncology*. 2021; 17:3951-3964. <https://doi.org/10.2217/fon-2021-0358>.

Muresan B, Mamolo C, Cappelleri JC, Postma MJ, Heeg B. Cost-effectiveness of bosutinib for the treatment of adult patients with chronic phase chronic myeloid leukemia in the second-line setting. *Applied Health Economics and Health Policy*. 2021; 19:929-940. <https://doi.org/10.1007/s40258-021-00666-0>.

de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Fleischmann R, Taylor PC, Azevedo VF, Fallon L, Woolcott J, Mease PJ. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. *RMD Open*. 2021; 7:e001609. doi:10.1136/rmdopen-2021-001609.

Garrison LP, Schepman P, Bushmakin AG, Robinson RL, Tive L, Hall J, Dzingina M, Jackson J, Berry M, Cappelleri JC, Silverman S. Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis. *Quality of Life Research*. 2021; 31:185-191. <https://doi.org/10.1007/s11136-021-02907-0>.

Calvert M, King MT, Mercieca-Bebber R, Aiyegebusi OL, Kyte D, Slade A, Chan A-W, Basch E, Bell J, Bennett AV, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck A, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis BL, Martin L, Mitchell S, Morel T, Nelsen L, Norquist JM, O'Connor D, Palmer MJ, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension

explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. *BMJ Open*. 2021; 11:e045105. doi:10.1136/bmjopen-2020-045105.

Muresan B, Mamolo C, Cappelleri JC, Mokgokong R, Palaka A, Soikkeli F, Heeg B. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in AML patients. *Future Oncology*. 2021; 17:2883-2892. <https://doi.org/10.2217/fon-2020-1287>.

Gooderham MJ, Chu C-Y, Rojo R, Valdez H, Biswas P, Cameron MC, Feeney C, Encinas Ga, Peeples-Lamirande K, Cappelleri JC, Myers DE, BiBonaventura M. Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-2 and JADE COMPARE. *JAAD International*. 2021; 4:46-48. <https://doi.org/10.1016/j.jdin.2021.05.004>.

Lim I, Richette P, Queiro-Silva R, Moser J, Cappelleri JC, Yin Ng H, Witcombe D. Patient perceptions of psoriatic arthritis management and communication with physicians in Australia: Results from a patient survey. *Rheumatology and Therapy*. 2021; 8:761-774. doi:10.1007/s40744-021-00297-w.

Simpson EL, Tom WL, Bushmakin AG, Cappelleri JC, Yosipovitch, Ständer S, Luger T, Sanders P, Gerber RA, Myers DE. Relationship among treatment, pruritus, Investigator's Static Global Assessment, and quality of life in patients with atopic dermatitis. *Dermatology and Therapy*. 2021; 22:587-598. doi: 10.1007/s13555-021-00506-y.

Ting N, Deng Q, Cappelleri JC, Huang L. Average response over time as estimand: an alternative implementation of the while on treatment strategy. *Statistics in Biosciences*. 2021; 13:479-494. <https://doi.org/10.1007/s12561-021-09301-x>.

Cappelleri JC, Chambers R. Addressing bias in responder analysis of patient-reported outcomes. *Therapeutic Innovation & Regulatory Science*. 2021; 55:989-1000. <https://doi.org/10.1007/s43441-021-00298-5>.

Deng Q, Cappelleri JC. An interview with Naitee Ting. *ICSA Bulletin*. 2021; 33(2):19-31. (ICSA = International Chinese Statistical Association). [https://www.icsa.org/icsa-bulletin/icsa\\_bulletin\\_july\\_2021/](https://www.icsa.org/icsa-bulletin/icsa_bulletin_july_2021/).

Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. *Journal of the European Academy of Dermatology & Venereology*.

2021; 35:1797-1810. <https://doi.org/10.1111/jdv.17351>. (One of the journal's most downloaded papers.)

Mansukhani SG, MacLean EA, Manzey LL, Possidente CJ, Cappelleri JC, Deal LS. Development of a new patient-reported medication adherence instrument: concerns influencing medication adherence. *Patient Preference and Adherence*. 2021; 15:1991-2007. <https://doi.org/10.2147/PPA.S318030>.

<https://onlinelibrary-wiley-com.eu1.proxy.openathens.net/doi/full/10.1111/jdv.17351> Deitelzweig S, Di Fusco M, Kang A, Savone M, Mokgokong R, Keshishian A, Gutierrez C, Cappelleri JC. Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: A systematic review and network meta-analysis. *Current Medical Research and Opinion*. 2021; 37:891-902.

Colombel J-F, Lakatos PL, Santana GO, Bushmakin AG, Cappelleri JC, Lawendy N, Pone de Leon D, Kulisek N. Diagnostic accuracy of patient-reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. *GastroHep*. 2021; 3:161-168.

Coates LC, Bushmakin, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC, Hsu M-A, Helliwell PS. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib. *Arthritis Research & Therapy*. 2021; 23:94.

Muresan B, Mamolo C, Cappelleri JC, Leip E, Viqueira A, Heeg B. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. *Current Medical Research and Opinion*. 2021; 37:801-809.

Shahraz S, Pham TP, Gibson M, de la Cruz M, Baara M, Karnik S, Dell C, Pease S, Nigam S, Cappelleri JC, Lipset C, Zornow P, Lee J, Byrom B. Does scrolling affect measurement equivalence of electronic patient-reported outcome measures (ePROM)? Results of a quantitative equivalence study. *Journal of Patient-Reported Outcomes*. 2021; 5:23.

Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kissner A, Modesto I, Sharma PP. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. *Journal of Medical Economics*. 2021; 24:279-290.

Cappelleri JC, Bushmakin AG. Test-retest reliability on the Sleep Quality Numeric Rating Scale for patients with fibromyalgia – How many measurements are enough? *Biopharmaceutical Report*. 2021; 28(1):6-10. <https://community.amstat.org/biop/biopharmreport>.

Cappelleri JC. James O'Malley wins award for methodological research. *Amstat News*. January 2021; 32.

Nalamachu S, Robinson R, Viktrup L, Cappelleri JC, Bushmakin A, Tive L, Mellor J. Pain severity and healthcare resource utilization in patients with osteoarthritis in the United States. Postgraduate Medicine. 2021; 133:10-19.

Russell C, McCarthy M, Cappelleri JC, Wong S. Choosing a mobile sensor technology for a clinical trial: Statistical considerations, developments and learnings. Therapeutic Innovation & Regulatory Science. 2021; 55:38-47.

Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. PharmacoEconomics. 2021; 39:121-131.

Ortsäter G, Geale K, Dun AR, Cappelleri JC, Cha A, Romero W, Henrohn D, Neregård P, Neary MP. Clinical and economic burden of pediatric mild-to-moderate atopic dermatitis: A population-based nested case-control study in Sweden. Dermatology and Therapy. 2021; 11:161-172.

Yeh Y-C, Cappelleri JC, Marston X, Shelbaya A. Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study. PLoS ONE. 2021; 16(1):e0242467.

Hall R, Lebwohl MG, Bushmakin AG, Simpson EL, Gooderham MJ, Wollenberg A, Gater A, Wells JR, Cappelleri JC, Hsu M-A, Papacharalambous J, Peeva E, Tallman AM, Zhang W, Chen L. Development and content validation of Pruritis and Symptoms Assessment for Atopic Dermatitis (PSAAD) in adolescents and adults with moderate-to-severe AD. Dermatology and Therapy. 2021; 11:221-233. Correction: <https://doi.org/10.1007/s13555-021-00567-z>.

Rubin DT, Hart A, Panaccione R, Armuzzi A, Suvanto U, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Wingate L, Schreiber S. Ulcerative colitis narrative global survey findings; Communication gaps and agreement between patients and physicians. Inflammatory Bowel Disease. 2021; 27:1096-1106.

Conaghan PG, Doane MJ, Jaffe DH, Dragon E, Abraham L, Viktrup L, Bushmakin AG, Cappelleri JC, Perrot S. Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilization for people with osteoarthritis in five large European countries? Clinical and Experimental Rheumatology. 2021; 39:819-828.

Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panés J. Tofacitinib in patients with ulcerative colitis: Inflammatory Bowel Disease

Questionnaire items in Phase 3 randomized controlled induction studies. *Inflammatory Bowel Diseases*. 2021; 27:983-993. Online access. <https://doi.org/10.1093/ibd/izaa193>.

Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib safety in moderate to severe ulcerative colitis: Comparison of clinical trial data with observational population cohort data from the IBM MarketScan® Administrative Claims Database. *Inflammatory Bowel Diseases*. 2021; 27:1394-1408. Online access. DOI:10.1093/ibd/izaa289.

Gladman DD, Orbai AM, Gomez-Reino J, Chang-Douglass S, Leoncini E, Buron HE, Kanik KS, Romero AB, Cappelleri JC, Hsu M-A. Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis. *Current Therapeutic Research, Clinical and Experimental*. 2020; 93:100601.

Farris MS, Larkin-Kaiser KA, Scory T, Boyne D, Wilner KD, Pastel M, Cappelleri JC, Ivanova JI. Network meta-analysis of first-line therapy for advanced EGFR mutation positive non-small cell lung cancer: updated OS. *Future Oncology*. 2020; 16:3107-3116.

Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. *Future Oncology*. 2020; 16:2475-2485.

Gossec L, Orbai A-M, Lobosco S, Moon R, Massey O, Piercy J, Cappelleri JC, Fallon L, Young P, Romero A-B, Hsu M-A. Patient-physician alignment in satisfaction with psoriatic arthritis treatment: Analysis from a cross-sectional study in the United States and Europe. *Journal of Psoriasis and Psoriatic Arthritis*. 2020; 5:168-173.

Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille M-H, Duh MS, Fakih I, Levenberg M, Cappelleri JC, Sikirica V. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: Analysis of a retrospective claims database. *Dermatology and Therapy*. 2020; 10:791-806.

Fahrbach K, Tarpey J, Bergrath Washington E, Hughes R, Thom H, Neary MP, Cha A, Gerber R, Cappelleri JC. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: Systematic literature review and network meta-analysis. *Dermatology and Therapy*. 2020; 10:681-694. <https://doi.org/10.1007/s13555-020-00389-5>. Correction: 2020; 10:1441-1444. <https://doi.org/10.1007/s13555-020-00452-1>.

Brümmendorf TH, Gambacorti-Passerini C, Bushmakin AG, Cappelleri JC, Viqueira A, Reisman A, Isfort S, Mamolo C. Relationship between molecular response and quality of life

with bosutinib or imatinib for chronic myeloid leukemia. *Annals of Hematology*. 2020; 99:1241-1249.

Hall JP, Chang J, Moon R, Higson O, Byrne K, Doherty JP, Cappelleri JC. Real-world treatment patterns in patients with advanced stage (stage III IV) ovarian cancer in the United States and Europe. *Future Oncology*. 2020; 16:1013-1030.

Nalamachu SR, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Hatchell N, Jackson JO. Multimodal treatment patterns for osteoarthritis and their relationships to patient-reported pain severity: a cross-sectional survey in the United States. *Journal of Pain Research*. 2020; 13:3415-3425.

Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. *Pediatric Dermatology*. 2020; 37:1030-1037.

Brookes MJ, Waller J, Cappelleri JC, Modesto I, DiBonaventura M, Bohm N, Mokgokong R, Massey O, Wood R, Bargo D. Living with Ulcerative Colitis Study (LUCY) in England: A retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. *BMJ Open Gastroenterology*. 2020; 7:e000456.

Coates LC, Orbai A-M, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, Lim I, Eder L, Richette P, Weng MY, Querio Silva R, Fallon L. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. *Health and Quality of Life Outcomes*. 2020; 18:173.

Solem C, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ, Cortes JE. A quality-adjusted survival time without symptoms or toxicities (Q-TWiST) analysis of glasdegib + LDAC vs LDAC as initial therapy for AML in patients who are not considered candidates for intensive chemotherapy. *Cancer*. 2020; 126:4315-4321.

Bungey G, Chang-Douglas, Hsu M-A, Cappelleri JC, Young P, Woolcott. Costs and health outcomes associated with tofacitinib treatment for active psoriatic arthritis in the United States. *Journal of Managed Care & Specialty Pharmacy*. 2020; 26:1027-1038.

Turk DC, Boeri M, Abraham L, Atkinson J, Bushmakin A, Cappelleri JC, Hauber B, Klein K, Russo L, Viktrup L, Walsh DA. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: A discrete choice experiment. *Osteoarthritis and Cartilage*. 2020; 28:1202-1213.

Cappelleri JC, Bushmakin AG. Test-rest reliability of a 11-point pain intensity numeric rating scale for patients with fibromyalgia. *Biopharmaceutical Report*. 2020; 27(2):15-19.  
<https://community.amstat.org/biop/biopharmreport>.

Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC. Treatment mode preferences in psoriatic arthritis: A qualitative multi-country study. *Patient Preference and Adherence*. 2020; 14:949-961.

Benigno M, Anastassopoulos KP, Mostaghimi A, Udall M, Daniel SR, Cappelleri JC, Chander P, Wahl PM, Lapthorn J, Kauffman L, Chen L, Peeva E. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. *Clinical Cosmetic and Investigational Dermatology*. 2020; 13:259-266.

Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura. The Inflammatory Bowel Disease Questionnaire in randomized controlled trials of treatment for ulcerative colitis: A systematic review and meta-analysis. *Journal of Patient-Centered Research and Reviews*. 2020; 7:189-205.

Dignass A, Waller J, Cappelleri JC, Modesto I, Kissner A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: A retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. *Journal of Medical Economics*. 2020; 23:415-427.

Armuzzi A, da Costa DiBonaventura, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Quirk D, Salese L. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. *PLoS ONE*. 2020; 15(1): e0227914. Online open access.

Walton MK, Cappelleri JC, Byrom B, Goldsack JC, Eremenco S, Harris D, Potero E, Patel N, Flood E, Daumer M. Consideration for development of an evidence dossier to support the use of mobile senior technology for clinical outcome assessments in clinical trials. *Contemporary Clinical Trials*. 2020; 91:105962. Online open access.

Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, DiBonaventura M. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. *BMC Gastroenterology*. 2020; 20:18. Online open access.

Johnson C, Stephens J, Walker C, Cappelleri JC, Shelbaya A. Economic outcomes related to persistence and dosing of celecoxib in patients with osteoarthritis (OA) using a retrospective claims database analysis. *ClinicoEconomics and Outcomes Research*. 2020; 12:57-67.

Franek J, Cappelleri JC, Larkin-Kaiser KA, Wilner KD, Sandin R. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small cell lung cancer. Future Oncology. 2019; 15:2857-2871.

Yang F, Yu S, Fan B, Liu Y, Chen YX, Kudel I, Concialdi K, DiBonaventura M, Hopps M, Hlavacek P, Cappelleri JC, Sadosky A, Parsons B, Udall M. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study. Pain and Therapy. 2019; 8:249-259.

Abogunrin S, Ashaye AO, Cappelleri JC, Clair AG, Fahrbach K, Ramaswamy K, Serfass L, Srinivas S, Thomaidu D, Zanotti G. Safety and effectiveness of sunitinib dosing schedules for metastatic renal cell carcinoma: A meta-analysis. Future Oncology. 2019; 15:2175-2190.

Margolis JM, Princic N, Smith DM, Abraham L, Cappelleri JC, Shah SN, Park PW. Economic impact of adherence to pain treatment guidelines in chronic pain patients. Pain Medicine. 2019; 20:1907-1918.

Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, Rider A, Walter RB. A real-world cross-sectional survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. Future Oncology. 2019; 15:1895-1909.

Mesa RA, Scherber R, Sun Y, Shields AL, Woolfson A, Krohe M, Prchal JT, Ojo F, Turnbull K, Pomplius, E, Jabbour, Cappelleri JC, Harrison C. Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings. Health and Quality of Life Outcomes. 2019; 17:61. Online open access.

Proskorovsky I, Su Y, Fahrbach K, Vandendries E, Pagé V, Onyekwere U, Wang Y, Cappelleri JC, Stelljes M. Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia. Advances in Therapy. 2019; 36:2147-2160.

Cappelleri JC. The International Index of Erectile Function (IIEF) – A systematic review of measurement properties. Journal of Sexual Medicine. 2019; 16:1861-1862.

Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A. Overall survival of glasdegib in combination with low-dose cytarabine, azacytidine, and decitabine among adult patients previously untreated AML: Comparative effectiveness using simulated treatment comparisons. ClinicoEconomics and Outcomes Research. 2019; 11:551-565.

Yu S-Y, Fan B-F, Yang F, DiBonaventura M, Chen Y-X, Li R-Y, King-Concialdi K, Kudel I, Hlavacek, Hopps M, Udall M, Sadosky A, Cappelleri JC. Patient and economic burdens of postherpetic neuralgia in China. ClinicoEconomics and Outcomes Research. 2019; 11:539-550.

Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. *Journal of the European Academy of Dermatology & Venereology* 2019; 33:1742-1746.

Mileve S, DiBonaventura daCosta M, Quon P, Goh Wern J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: Modeling the cost of treatment strategies in the United States. *Journal of Medical Economics*. 2019; 22:859-868.

Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B. Matching-adjusted indirect comparison of bosutinib, dasatinib, and nilotinib on survival and major cytogenetic response for treatment of second-line chronic phase chronic myeloid leukemia. *Current Medical Research and Opinion*. 2019; 35:1615-1622.

Simpson E, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA. Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis. *Acta Dermato-Venereologica*. 2019; 99:756-761.

Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin DT. Patient and physician preferences for ulcerative colitis treatments in the United States. *Clinical and Experimental Gastroenterology*. 2019; 12:263-278.

Duffin Callis K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. *BMC Dermatology*. 2019; 19:18. Online open access.

Cappelleri JC, Brinkley J. Guest editorial summary on articles selected from the 2018 International Conference on Health Policy Statistics. *Health Services and Outcomes Research Methodology*. 2019; 19:1-7. Online open access.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AB, Kudlacz, Hsu M-A. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy – Fatigue in patients with psoriatic arthritis. *Journal of Patient-Reported Outcomes*. 2019; 3:30. Online open access.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu M-A. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden – a phase III study of active psoriatic arthritis in patients

with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. *RMD Open*. 2019; 5:e000806. Online open access.

Feldman SR, Cox LS, Stowd LC, Gerber RA, Faulkner S, Sierka D, Smith TW, Cappelleri JC, Levenberg ME. The challenge of managing atopic dermatitis in the United States. *American Health & Drug Benefits*. 2019; 12:83-93.

Kudel I, Hopps M, Cappelleri JC, Sadosky A, Concialdi K, Liebert R, Parsons B, Hlavacek P, Alexander AH, Di Bonaventura M, Markman JD, Farrar JT, Stacey BR. Characteristics of patients with neuropathic pain syndromes screened by the painDETECT and diagnosed by physician exam. *Journal of Pain Research*. 2019; 12:255-268.

Udall M, Kudel I, Cappelleri JC, Sadosky A, Concialdi K, Parsons B, Hlavacek H, Hopps M, Salomon P, DiBonaventura M, Clark P, Garcia JB. Epidemiology of physician-diagnosed neuropathic pain in Brazil. *Journal of Pain Research*. 2019; 12:243-253.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu M-A. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised, controlled trial: OPAL Beyond. *RMD Open*. 2019; 5:e000808. Online open access.

Ashaye AO, Khankhel Z, Xu Y, Fahrbach K, Mokgolong R, Orme ME, Lang K, Cappelleri JC, Mamolo C. A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia. *Future Oncology*. 2019; 15:663-681. Online open access.

Bauer V, Goodman N, Lapin B, Cooley C, Wang E, Craig T, Glosner SE, Juhn MS, Cappelleri JC, Sadosky AB, Masi C. Text messaging to improve disease management in patients with painful diabetic peripheral neuropathy. *Diabetes Educator*. 2018; 44:237-248.

Yarlas A, Rubin D, Panés J, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, DiBonaventura M. Burden of ulcerative colitis on functioning and well-being: A systematic literature review of the SF-36® health survey. *Journal of Crohn's and Colitis*. 2018; 12:600-609.

Ständer S, Luger TA, Cappelleri JC, Bushmakin AG, Mamolo C, Zielinski MA, Tallman AM, Yosipovitch G. Validation of the Itch Severity Item as a measurement tool for pruritus in patients with psoriasis: Results from a phase 3 tofacitinib program. *Acta Dermato-Venereologica*. 2018; 98:340-345.

Davis F, Gostine M, Roberts BA, Risko R, Cappelleri JC, Sadosky A. Interpreting the effectiveness of opioids and pregabalin for pain severity, pain interference, and fatigue in fibromyalgia patients. *Pain Practice*. 2018; 18:611-624.

Yosipovitch G, Simpson EL, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Tom WL, Benjamin K, Ports WC, Tallman AM, Tan H, Gerber RA. Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS). *Itch*. 2018; 3:e13. Online open access.

Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri, DiBonaventura M. Psychometric validation of the Work Productivity and Activity Impairment Questionnaire in ulcerative colitis: results from a systematic literature review. *Journal of Patient-Reported Outcomes*. 2018; 2:62. Online open access.

Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. *Cancer*. 2018; 124:2151-2160.

Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: A retrospective medical record review. *International Journal of Gynecological Cancer*. 2018; 28:738-748.

Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, Arondekar B, Bushmakin AG. Important group differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in patients with metastatic renal cell carcinoma. *Value in Health*. 2018; 21:1413-1418.

Cappelleri JC. Christopher Schmid Talks Health Statistics. *Amstat News*. November 2018; 13-15.

Proskorovsky I, Benedict A, Negrier S, Bargo D, Sandin R, Ramaswamy K, Desai J, Cappelleri JC, Larkin J. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. *BMC Cancer*. 2018; 18:1271. Online open access.

Xu Y, Sudharshan L, Hsu M-A, Koenig A, Cappelleri JC, Liu W, Smith TW, Pasquale M. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. *American Health & Drug Benefits*. 2018; 11:408-417.

Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM, Zielinski MA, Frajzyngier V, Gerber RA. Patient impact and economic burden of mild to moderate atopic dermatitis. *Current Medical Research and Opinion*. 2018; 34:2177-2185.

Davis F, Gostine M, Roberts B, Risko R, Cappelleri JC, Sadosky A. Characterizing classes of fibromyalgia within the continuum of central sensitization syndrome. *Journal of Pain Research*. 2018; 11:2551-2660.

Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale M. Factors related to the use of topical vs. oral NSAIDs for sprains, strains, and contusions in a senior population: A retrospective analysis of administrative claims data. *Drugs & Aging*. 2018; 35:937-950.

Cappelleri JC, Tseng L-J, Stecher V, Goldstein I. Enriching the interpretation of the Erectile Dysfunction Inventory of Treatment Satisfaction: Characterizing success in treatment satisfaction. *Journal of Sexual Medicine*. 2018; 15:732-740.

Yosipovitch G, Simpson EL, Tan H, Gerber RA, Luger T, Ständer S, Tom WL, Cappelleri JC, Bushmakin AG, Ports WEC, Tallman AM. Effect of crisaborole topical ointment, 2%, on atopic dermatitis-associated pruritus: an extended analysis of 2 phase 3 clinical trials. *Itch*. 2018; 3:e12. Online open access.

Cappelleri JC, Tseng L-J, Stecher VJ, Althof SE. Clinically important difference on the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire in patients with erectile dysfunction. *International Journal of Clinical Practice*. 2018; 72:e13073.

Castejón N, Cappelleri JC, Cuervo J, Lang K, Mehta P, Mokgokong R, Mamolo C. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom. *Health and Quality of Life Outcomes*. 2018; 16:66. Online open access.

Shelbaya A, Solem C, Walker C, Wan Y, Johnson G, Cappelleri JC. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. *ClinicoEconomics and Outcomes Research*. 2018; 10:213-222.

Panés J, Vermeire S, Lindsay JO, Sands BF, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in patients with ulcerative colitis: Health-related quality of life in phase 3 randomized controlled induction and maintenance studies. *Journal of Crohn's and Colitis*. 2018; 12:145-156.

Gostine M, Davis F, Roberts B, Risko R, Asmus M, Cappelleri JC, Sadosky A. Clinical characteristics of fibromyalgia in a chronic pain population. *Pain Practice*. 2018; 18:67-78.

Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger C, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the tolerability of cancer treatments using patient-reported outcomes measures: Summary of an FDA and Critical Path Institute Workshop. *Value in Health*. 2018; 21:742-747.

Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: Results from a systematic literature review. *Quality of Life Research*. 2018; 27:273-290.

Cappelleri JC, Deal LS, Petrie CD. Editorial. Reflections on ISPOR's clinician-reported outcomes good measurement practice recommendations. *Value in Health*. 2017; 20:15-17.

Eichholz M, Alexander AH, Cappelleri JC, Hlavacek P, Parsons B, Sadosky A, Tuchman M. Perspectives on the impact of painful diabetic peripheral neuropathy in a multicultural population. *Clinical Diabetes and Endocrinology*. 2017; 3:12. Online open access.

Barsdorf AI, Carlsson M, Bushmakin AG, Quinn S, Cappelleri JC, Pleil A. Validation of Overactive Bladder Questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder. *International Urogynecology Journal*. 2017; 218:1857-1863.

Bonanad S, Schulz M, Gordo A, Spurden D, Cicchetti M, Cappelleri JC, Tolley C, Staunton H, Brohan E. HaemoPREF: Further evaluation of patient perception and preference for treatment in a real world setting. *Haemophilia*. 2017; 23:884-893.

DiBonaventura MD, Sadosky A, Concialdi K, Hopps M, Kudel I, Parsons B, Cappelleri JC, Hlavacek P, Alexander AH, Stacey BR, Markman JD, Farrar JT. The prevalence of probable neuropathic pain in the United States: Results from a multimodal general population health survey. *Journal of Pain Research*. 2017; 10:2525-2538.

Bennetts M, Whalen E, Ahadieh S, Cappelleri JC. An appraisal of meta-analysis guidelines: How do they relate to safety outcomes? *Research Synthesis Methods*. 2017; 8:64-78.

Kammerman LA, Cappelleri JC, Bartlett J. Patient-reported outcomes. Wiley StatsRef: Statistics Reference Online. 2017. DOI: 10.1002/9781118445112.stat07929.

Packham T, Cappelleri JC, Sadosky A, MacDermid JC, Brunner F. Measurement properties of painDETECT: Rasch analysis of responses from community-dwelling adults with neuropathic pain. *BMC Neurology*. 2017; 17:48. Online open access.

Hsu M-A, Lucas J, Wood R, Cappelleri JC, Piercy J. Frequency, prevalence and burden of flares on patients with moderate to severe psoriasis: A retrospective cross-sectional analysis. *Journal of Psoriasis and Psoriatic Arthritis*. Vol 2, No 3, Summer 2017. E-odd.

Schaefer C, Mamolo C, Cappelleri JC, Daniel S, Le C, Tatulych S, Griffiths CeM, Hampton PJ. Treatment patterns and outcomes among adults admitted to hospital in the United Kingdom (UK) due to plaque or erythrodermic psoriasis. *British Journal of Dermatology*. 2017; 177:e52-e54.

Romanelli RJ, Ikeda L, Lynch B, Craig T, Cappelleri JC, Jukes T, Ishisaka DY. Opioid prescribing for chronic pain in a community-based healthcare system. *American Journal of Managed Care*. 2017; 23:e138-e145.

Cappelleri JC. Cultivating a culture of collaboration (with gusto) in your career. *Amstat News*. May 2017; 10-13.

Margolis JM, Princic N, Smith DM, Abraham L, Cappelleri JC, Shah SN, Park PW. Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims. *Journal of Pain Research*. 2017; 10:327-329.

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. Mapping painDETECT, a neuropathic pain screening tool, to the EuroQoL (EQ-5D-3L). *Quality of Life Research*. 2017; 26:467-477.

Romanelli RJ, Shah SN, Ikeda L, Lynch B, Craig TL, Cappelleri JC, Jukes T, Ishisaka D. Patient characteristics and healthcare utilization of a chronic pain population within an integrated healthcare system. *American Journal of Managed Care*. 2017; 23:e50-e56.

Bushmakin AG, Cappelleri JC. Response to editorial comment: “Quantifying barriers to improvement of treatment satisfaction in men with erectile dysfunction: Use of person-item maps.” *Journal of Sexual Medicine*. 2017; 14:162.

Bushmakin AG, Cappelleri JC, Stecher V, Lue TF. Quantifying barriers to improvement of treatment satisfaction in men with erectile dysfunction: Use of person-item maps. *Journal of Sexual Medicine*. 2017; 14:152-159.

Coyne KS, Currie BM, Donevan S, Cappelleri JC, Hegeman-Dingle R, Abraham L, Thompson C, Sadosky A, Brodsky M. Discriminating between neuropathic pain and sensory hypersensitivity using the Chronic Pain Questions (CPQ). *Postgraduate Medicine*. 2017; 129:22-31.

Coyne KS, Currie BM, Donevan S, Brodsky M, Asmus MJ, Krichbaum DW, Cappelleri JC, Hegeman-Dingle R, Sadosky A, Whipple SZ, Burbridge C, Mulhem E, Hillenberg JB.

Psychometric validation of the Electronic Chronic Pain Questionnaire (eCPQ) in a primary care setting. *Current Medical Research and Opinion*. 2017; 33:137-148.

Panés J, Su C, Bushmakin AG, Cappelleri JC, Healey P. Direct and indirect effects of tofacitinib on treatment satisfaction in patients with ulcerative colitis. *Journal of Crohn's and Colitis*. 2016; 10:1310-1315.

Pinkerton JV, Bushmakin AG, Abraham L, Cappelleri JC, Komm BS. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effect. *Menopause*. 2016; 23:1092-1101.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Komm BS. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. *Menopause*. 2016; 23:1060-1066.

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, Ståhle M. Economic burden of psoriasis and potential cost offsets with biologic treatment – A Swedish register analysis. *Acta Dermato-Venereologica*. 2016; 96:651-657.

Schaefer C, Mann R, Masters ET, Cappelleri JC, Daniel SR, Zlateva G, McElroy HJ, Chandran AB, Adams EH, Assaf AR, McNett M, Mease P, Silverman S, Staud R. The comparative burden of chronic widespread pain and fibromyalgia in the United States. *Pain Practice*. 2016; 16:565-579.

Halpern R, Shah S, Cappelleri JC, Masters ET, Clair A. Evaluating guideline-recommended pain medication use among patients with newly diagnose fibromyalgia. *Pain Practice*. 2016; 16:1027-1039.

Jansen JP, Vieira M-C, Bradley JC, Cappelleri JC, Zwillich SH, Wallenstein GV. Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. *BMC Musculoskeletal Disorders*. 2016; 17:348. Online open access.

McLeod LD, Cappelleri JC, Hays RD. Erratum to “Best (but of forgotten) practices: Expressing and interpreting meaning and effect sizes in clinical outcome assessments.” *The American Journal of Clinical Nutrition*. 2017; 105:241. <https://doi.org/10.3945/ajcn.116.148593>.

McLeod LD, Cappelleri JC, Hays RD. Best (but of forgotten) practices: Expressing and interpreting meaning and effect sizes in clinical outcome assessments.” *The American Journal of Clinical Nutrition*. 2016; 103:685-693. <https://doi.org/10.3945/ajcn.115.120378>.

Sadosky A, Koduru V, Bienen EJ, Cappelleri JC. Characterizing individual painDETECT symptoms by average pain severity. *Clinicoeconomics and Outcomes Research*. 2016; 8:361-366.

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. Characterizing neuropathic pain profiles: Enriching interpretation of painDETECT. *Patient Related Outcome Measures*. 2016; 7:93-99.

Adams EH, McElroy HJ, Udall M, Masters ET, Mann RM, Schaefer CP, Cappelleri JC, Clair AG, Hopps M, Daniel SR, Mease P, Silverman SL, Staud R. Progression of fibromyalgia: results from a two-year observational fibromyalgia and chronic pain study in the United States. *Journal of Pain Research*. 2016; 9:325-336.

Cappelleri JC, Tseng L-J, Luo X, Stecher V, Lue TF. Simplified interpretation of the erectile function domain of the International Index of Erectile Function. *Journal of Sexual Medicine*. 2016; 13:690-696.

Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, Pasquale MK. Patient preference for route of administration among rheumatoid arthritis therapies: A conjoint analysis. *American Health & Drug Benefits*. 2016; 9:84-93.

Null K, Moll K, Sadosky A, Pasquale MK, Cappelleri JC, Parsons B. Trends associated with implementing and lifting a pregabalin step therapy policy. *American Journal of Pharmacy Benefits*. 2016; 8:e17-e24.

Martin C, Odell K, Cappelleri JC, Bancroft T, Halpern R, Sadosky A. Impact of a novel cost saving pharmacy program on pregabalin utilization and healthcare costs. *Journal of Managed Care & Specialty Pharmacy*. 2016; 22:132-144.

Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. *Therapeutic Innovation & Regulatory Science*. 2016; 50:22-29.

Lee LK, Ebata N, Hlavacek P, DiBonaventura M, Cappelleri JC, Sadosky A. Humanistic and economic burden of fibromyalgia in Japan. *Journal of Pain Research*. 2016; 9:967-978.

Snedecor SJ, Wan Y, Cappelleri JC, Stevens JW. Multivariate meta-analysis: Concepts and applications. *Value & Outcomes Spotlight*. 2016; 2:9-10.

Margolis J, Masters ET, Cappelleri JC, Smith D, Faulkner S. Evaluating increased resource use in fibromyalgia using electronic health records. *ClinicoEconomics and Outcomes Research*. 2016; 8:675-683.

Schaefer CP, Adams EH, Udall M, Masters ET, Mann RM, Daniel SR, McElroy HJ, Cappelleri JC, Clair AG, Hopps M, Staud R, Mease P, Silverman SL. Fibromyalgia outcomes over time: Results from a prospective observational study in the United States. *The Open Rheumatology Journal*. 2016; 10:109-121.

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Petersson IF, Ståhle M. Treatment patterns with topical, traditional systemics and biologics in psoriasis – A Swedish database analysis. *Journal of the European Academy of Dermatology & Venereology*. 2015; 29:215-223.

Schaefer CP, Cappelleri JC, Cheng R, Cole JC, Guenthner S, Fowler J, Johnson S, Mamolo C. Health care resource use, productivity, and costs among patients with moderate-to-severe psoriasis in the United States. *Journal of the American Academy of Dermatology*. 2015; 73:585-593. Video that summarizes manuscript has been recorded on the journal's website.

Emery P, Solem C, Majer I, Cappelleri JC, Tarallo M. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. *Rheumatology International*. 2015; 35:1837-1849.

Svedhom A, Dalén J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, Ståhle M. Increased cause-specific mortality in patients with mild and severe psoriasis – A population-based Swedish register study. *Acta Dermato-Venereologica*. 2015; 95:809-815.

Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndehi L, Suehs BT, Parsons B. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated in pregabalin or duloxetine. *BMC Health Services Research*. 2015; 15:159. Online open access.

Cappelleri JC, Spielberg SP. Advances in clinical outcome assessments. *Therapeutic Innovation & Regulatory Science*. 2015; 49:780-782.

Menon J, Cappelleri JC, Mardekian J, Vendetti NJ, Mychaskiw M, Thomas J III. Psychometric properties of the SF-12, Penn Shoulder Score, and Visual Analogue Scale-Pain for rotator cuff tears. *Applied Medical Research*. 2015; 1:109-117.

Paul C, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C. Do patients and physicians agree in their assessment of the severity of psoriasis? Insights from tofacitinib phase 3 clinical trials. *Journal of Dermatology and Clinical Research*. 2015; 3(3):1048. Online open access.

Sadosky A, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K. The association between lower back pain and health status, work productivity, and health resource use in Japan. *Journal of Pain Research*. 2015; 8:119-130.

Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo CM, Healey PJ. Randomized trial of tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes. *BMC Gastroenterology*. 2015; 15(1):14. Online open access.

Placzek H, Masters ET, Gu T, Cappelleri JC, Clair AG, Cook J, Eisenberg D. Prior authorization in the treatment of patients with pDPN and FM. *Pain Practice*. 2015; 15:E9-E19.

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain. *Journal of Pain Research*. 2015; 8:159-167.

Cappelleri JC, Ingerick M. A conversation with Joseph Lau. *Research Synthesis Methods*. 2015; 6:2-20.

Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. *Journal of Dermatological Treatment*. 2015; 26:19-22.

Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analysis. *Journal of Dermatological Treatment*. 2015; 26:121-123.

Johnston SS, Sadosky A, Cappelleri JC, Johnson BH, Shrady G, Chu B-C, Silverman S. Pregabalin prior authorization and potential medication-medication and medication-condition interactions. *American Journal of Pharmacy Benefits*. 2014; 6:e185-e192.

Bushmakin AG, Abraham L, Pinkerton JV, Cappelleri JC, Mirkin S. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. *Menopause*. 2014; 21:815-822.

Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Chu B-C, Silverman SL. Potential drug-drug interactions among fibromyalgia patients initiating pregabalin or duloxetine: Prevalence and healthcare expenditure impact. *Pain Medicine*. 2014; 15:1282-1293.

Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step-therapy policy among Medicare Advantage beneficiaries. *Pain Practice*. 2014; 14:419-426.

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. *Pain Practice*. 2014; 14:167-184.

Pinkerton JV, Bushmakin AG, Racketa J, Cappelleri JC, Chines AA, Mirkin S. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling. *Menopause*. 2014; 21:243-251.

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundwala Y, Botteman M. Systematic review and meta-analysis of pharmacological therapies for pain associated with post-herpetic neuralgia and less common neuropathic conditions. *International Journal of Clinical Practice*. 2014; 68:900-918.

Cella D, Davis MP, Negrer S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. *Cancer*. 2014; 120:1871-1880.

Bernabé B, Lasbleiz S, Gerber RA, Cappelleri JC, Yelnik A, Orcel P, Bardin T, Beaudreuil J. URAM scale for functional assessment in Dupuytren's disease: A comparative study of its properties. *Joint Bone Spine*. 2014; 81:441-444.

Teal S, Brohan E, Hettema Y, Humphrey L, Willgoss T, Hudgens S, Westfield M, Cappelleri JC. Development and psychometric evaluation of a novel tool for assessing patient perception and preference for haemophilia treatment (HaemoPREF). *Haemophilia*. 2014; 20:666-673.

Negrer S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ. Assessment of progression-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma. *European Journal of Cancer*. 2014; 50:1766-1771.

Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff NC. Healthcare resource utilization and costs of spinal cord injury with neuropathic pain in a Medicare population. *Journal of Pain & Relief*. 2014; 53:007. Online open access.

Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC. Health care resource utilization and medical costs of spinal cord injury with neuropathic pain in a commercially insured population in the United States. *Archives of Physical Medicine and Rehabilitation*. 2014; 95:2279-2287.

Coleman CI, Cappelleri JC, Kohn CG. Considerations when meta-analyzing diagnostic test sensitivity and specificity when an adequate reference standard exists. *ISPOR Connections*. November/December 2014; 20(6):4-6.

Cappelleri JC, Bienen EJ, Koduru V, Sadosky A. Measurement properties of painDETECT by average pain severity. *ClinicoEconomics and Outcomes Research*. 2014; 6:497-504.

Ellis JJ, Sadosky AB, Ten Eyck LT, Cappelleri JC, Brown CR, Suehs BT, Parsons B. Impact of potential pregabalin or duloxetine drug-drug interactions on healthcare costs and utilization

among Medicare members with fibromyalgia. *ClinicoEconomics and Outcomes Research*. 2014; 6:389-399.

Cappelleri JC, Lundy JJ, Hays RD. Overview of classical test theory and item response theory for quantitative assessment of items in developing patient-reported outcomes measures. *Clinical Therapeutics*. 2014; 36:648-662.

Ellis AG, Reginster J-Y, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP. Bazedoxifene versus oral bisphosphonates for the prevention of non-vertebral fractures in post-menopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. *Value in Health* 2014; 17:424-432.

Margolis J, Juneau P, Sadosky A, Cappelleri JC, Bryce T, Nieshoff E. Healthcare utilization and expenditures among Medicaid beneficiaries with neuropathic pain following spinal cord injury. *Journal of Pain Research*. 2014; 7:379-387.

Bailey J, Hawker GA, Wood R, Cappelleri JC, Higgins V, Joyce N, Hsu M-A. Impact of physician specialty on classification of physician-perceived patient severity for patients with osteoarthritis. *Osteoarthritis and Cartilage*. 2014; 22:647-651.

Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: An ISPOR-AMCP-NPC Good Practice Task Force Report. *Value in Health*. 2014; 17:157-173.

Alemayehu D, Cappelleri JC. Evaluating methodological assumptions in comparative effectiveness research: Overcoming pitfalls. *Journal of Comparative Effectiveness Research*. 2014; 3:79-93.

Cappelleri JC, Bushmakin AG. Interpretation of patient-reported outcomes. *Statistical Methods in Medical Research*. 2014; 23:460-483.

Bushmakin AG, Cappelleri JC, Symonds T, Stecher VJ. Further understanding of the International Index of Erectile Function at 15+ years: confirmatory factor analysis and multidimensional scaling. *Therapeutic Innovation & Regulatory Science*. 2014; 48:246-254.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective Estrogens, Menopause, And Response to Therapy (SMART) Trials. *Journal of Women's Health*. 2014; 23:18-28.

Bushmakin AG, Cappelleri JC, Symonds T, Stecher VJ. Enhanced understanding of the relationship between erection and satisfaction in erectile dysfunction treatment: Application of a longitudinal mediation model. *International Journal of Impotence Research*. 2013; 26:20-23.

Cappelleri JC, Bushmakin AG. Using the probability-probability plot and index to augment interpretation of treatment effect for patient-reported outcome measures. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013; 13:707-713.

Cappelleri JC, Hwang L-J, Mardekian J, Mychaskiw MA, Teal SA. Cumulative distribution functions of sildenafil citrate on exercise capacity and hemodynamic function in children with pulmonary arterial hypertension. *Journal of Pulmonary & Respiratory Medicine*. 2013. S4:002. doi:10.4172/2161-105X.S4-002.

Wagner JS, Chandran A, DiBonaventura M, Cappelleri JC. The costs associated with sleep symptoms among patients with fibromyalgia. *Expert Reviews of Pharmacoeconomics & Outcomes Research*. 2013; 13:131-139.

Gore M, Finnerup NB, Sadosky A, Tai K-S, Cappelleri JC, Mardekian J, Rice CG, Nieshoff E. Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin. *Spinal Cord*. 2013; 51:126-133.

Lane PW, Higgins JPT, Anagnostelis B, Anzures-Cabrera J, Baker NF, Cappelleri JC, Haugie S, Lewis SC, Moneuse P, Whitehead A. Methodological quality of meta-analyses: match-pairs comparison over time and between industry-sponsored and academic-sponsored reports. *Research Synthesis Methods*. 2013; 4:342-350.

Higgins JPT, Lane PW, Anagnostelis B, Anzures-Cabrera J, Baker NF, Cappelleri JC, Haugie S, Lewis SC, Moneuse P, Whitehead A. A tool to assess the quality of meta-analysis. *Research Synthesis Methods*. 2013; 4:351-366.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. *Journal of Medical Economics*. 2013; 16:784-792.

Sobieraj DM, Cappelleri JC, Baker WL, Phung OJ, White CM, Coleman CI. Methods used to conduct and report closed loop Bayesian mixed treatment comparisons published in the medical literature: A systematic review. *BMJ Open*. 2013; 3:e003111.doi:10.1136/bmjopen-2013-003111.

Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Chu B-C, Silverman SL. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic

peripheral neuropathy treated with pregabalin versus duloxetine. *American Journal of Health-System Pharmacy*. 2013; 70:2207-2217.

Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. *Quality of Life Research*. 2013; 22:2489-2499.

Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, Sianos G, Anthony I, Cappelleri JC, Szczypl P, van Hout BA. Eliciting health state utilities for Dupuytren's contracture using discrete choice experiment (DCE). *Acta Orthopaedica*. 2013; 84:571-578.

Sotomayor M, Cappelleri JC, Bushmakin AG, Mould J, Gómez-Palacio R, Davila G, Abreu P. A multicenter open-label study to understand individual and couple satisfaction in men treated with sildenafil for erectile dysfunction. *Journal of Symptoms and Signs*. 2013; 2:181-187.

Alemayehu D, Cappelleri JC. Revisiting issues, drawbacks and opportunities with observational studies in comparative effectiveness research. *Journal of Evaluation in Clinical Practice*. 2013; 19:579-583.

Arnold LM, Cappelleri JC, Clair A, Masters ET. Effect sizes and clinical relevance of pharmacological treatments for fibromyalgia. *Pain and Therapy*. 2013; 2:65-71.

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundwala Y, Botteman M. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. *Journal of Pain Research*. 2013; 6:539-547. Online open access.

Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. *Patient Preference and Adherence*. 2013; 7:419-434. Online open access.

Coyne KS, Margolis MK, Cappelleri JC, Hsieh R, Essex MN, Park PW, Joshi AV. Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States. *Current Medical Research and Opinion*. 2013; 29:421-433.

Cappelleri JC, Zou KH, Bushmakin AG, Carlsson MO, Symonds T. Cumulative response curves to enhance interpretation of treatment differences on the Self-Esteem And Relationship questionnaire for men with erectile dysfunction. *BJU International*. 2013; 11:E115-E120.

Dias J, Bainbridge C, Leclercq C, Gerber RA, Guérin D, Cappelleri JC, Szczypl P, Dahlin LB. Surgical management of Dupuytren's contracture in Europe: Regional analysis of a surgeon survey and patient chart review. *International Journal of Clinical Practice*. 2013; 67:271-281.

Dahlin LB, Bainbridge C, Leclercq C, Gerber RA, Guérin D, Cappelleri JC, Szczyga PP, Dias J. Dupuytren's disease presentation, referral pathways, and resource utilization in Europe: Regional analysis of a surgeon survey and patient chart review. *International Journal of Clinical Practice*. 2013; 67:261-270.

Goldstein JL, Luo X, Cappelleri JC, Sands GH. Healthcare resource utilization and economic impact of a  $\geq 2$  g/dL decrease in hemoglobin in osteoarthritis patients. *Journal of Medical Economics*. 2013; 16:430-439.

Bushmakin AG, Cappelleri JC, Symonds T, Stecher VJ. Multi-domain longitudinal modeling: An application to the International Index of Erectile Function. *Therapeutic Innovation & Regulatory Science*. 2013; 47:57-64.

Larkin J, Paine A, Chen C, Tumur I, Cappelleri JC, Healey PH, Foley G, Mitchell S, Kroes M. Treatments in the second-line management of advanced renal cell carcinoma: systematic review and meta-analysis. *Expert Opinion on Pharmacotherapy*. 2013; 14:27-39.

Langley P, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. *Journal of Medical Economics*. 2013; 16:85-95.

Bushmakin AG, Cappelleri JC, Chandran A, Zlateva G. Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin. *International Journal of Clinical Practice*. 2013; 67:52-59.

Symonds T, Abraham L, Bushmakin AG, Williams K, Martin M, Cappelleri JC. Sexual Function Questionnaire: Further refinement and validation. *Journal of Sexual Medicine*. 2012; 9:2609-2616.

Baker EL, Coleman CI, Reinhart KM, Phang OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL. Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analysis. *Dermatology and Therapeutics*. 2012; 2:9. Online open access.

Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. *OncoTargets and Therapy*. 2012; 5:287-296.

Wagner J-S, DiBonaventura M, Chandran AB, Cappelleri JC. The association of sleep difficulties with health-related quality of life among patients with fibromyalgia. *BMC Musculoskeletal Disorders*. 2012; 13:199. Online open access.

Cappelleri JC, Bushmakin AG, Zlateva G, Chandran A. Estimating the economic benefits of positive shifts in fibromyalgia severity: An exploratory analysis based on modeling of clinical trial data of pregabalin. *Journal of Medical Economics.* 2012; 28:1-7. (Selected among thousands to be included in the American Academy of Pain Management's 10/12/2012 E-newsletter entitled Currents: Pain Management News and Research.)

Cappelleri JC, Hwang L-J, Mardekian J, Mychaskiw MA. Assessment of measurement properties of peak VO<sub>2</sub> in children with pulmonary arterial hypertension. *BMC Pulmonary Medicine.* 2012; 12:54. Online open access.

Coleman CI, Phung OJ, Cappelleri JC, Baker WL, Kluger J, White CM, Sobieraj DM. Use of mixed treatment comparisons in systematic reviews. Methods research report. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I.) AHRQ Publication No. 12-EHC119-EF. Rockville, MD: Agency for Healthcare Research and Quality. August 2012. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

Alemayehu D, Cappelleri JC. Conceptual and analytical considerations for use of patient-reported outcomes in personalized medicine. *American Health & Drug Benefits.* 2012; 5:310-316.

Cappelleri JC, Bushmakin AG, Stecher V, Symonds T. Successful sexual intercourse: Time-to-event modeling in a sildenafil trial. *Journal of Symptoms and Signs.* 2012; 1:67-72.

Sanchez RJ, Mardekian J, Clair A, Cappelleri JC. Therapeutic and sub-therapeutic dosing of pregabalin: Medication adherence, healthcare, resource utilization, and costs. *American Journal of Pharmacy Benefits.* 2012; 4:158-164.

Burke JP, Sanchez R, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. *Pain Practice.* 2012; 12:209-218.

Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Michaelson MD, Motzer RJ. Baseline quality of life as a prognostic tool of median survival in patients receiving sunitinib for metastatic renal cell carcinoma. *British Journal of Cancer.* 2012; 106:646-650.

Dahlin LB, Bainbridge C, Szczyga PP, Cappelleri JC, Guérin D, Gerber RA. Current trends in the surgical management of Dupuytren's disease in Europe: the surgeon's perspective. *European Orthopaedics and Traumatology.* 2012; 3:25-30.

Bainbridge C, Dahlin LB, Szczyga PP, Cappelleri JC, Guérin D, Gerber RA. Current trends in the surgical management of Dupuytren's disease in Europe: an analysis of patient charts. European Orthopaedics and Traumatology. 2012; 3:31-41.

Luo X, Cappelleri JC, Chandran A. The burden of fibromyalgia: Assessment of health status using the EuroQol (EQ-5D) in patients with fibromyalgia relative to other chronic conditions. Health Outcomes Research in Medicine. 2011; 2:e203-e214.

Burke JP, Sanchez R, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with fibromyalgia on pregabalin versus duloxetine. Pain Practice. 2011; 12:14-22.

Jones B, Roger J, Lane PW, Lawton A, Fletcher C, Cappelleri JC, Tate H, Moneuse P. Statistical approaches for conducting network meta-analysis in drug development. Pharmaceutical Statistics. 2011; 10:523-531.

Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott P, Kim S, Stadler WM, Rini B. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship. 2011; 5:255-262.

DiBonaventura MD, Cappelleri JC, Joshi AV. Association between pain severity and healthcare resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Medicine. 2011; 12:799-807.

Withaut J, Bushmakin AG, Gerber RA, Cappelleri JC, Hellio Le Graverand-Gastineau M-P. Determining clinically important changes in range of motion among patients with Dupuytren's contracture: Secondary analysis of the CORD I study. Clinical Drug Investigation. 2011; 31:791-798.

Crean SM, Gerber RA, Hellio Le Graverand M-P, Boyd DM, Cappelleri JC. A structured literature review on the efficacy and safety of fasciectomy and fasciotomy procedures for Dupuytren's contracture in Europe. Journal of Hand Surgery: European Volume. 2011; 36:396-407.

Overbeek JPA, FJA Penning-van Beest, Heintjes EM, Gerber RA, Cappelleri JC, Hovius SER, Herings RMS. Dupuytren's contracture: a retrospective database analysis to determine hospitalizations in the Netherlands. BMC Research Notes. 2011; 4:402. Electronic (online) open access.

Alemayehu D, Sanchez RJ, Cappelleri JC. Considerations on the use of patient-reported outcomes in comparative effectiveness research. Journal of Managed Care Pharmacy. 2011; 17:S27-S33.

Beaudreuil J, Allard A, Zerkak D, Gerber RA, Cappelleri JC, Quintero N, Lasbleis S, Bernabe B, Orcel P, Bardin T, for the URAM Study Group. URAM (Unite Rhumatologique des Affections de la Main) scale: Development and validation of a tool to assess Dupuytren's disease-specific disability. *Arthritis Care & Research*. 2011; 63:1448-1455.

Louder AM, Joshi AV, Ball AT, Cappelleri JC, Deminski MC, Sanchez RJ. Impact of celecoxib restrictions in Medicare beneficiaries. *American Journal of Managed Care*. 2011; 17:503-512.

Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices – Part 2. *Value in Health*. 2011; 14:429-437.

Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. *Value in Health*. 2011; 14:417-428.

Bushmakin AG, Cappelleri JC. A note on cumulative distribution functions for patient-reported outcomes. *Patient Reported Outcomes (PRO) Newsletter*. 2011; 45 (spring issue):11-12.

Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky A. Applying area-under-the-curve analysis to enhance interpretation of response profiles: An application to sleep quality scores in patients with fibromyalgia. *Quality of Life Research*. 2011; 20:491-498.

van Seventer R, Serpell M, Bach FW, Morlion B, Zlateva G, Bushmakin AG, Cappelleri JC, Nimour M. Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain. *Health and Quality of Life Outcomes*. 2011; 9:17. Electronic (online) open access.

Kleinman NL, Sanchez RJ, Lynch WD, Cappelleri JC, Beren IA, Joshi AV. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. *Pain Practice*. 2011; 11:540-557.

DiBonaventura MD, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and healthcare utilization and cost. *Pain Medicine*. 2011; 12:118-126.

Bushmakin AG, Cappelleri JC, Taylor-Stokes G, Sayers J, Sadosky A, Carroll D, Gosden T, Emery P. Relationship between patient-reported disease severity and other clinical outcomes in osteoarthritis: A European perspective. *Journal of Medical Economics*. 2011; 14:381-389.

Strand V, Cryer B, Luo X, Bushmakin AG, Cappelleri JC, Cuffel B, Sands G, Assaf AR. Effect of blood loss on physical function in arthritis patients: A pooled analysis. *Health Outcomes Research in Medicine*. 2011; 2:e27-e38.

Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG. Changes in health-related quality of life with smoking cessation treatment. *European Journal of Public Health*. 2010; 22:224-229.

Sadosky A, Bushmakin AG, Cappelleri JC, Lionberger DR. Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity. *Arthritis Research and Therapy*. 2010; 12:R162.

Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon-alfa in a phase III trial: final results and geographical analysis. *British Journal of Cancer*. 2010; 102:658-664.

Cappelleri JC, Stecher VJ. Analysis of dyadic data: A guideline applied to erectile dysfunction. *Journal of Evaluation in Clinical Practice*. 2010; 16:1340-1344.

Althof SE, Berner MM, Goldstein I, Claes HIM, Cappelleri JC, Bushmakin AG, Symonds T, Schetzler G. Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology. *Journal of Sexual Medicine*. 2010; 7:3170-3178.

Bennett RM, Russell IJ, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Identification of symptom and functional domains that fibromyalgia patients would like to see improved: A cluster analysis. *BMC Musculoskeletal Disorders*. 2010; 11:134. Electronic (online) open access.

Claes HIM, Goldstein I, Althof SE, Berner M, Cappelleri JC, Bushmakin AG, Symonds T, Schnetzler G. Understanding the effects of sildenafil treatment on erection maintenance and erection hardness. *Journal of Sexual Medicine*. 2010; 7:2184-2191. (Abridged version in UroToday.com in Beyond the Abstract, accessed September 30, 2010.)

Logman JFS, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout BA. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. *Current Medical Research and Opinion*. 2010; 26:1565-1578.

Bollu V, Bushmakin AG, Cappelleri JC, Chen C-C, Feltner D, Wittchen H-U. Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. *European Journal of Psychiatry*. 2010; 24:18-27.

Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimally clinically important difference in the Fibromyalgia Impact Questionnaire (FIQ). *The Journal of Rheumatology*. 2009; 36:1304-1311.

Cappelleri JC, Bushmakin AG, Gerber RA, Kline Leidy N, Sexton CC, Lowe MR, Karlsson J. Psychometric analysis of the Three-Factor Eating Questionnaire-R21: Results from a large diverse sample of obese and non-obese subjects. *International Journal of Obesity*. 2009; 33:611-620.

Cappelleri JC, Bushmakin AG, Gerber RA, Kline Leidy N, Sexton CC, Karlsson J, Lowe MR, Evaluating the Power of Food Scale in obese subjects and a general sample of individuals: Development and measurement properties. *International Journal of Obesity*. 2009; 33:913-922.

Baker WL, White CM, Cappelleri JC, Coleman CI. A clinical perspective on the use of meta-regression in systematic reviews: Caveats and cautions. *International Journal of Clinical Practice*. 2009; 63:1426-1434.

Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Pain responder analysis: Use of area under the curve to enhance interpretation of clinical trial results. *Pain Practice*. 2009; 9:348-353.

Cappelleri JC, Bushmakin AG, McDermott A, Dukes E, Sadosky A, Petrie CD, Martin S. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. *Sleep Medicine*. 2009; 10:766-770.

Luo X, Cappelleri JC, Cella D, Li JZ, Charbonneau C, Kim ST, Chen I, Motzer RJ. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms. *Value in Health*. 2009; 12:580-586.

Ting N, Cappelleri JC, Bushmakin AG. Two confidence interval approaches on the dependability coefficients in a two-factor crossed design. *Journal of Biopharmaceutical Statistics*. 2009; 19:610-624.

Cappelleri JC, Bushmakin AG, McDermott AM, Sadosky AB, Petrie CD, Martin S. Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia. *Health and Quality of Life Outcomes*. 2009; 7:54. 17 June 2009. Electronic (online) open access.

Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, Whalen E, Barrett JA, Sadosky A. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. *Sleep Medicine*. 2009; 10:604-610.

Cella D, Cappelleri JC, Bushmakin A, Charbonneau C, Li JZ, Kim ST, Chen I, Michaelson MD, Motzer RJ. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib vs. interferon-alfa. *Journal of Oncology Practice*. 2009; 5:66-70.

Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): A new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. *CNS Neuroscience & Therapeutics*. 2009; 15:12-18.

Cappelleri JC, Bushmakin AG, Symonds T, Schnetzler G. Scoring Correspondence in Outcomes Related to Erectile Dysfunction Treatment on a 4-Point Scale (SCORE-4). *Journal of Sexual Medicine*. 2009; 9:809-819.

Gilbert C, Brown MCJ, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. *Chest*. 2009; 135:137-142.

Morlock RJ, Williams VSL, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and validation of the Daily Assessment of Symptoms-Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. *Journal of Psychiatric Research*. 2008; 42:1024-1036.

Lenderking WR, Hu M, Tennen H, Cappelleri JC, Petrie CD, Rush AJ. Daily process methodology for measuring earlier antidepressant response. *Contemporary Clinical Trials*. 2008; 29:867-877.

Luo X, Cappelleri JC. A practical guide on interpreting and evaluating patient-reported outcomes in clinical trials. *Clinical Research and Regulatory Affairs*. 2008; 25:197-211.

Cappelleri JC, Gerber RA, Quattrin T, Deutschmann R, Luo X, Arbuckle R, Abetz L. Development and validation of the WELL-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE). *Health and Quality of Life Outcomes*. 2008; 6:3. 18 January 2008. Electronic (online) open access.

Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: Results from a phase II study of axitinib. *Acta Oncologica*. 2008; 47:843-851.

Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. The Erection Hardness Score and its relationship to successful sexual intercourse. *Journal of Sexual Medicine*. 2008; 5:2374-2380.

Gerber RA, Cappelleri JC. Patient Satisfaction with Insulin Therapy (PSIT) Questionnaire. PRO Newsletter. 2008; 40 (fall issue):11-13.

West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology. 2008; 197:371-377.

Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Michaelson MD, Motzer RJ. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon-alfa: Results from a phase III randomized trial. Journal of Clinical Oncology. 2008; 26:3763-3769.

Cappelleri JC, Stecher VJ. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective. International Journal of Impotence Research. 2008; 20:343-357.

Mulhall JP, King R, Kirby M, Hvidsten K, Symonds T, Bushmakin AG, Cappelleri JC. Evaluating the sexual experience in men: Validation of the Sexual Experience Questionnaire. Journal of Sexual Medicine. 2008; 5:365-376.

Messerli FH, Pinto L, Tang SSK, Thakker KM, Cappelleri JC, Sichrovsky T, Dubois RW. Impact of systemic hypertension on the cardiovascular benefits of statin therapy – A meta-analysis. American Journal of Cardiology 2008; 101:319-325.

Cappelleri JC, Althof SE, O'Leary MP, Tseng L-J, on behalf of the US and International SEAR Study Group. Analysis of single items on the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: Results of two double-blind placebo-controlled trials. BJU International. 2007; 101:861-866.

Cappelleri JC, Althof SE, O'Leary MP, Glina S, King R, Stecher VJ, Carlsson M, Siegel RL. Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction. Quality of Life Research. 2007; 16:1203-1210.

Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcomes: Conceptual issues. Value in Health. 2007; 10 (Supplement 2):S66-S75.

Mulhall JO, Goldstein I, Bushmakin A, Cappelleri JC, Hvidsten K. Validation of the Erectile Hardness Score. Journal of Sexual Medicine. 2007; 4:1626-1634.

Cappelleri JC, Symonds T. The Self-Esteem And Relationship questionnaire: An overview. PRO Newsletter. 2007; 38 (fall issue):19-22.

Frost M, Bonomi AE, Cappelleri JC, Schünemann HJ, Moynihan TJ, Aaronson N and the Clinical Significance Consensus Meeting Group. Applying quality-of-life data formally and systematically into clinical practice. Mayo Clinic Proceedings. 2007; 82:1214-1228.

Hu M, Cappelleri JC, Lan KKG. Applying the law of iterated logarithm to control type 1 error in cumulative meta-analysis of binary outcomes. Clinical Trials. 2007; 4:329-340.

Luo X, Doherty J, Cappelleri JC, Frush K. Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics. Current Medical Research and Opinion. 2007; 23:2607-2615.

Cappelleri JC, Bell SS, Siegel RL. Interpretation of a self-esteem subscale for erectile dysfunction by cumulative logit model. Drug Information Journal. 2007; 41:723-732.

Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Multivariate framework of the Brief Questionnaire of Smoking Urges. Drug and Alcohol Dependence. 2007; 90:234-242.

Thompson JR, Cappelleri JC, Getter C, Pleil A, Reichel M, Wolf S. Enhanced interpretation of instrument scales using the Rasch model. Drug Information Journal. 2007; 41:541-550.

Cappelleri JC, Hvidsten K. Pfizer's commitment to patient-reported outcomes: Treating to a goal that is meaningful for your patient. Journal of Sexual Medicine. March issue, 2007. Journal outsert for promotional and educational use.

Luo X, Cappelleri JC, Frush K. A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics. Current Medical Research and Opinion. 2007; 23:1015-1024.

Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the Modified Cigarette Evaluation Questionnaire. Addictive Behaviors. 2007; 32:912-923.

Gilder K, Ting N, Tian L, Cappelleri JC, Hanumara RC. Confidence intervals on intraclass correlation coefficients in a balanced two-factor random design. Journal of Statistical Planning and Inference. 2007; 137:1199-1212.

Althof SE, O'Leary MP, Cappelleri JC, Crowley AR, Tseng L-J, Collins S. Impact of erectile dysfunction on confidence, self-esteem, and relationship satisfaction after 9 Months of sildenafil citrate. *Journal of Urology*. 2006; 176:2132-2137.

Althof SE, O'Leary MP, Cappelleri JC, Glina S, King R, Tseng L-J, Bowler JL, on behalf of the SEAR Study Group. Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction. *Journal of General Internal Medicine*. 2006; 21:1069-1074.

Althof SE, O'Leary MP, Cappelleri JC, Hvidsten K, Stecher VJ, Glina S, King R, RL Siegel on behalf of the International SEAR Study Group. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. *Journal of Sexual Medicine*. 2006; 3:521-529.

Mackey WC, Fleisher LA, Haider S, Sheikh S, Cappelleri JC, Lee WC, Wang Q, Stephens JM. Perioperative myocardial ischemic injury in high risk vascular surgery patients: Incidence and clinical significance in a prospective clinical trial. *Journal of Vascular Surgery*. 2006; 43:533-538.

O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, and Duttagupta S on behalf of the US SEAR Study Group. Self-esteem, confidence, and relationship satisfaction in men with erectile dysfunction treated with sildenafil citrate: A multicenter, randomized, parallel-group, double-blind, placebo-controlled study in the United States. *Journal of Urology*. 2006; 175:1058-1062.

Cappelleri JC, Bell SS, Althof SE, Siegel RL, Stecher VJ. Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem And Relationship questionnaire. *Journal of Sexual Medicine*. 2006; 3:274-282.

Cappelleri JC, Althof SE, Siegel RL, Stecher VJ, Tseng L-J, Duttagupta S. Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem And Relationship questionnaire following treatment with sildenafil citrate for men with erectile dysfunction. *Value in Health*. 2005; 8(Supplement 1):S54-S60.

Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among outpatient pharmacy consumers. *Value in Health*. 2005; 8(Supplement 1):S9-S24.

Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *International Journal of Impotence Research*. 2005; 17:307-319.

Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. *Current Medical Research and Opinion*. 2005; 21:749-760.

Tian L, Cappelleri JC. A new approach for interval estimation and hypothesis testing of a certain intraclass correlation coefficient: the generalized variable method. *Statistics in Medicine*. 2004; 23:2125-2135.

Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. *Diabetes Care*. 2004; 27:1318-1323.

Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. *International Journal of Impotence Research*. 2004; 16:30-38.

Lan KKG, Hu M, Cappelleri JC. Applying the law of iterated logarithm to cumulative meta-analysis of a continuous endpoint. *Statistica Sinica*. 2003; 13:1135-1145.

Rosen RC, Cappelleri JC, Quirk F, Duttagupta S, Symond T, Althof S. Pfizer's role in the development of research tools for sexual medicine. *International Journal of Impotence Research*. 2003; 15(3): Invited journal insert in August issue for promotional and educational use.

Cappelleri JC, Ting N. A modified large-sample approach to approximate interval estimation for a particular intraclass correlation coefficient. *Statistics in Medicine*. 2002; 22:1861-1877.

Althof SE, Cappelleri JC, Shpilsky A, Stecher V, Diuguid C, Sweeney M, Duttagupta S. Treatment responsiveness of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. *Urology*. 2003; 61:888-893.

Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): A state-of-the-science review. *International Journal of Impotence Research*. 2002; 14:226-244.

Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C, and the Clinical Significance Consensus Meeting Group. Assessing the clinical significance of single items relative to summated scores. *Mayo Clinic Proceedings*. 2002; 77:488-494.

Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. *Clinical Therapeutics*. 2002; 24:552- 564.

Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life – PhRMA Health Outcomes Committee Workshop, 1999. *Value in Health*. 2002; 5:14-25.

Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the Behavioural Activity Rating Scale (BARS)<sup>TM</sup>: A novel measure of activity in agitated patients. *Journal of Psychiatric Research*. 2002; 36:87-95.

Snyder PJ, Cappelleri JC, Archibald CJ, Fisk JD. Improved detection of differential information processing speed deficits between two disease-course types of multiple sclerosis. *Neuropsychology*. 2001; 15:617-625.

Cappelleri JC, Siegel RL, Glasser DB, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the Sexual Health Inventory for Men. *Clinical Therapeutics*. 2001; 23:1707-1719.

Cappelleri JC. A brief introduction to meta-analysis. *ISPOR News*. 2001; 7:8-9 (August 15).

Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: A randomized controlled trial. *Diabetes Care*. 2001; 24:1556-1559.

Snyder PJ, Cappelleri JC. Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. *Brain and Cognition*. 2001; 46:279-284.

Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. *Diabetes Care*. 2000; 23:1799-1803.

Jovell A, Cappelleri JC. Evidence of the therapeutic effect of antihypertensive therapy: meta-analysis and meta-regression of randomized and controlled trials [Spanish]. *Medicina Clinica*. 2000; 114 (Suppl 2):28-33.

Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the International Index of Erectile Function. *Urology*. 2000; 56:477-481.

Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. *International Journal of Impotence Research*. 1999; 11:319-326.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. *American Journal of Psychiatry*. 1999; 156:1686-1696.

Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. *Urology*. 1999; 54:346-351.

Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden P, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. *Journal of Clinical Psychiatry*. 1999; 60:215-220.

Cappelleri JC, Yuh L. Opportunities and challenges for industry and FDA. *Biopharmaceutical Report*. 1999; 7(1):1-12.

Cappelleri JC, Rosen RC, Smith MD, Quirk F, Maytom MC, Mishra A, Osterloh IH. Some developments on the International Index of Erectile Function (IIEF). *Drug Information Journal*. 1999; 33:179-190.

Cappelleri JC. Guest editor's note: Randomized controlled trials and outcomes research. *Drug Information Journal*. 1999; 33:177-178.

Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. *Statistics in Medicine*. 1998; 17:1923-1942.

Ioannidis JPA, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. *Journal of the American Medical Association (JAMA)*. 1998; 279:1089-1093.

Bonis PAL, Ioannidis JPA, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to alpha interferon with histological improvement in hepatitis C: A metaanalysis of diagnostic test characteristics. *Hepatology*. 1997; 26:1035-1044.

Ioannidis JPA, Sacks HS, Cappelleri JC, Lau J. Clinical efficacy antiretrovirals changes in treatment-experienced HIV-infected patients: A metaanalysis. *Online Journal of Current Clinical Trials*. 1997 May 15; (Doc. No. 204). Electronic (online) open access.

Ioannidis JPA, Cappelleri JC, Melville B, Sacks HS, Lau J. The relationship between study design, results and reporting of randomized clinical trials of HIV infection. *Controlled Clinical Trials*. 1997; 18:431-444.

Cook JA, Razzano L, Cappelleri JC. Canonical correlation analysis of residential and vocational outcomes following psychiatric rehabilitation. *Evaluation and Program Planning*. 1996; 19:351-363.

Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on population diversity in clinical trials: An example from trials of human immunodeficiency virus infection. *American Journal of Epidemiology*. 1996; 144:1074-85.

Cappelleri JC, Ioannidis JPA, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J. Large trials vs meta-analysis of smaller trials: How do their results compare? *Journal of the American Medical Association (JAMA)*. 1996; 276:1332-1338.

Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: A mathematical model. *AIDS*. 1996; 10:255-262.

Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. *BMJ*. 1996; 312:338-45.

Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of pneumocystis carinii prophylactic regimens. *Archives of Internal Medicine*. 1996; 156:177-188.

Cappelleri JC, Trochim WMK. Ethical and scientific features of cutoff-based designs. *Medical Decision Making*. 1995; 15:387-394.

Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of anticoagulant and antiplatelet therapy versus anticoagulant therapy after heart valve replacement: A meta-analysis. *American Heart Journal*. 1995; 130:547-52.

Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, Sacks HS. Early or deferred zidovudine in HIV-infected patients without an AIDS-defining illness. A meta-analysis. *Annals of Internal Medicine*. 1995; 122:856-866.

Cappelleri JC, Lau J, Kupelnick B, Chalmers TC. Efficacy and safety of different aspirin dosages on vascular diseases: A metaregression analysis. *Online Journal of Current Clinical Trials*. 1995; Mar 14 (Doc. No. 174). Electronic (online) open access.

Reichardt CS, Trochim WMK, Cappelleri JC. Reports of the death of the regression-discontinuity design are greatly exaggerated. *Evaluation Review*. 1995; 19:39-63.

Cappelleri JC, Trochim WMK. An illustrative statistical analysis of cutoff-based randomized clinical trials. *Journal of Clinical Epidemiology*. 1994; 47:261-270.

Cappelleri JC, Darlington RB, Trochim WMK. Power analysis of cutoff-based randomized clinical trials. *Evaluation Review*. 1994; 18:141-152.

Cappelleri JC, Eckenrode J, Powers J. The epidemiology of child abuse: Findings from the second national incidence and prevalence study of child abuse and neglect. *American Journal of Public Health*. 1993; 83:1622-1624.

Trochim WMK, Cappelleri JC. Cutoff assignment strategies for enhancing randomized clinical trials. *Controlled Clinical Trials*. 1992; 13:190-212.

Trochim WMK, Cappelleri JC, Reichardt CS. Random measurement error does not bias the treatment effect estimate in the regression-discontinuity design: II. When an interaction effect is present. *Evaluation Review*. 1991; 15:571-604.

Cappelleri JC, Trochim WMK, Stanley TD, Reichardt CS. Random measurement error does not bias the treatment effect estimate in the regression-discontinuity design: I. The case of no interaction. *Evaluation Review*. 1991; 15:395-419.

Buchanan RJ, Cappelleri JC, Ohsfeldt RL. The social environment and Medicaid expenditures: Factors influencing the level of state Medicaid spending. *Public Administration Review*. 1991; 51:67-73.

Cappelleri JC. Cable TV and reading. *New York Statistician*. 1988; 40(2):3.

Cappelleri JC. Classifying methodological and conceptual problems in health statistics. *New York Statistician*. 1987; 39(2):2-3.

Cappelleri JC. Faulty probabilistic interpretation in clinical medicine. *New York Statistician*. 1987; 38(5):2-3.

Cappelleri JC, Rosen HM. An inappropriate mortality rate model. *New York Statistician*. 1987; 38(3):1-2.

### **Selected Consensus Meeting Groups**

Sloan JA, Halyard MY, Frost MH, Dueck AC, Teschendorf B, Rothman ML, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug

Administration guidance on patient-reported outcomes. *Value in Health*. 2007; 10(Supplement 2):S59-S63.

Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcomes instruction selection: Designing a measurement strategy. *Value in Health*. 2007; 10(Supplement 2):S76-S85.

Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcomes: Instrument development and selection issues. *Value in Health*. 2007; 10(Supplement 2):S86-S93.

Frost MH, Reeve BB, Liepa AM, Reeve BB, Stauffer JW, Hays RD, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. What is sufficient evidence for the reliability and validity of patient-reported outcomes? *Value in Health*. 2007; 10(Supplement 2):S94-S105.

Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Analysis and interpretation of results results based on patient-reported outcomes. *Value in Health*. 2007; 10(Supplement 2):S106-S115.

Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santanello NC, the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Interpreting and reporting results based on patient-reported outcomes. *Value in Health*. 2007; 10(Supplement 2):S116-S124.

Guyatt GH, Ferrans CE, Halyard MY, Revicki DA, Symonds TL, Varicchio CG, Kotzera A, Valderas JM, Alonso JL, and the Clinical Significance Consensus Meeting Group. Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. *Mayo Clinic Proceedings*. 2007; 82:1229-1239.

Hahn EA, Cella D, Chassany O, Fairclough DL, Wong GY, Hays RD, and the Clinical Significance Consensus Meeting Group. Precision of health-related quality-of-life data compared with other clinical measures. *Mayo Clinic Proceedings*. 2007; 82:1244-1254.

Sloan J, Frost M, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D for the Clinical Significance Consensus Meeting Group. The clinical significance of quality of life assessments in oncology: A summary for clinicians. *Supportive Care in Cancer*. 2006; 14:988-998.

Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T & The Clinical Significance Consensus Meeting Group. Estimating clinically significant differences in quality of life outcomes. *Quality of Life Research*. 2005; 14:285-295.

Sloan JA, Cella D, Frost MH, Guyatt G, and Osoba D, for the Clinical Significance Consensus Meeting Group. Quality of life III: Translating the science of quality-of-life assessment into clinical practice – An example-driven approach for practicing clinicians and clinical researchers. *Clinical Therapeutics*. 2003; 25(Suppl. D):D1-D5.

Guyatt G, Ferrans C, Halyard M, Revicki D, Symonds T, Varricchio C, and Alonso J, for the Clinical Significance Consensus Meeting Group. What is the value added to the clinician of health-related quality-of-life information from clinical research and using QOL measures in clinical practice. *Clinical Therapeutics*. 2003; 25(Suppl D):D6-D7.

Cella D, Chassany O, Fairclough D, Hahn EA, Hays RD, and Wong G, for the Clinical Significance Consensus Meeting Group. A guide for clinicians to compare the accuracy and precision of health-related quality-of-life data relative to other clinical measures. *Clinical Therapeutics*. 2003; 25(Suppl D):D7-D8.

Osoba D, Sprangers M, Wyrwich K, Patrick D, Gorkin L, and Richardson III J, for the Clinical Significance Consensus Meeting Group. The use of health-related quality-of-life data to support medical decision making. *Clinical Therapeutics*. 2003; 25(Suppl D):D8.

Sloan JA, Moinpour C, Berzon R, Bullinger M, Barofsky I, and Wu AW, for the Clinical Significance Consensus Meeting Group. The costs of incorporating quality-of-life assessments into clinical practice and research: What resources are required? *Clinical Therapeutics*. 2003; 25(Suppl D):D9.

Frost MH, Bonomi AA, Cappelleri JC, Schunemann H, Moynihan T, and Aaronson N, for the Clinical Significance Consensus Meeting Group. Applying quality-of-life data formally and systematically into clinical practice. *Clinical Therapeutics*. 2003; 25(Suppl D):D10.

Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T, and the Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. *Mayo Clinic Proceedings*. 2002; 77:367-370.

Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, and the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. *Mayo Clinic Proceedings*. 2002; 77:371-383.

Cella D, Bullinger M, Scott C, Barofsky I, and the Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. *Mayo Clinic Proceedings*. 2002; 77:384-392.

Frost MH, Bonomi AE, Ferrans CE, Wong GY, Hays RD, and the Clinical Significance Consensus Meeting Group. Patient, clinician and population perspectives on determining the clinical significance of quality of life scores. Mayo Clinic Proceedings. 2002; 77:488-494.

Sprangers MAG, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA, and the Clinical Significance Consensus Meeting Group. Assessing meaningful change over time in quality of life: A users' guide for clinicians. Mayo Clinic Proceedings. 2002. 77:561-571.

Symonds T, Berzon R, Marquis P, Rummans T, and the Clinical Significance Consensus Meeting Group. The clinical significance of QOL results: Practical considerations for specific audiences. Mayo Clinic Proceedings. 2002. 77:572-583.

## Letters to the Editor

Fahrbach K, Cichewicz A, Chu H, Di Fusco M, Burnett H, Volkman HR, Morodoluwa A-F, Mendoza CF, Cappelleri JC. Reply to Letter to Editor "Comparative effectiveness of Omicron XBB.1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis." Expert Review of Vaccines. In press.

<https://doi.org/10.1080/14760584.2025.2554690>.

Volkman HR, Lopez SMC, Moran MM, Chu H, Cappelleri JC, Nguyen JL, McLaughlin JM, Cane AD. A letter to the editor in response to: Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults. Current Medical Research and Opinion. 2025; 41:917-919.

<https://doi.org/10.1080/03007995.2025.2502123>.

Bachelez H, Griffiths CEM, Papp KA, Hall S, Merola JF, Feldman SR, Khraishi M, Tan H, Fallon L, Cappelleri JC, Bushmakina AG, Young P. Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology. 2024; 38:e557-e561. <https://doi.org/10.1111/jdv.19701>.

Cappelleri JC. Further reduction in statistical power for responder analysis of patient-reported outcomes with measurement error. Journal of Clinical Epidemiology. 2021; 140:200-201. <https://doi.org/10.1016/j.jclinepi.2021.08.017>.

Woolcott J, Cappelleri JC, Sharma P, Modesto I. Comment on "Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases." Advances in Therapy. Published online (open access) March 17, 2020.

Coelho T, Cappelleri JC, Stewart M, Vidot S, Huertas. PE. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. *Neurology*. Published online (open access) July 10, 2013.

Sobel RE, Cappelleri JC. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction: reply from Pfizer. *British Journal of Ophthalmology*. 2006; 90:927.

Cappelleri JC, Rosen RC. A comparison of the International Index of Erectile Function and erectile dysfunction studies: reply to Kassouf and Carrie. *BJU International*. 2003; 92:654.

Rosen RC, Cappelleri JC. Correspondence. The sexual health inventory for men (IIEF-5): Reply to Vroege. *International Journal of Impotence Research*. 2000; 12:342-343.

Cappelleri JC, Rosen RC. Correspondence. The sexual health inventory for men (IIEF-5). *International Journal of Impotence Research*. 1999; 11:353-354.

Ioannidis JPA, Cappelleri JC, Lau J. Correspondence. Comparing results from meta-analyses vs large trials. *Journal of the American Medical Association (JAMA)*. 1998; 280:518-519.

Ioannidis JPA, Cappelleri JC, Lau J. Correspondence. Meta-analyses and large randomized, controlled trials. *New England Journal of Medicine*. 1998; 338:59.

Cappelleri JC, Ioannidis JPA, Schmid CH, Lau J. Correspondence. Large trials versus meta-analysis of smaller trials. *Journal of the American Medical Association (JAMA)*. 1997; 277:377-378.

Cappelleri JC. Correspondence. A personal view of some controversies in allocating treatment to patients in clinical trials. *Statistics in Medicine*. 1996; 15:113-114.

Ioannidis JPA, Cappelleri JC, Lau J. Correspondence. Viral load and response to treatment of HIV. *New England Journal of Medicine*. 1996; 334:1671.

## Conference Proceedings

Roydhouse J, Cappelleri JC, Colantuoni E, Alemayehu D. 2020. Methods to evaluate and correct for bias in patient-reported outcomes in clinical trials: A discussion. In JSM Proceedings, Biopharmaceutical Section. Alexandria, Virginia: American Statistical Association, pp. 7-14.

Cappelleri JC. 2017. Generalizability theory for clinician-rated outcomes. In JSM Proceedings, Biopharmaceutical Section. Alexandria, Virginia: American Statistical Association, pp. 603-613.

Cappelleri JC. Embedding the regression-discontinuity design within the randomized design. In JSM Proceedings, Biopharmaceutical Section. Alexandria, Virginia: American Statistical Association, pp. 290-296.

Schmid CH, Cappelleri JC, Lau J. Bayesian methods to improve sample size approximations. In JSM Proceedings, Biopharmaceutical Section. Alexandria, Virginia: American Statistical Association, pp. 89-94.

Cappelleri JC. Coupling outcome pattern matching and program theory with ordinal categorical methods for the m by 2 ordered contingency table. In: Rinn C. Proceedings of the 1990 Edward Kelly Evaluation Conference. Albany, New York: The Evaluation Consortium at SUNY/Albany; 1990:95-109.

## **Book Reviews**

Abramson JH. Making sense of data: A self-instructional manual on the interpretation of epidemiological data. New York: Oxford University Press. 1988. Reviewed for Evaluation Practice. 1990; 11:63-65.

Agresti A. Analysis of ordinal categorical data. New York: John Wiley & Sons. 1984. Reviewed for the New York Statistician. 1987; 38(3):4-5.

## **Book Chapters**

Ye J, Chen D-G, Zhou W, Deng Q, Cappelleri JC. “Emerging Topics in Dose-Finding and Beyond.” In: Ye J, Chen D-G, Zhou W, Deng Q, Cappelleri JC (editors). Dose Finding and Beyond in Biopharmaceutical Development. Cham, Switzerland: Springer Nature Switzerland AG. 2024, 3-12.

Ren J, Cappelleri JC. “Treatment Effect Estimation Using Observational Cohort and Non-Randomized Trial Dat.” In: Chen D-G (editor), Biostatistics in Biopharmaceutical Research and Development: Clinical Trial Analysis, Volume 2. 2024: Chapter 10, 287-315.

Chen W-H, Cappelleri JC. "Item Response Theory." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: Volume I - IV. 4<sup>th</sup> edition. Boca Raton, Florida: CRC Press/Taylor & Francis Group. 2018: Volume III, 1207-1215.

Dueck AC, Cappelleri JC. "Patient-Reported Outcomes." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: Volume I - IV. 4<sup>th</sup> edition. Boca Raton, Florida: CRC Press/Taylor & Francis Group. 2018: Volume III, 1633-1642.

Cappelleri JC, Gerber RA. "Exploratory Factor Analysis." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: Volume 1 - IV, 4<sup>rd</sup> edition. Boca Raton, Florida: CRC Press/Taylor & Francis Group. 2018: Volume II, 985-991.

Cappelleri, JC, Trochim WMK. "Cutoff Designs." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: Volume I - IV. 4<sup>rd</sup> edition. Boca Raton, Florida: CRC Press/Taylor & Francis Group. 2018: Volume I, 798-804.

Cappelleri JC, Ioannidis JPA, Lau, J. "Meta-Analysis of Therapeutic Trials." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: Volume 1 - IV, 4<sup>rd</sup> edition. Boca Raton, Florida: CRC Press/Taylor & Francis Group. 2018: Volume III, 1362-1376.

Cappelleri JC, Bushmakin AG. "Advancing Interpretation of Patient-Reported Outcomes." In: Peace KE, Chen D-G, Menon S (editors). Biopharmaceutical Applied Statistics Symposium: Biostatistical Analysis of Clinical Trials, Volume 2, Chapter 5. Singapore: Springer Nature Singapore Pte Ltd; 2018: 69-81.

McLeod LD, Fehnel SE, Cappelleri JC. "Patient-Reported Outcome Measures: Development and Psychometric Validation." In: Peace KE, Chen D-G, Menon S (editors). Biopharmaceutical Applied Statistics Symposium: Design of Clinical Trials, Volume 1, Chapter 13. Singapore: Springer Nature Singapore Pte Ltd; 2018: 317-346.

Cappelleri JC, Baker WL. "Network Meta-analysis." In: Peace KE, Chen D-G, Menon S (editors). Biopharmaceutical Applied Statistics Symposium: Biostatistical Analysis of Clinical Trials, Volume 2, Chapter 6. Singapore: Springer Nature Singapore Pte Ltd; 2018: 91-105.

Zou KH, Baker CL, Cappelleri JC, Chambers RB. "Data Sources for Health Economics and Outcomes Research." In: Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press; 2017: 1-13.

Cappelleri JC, Bushmakin AG, Alvir JMJ. "Patient-Reported Outcomes: Development and Validation." In: Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in

Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press; 2017: 15-46.

Alemayehu D, Bushmakin AG, Cappelleri JC. "Analysis of Aggregate Data." In: Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press; 2017: 123-149.

Alemayehu D, Cappelleri JC, Emir B, Sollano J. "Health Economics and Outcomes Research in Precision Medicine." In: Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press; 2017: 151-175.

Zou KH, Cappelleri JC, Baker CL, Yan EC. "Best Practices for Conducting and Reporting Health Economics and Outcomes Research." In: Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press; 2017: 177-183.

Cappelleri JC, Bushmakin AG. "Measurement of Patient-Reported Outcomes of Health Services." In: Sobolev B and Gatsonis C (editors), Methods in Health Services Research, Part of the series Health Services Research. New York, NY: Springer Science+Business Media LLC. 2017:1-21. Online access. DOI:10.1007/978-1-4939-6704-9\_10-1.

Baker WL, Bennetts M, Coleman CI, Cappelleri JC. "Appraising Evidence." In: Biondi-Zocca G (editor), Umbrella Reviews: Evidence Synthesis with Overviews of Reviews and Meta-Epidemiologic Studies. Switzerland: Springer International Publishing; 2016: 115-136.

Cappelleri JC, Ting N. "Evaluation of a Confidence Interval Approach for Relative Agreement in a Crossed Three-way Random Effects Model." In: Chen Z, Liu A, Qu Y, Tang L, Ting N and Tsong Y (editors), Applied Statistics in Biomedicine and Clinical Trials Design: Selected Papers from 2013 ICSA/ISBS Joint Statistical Meetings. Switzerland: Springer International Publishing; 2015: 381-392.

Cappelleri JC, Trochim WM. "Regression Discontinuity Design." In: Wright JD (editor), The International Encyclopedia of Social & Behavioral Sciences, 2<sup>nd</sup> edition, Volume 20. Oxford, United Kingdom: Elsevier Ltd.; 2015: 152-159.

Snedecor SJ, Patel DA, Cappelleri JC. "From Pairwise to Network Meta-Analyses." In: Biando-Zocca G (editor), Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison. New York, NY: Nova Science Publishers; 2014: 21-41.

Alemayehu D, Cappelleri JC. "Patient-reported Outcomes in Personalized Medicine." In: Carini C, Menon SM, Chang M (editors). Clinical and Statistical Considerations in Personalized Medicine. Boca Raton, Florida: Chapman & Hall/CRC Press; 2014: 297-312.

Cappelleri JC, Bushmakin AG, Sadosky AB, Lionberger DR. "Health Status and Patient-Reported Osteoarthritis Severity in Clinical Practice." In: Abdel-Rahman EMO and Balogun RA (editors), Functional Impairment: Management, Types and Challenges. Hauppauge, New York: Nova Science Publishers; 2012: 15-27.

Cappelleri JC, Gerber RA. "Exploratory Factor Analysis." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 3<sup>rd</sup> edition, Revised and Expanded. New York, NY: Informa Healthcare; 2010: 480-485.

Cappelleri JC, Ioannidis JPA, Lau, J. "Meta-Analysis of Therapeutic Trials." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 3<sup>rd</sup> edition, Revised and Expanded. New York, NY: Informa Healthcare; 2010: 768-779.

Cappelleri, JC, Trochim WMK. "Cutoff Designs." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 3<sup>rd</sup> edition, Revised and Expanded. New York, NY: Informa Healthcare; 2010: 386-391.

Copley-Merriman K, Jackson J, Boyer JG, Cappelleri JC, DeMarinis R, DiCesare J, Erder MH, Gagnon JP, Garrison L, Gondek K, Heithoff KA, Hughes T, Miller D, Rothman M, Santanello N, Willke R, Wong B. "Industry Perspective Regarding Outcomes Research in Oncology." In: Lipscomb J, Gotay CC, Snyder C (editors), Outcomes Assessment in Cancer: Measures, Methods, and Applications. New York, NY: Cambridge University Press; 2005: 623-638.

Schmid CH, Cappelleri JC, Lau J. "Bayesian Methods to Improve Sample Size Approximations." In: Brand L, Johnson ML (editors), Methods of Enzymology 3 (volume 383): Numerical Computer Methods, Part D. San Diego, California: Elsevier Inc.; 2004: 406-427 (Chapter 17).

Cappelleri JC. "Pharmacoepidemiology" and "Responsiveness." In: Berger ML, Binge fors K, Hedblom EC, Pashos CL, Torrance GW (editors). "Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms." Lawrenceville, New Jersey: International Society for Pharmacoeconomics and Outcomes Research; 2003: 182-184, 214-216.

Cappelleri JC, Gerber RA. "Exploratory Factor Analysis." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 2<sup>nd</sup> edition, Revised and Expanded. New York, NY: Marcel Dekker, Inc.; 2003: 343-348.

Cappelleri JC, Ioannidis JPA, Lau, J. "Meta-Analysis of Therapeutic Trials." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 2<sup>nd</sup> edition, Revised and Expanded. New York, NY: Marcel Dekker, Inc.; 2003: 586-598.

Cappelleri, JC, Trochim WMK. "Cutoff Designs." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics: 2<sup>nd</sup> edition, Revised and Expanded. New York, NY: Marcel Dekker, Inc.; 2003: 263-269.

Cappelleri, JC, Ioannidis, JPA, Lau J. "Meta-Analysis of Therapeutic Trials." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics. New York, NY: Marcel Dekker, Inc.; 1999: 307-316.

Cappelleri, J.C., Trochim, WMK. "Cutoff Designs." In: Chow S-C (editor), Encyclopedia of Biopharmaceutical Statistics. New York, NY: Marcel Dekker, Inc.; 1999: 149-156.

Allison DB, Cappelleri JC, Carpenter KM. "Design and Analysis of Obesity Treatment and Prevention Trials." In: Dalton S (editor), Overweight and Weight Management: The Health Professional's Guide to Understanding and Practice. Gaithersburg, Maryland: Aspen Publishers; 1997:557-597.

In: Gujarati DN. Basic Econometrics. 4<sup>th</sup> ed. New York: McGraw-Hill. 2003, p. 592. Results of an unpublished term paper "Predicting a bond rating: An approach revisited."

In: Berenson ML, Levine DM. Basic Business Statistics: Concepts and Applications. 3rd ed. Englewood Cliffs, New Jersey: Prentice Hall. 1987, Chapter 18. Solutions to problem sets in Chapter 18, "Index Numbers, Time Series, and Business Forecasting."

## Books

Ye J, Chen D-G, Zhou W, Deng Q, Cappelleri JC (editors). Dose Finding and Beyond in Biopharmaceutical Development. Cham, Switzerland: Springer Nature Switzerland AG. 2024.

Bushmakin AG, Cappelleri JC. A Practical Approach to Quantitative Validation of Patient-Reported Outcomes: A Simulation-based Guide Using SAS. Hoboken, New Jersey: John Wiley & Sons. 2022.

Ting N, Cappelleri JC, Ho S, Chen D-G (editors). Design and Analysis of Subgroups with Biopharmaceutical Applications. Cham, Switzerland: Springer Nature Switzerland AG. 2020.

Alemayehu D, Cappelleri JC, Emir B, Zou KH (editors). Statistical Topics in Health Economics and Outcomes Research. Boca Raton, Florida: Chapman & Hall/CRC Press. 2017.

Ting N, Ho S, Chen D-G, Cappelleri JC. Phase II Clinical Development of New Drugs. Singapore: Springer Nature Singapore Pte Ltd. 2017.

Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-Reported Outcomes: Measurement, Implementation and Interpretation. Boca Raton, Florida: Chapman & Hall/CRC Press. 2013.

### **Edited Journal Issues**

Roydhouse J, Camerlingo N, Cappelleri JC (editors). Introduction to the special issue “Advances in statistical methods for the assessment of patient-centered outcomes.” *Journal of Biopharmaceutical Statistics*. In press. <https://doi.org/10.1080/10543406.2025.2472801>

Cappelleri JC, Brinkley J (editors). Special Issue: 12<sup>th</sup> International Conference on Health Policy Statistics, Charleston, South Carolina, USA, 10-12 January 2018. *Health Services and Outcomes Research Methodology*. 2019; 19(1):1-86.

Cappelleri JC, Brinkley J (editors). Special Issue: 12<sup>th</sup> International Conference on Health Policy Statistics, Charleston, South Carolina, USA, 10-12 January 2018. *Health Services and Outcomes Research Methodology*. 2018; 18(4):227-297.

Cappelleri JC (editor). Special Section on Clinical Outcome Assessments. *Therapeutic Innovation & Regulatory Science*. 2016; 50(1):22-43.

Cappelleri JC (editor). Special Section on Clinical Outcome Assessments. *Therapeutic Innovation & Regulatory Science*. 2015; 49(6):783-830.

Cappelleri JC (editor). Randomized Controlled Trials and Outcomes Research. *Drug Information Journal*. 1999; 33(1):177-224.

Colditz GA, Kazda EK, Cappelleri JC (editors). First National Meeting on Research Synthesis: Applications to Drug Regulatory Policy and Health Care Policy. *Clinical Research and Regulatory Affairs*. 1996; 13(1):1-64.

### **User Guides**

Cappelleri JC, Eckenrode J, Powers JL. A User's Guide for the Second National Incidence Study on Child Abuse and Neglect. Ithaca, New York: National Data Archive on Child Abuse and Neglect, Cornell University. 1991.

## Theses

Cutoff-based designs in comparison and combination with randomized clinical trials. Ph.D. Thesis, Cornell University, May 1991.

A survey of strategies for ordinal categorical data analysis. M.S. Thesis, City University of New York (Baruch College), June 1986.

## Selected Published Abstracts (numerous others not shown)

Jairath V, Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, Bartolome L. Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapy. *Journal of Crohn's and Colitis*. 2024; 18(Suppl 1):i1566-i1567.

Kristensen LE, Taylor PC, Navarro-Compán V, Magrey M, Cappelleri JC, Bushmakin AG, Yndestad A, Oluwaseyi Dina O. Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis. *Annals of Rheumatic Disease*. 2022; 81(Suppl 1):1500, AB0750. European League Against Rheumatology (EULAR) abstract accepted in 2022 E-Congress Abstract Book/Publication Only, June 1-4, 2022.

Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merolo JF, Yosipovitch G. Itch as the major mediator of the effect of tofacitinib in health-related quality of life in PsA: a mediation analysis. *Annals of Rheumatic Disease*. 2020; 79(Suppl 1):1723, AB0837. European League Against Rheumatology (EULAR) abstract accepted in 2020 E-Congress Abstract Book/Publication Only, June 3-6, 2020.

Taylor PC, de Vlam K, Bushmakin AG, Fallon L, Merola JF, Cappelleri JC, Hsu M-A, Mease PJ. Identifying mediators of pain reduction with patients with psoriatic arthritis treated with tofacitinib: role of inflammation with peripheral activities, enthesitis and skin disease. *Annals of Rheumatic Disease*. 2020; 79(Suppl 1):1724, AB0838. European League Against Rheumatology (EULAR) abstract accepted in 2020 E-Congress Abstract Book/Publication Only, June 3-6, 2020.

Ogdie A, Schmerold L, Tillets W, Germino R, Cappelleri JC, Young P. Demographic, treatment and disease characteristics of patients with psoriatic arthritis receiving tofacitinib in the United States, France, Germany, Italy, Spain, and the United Kingdom. *Annals of Rheumatic Disease*.

2020; 79(Suppl 1):1707, AB0811. European League Against Rheumatology (EULAR) abstract accepted in 2020 E-Congress Abstract Book/Publication Only, June 3-6, 2020.

Gladman D, Coates L, Wu J, Fallon L, Hsu M-A, Bushmakin AG, Bacci E, Cappelleri JC, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriasis arthritis treated with tofacitinib, adalimumab, or placebo. *Annals of Rheumatic Disease*. 2020; 79(Suppl 1):1685, AB07774. European League Against Rheumatology (EULAR) abstract accepted in 2020 E-Congress Abstract Book/Publication Only, June 3-6, 2020.

Sardesai A, Milev S, Quon P, Peeples-Lamirande K, Salese L, Cappelleri JC, Sharma PP. Treatment cost analysis for patients in the United States with moderately-to-severely active ulcerative colitis who have an inadequate response or who are intolerant to TNF blockers. *Value in Health* 2020; 23(S1):S146. Abstract PCI23.

Tarallo M, Pawar V, Hall J, Bailey H, Bailey A, Foley G, Cappelleri JC. Real world evidence on patient characteristics and frontline treatment patterns in local advanced squamous cell carcinoma of the head and neck from Europe and US. *Value in Health* 2020; 23(S1):S86. Abstract PCN351.

Tarallo M, Pawar V, Hall J, Bailey H, Bailey A, Foley G, Cappelleri J. Treatment outcomes in locally advanced squamous cell carcinoma of head and neck patients who subsequently progress: Realworld evidence from Europe and US. *Value in Health* 2020; 23(S1):S84. Abstract PCN340.

Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille MH, Duh MS, Fakih I, Levenberg M, Cappelleri JC, Sikirica V. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: analysis of a retrospective claims database. *Journal of Managed Care and Specialty Pharmacy* 2020; 26(4-a):S58-9. Abstract L3.

Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Jackson J. Opioid use for the treatment of osteoarthritis among primary care physicians rheumatologists, and orthopedic surgeons. *Postgraduate Medicine* 2019; 131(S1):87.

Mamolo CM, Cappelleri JC, Hoang CJ, Ki, R, Hadfield A, Middleton C, Rider A, Walter RB. Cross-sectional survey of symptoms and health-related quality of life of adults with *de novo* acute myeloid leukemia (AML) in clinical practice. *Blood* 2017; 130:5660.

Cappelleri JC, Bushmakin AG, Whipple S, Hlavacek P, Sadosky A, Willke RJ. Mapping the Western Ontario and McMaster Universities Arthritis Index (WOMAC) to the EQ-5D. *Value in Health* 2016; 19:A235-A236.

Bushmakin AG, Cappelleri JC, Stecher V, Lue TF. Measuring treatment satisfaction in erectile dysfunction: Use of a person-item map. *Value in Health* 2016; 19:A178.

Shelbaya A, Solem CT, Walker C, Wan Y, Johnson C, Cappelleri JC. Clinical and economic burden of early versus late initiation of branded celecoxib among patients with osteoarthritis. *Value in Health* 2016; 19:A239.

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. Characterizing neuropathic pain profiles: Enriching interpretation of painDETECT. *Postgrad Medicine*. 2015; 127 (Suppl 1):S81-82.

Louder A, Singh A, Cappelleri J, Koenig A, Aten A, Saverno K, Pasquale M. Patient preference associated with therapies for rheumatoid arthritis among Humana Medicare members. *Journal of Managed Care & Specialty Pharmacy*. 2015; 21(4-a):S67. Earned platinum award from the Academy of Managed Care Pharmacy.

Sudharshan L, Snedecor SJ, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, Botteman M. Systematic review of pharmacologic therapies for neuropathic pain associated with stroke, HIV, trauma, and multiple sclerosis. *Value in Health*. 2013; 16(3):A113.

Bernabe B, Lasbleiz S, Gerber R, Cappelleri J, Yelnik A, Orcel P, Bardin T, Beaudreuil J. URAM scale for disability assessment in Dupuytren's disease: A comparative study of its properties. *Annals of Physical and Rehabilitation Medicine*. 2012; 55(Suppl1):e65.

Louder AM, Udall M, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy policy restriction for pregabalin on healthcare utilization and expenditures in a commercial population. *Journal of Managed Care Pharmacy*. 2012; 18(7):549.

Cappelleri JC, Hwang L-J, Mardekian J, Mychaskiw MA. Measurement properties of peak VO<sub>2</sub> in children with pulmonary arterial hypertension. *Value in Health*. 2010; 13(7):A367.

Cappelleri JC, Hwang L-J, Mardekian J, Mychaskiw MA. Response profiles of sildenafil citrate on exercise capacity, hemodynamic function, and health-related quality of life in children with pulmonary arterial hypertension. *Value in Health*. 2010; 13(7):A343.

Cappelleri JC, Bushmakin AG, Zeiher, Pauer L, Zlateva G, Sadosky A, Bennett RM. Examining the structure of the Fibromyalgia Impact Questionnaire. *Journal of Pain*. 2010; 11(4):S13.

DiBonaventura MD, Cappelleri JC, Joshi AV. The incremental and extended impact of painful diabetic peripheral neuropathy on health outcomes over time. *Journal of Pain*. 2010; 11(4):S2.

DiBonaventura MD, Cappelleri JC, Joshi AV. The impact of pain severity on healthcare resource use and associated direct costs in patients with painful diabetic peripheral neuropathy. *Journal of Pain*. 2010; 11(4):S22.

DiBonaventura MD, Cappelleri JC, Joshi AV. The relationship between pain severity and health-related quality of life, work productivity, and associated indirect costs in patients with painful diabetic peripheral neuropathy. *Journal of Pain*. 2010; 11(4):S22.

Sadosky AB, Bushmakin AG, Cappelleri JC, Lionberger DR. Relationship of disease severity in osteoarthritis with pain, function, and work productivity. *Journal of Pain*. 2010; 11(4):S4.

Sadosky AB, Bushmakin AG, Cappelleri JC, Lionberger DR. Health status and disease severity in osteoarthritis. *Journal of Pain*. 2010; 11(4):S1.

Treglia M, Mancuso J, Cappelleri JC, Bushmakin AG, Pitman V. A comprehensive paradigm to estimate minimal clinically important differences (MCID). *Value in Health*. 2008; 11:A180.

Cappelleri JC, Nurnberg HG, Tseng L-J, Siegel RL. Efficacy of sildenafil for the treatment of erectile dysfunction in men with depression: Meta-analysis of randomized, double-blind, placebo-controlled trials. *Journal of Sexual Medicine*. 2007; 4(Supplement 1):80.

Nurnberg HG, Siegel RL, Cappelleri JC. Improved depression severity by sildenafil treatment of erectile dysfunction associated with treated or untreated major depressive disorder. *Journal of Sexual Medicine*. 2007; 4 (Supplement 1):92-93.

Cappelleri JC, Nurnberg HG, Tseng L-J, Tellier C, Siegel RL. Efficacy of sildenafil for the treatment of erectile dysfunction in men taking antidepressant medication: Meta-analysis of randomized, double-blind, placebo-controlled studies. *Journal of Andrology*. 2006; March/April Supplement:64.

Cappelleri JC, Glina S, Duttagupta S, Sherman N, Stecher V, Siegel R, Tseng L. Assessing responsiveness of the Self-Esteem And Relationship questionnaire in men with erectile dysfunction treated with Viagra® (sildenafil citrate) in an international, double-blind, placebo-controlled trial. *Medical Decision Making*. 2005; 25(1):E52.

Lee WC, Cappelleri JC, Sheikh S, Haider S, Gold KF, Stephens JM. Using a pattern mixture model to understand the impact of non-random missing data in health-related quality of life among patients undergoing non-cardiac vascular surgery. *Value in Health*. 2004; 7:708.

Takei M, Takamoto H, Glina S, Cappelleri JC, Duttagupta S, Sherman N, Stecher VJ, Siegel R, Tseng L-J. Relationship between erectile functioning and psychosocial functioning following treatment with Viagra® (sildenafil citrate): Results from an international trial. *Quality of Life Research*. 2004; 13:1558.

Cappelleri JC, O'Leary MP, Althof SE, Duttagupta S, Sherman N, Crowley AR, Siegel R, Tseng L-J, Glasser DB. Responsiveness of the Self-Esteem And Relationship questionnaire in men with

erectile dysfunction treated with sildenafil citrate in a double-blind, placebo-controlled trials. *Pharmacoepidemiology and Drug Safety*. 2004; 13:S218.

Lau DT, Cappelleri JC, Morlock R, Feltner D. Comparing psychometric properties of self-versus interview-rated instruments used in clinical trials for patients with anxiety disorders. *Value in Health*. 2004; 7(3):286.

Treglia M, Bushmakin A, Siddiqi S, Cappelleri JC. How cognitive function affects activities of daily living in patients with Alzheimer's Disease. *Value in Health*. 2004; 7(3):288.

Harnett J, Enuha S, Xuan J, Cappelleri J. A meta-analysis of three-day azithromycin therapy versus longer courses of comparator antibiotics in acute sinusitis. *Value in Health*. 2004; 7(3):352.

Cappelleri JC, Gerber RA, Abetz L, Quattrin T. Development and validation of the Children with Diabetes Questionnaire - a questionnaire to assess treatment satisfaction and well-being. *Diabetes* 2003; 52(Suppl 1):1737-P. *Diabetes & Metabolism*. 2003; 29:4S7-4S428.

Lustig SP, Reichel MB, Cappelleri J, Clouse B, Getter CA, Chisholm JA. A baseline assessment of the validity of the 39-item National Eye Institute Visual Function Questionnaire in German patients with age-related macular degeneration. *Value in Health*. 2003; 6(3):240.

Treglia M, Clouse B, Cappelleri J. Assessing behavioral functioning in Alzheimer's Disease: Benchmarking with the BEHAVE-AD-FW. *Value in Health*. 2003; 6(3):281.

Althof SE, Cappelleri JC, Shpilsky AB, Duttagupta S, Stecher VJ, Diuguid C, Sweeney M. Responsiveness of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction (ED). *Quality of Life Research*. 2002; 11(7):664 [Abstract # 171].

Gerber RA, Cappelleri JC, Nadkarni S, Petrie CD, Rosenstock J. Balancing compliance, patient satisfaction and improved glycemic control in patients with type 1 and type 2 diabetes mellitus: long-term studies with inhaled insulin (Exubera). *Diabetologia*. 2002; 45 (Suppl 1):A751.

Cappelleri JC, Gerber RA, Mishra AK. Using the Mann-Whitney statistic to improve the interpretation of ordinal scales: An application to the Patient Satisfaction with Insulin Therapy Questionnaire. *Quality of Life Research*. 2001; 10(3):276 [Abstract # 335].

Lustig SP, Shaw AR, Cappelleri JC, Vazquez-Abad M-D. The WOMAC discriminates between patients with mild and severe osteoarthritis. *Arthritis & Rheumatism*. 2000; 43(9):S110 [Abstract #261].

Woodworth TG, Mackillop N, Edwards M, Vazquez-Abad M-D, Shaw AR, Cappelleri JC, Ting N, Buckland-Wright C, Lustig S. Relationship between changes in joint space width (JSW) and c-reactive protein (CRP), clinical assessments, and health-related quality of life (HRQoL) instruments in mild/moderate osteoarthritis (OA). *Arthritis & Rheumatism*. 2000; 43(9):S222 [Abstract #931].

Cappelleri JC, Selker HP, Schmid CH, Chalmers TC, Lau J. Applying the “real-time meta-analysis system” to randomized control trials of congestive heart failure. *Controlled Clinical Trials*. 1995; 16(3S):62S.

Schmid CH, Cappelleri JC, Lau J. Applying Bayesian meta-regression to studies of thrombolytic therapy. *Clinical Research*. 1994; 42(2):290a.

## **Presentations Personally Delivered**

2025 Real-world evidence to inform regulatory decision making: A scoping review. Invited oral presentation and co-lead at workshop “Strategies to Streamline Collaboration, Accelerate Decision Making & Improve Real-World Evidence Acceptance Across Pharma, Regulators & Payers,” at the 13<sup>th</sup> Annual IMPACCT Real World Evidence Summit, Boston, Massachusetts, October 27-29.

2025 Gift planning basics workshop. Oral presentation at Harvard T.H. Chan School of Public Health, Boston, Massachusetts, September 27.

2025 Why SISAQOL-IMI? Overview, aims and goals. Oral presentation at the Joint Statistical Meetings, Nashville, Tennessee, August 2-7.

2025

2024 Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analyses. Invited oral presentation at the Joint Statistical Meetings, Nashville, Tennessee, August 2-7, 2025; invited oral presentation at the 7<sup>th</sup> International Symposium on Biopharmaceutical Statistics, Baltimore, Maryland, March 6-9, 2024.

2025

2023 Cultivating a career as a statistical collaborator and medical researcher in the pharmaceutical industry. SPAIG lunchtime speaker presentation at the Joint Statistical Meetings, Nashville, Tennessee, August 2-7, 2025; seminar presentation at Brown University, School of Public Health, Providence, Rhode Island, November 6, 2023; virtual webinar presentation at Georgia Southern University, Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, April 10, 2023.

2023-

2025 Advances in interpretation of patient-reported outcomes. Invited 2-hour tutorial session at the UConn Pharma-Stat December Seminar, University of Connecticut, Storrs, Connecticut, December 20, 2025; invited 3-hour tutorial session at the Eightieth (80<sup>th</sup>) Annual Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 8-12, 2025; invited seminar presentation at the University of Pennsylvania, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, Pennsylvania, April 2, 2024; invited 90-minute tutorial at BASS XXX – 30<sup>th</sup> Annual Biopharmaceutical Applied Statistics Symposium. Savannah, Georgia, October 23-25, 2023.

2025 Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: Quality of life, symptoms, and work productivity among US adult outpatients. Invited oral presentation at the 2025 Applied Statistics Symposium, International Chinese Statistical Association, Storrs, Connecticut, June 15-18.

2025 Issues in time to deterioration of symptoms or function of patient-reported outcomes in cancer clinical trials. Invited oral presentation at the 2025 Lifetime Data Science Conference, Brooklyn, New York, May 28-30.

2025 Panel discussion on future research. Invited panelist at the SISAQOL-IMI Consensus Meeting #5, February 5.

2025 Statistical partnerships among academe, industry, and government (SPAIG) award – meet recent winners webinar. Invited panelist. January 16.

2024 How to make patient-reported outcomes more meaningful. Invited guest faculty seminar at HITLAB's Virtual Knowledge Convene, November 4.

2024 Leveraging machine learning methods in HEOR to enhance quality of RWE in healthcare. Invited oral presentation and workshop co-leader at the 12<sup>th</sup> Annual IMPACCT Real World Evidence Summit, Boston, Massachusetts, October 29-31.

2020-

2024 Adjusting for bias in responder analysis of patient-reported outcomes. Invited webinar at the University of Mississippi Medical Center, Department of Data Science, November 7, 2024; American Statistical Association, Biopharmaceutical Section, October 25, 2024; Centers for Disease Control and Prevention (CDC), December 13, 2023; University of Kansas Medical Center, Department of Biostatistics & Data Science, October 21, 2022; 2021 Virtual Annual Meeting of the American Educational Research Association, April 8-12, 2021; Joint Statistical Meetings Virtual Conference, August 2-6, 2020.

2024 Welcome and congratulations to Prof. Nancy Redi. The 30<sup>h</sup> Pfizer/ASA/UConn Distinguished Statistician Colloquium, Storrs, Connecticut, October 2.

2024 Startup symphony: Ventures and innovation in health. Invited panelist at the HITLAB Digital Health Symposium, virtual, August 29.

2024 Anchor-based approaches for patient-reported outcomes. Invited oral presentation at the 4<sup>th</sup> Joint Annual Spring Symposium of the New Jersey and Princeton-Trenton Chapters of the American Statistical Association, Piscataway, New Jersey, June 28.

2024 Panel discussion on patient-reported outcomes (PRO) and related topics in clinical trials. Invited panelist at the 4<sup>th</sup> Joint Annual Spring Symposium of the New Jersey and Princeton-Trenton Chapters of the American Statistical Association, Piscataway, New Jersey, June 28.

2024 Reflective vs. formative measurement models for psychometric validation. Invited oral presentation at the International Chinese Statistical Association (ICSA) 2024 Applied Statistics Symposium, Nashville, Tennessee, June 16-19.

2024 Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research. Virtual ISPOR short course. Recorded May-June 2024. LMS Session Details ([ispor.org](http://ispor.org)).

2024 Patient-focused drug development: Patient-centered outcomes assessment and patient preferences – Discussion. Invited oral presentation at the 7<sup>th</sup> International Symposium on Biopharmaceutical Statistics, Baltimore, Maryland, March 6-9.

2024 How can PROs and HRQoL data inform regulatory decision as well as cover HTA needs. Invited panelist for discussion at the EMA and European Organisation for Research and Treatment of Cancer (EORTC) Workshop: How Can Patient-Reported Outcomes (PRO) and Health-Related Quality of Life (HRQoL) Data Inform Regulatory Decisions? Hybrid meeting -- virtual and Amsterdam, The Netherlands, February 29.

2024 Classical test theory vs. item response theory (IRT). Invited 2-hour virtual lecture for Health Outcomes Assessment Course (PHSR707), University of Maryland, Baltimore, School of Pharmacy, February 14.

2023 The Data Science and Literacy Act (DSLA) of 2023. Invited presentation at NextGen: Data Science Day, Storrs, Connecticut, October 21.

2023 Networking session. Invited panelist at NextGen: Data Science Day, Storrs, Connecticut, October 21.

2023 Using the Rasch model to validate and interpret the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms. Invited oral presentation at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Rockville, Maryland, September 27-29, 2023; invited oral presentation at the 2016 New England Statistics Symposium, New Haven, Connecticut, April 23, 2016; and poster presentation at the 12<sup>th</sup> Annual International Meeting of the International Society for Quality of Life Research, Budapest, Hungary, June 24-26, 2007.

2023 Network and multivariate meta-analysis. Short course at the American Statistical Association, New York City Metro Area Chapter, virtual, September 21-22.

2023 Development and psychometric evaluation of a novel tool for assessing patient perception and preference for haemophilia treatment (HaeomoPREF). Invited presentation at the National Heart, Blood, and Lung Institute (NHBLI) Biostatistics Workshop on Clinical Trial Designs: Innovative Endpoints and Futility Monitoring, National Institutes of Health, Bethesda, Maryland, September 18-19.

2023 Panel discussion, summary & recommendations to NHBLI. Invited panelist at the National Heart, Blood, and Lung Institute (NHBLI) Biostatistics Workshop on Clinical Trial Designs: Innovative Endpoints and Futility Monitoring, National Institutes of Health, Bethesda, Maryland, September 18-19.

2023 Analysis of meaningful within-patient change on patient-reported outcomes: Renewed insights. Oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 5-10.

2023 Triangulation of multiple meaningful change thresholds in clinical outcome assessments. Invited oral presentation at the Drug Information Association (DIA) 2023 Global Annual Meeting, Boston, Massachusetts, June 25-29.

2023 Statistics and data science skills in the real-world: A panel of experienced experts. Invited panelist at the International Chinese Statistical Association (ICSA) 2023 Applied Statistics Symposium, Ann Arbor, Michigan, June 11-14.

2023 Conference banquet: Keynote speech. Invited oral presentation at Dose Finding and Other Topics in Drug Development Honoring Dr. Naitee Ting's 70<sup>th</sup> Birthday, Storrs, Connecticut, and virtual, June 7-9.

2023 Panel on mentoring and career events. Invited oral presentation at Dose Finding and Other Topics in Drug Development Honoring Dr. Naitee Ting's 70<sup>th</sup> Birthday, Storrs, Connecticut, and virtual, June 7-9.

2023 Keynote session: Opening remarks. Invited oral presentation at Dose Finding and Other Topics in Drug Development Honoring Dr. Naitee Ting's 70<sup>th</sup> Birthday, Storrs, Connecticut, and virtual, June 7-9.

2023 Assessing the impact of COVID-19 and the effects of COVID-19 vaccination on patient-reported outcomes: Findings from a nationwide retail pharmacy test database. Invited oral presentation and educational symposium at ISPOR 2023, Boston, Massachusetts, May 7-10.

2022-

2023 International standards in analyzing patient-reported outcomes and quality of life endpoints data (SISAQOL) consortium: An update. Invited oral presentation at the International Chinese Statistical Association (ICSA) 2023 Applied Statistics Symposium, Ann Arbor, Michigan, June 11-14, 2023; oral presentation at panel session at the Joint Statistical Meetings, Washington, D.C., August 6-11, 2022.

2018-2019

2022-2023

Statistical topics in health economics and outcomes research: Patient-reported outcomes, meta-analysis, and health economics. Half-day short course at Dose Finding and Other Topics in Drug Development Honoring Dr. Naitee Ting's 70<sup>th</sup> Birthday, Storrs, Connecticut, and virtual, June 7-9, 2023; the American Statistical Association's New York City Metro Area Chapter, virtual, March 3, 2023; 78<sup>th</sup> Annual Deming Conference on Applied Statistics, Philadelphia, Pennsylvania, December 4-9, 2022; 35<sup>th</sup> New England Statistics Symposium, Storrs, Connecticut, and virtual, May 22-25, 2022; 75<sup>th</sup> Annual Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 2-6, 2019; 74<sup>th</sup> Annual Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 3-7, 2018; International Chinese Statistical Association 2018 Applied Statistics Symposium, New Brunswick, New Jersey, June 14-17, 2018.

2022 From meaningful outcomes to meaningful change thresholds: Path to progress for establishing digital endpoints. Invited oral presentation and panelist at A Joint DIA Webinar: Digital Technology and Meaningful Change, December 8.

2022 Use of retrospective claims data for cost-effectiveness analysis (CEA): Illustrative case studies. Invited oral virtual presentation at the China CCFDIE RWE Meeting, December 7-8.

2022 Use decentralized clinical trials to digitally enhance your patient engagement. Invited panel discussion at Reuters Events, exclusive webinar, December 1.

2022 Ways for statisticians and data scientists to thrive in the pharmaceutical industry. Invited panel session on Careers in Data Science at NESS-NextGen Data Science Day, November 12.

2022 Career panel on pharmaceuticals. Invited panelist at A Special Conference Celebrating UConn Department of Statistics 60<sup>th</sup> Anniversary, Storrs, Connecticut, October 14-16.

2022 Data: The Rx to faster drug discovery and patient-centered clinical trials. Invited panelist at Reuters Events, webinar, June 21.

2022 Key developments and learnings in eCOA/ePRO: Resources of interest. Invited plenary presentation at Clinical Digital Week (virtual), eCOA/ePRO 2022, June 13-15.

2022 The Chernoff Excellence in Statistics Award: Nitis Mukhopadhyay. Invited plenary presentation at the 35th Annual New England Statistics Symposium, Storrs, Connecticut, and virtual, May 22-25.

2022 Welcome to NESS 2022! Opening remarks delivered at the 35<sup>th</sup> Annual New England Statistics Symposium, Storrs, Connecticut, and virtual, May 22-25.

2022 Faster trials need unified data standards across healthcare. Invited panelist at Reuters Events: Pharma Clinical 2022, virtual, May 17-19.

#### 2021-2022

2019 Cultivating a career as a statistical collaborator in the pharmaceutical industry. Invited presentations at Denison University, September 6, 2022 (virtual seminar); Brown University, School of Public Health, May 4, 2022 (virtual seminar); Boston University, Department of Mathematics and Statistics, October 27, 2021 (virtual seminar); Florida State University, Department of Statistics, Tallahassee, Florida, January 22, 2021 (virtual colloquium); Graduate Learning Camp, University of Pretoria, South Africa, July 17, 2019; Seventeenth Annual ASA CT Chapter Mini-Conference, Wesleyan University, Middletown, Connecticut, April 24, 2019.

2022 Pathways to careers in biopharmaceutical statistics: Perspectives on research and training. Invited panelist (virtual panel discussion) at the 10<sup>th</sup> Joint Conference of the Upstate Chapters of the American Statistical Association (ASA UP-STAT), Hybrid Conference (virtual and Buffalo, New York), May 2-4.

2022 Leveraging real-world registries to make a meaningful difference to your product value. Invited panelist at Next Generation Real-World Registries, Online Conference, February 22-23.

2022 Item response theory. Invited 2-hour virtual lecture for the course Health Outcomes, University of Maryland School of Pharmacy, February 2.

2021 Remarks on being the 2021 winner of the ISPOR Avedis Donabedian Outcomes Research Life Achievement Award. ISPOR Virtual Ceremony on Scientific and Service Awards, December 7.

2021 Necessity of approving drugs based on single-arm trials – to ensure timely access to highly specialized products. Invited speaker at issue panel on “Do Single-Arm Trials Bring Peril to Network Meta-Analyses (NMAs)” at Virtual ISPOR Europe 2021, November 30-December 3.

2021 Message of congratulations to Dr. Mary Gray. The 27<sup>th</sup> Pfizer/ASA/UConn Distinguished Statistician Colloquium (virtual). October 25.

2021 The Chernoff Excellence in Statistics Award: Stuart Geman. Invited plenary presentation at the 34<sup>rd</sup> Annual New England Statistics Symposium, Providence, Rhode Island, and virtual, September 30-October 2.

2021 Multivariate and network meta-analysis methods. Invited half-day short course at the 40<sup>th</sup> Annual American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop (virtual), September 21-24.

2021 Welcome to SIP2021! Invited presentation at Statistics in Pharmaceuticals 2021, Virtual Conference, August 27-28.

2021 Psychometric evaluation of Functional Assessment of Chronic Illness Therapy – Fatigue in patients with active ankylosing spondylitis. Discussion of oral presentation at EULAR (European Alliance of Associations for Rheumatology) 2021 - Annual European (Virtual) Congress of Rheumatology, June 2-5.

2021 Industry perspective about SISAQOL-IMI. Invited oral presentation at Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life endpoints – Innovative Medicines Initiatives (SISAQOL-IMI): Virtual Kick-off Meeting (General Meeting # 1), May 17-18.

2021 Patient-reported outcomes podcast. Interviewed on some key areas and developments on patient-reported outcomes. American Statistical Association, Biopharmaceutical Section. March 25.

2021-

2020 Welcoming remarks. Online interdisciplinary seminar on statistical methodology for social and behavioral research, January 29, 2021; New England Rare Disease Statistics (NERDS) Workshop, Webinar Session #3: Gene Therapy in Rare Disease Drug Development, November 20, 2020.

2020 Welcome remarks. 2020 NextGen Data Science Day Virtual Conference, November 7.

2020 Tips for interviewing well. Invited virtual seminar presentation at Brown University, Master's Program Spring 2020 Career Information Series. April 13.

2020 Simplified interpretation of the erectile function domain of the International Index of Erectile Function. Invited seminar presentation at Connecticut College, New London, March 4.

2018-

2020 Methods for interpretation of patient-reported outcomes. Invited 90-minute seminar at the Institutional Centers for Clinical & Translational Research, Biostatistics and Research Design (BARD) Center, Boston Children's Hospital, Harvard Medical School, September 15, 2020; one-hour seminar presentation at the Center for Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, September 12, 2019; invited one-hour tutorial at BASS XXV – 25<sup>th</sup> Annual Biopharmaceutical Applied Statistics Symposium, Savannah, Georgia, October 15-19, 2018.

2019 Time to response for clinical and patient-reported outcomes in patients with psoriasis arthritis treated with tofacitinib, adalimumab, or placebo. Poster presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 Relationship between minimal disease activity and patient-reported outcomes in patients with psoriatic arthritis: post hoc analysis of two Phase 3 studies. Poster presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 Best practices in response scale options for electronic implementation of patient-reported outcomes. Invited oral presentation at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 23-25.

2019 Advances in clinical outcome assessments: Discussion. Presentation at invited session at the Joint Statistical Meetings, Denver, Colorado, July 27-August 1.

2019 Questionnaire on network meta-analysis to assess its relevance and credibility. Invited presentation at the International Chinese Statistical Association 2019 Applied Statistics Symposium, Raleigh, North Carolina, June 9-12.

2019 Leadership forum for biostatistics/data science professionals. Invited panelist at the 33<sup>rd</sup> Annual New England Statistics Symposium, Hartford, Connecticut, May 15-17.

2019 The Chernoff Excellence in Statistics Award: Shaw-Hwa Lo. Invited plenary presentation at the 33<sup>rd</sup> Annual New England Statistics Symposium, Hartford, Connecticut, May 15-17.

2019 Critical issues in drug development: Discussion. Invited presentation at the 33<sup>rd</sup> Annual New England Statistics Symposium, Hartford, Connecticut, May 15-17.

2019 Network meta-analysis: A tool for comparative effectiveness research. Webinar sponsored by the Dahshu Journal Club, June 7; co-sponsored by the American Statistical Association, Boehringer Ingelheim Pharmaceuticals and the New England Statistical Society, February 26.

2019 Advancing interpretation of patient-reported outcomes. Statistics colloquium presentation at the University of Connecticut, Storrs, CT, February 20.

2019 A career in the pharmaceutical industry: Opportunities for statisticians (and other researchers). Invited seminar presentation at Brown University, Master's Program Spring 2019 Career Information Series, Providence, Rhode Island, February 11.

2018-

2019 Analysis of patient-reported outcomes. Invited 105-minute tutorial at the 2019 Eastern North American Region (ENAR) Spring Meeting, Philadelphia, Pennsylvania, March 24-27, 2019; invited 90-minute lecture at the 3<sup>rd</sup> Statistical Consulting Services Workshop, University of Connecticut, Storrs, Connecticut, May 10, 2018.

2015-

2019 Network meta-analysis. Co-instructor for 4-hour short course and faculty member at the 24<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2019), New Orleans, Louisiana, May 18-22, 2019; 23<sup>rd</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018), Baltimore, Maryland, May 19-23, 2018; the 22<sup>nd</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Boston, Massachusetts, May 20-24, 2017; the 21<sup>st</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, May 21-25, 2016; the 20<sup>th</sup> Annual International Meeting of

the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20, 2015.

2012-13

2015-19

2023

Meta-analysis and systematic reviews in comparative effectiveness research. Co-instructor and faculty member for 4-hour short course at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Virtual Short Course, April 10-11, 2023; the 24<sup>th</sup> International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2019), New Orleans, Louisiana, May 18-22, 2019; 23<sup>rd</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018), Baltimore, Maryland, May 19-23, 2018; the 22<sup>nd</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Boston, Massachusetts, May 20-24, 2017; the 21<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, May 21-25, 2016; the 20<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20, 2015; the 18<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22, 2013; and the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, June 2-6, 2012. Instructor for 3-hour lecture for a course on clinical trials at the University of Connecticut, Storrs, CT, October 23, 2015.

2010-14,

2019

Network meta-analysis for comparative effectiveness research. Invited presentation at the Graduate Learning Camp, University of Pretoria, South Africa, July 17, 2019; invited oral virtual presentation for CBPartners, New York, NY, September 16, 2014; invited seminar at the University at Buffalo, State University of New York, Buffalo, NY, April 18, 2013; invited tutorial at the 19th Annual Biopharmaceutical Applied Statistics Symposium, Savannah, Georgia, November 5-9, 2012; invited seminar at the Food and Drug Administration, Silver Spring, Maryland, July 25, 2011; invited seminar at New York University School of Medicine, New York, NY, April 13, 2011; and invited seminar at the Mini-Symposium of the New York City Metropolitan Chapter of the American Statistical Association, New York, NY, November 22, 2010.

2018 Advancing clinical trial design and analysis with patient and regulatory input. Panelist for Fifth Drug Information Association (DIA) Webinar on Getting the Questions Right Series, November 13.

2018 Longitudinal model approaches to assess the association between changes in 2 clinical outcome assessments: Discussion. Webinar presentation at the Drug Information Association (DIA) Virtual Journal Club, October 17.

2018 Quantile regression: Thinking beyond the mean. Invited seminar presentation at the Data Science Initiative Colloquium, Brown University, Providence, Rhode Island, October 3.

2018 A review of patient-reported outcome labeling in the United States (2011-2015). Invited oral presentation at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 12-14.

2018 Methods for patient-reported outcomes: Evaluating clinical meaning using quantitative techniques. Invited seminar presentation at Evidera, Waltham, Massachusetts, September 6.

2018 Advocating and embodying equality in career development and leadership. Invited oral presentation at the Joint Statistical Meetings, Vancouver, Canada, July 28-August 2.

2018 Conjoint analysis: An illustrative primer and case study in rheumatoid arthritis. Invited presentation at the Boston Chapter of the American Statistical Association, Second Annual Boston Pharmaceutical Symposium, Cambridge, Massachusetts, May 4.

2018 Enriching interpretation of patient-reported outcomes. Invited seminar presentation at the University at Buffalo, New York, April 19.

2018 Analysis, interpretation, and presentation of data. Invited oral presentation at LUNGevity Foundation's Scientific and Clinical Roundtable – Patient Reported Outcomes, Bethesda, Maryland, March 23.

2018 Advancing the interpretation of patient-reported outcome data. Invited two-hour webinar sponsored by the American Statistics Association (Biopharmaceutical Section), February 22. Two-hour workshop at the 2018 International Conference on Health Policy Statistics, Charleston, South Carolina, January 10-12.

2017-

2018 Generalizability theory for clinician-rated outcomes. Oral presentation at the 2018 International Conference on Health Policy Statistics, Charleston, South Carolina, January 10-12, 2018, and at the Joint Statistical Meetings, Baltimore, Maryland, July 29-August 2, 2017.

2013-

2018 Patient-reported outcomes: Measurement, implementation and interpretation. 4-hour short course at the 32<sup>nd</sup> Annual New England Statistics Symposium, Amherst, Massachusetts, April 13-14, 2018; 3.5-hour short course at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, September 25-27, 2017; 3-hour short course at the Duke-Industry Statistics Symposium, September 14-16, 2016; 4-hour Professional Development Continuing Education Course at the Joint Statistical Meetings, Chicago, Illinois, July 30-August 4, 2016; 2-day short course at the Center for Evidence-based Medicine, Brown University School of Public Health, Providence, Rhode Island, January 23-24, 2016; 2-hour workshop at the 11<sup>th</sup> International Conference on Health Policy Statistics, Providence, Rhode Island, October 7-9, 2015; invited 4-short course at the Boston Chapter of the American Statistical Association, Boston, Massachusetts, June 26, 2015; 4-hour short course at the Joint 24<sup>th</sup> ICSA Applied Statistics Symposium and 13<sup>th</sup> Graybill Conference, Fort Collins, Colorado, June 14-17, 2015; 2-day short course at the 70<sup>th</sup> Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 8-12, 2014; 3.5-hour short course at the ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, D.C., September 22-24, 2014; 4.5-hour short course at the Connecticut Chapter of the American Statistical Association, Glastonbury, Connecticut, September 18, 2014; 4-hour short course at the New York City Metropolitan Area Chapter of the American Statistical Association, New York, NY, April 1, 2014; 3-hour book tutorial at the 69<sup>th</sup> Annual Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 9-11, 2013.

2017-2018 Methods for population-adjusted indirect comparisons: Recommendations from the NICE technical support document. Oral presentation at the Joint Statistical Meetings, Vancouver, Canada, July 28-August 2, 2018, and at the 12<sup>th</sup> Annual Meeting of the Society for Research Synthesis, Montreal, Canada, July 2-5, 2017.

2017 An update on eCOA and ePRO – Innovative new technologies and strategies for implementation. Invited opening address at the eCOA/ePRO Summit, Philadelphia, Pennsylvania, December 13-14.

2017 Meta-analysis and network meta-analysis in clinical trials. Invited 3-hour tutorial at the 73<sup>rd</sup> Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 4-8.

2017 A descriptive look at the PRO-CTCAE. Invited oral presentation and panelist at the Second Annual Workshop on Clinical Outcome Assessments in Cancer Clinical Trials, Bethesda, Maryland, April 25.

2017 Meta-analysis of clinical trial safety data. Invited oral presentation at the 31<sup>st</sup> New England Statistics Symposium, Storrs, Connecticut, April 21-22.

2017 Responder analyses – PhRMA position. Invited webinar presentation sponsored by the Drug Information Association (DIA) Study Endpoints Community, March 1.

2013-  
2015

2017 Interpretation of patient-reported outcomes. Invited audio tutorial at the FX Conference, February 15, 2017; invited webinar presentation sponsored by the Biopharmaceutical Section of the American Statistical Association, May 14, 2015; invited seminar presentation as Visiting Scholar at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, November 5, 2014; invited tutorial at the Twenty-First Annual Biopharmaceutical Applied Statistics Symposium, Rockville, Maryland, November 3-7, 2014; invited presentation at the Patient Reported Outcomes Symposium sponsored by the New Jersey Chapter of the American Statistical Association, Bridgewater, New Jersey, October 18, 2013.

2016-

2017 Applying the Rasch model to validate and interpret a kidney symptom index for patients with metastatic renal cell carcinoma. Invited oral presentation at the Brown University Seminar Series, Department of Health Services, Policy and Practice, Providence, Rhode Island, October 4, 2017; American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 25-27, 2017; and at the Brown University Statistics Seminar Series, Providence, Rhode Island, October 31, 2016.

2016 eCOA/ePRO: Electronic clinical outcome assessment and electronic patient reported outcome summit – Orientation. Invited oral presentation at the eCOA/ePRO Summit, Philadelphia, Pennsylvania, December 13-14.

2016 Patient-reported outcomes: reliability and validity. Invited audio tutorial presented at the FX Conference, June 14.

2016 Mapping the Western Ontario and McMaster Universities Arthritis Index (WOMAC) to the EQ-5D. Poster presentation at the 21<sup>st</sup> Annual International Meeting of the International Society for Pharmacoeconomics & Outcomes Research, Washington, DC, May 21-25.

2016 Measuring treatment satisfaction in erectile dysfunction: Use of a person-item map. Poster presentation at the 21<sup>st</sup> Annual International Meeting of the International Society for Pharmacoeconomics & Outcomes Research, Washington, DC, May 21-25.

2016 Assessing the validity and reliability of patient-reported outcomes. Invited seminar presentation at Georgia Southern University, Statesboro, Georgia, April 12.

2016 Methods for determining clinically meaningful change. Invited oral presentation at the Critical Path Institute PRO Consortium Webinar, March 29.

2016 Network meta-analysis: A brief tutorial. Invited audio presentation at the FX Conference, March 30; invited plenary presentation at the 12<sup>th</sup> Annual Scientific Meeting for CNS Clinical Trials and Methodology, Washington, D.C., February 16-18.

2016 Network meta-analysis: Integrating results of direct and indirect treatment comparisons. Invited panelist at the 12<sup>th</sup> Annual Scientific Meeting for CNS Clinical Trials and Methodology, Washington, D.C., February 16-18.

2015-

2016 Questionnaire on network meta-analysis to assess its relevance and credibility. Oral presentation at the Joint Statistical Meetings, Chicago, Illinois, July 30-August 4, 2016; invited oral presentation at the 29<sup>th</sup> New England Statistics Symposium, Storrs, Connecticut, April 24-25, 2015.

2013-2014 A career in the pharmaceutical industry: Stimulating, challenging, rewarding.

2016 Invited seminar on career information and discussion for students at Career Week, rSQUAREdge, New York, NY, September 6-9, 2016; Brown University, Providence, Rhode Island, March 7, 2016 and April 11, 2014; in the graduate course “Advanced Topics in Biostatistics” at Brown University, Providence, Rhode Island, March 13, 2013.

2015 Meta-analysis and systematic literature reviews. Invited audio tutorial presented at the FX Conference, December 1.

2015 Careers in public health – Advice from alumni in the field. Invited alumnus presentation at the Harvard T.H. Chan School of Public Health, Boston, Massachusetts, September 15.

2015 A look at multivariate meta-analysis. Oral presentation at the Joint Statistical Meetings, Seattle, Washington, August 8-13.

2015 Missing data: National Research Council Report – Guidance to FDA and industry. Invited lecture at the Summer Workshop in Clinical Research, Icahn School of Medicine at Mount Sinai, New York, NY, August 5.

2015 Meta-analysis of clinical trial safety data: Issues and discussion. Oral presentation at the 10<sup>th</sup> Annual Meeting of the Society for Research Synthesis Methodology, Nashville, Tennessee, July 8-10.

2015 Patient-reported outcomes: Development, validity, & reliability. Invited seminar presentation at the University of Connecticut Health Center, Farmington, Connecticut, May 22.

2015 Statistical methods used for the assessment of non-redundancy among clinical trial endpoints. Invited oral presentation at Evidera Webinar, September 29; oral presentation at the 20<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20.

2015 Two methods for responder analysis of patient-reported outcome measures. Invited oral presentation at the Sixth Annual Patient-Reported Outcome Consortium Workshop, Silver Spring, Maryland, April 29-30.

2015 Group concept mapping: A patient-centric, mixed methods approach to understanding the patients' experiences and supporting outcomes strategy. Invited oral webinar presentation sponsored by the International Society for Quality of Life Research, January 28.

2014 Enriching meaning of patient-reported outcomes. Invited seminar presentation at Brown University, Providence, Rhode Island, November 20.

2014 Multivariate meta-analysis: Uses and applications. Invited seminar presentation as Visiting Scholar at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, November 5.

2014 Mediation models in patient-reported outcomes research. Invited seminar presentation as Visiting Scholar at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, November 5; invited oral presentation at the Joint Statistical Meetings, Boston, Massachusetts, August 2-7.

2014 Patient-centered outcomes research. Invited panelist as Visiting Scholar at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, November 5.

2014 Psychometrics – Rasch item response theory vs. classical test theory. Invited oral presentation at the Patient Reported Outcomes and Clinical Outcome Assessment Summit, Philadelphia, Pennsylvania, May 6-7.

2014 Evaluation of a confidence interval approach for relative agreement in a cross three-way random effects model. Oral presentation at the 28<sup>th</sup> Annual New England Statistics Symposium, Boston, Massachusetts, April 25-26.

2013 Basic concepts of medical statistics. Invited 6-hour short course at Mapi Consultancy, Boston, Massachusetts, October 30.

2013 Interpreting change and responder analysis for patient-reported outcomes. Organizer and instructor for invited 2-hour workshop at the 10<sup>th</sup> International Conference on Health Policy Statistics, Chicago, Illinois, October 9-11.

2013 Use of patient-reported outcomes in comparative effectiveness research. Oral presentation at the Joint Statistical Meetings, Montreal, Canada, August 3-8.

2013 Methodological quality of meta-analyses: Matched-pairs comparison over time and between industry-sponsored and academic-sponsored reports. Oral presentation at the 8<sup>th</sup> Annual Meeting of the Society for Research Synthesis Methods, Brown University, Providence, Rhode Island, June 26-28.

2013 Multi-domain longitudinal modeling: An application to the International Index of Erectile Function. Invited and featured oral presentation at the Drug Information Association (DIA) Virtual Journal Club Podcast, June 6. Online.

2013 Overview of the collaborative initiative & an introduction to assessing the evidence questionnaires. Invited speaker at plenary session of the 18<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22.

2013 Develop content validity – A mixed methods approach. Invited oral presentation at the Center for Business Intelligence's 10<sup>th</sup> Forum on Patient Reported Outcomes, Philadelphia, Pennsylvania, May 6-7.

2013 Mixed methods approach to evaluating content validity: Review and update. Invited speaker and panelist on Mixed Methods in Assuring Content Validity at the Fourth Annual Critical Path Institute/FDA Patient-Reported Outcome (PRO) Consortium Workshop, Silver Spring, Maryland, April 24-25.

2013 PROs: Measuring and interpreting patient reported product benefits. Invited oral presentation at the conference on Late Phase Drug Development World Americas 2013, Boston, MA, March 20-21.

2012-13 Network meta-analysis for indirect treatment comparison. Co-instructor for 4-hour short course and faculty member at the 18<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22. 2013; and at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, June 2-6, 2012.

2012-13      Evaluation of a confidence interval approach for relative inter-rater reliability in a crossed three-way random effects model. Invited oral presentation at the International Chinese Statistical Association and the International Society for Biopharmaceutical Statistics Conference, Bethesda, Maryland, June 9-12, 2013. Oral presentation at the Joint Statistical Meetings, San Diego, California, July 28-August 2, 2012.

2012      Responder definitions and non-inferiority margins for patient reported outcomes. Discussant at a session of the ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, D.C., September 12-14.

2010-12      Introduction to patient-reported outcomes. Co-instructor for 4-hour short course and faculty member at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, June 2-6, 2012; 16<sup>th</sup> Annual International Meeting of ISPOR, Baltimore, Maryland, May 21-25, 2011; and 15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, Georgia, May 15-19, 2010.

2012      Responder analyses – a PhRMA position paper. Invited seminar presentation sponsored by the New York Metropolitan Chapter of the American Statistical Association, New York, NY, May 23.

2012      Responder analysis and cumulative distribution functions on patient-reported outcomes for label claims. Invited workshop at the Center for Business Intelligence's 9<sup>th</sup> Forum on Patient Reported Outcomes, Philadelphia, Pennsylvania, May 7-8.

2012      Classical test theory and item response theory: A brief overview. Invited speaker and panelist on Mixed Methods in Assuring Content Validity at the Third Annual Critical Path Institute/FDA Patient-Reported Outcome (PRO) Consortium Workshop, Silver Spring, Maryland, April 4.

2011      Interpreting changes, responder analyses & statistical considerations for patient-reported outcomes. Invited oral presentation for 3-hour tutorial at the 67<sup>th</sup> Annual Deming Conference on Applied Statistics, Atlantic City, New Jersey, December 5-7.

2011      Cumulative distribution plots to enhance interpretation of treatment differences on the Self-Esteem And Relationship questionnaire for men with erectile dysfunction. Oral presentation at the 9<sup>th</sup> International Conference on Health Policy Statistics, Cleveland, Ohio, October 5-7.

2011 Evaluation of a confidence interval approach for absolute inter-rater reliability in a crossed three-way random effects model. Oral presentation at the Joint Statistical Meetings, Miami Beach, Florida, July 30-August 4.

2011 Some approaches to enhance interpretation of patient-reported outcomes. Invited oral presentation at the National Institutes of Health, Bethesda, Maryland, June 9.

2011 Interrelationships of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction: An application of structural equation modeling. Oral presentation delivered at the Modern Modeling Methods Conference, Storrs, Connecticut, May 25-26.

2011 Do patient-reported outcomes add value in health care decisions? Invited speaker at issue panel at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 Estimating the economic benefits of positive shifts in fibromyalgia severity. Poster presentation at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 Multi-domain longitudinal modeling: Application to the International Index of Erectile Function. Poster presentation at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 Successful sexual intercourse: Time-to-event modeling in a sildenafil trial. Poster presentation at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 Mediation modeling and measurement characteristics of the Itch Severity Score from a Phase 2b trial of oral tofacitinib (CP-690,550) in patients with moderate-to-severe plaque psoriasis. Poster presentation at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 The effect of oral tofacitinib (CP-690,550) on pruritis in patients with moderate-to-severe plaque psoriasis. Poster presentation at the 16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25. (Finalist for best poster presentation.)

2011 Basic and network meta-analysis in comparative effectiveness research. Instructor for 4-hour short course and faculty member at the 16<sup>th</sup> Annual International Meeting of the

International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21-25.

2011 Statistical considerations on patient-reported outcomes for a labeling claim. Invited oral presentation at the Eastern North American Region of the International Biometric Society 2011 Spring Meeting, Miami, Florida, March 20-23.

2011 Enhancing interpretation of patient-reported outcomes: responder analysis, cumulative distributions, and regulatory insights. Invited panelist presentation at the Second Annual Critical Path Institute/FDA Patient-Reported Outcome (PRO) Consortium Workshop, Silver Spring, Maryland, March 15.

2011 Network meta-analysis: What can go wrong? Presentation posted as part of the DIA/FDA Best Practices for Regulatory Information Synthesis of Randomized Controlled Trials for Product Safety Evaluation, Bethesda, Maryland, March 10-11.

2011 Synthesis of evidence across a class of products. Invited panelist at the DIA/FDA Best Practices for Regulatory Information Synthesis of Randomized Controlled Trials for Product Safety Evaluation, Bethesda, Maryland, March 10-11.

2011 Good research practices for nonrandomized studies of treatment effects using secondary data sources. Invited oral presentation at the Second International Symposium on Biopharmaceutical Statistics, Berlin, Germany, March 1-3.

2010-11 Interpreting change and responder analysis for patient-reported outcomes. Organizer and co-instructor for invited 3.5-hour short course at the ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, DC, September 20-22, 2010; and for 4-hour short course at the 9<sup>th</sup> International Conference on Health Policy Statistics, Cleveland, Ohio, October 5-7, 2011.

2010-11 Conducting & interpreting indirect treatment comparison and network meta-analysis: Learning the basics. Invited podium workshop at the 13<sup>th</sup> European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic, November 6-9, 2010; and at 1SPOR 16<sup>th</sup> Annual International Meeting, Baltimore, Maryland, May 21-25, 2011.

2010 Enhancing interpretation of patient-reported outcomes. Oral presentation at the 24<sup>th</sup> New England Statistics Symposium, Cambridge, Massachusetts, April 16-17; invited seminar presentation at Boehringer-Ingelheim as part of its educational and scientific series, Ridgefield, Connecticut, December 16.

2010 Use responder analysis to support label claims for patient reported outcomes. Invited workshop presentation at the Center for Business Intelligence's 7<sup>th</sup> Forum on Patient Reported Outcomes, Philadelphia, Pennsylvania, November 17-18.

2010 Response profiles of sildenafil citrate on exercise capacity, hemodynamic function, and health-related quality of life in children with pulmonary arterial hypertension. Poster presentation at the 13<sup>th</sup> European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Prague, Czech Republic, November 6-9.

2010 Measurement properties of peak VO<sub>2</sub> in children with pulmonary arterial hypertension. Poster presentation at the 13<sup>th</sup> European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Prague, Czech Republic, November 6-9.

2010 Meta-analysis in comparative effectiveness research. Invited class lecture for a course on clinical trials, Brown University, Providence, Rhode Island, November 3.

2010 Quantitative assessments of patient reported outcomes: Questionnaire design and analysis. Invited oral presentation at the ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, DC, September 20-22.

2010 Confidence interval estimation for inter-rater reliability in a two-factor random-effects design. Oral presentation at the Joint Statistical Meetings, Vancouver, Canada, August 1-5; invited oral presentation at the Seventh Conference on Frontiers in Applied and Computational Mathematics at the New Jersey Institute of Technology. Newark, New Jersey, May 21-23.

2010 Examining the structure of the Fibromyalgia Impact Questionnaire. Poster presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2008-2010 Statistical considerations for patient-reported outcomes. Oral presentation at the 8<sup>th</sup> International Conference on Health Policy Statistics, Washington, D.C., January 20-22, 2010; invited oral presentation at the International Indian Statistical Association Conference, Storrs, Connecticut, May 22-25, 2008; invited oral presentation at the First International Symposium on Biopharmaceutical Statistics, Shanghai, China, June 30-July 2, 2008.

2010 Basic concepts of medical statistics. Invited 3-hour lecture to oncology faculty and fellows at West Penn Allegheny Health System, Pittsburgh, Pennsylvania, January 14.

2009 Examining the multilevel model's error covariance structure. Invited oral presentation at Tufts Medical Center, Boston, Massachusetts, August 12.

2009 Analysis of dyadic data. Oral presentation at the Joint Statistical Meetings, Washington, D.C., August 3-7.

2009 Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia. Poster presentation at the SLEEP 23<sup>rd</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, Seattle, Washington, June 6-11.

2009 Novel approach to interpreting treatment responders when assessing sleep in patients with fibromyalgia (FM). Poster presentation at the SLEEP 23<sup>rd</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, Seattle, Washington, June 6-11.

2009 Content Validity of the Sleep Quality Numeric Rating Scale (NRS) and the Medical Outcomes Study Sleep Scale (MOS-Sleep) in Patients with Fibromyalgia (FM). Poster presentation at the SLEEP 23<sup>rd</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, Seattle, Washington, June 6-11.

2009 Interpreting change and responder analyses for patient reported outcomes. Invited workshop presentation at Center for Business Intelligence's 4<sup>th</sup> Forum on Patient Reported Outcomes (PRO), Alexandria, Virginia, May 27-28.

2009 Pregabalin in fibromyalgia – Systematic review of efficacy and safety from company clinical trial reports. Poster presentation at the American Academy of Neurology, Seattle, Washington, April 25-May 2.

2009 Identification of symptom clusters in patients with fibromyalgia. Poster presentation at the American Academy of Neurology, Seattle, Washington, April 25-May 2.

2009 Experiences and lessons from my career. Invited oral presentation at the Career Development Workshop at the University of Alabama at Birmingham, Birmingham, Alabama, April 17-18.

2009 Comparison between sildenafil-treated patients with erectile dysfunction and control subjects on the Self-Esteem And Relationship (SEAR) questionnaire. Invited oral presentation at Boston University Medical School, Boston, Massachusetts, March 31. Podium presentation at the 5<sup>th</sup> Annual Drug Information Association Workshop on Pharmaceutical Outcomes Research, Tucson, Arizona, January 21-23, 2004.

2009 Using receiver operating characteristic curves and regression analyses to examine and quantify onset of benefit. Invited oral presentation at the International Society for CNS Drug Development, Las Vegas, Nevada, March 25-27.

2008 The Sleep Quality Scale and the Medical Outcomes Study Sleep Scale in subjects with fibromyalgia: Psychometric evaluation and mediation effects. Poster presentations at the American Psychiatric Association's 60<sup>th</sup> Institute on Psychiatric Services, Chicago, Illinois, October 2-5; and at SLEEP 22<sup>nd</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, Baltimore, Maryland, June 7-12.

2008 Using a yardstick approach to enrich understanding of treatment effect on urge to smoke: An application to a smoking cessation trial. Oral presentation at the Joint Statistical Meetings, Denver, Colorado, August 3-7.

2008 Measurement properties of the Daily Sleep Quality Numeric Rating Scale in subjects with fibromyalgia. Poster presentation at the SLEEP 22<sup>nd</sup> Annual Meeting of the Associated Professional Sleep Societies, LLC, Baltimore, Maryland, June 7-12.

2008 Longitudinal data analysis. Invited oral presentation delivered over the web to Wellpoint, a large U.S.-based health benefits company and the largest member of the Blue Cross/Blue Shield Association, as part of Pfizer's educational partnership with the Wellpoint Clinical Analytic Strategies Team – Study Methodologies. June 6.

2008 Interpreting and reporting results based on patient reported outcomes. Invited oral presentation at the Center for Business Intelligence's 2<sup>nd</sup> Forum on Patient Reported Outcomes (PRO), Philadelphia, Pennsylvania, May 21-22.

2008 Applications of a Sleep Quality Scale and the Medical Outcomes Study Sleep Scale in subjects with fibromyalgia: Psychometric evaluation and mediation. Poster presentation at the 161<sup>st</sup> Annual Meeting of the American Psychiatric Association, Washington, DC, May 3-8.

2008 Scoring correspondence in outcomes related to erectile dysfunction treatment on a 4-point scale (SCORE-4). Moderated poster presentation at the European Urology Association Meeting, Milan, Italy, March 26-29.

2008 Using a modified Lorenz curve and Gini coefficient to enhance interpretation of treatment effect on patient-reported outcomes. Oral presentation at the 7<sup>th</sup> International Conference on Health Policy Statistics, Philadelphia, Pennsylvania, January 17-18.

2007 Evaluating the sexual experience in men: Validation of the Sexual Experience Questionnaire. Moderated poster presentation at the Sexual Medicine Society of North America, Chicago, Illinois, December 6-9.

2007 Further evidence of the Sexual Function Questionnaire as a screening tool for women with sexual dysfunction. Moderated poster presentation at the Sexual Medicine Society of North America, Chicago, Illinois, December 6-9.

2007 Meta-analysis. Invited class lecture for a course on clinical trials, Brown University, Providence, Rhode Island, November 28.

2007 Endpoints. Invited panelist on Challenges & Opportunities of Multi-Regional Clinical Trials (PhRMA and FDA-sponsored program), North Bethesda, Maryland, October 29-30, 2007.

2007 Meta-analysis and systematic literature review workshop. Invited workshop presentation (3.5 hours) at Understanding Motivators in Evidence Based Medicine: Finding Value in Comparative Effective Studies to Drive Improved Health Outcomes & Economic Value. Baltimore, Maryland, October 22-23.

2007 An overview of regression-discontinuity designs. Invited oral presentation at Tufts- New England Medical Center, Boston, Massachusetts, October 17; University of Connecticut, Storrs, Connecticut, February 23.

2007 Evaluating the sexual experience in men: Validation of the Sexual Experience Questionnaire. Poster presentation at the 14<sup>th</sup> Annual Conference of the International Society for Quality of Life Research, Toronto, Canada, October 10-13.

2007 A single-item analysis of the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: Results of two double-blind, placebo-controlled trials. Poster presentation at the 14<sup>th</sup> Annual Conference of the International Society for Quality of Life Research, Toronto, Canada, October 10-13.

2007 Understand how the FDA draft guidance document review on PRO affects the formulary decision making process. Invited oral presentation at the Center for Business Intelligence's 4<sup>th</sup> Annual Forum on Formulary and Reimbursement Strategies for Effective Product Planning, King of Prussia, Pennsylvania, September 27-28.

2007 Proposal for SoTC analyses. Invited oral presentation at the National Cancer Institute Strength of Tobacco Control (SoTC) Survey Workshop, Rockville, Maryland, September 25.

2007 Statistical issues and novel models for quantifying the effects of continuous traits on mortality: Examples from obesity. Discussant at an invited session, Joint Statistical Meetings, Salt Lake City, Utah, July 29-August 2.

2007 Measuring sildenafil effects on erectile function and antidepressant-treated or untreated depression: Meta-analysis of randomized treatment studies. Podium poster presentation at the Annual Meeting of the American Urological Association, Anaheim, California, May 19-24.

2007 Statistical methods appropriate for determining efficacy onset: Measuring onset of antidepressant action in clinical trials. Invited oral presentation at the Onset of Efficacy Consensus Conference, Washington, DC, April 19.

2007 Tutorial on longitudinal data. Invited presentation at the Fifth Annual American Statistical Association Connecticut Chapter Mini-Conference, New Haven, Connecticut, March 31.

2007 Effects of sunitinib versus interferon-alfa on health-related quality of life in patients with metastatic renal cell carcinoma (mRCC); Comparing the results of mixed-effects and pattern mixture models. Oral and poster presentations at the 18<sup>th</sup> International Congress on Anti Cancer Treatment, Paris, France, February 6-9.

2006 Clinically meaningful improvement on the Self-Esteem And Relationship (SEAR) questionnaire in men with erectile dysfunction. Moderated presentation at the Sexual Medicine Society of North America Fall Meeting, Las Vegas, Nevada, November 2-5.

2006 Efficacy of sildenafil for the treatment of erectile dysfunction in men with depression: Meta-analysis of randomized, double-blind, placebo-controlled trials. Moderated presentation at the Sexual Medicine Society of North America Fall Meeting, Las Vegas, Nevada, November 2-5.

2006 The effects of varenicline, a novel selective alpha 4 beta 2 receptor partial agonist, in reducing the craving and withdrawal effects associated with smoking cessation. Poster presentation at the 13<sup>th</sup> World Conference on Tobacco OR Health, Washington, DC, July 12-15.

2006 The effects of varenicline, a novel selective alpha 4 beta 2 nicotinic receptor partial agonist, on the reinforcing and rewarding effects of smoking. Poster presentation at the 13<sup>th</sup> World Conference on Tobacco OR Health, Washington, DC, July 12-15.

2006 Large trials vs. meta-analysis of smaller trials: Implications to evidence-based medicine. Invited oral presentation at the 15<sup>th</sup> Annual Applied Statistics Symposium of the International Chinese Statistical Association, Storrs, Connecticut, June 14-17. Invited oral presentation at the Institute of Medicine's Clinical Research Roundtable (What is evidence based medicine and how do we get there?), Washington, D.C., December 12-13, 2000.

2006 Efficacy of sildenafil for the treatment of erectile dysfunction in men taking antidepressant medication: Meta-analysis of randomized, double-blind, placebo-controlled studies. Podium presentation at the 159<sup>th</sup> Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25. Poster presentation at the 31<sup>st</sup> Annual Meeting of the American Society of Andrology, Chicago, Illinois, April 8-11.

2006 Overview of new & enhanced technologies to enhance PRO collection & management. Invited discussant at the Patient Reported Outcomes Research Conference, Washington, DC, April 24-25.

2006 New FDA draft guidance document review and dissemination on patient reported outcomes. Invited workshop presenter at the Patient Reported Outcomes Research Conference, Washington, DC, April 24-25.

2006 Patient-reported outcomes: Conceptual issues. Invited oral plenary presentation and coauthored draft manuscript at the Mayo Clinic/FDA meeting on FDA Guidance on Patient Reported Outcomes, Chantilly, Virginia, February 23-25.

2006 Effect of varenicline on craving and withdrawal symptoms. Oral presentation at the the 12<sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, Florida, February 15-18.

2006 Effect of varenicline on reinforcing effects associated with smoking. Poster presentation at the 12<sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, Florida, February 15-18.

2005-6 Using the cumulative logit model to enhance interpretation of health status measures: An application to the Self-Esteem And Relationship questionnaire for men with erectile dysfunction. Oral presentation at the Joint Statistical Meetings, Minneapolis, Minnesota, August 7-11, 2005; invited colloquium presentation at the University of Connecticut, Department of Statistics, Storrs, CT, March 13, 2006.

2005 A modified large-sample approach to approximate interval estimation for a particular intraclass correlation coefficient. Invited oral presentation at the Connecticut Chapter Meeting of the American Statistical Association and at Yale University, New Haven, Connecticut, November 15.

2005 Evaluating the sample invariance property of the standard error of measurement. Oral presentation at the 6<sup>th</sup> International Conference on Health Policy Research:

Methodological Issues in Health Services and Outcomes Research, Boston, Massachusetts, October 28-30.

2005 A comparison of two confidence interval approaches for the dependability coefficient in a two-factor crossed design. Invited oral presentation at the Applied Statistics Symposium of the International Chinese Statistical Association, Bethesda, Maryland, June 12-15.

2005 Sildenafil: Improved erectile function associated with gains in self-esteem. Poster presentation at the 158<sup>th</sup> Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26.

2005 Confirmatory validation of the Brief Questionnaire of Smoking Urges. Poster presentation at the 10<sup>th</sup> Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, May 15-18.

2005 Confirmatory factor analysis and reliability of the “Smoking Effects Inventory.” Poster presentation at the 10<sup>th</sup> Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, May 15-18.

2005 Utilize patient reported outcomes to lend meaning to drug benefit. Invited oral presentation at the Center for Business Intelligence’s Forum on Early Stage Commercialization Strategies for the Pharmaceutical Industry. Philadelphia, Pennsylvania, April 21-22.

2004-5 Using CART to develop a diagnostic tool for erectile dysfunction. Invited oral presentations at CART Data Mining 2005, New York, New York, March 30; CART Data Mining 2004, San Francisco, California, March 22-24, and at the Second Annual CT ASA Statistics Mini-Conference, Wallingford, Connecticut, March 13, 2004.

2001-5 Meta-analysis and systemic literature review – Introduction. Instructor for four-hour short course and faculty member at the Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: Arlington, Virginia, May 20-23, 2001; May 19-22, 2002; May 18-21, 2003; May 16-19, 2004; Washington, DC, May 15-18, 2005.

2004 Assessing responsiveness of the Self-Esteem And Relationship questionnaire in men with erectile dysfunction treated with Viagra® (sildenafil citrate) in an international, double-blind, placebo-controlled trial. Poster presentation at the 26<sup>th</sup> Annual Meeting of the Society for Medical Decision Making, Atlanta, Georgia, October 17-20.

2004 Viagra case study – Measuring meaningful change in patient reported outcomes. Invited workshop presentation at the Center for Business Intelligence's 5<sup>th</sup> Annual Forum on Phase IV Clinical Trials. Philadelphia, Pennsylvania, September 20-21.

2004 Responsiveness of the Self-Esteem And Relationship questionnaire in men with erectile dysfunction treated with sildenafil citrate in a double-blind, placebo-controlled trial. Poster presentation at the 20<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Bordeaux, France, August 22-25.

2004 Assessing self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil citrate: Combined analysis of 2 double-blind, placebo-controlled trials. Oral presentation at the 20<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Bordeaux, France, August 22-25.

2004 Applying the law of iterated logarithm to cumulative meta-analysis. Invited oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 8-12.

2004 Session on Advanced Statistical Analysis I: Discussion. Discussant – invited oral presentation at the International Society for Quality of Life Research 2004 Symposium, Boston, MA, June 27-29.

2004 Linking self-esteem, confidence, and relationships with severity of erectile dysfunction. Poster presentation at the International Society for Quality of Life Research 2004 Symposium, Boston, MA, June 27-29.

2004 Self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil citrate: combined analysis of 2 double-blind, placebo-controlled trials. Poster presentations at the International Society for Quality of Life Research 2004 Symposium, Boston, MA, June 27-29, and at the Drug Information Association 40<sup>th</sup> Annual Meeting, Washington, DC, June 13-17.

2004 Self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil citrate. Poster presentation at the 27<sup>th</sup> Annual Meeting of the Society of General Internal Medicine, Chicago, Illinois, May 12-15.

2004 Self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil: An international study. Poster presentation at the 27<sup>th</sup> Annual Meeting of the Society of General Internal Medicine, Chicago, Illinois, May 12-15.

2003-4      Introduction to meta-analysis. Three-hour lecture for a clinical trials course at the University of Connecticut, Storrs, CT, April 16 and 23, 2003; November 15, 2004.

2003-4 Using ordinal logistic regression to enhance interpretation of health status measures: An application to the Self-Esteem And Relationship questionnaire for men with erectile dysfunction. Invited seminar presentation at Tufts-New England Medical Center, Boston, Massachusetts, July 29, 2004. Poster presentation at Quality of Life III: Translating the Science of QOL Assessment into Clinical Practice, Scottsdale, Arizona, October 2-4, 2003.

2002-4 Methods to explain clinical significance of health status measures. Invited oral presentations at the 2<sup>nd</sup> Annual Pharmaceutical Outcomes Research Conference, Washington, D.C., February 23-24, 2004; Use Outcomes Research for Marketplace Positioning, Philadelphia, Pennsylvania, March 17-18, 2003; and Tufts-New England Medical Center, Boston, Massachusetts, July 9, 2002. Oral presentation at the International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Chicago, Illinois, October 17-19, 2003.

2003 Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Invited seminar presentation at University of Connecticut Health Center, Farmington, Connecticut, December 2.

2003 "An overview of outcomes research" and "An overview of the International Index of Erectile Function." 3-hour lecture for a managerial statistics seminar at Rensselaer Polytechnic Institute, Groton, Connecticut, November 7.

2003 Applying quality of life data formally and systematically into clinical practice. Invited oral plenary presentation at Quality of Life III: Translating the Science of QOL Assessment into Clinical Practice, Scottsdale, Arizona, October 2-4.

2003 Development and validation of the Children with Diabetes Questionnaire – a questionnaire to assess treatment satisfaction and well-being. Poster presentation at the 18<sup>th</sup> International Diabetes Federation Congress, Paris, France, August 24-29.

2003 Methods for assessing clinical significance in quality of life measurement. Oral presentation at the Joint Statistical Meetings, San Francisco, California, August 3-7.

2003 An overview of the International Index of Erectile Function (IIEF). Invited seminar presentation at Tufts-New England Medical Center, Boston, Massachusetts, July 30.

2003 Development and validation of the Parents of Children with Diabetes Questionnaire – a questionnaire to assess treatment satisfaction and well-being. Poster presentation at the

American Diabetes Association's 63rd Scientific Sessions, New Orleans, Louisiana, June 13-17. Poster presentation at the 18<sup>th</sup> International Diabetes Federation Congress, Paris, France, August 24-29.

- 2003 A baseline assessment of the validity of the 39-item National Eye Institute Visual Function Questionnaire in German patients with age-related macular degeneration. Poster presentation at the Eight Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 18-21. (Finalist for best poster presentation.)
- 2002 An overview of cutoff designs. Invited oral presentation at the Tufts-New England Medical Center, Boston, Massachusetts, June 27.
- 2002 Using meta-analysis to explore differences in study effects. Oral presentation (guest faculty) at the Ninth Annual Biopharmaceutical Applied Statistics Symposium, Savannah, Georgia, December 9-13.
- 2002 Some developments on the International Index of Erectile Function (IIEF). Invited seminar presentation at Brown University School of Medicine, Department of Community Health, Providence, Rhode Island, November 13.
- 2002 Correlating scores on the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) with the Self-Esteem And Relationship (SEAR) Questionnaire following treatment with Viagra® (sildenafil citrate) for men with erectile dysfunction: Results from a multicenter open-label study. Poster presentation at the 9<sup>th</sup> Annual Meeting of the International Society of Quality of Life Research, Orlando, Florida, October 30-November 2.
- 2002 Responsiveness of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction (ED). Poster presentation at the 9<sup>th</sup> Annual Meeting of the International Society of Quality of Life Research, Orlando, Florida, October 30-November 2.
- 2002 Development, psychometric validation, and treatment responsiveness of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Oral presentation at the Fourth Annual Drug Information Association Workshop on Pharmaceutical Outcomes Research, Newport, Rhode Island, October 16-18.
- 2002 Beyond the simple average: Adjusting for heterogeneity and bias in meta-analysis. Discussant – oral presentation at the Joint Statistical Meetings, New York, NY, August 11-15.

2002 Applying the law of iterated algorithm to cumulative meta-analysis of continuous outcomes. Oral presentation at the Mathematical Sciences Research Institute's Symposium on Statistical Challenges for Meta-Analysis of Medical and Health-Policy Data. Berkeley, California, May 9-11.

2002 Single item versus summated scale scores. Invited oral plenary presentation and participated in panel discussion at Assessing Clinical Significance for Quality of Life Measures in Oncology Research: State-of-the-Science. Rochester, Minnesota, April 5-6.

2002 Bayesian methods in cost-effectiveness analysis: Discussion. Discussant – invited oral presentation at the Drug Information Association workshop on Innovative Statistical Strategies in Today's Environment. Hilton Head, South Carolina, March 10-12.

2001 A modified large sample approach to approximate interval estimation for a certain intraclass correlation coefficient. Oral presentation at the International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Boston, Massachusetts, December 7-9.

2001 Using the Mann-Whitney statistic to improve the interpretation of ordinal scales: An application to the Patient Satisfaction with Insulin Therapy questionnaire. Poster presentation at the 8<sup>th</sup> Annual Conference of the International Society for Quality of Life Research, Amsterdam, The Netherlands, November 7-10.

2001 Assessing the clinical significance of single items relative to summated scores. Invited oral presentation at the 8<sup>th</sup> Annual Conference of the International Society for Quality of Life Research, Amsterdam, The Netherlands, November 7-10.

2001 A brief introduction to meta-Analysis. Oral presentation given at the panel session on Frontiers in Meta-Analysis, Sixth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 20-23.

2001 Correlation between patient self-assessment of erectile function and the International Index of Erectile Function (IIEF-5). Oral presentation at the 154<sup>th</sup> Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, May 5-10.

2000 Opportunities for and in outcomes research. Oral presentation as part of the Fall Lecture Series in the Clinical Research Graduate & Training Program, Tufts-New England Medical Center, Boston, Massachusetts, December 6.

2000 Meet the developers session: The International Index of Erectile Function (IIEF). 7th Annual Conference of the International Society for Quality of Life Research, Vancouver, Canada, October 29-31.

2000 Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: Results from a multicenter extension trial. Invited oral presentation at the 11<sup>th</sup> Biennial Meeting of the International Study Group on Innovative Insulin Delivery, Evian, France, September 13-16.

2000 Inhaled insulin improves satisfaction with treatment in type 1 patients: A randomized controlled trial. Invited oral presentation at the 11<sup>th</sup> Biennial Meeting of the International Study Group on Innovative Insulin Delivery, Evian, France, September 13-16.

2000 Issues in comparisons between meta-analyses and large trials. Invited oral presentation at the Joint Statistical Meetings, Indianapolis, Indiana, August 13-17.

2000 An application of patient satisfaction in a multicenter randomized controlled trial of inhaled insulin in subjects with type 1 diabetes mellitus. Invited oral presentation at the 2000 International Chinese Statistical Association Applied Statistics Symposium, Piscataway, New Jersey, June 1-3.

2000 Regulatory issues for health-related quality of life: A report on a workshop. Invited oral presentation at the Harvard/Schering-Plough conference on Measurement and Analysis of Quality-of-Life Outcomes for Drug Development, Boston, Massachusetts, June 1-2.

2000 Correlation between subject self-assessment of erectile function and the erectile function domain of the International Index of Erectile Function. Poster presentation at the 2nd Annual Drug Information Association Workshop on Pharmaceutical Outcomes Research, Seattle, Washington, May 11-12.

1999-2000 Large trials vs meta-analysis of smaller trials: How do their results compare? Invited seminar presentation, Yale University, New Haven, Connecticut, April 4, 2000; invited oral presentation at the 1999 Joint Statistical Meetings, Baltimore, Maryland, August 8-12, 1999; oral presentation at the Thirteenth New England Statistics Symposium, Storrs, Connecticut, April 24, 1999.

1999 Development and evaluation of the IIEF-5 as a diagnostic tool for erectile dysfunction. Poster presentation at the 21<sup>st</sup> Annual Meeting of the Society for Medical Decision Making, Reno, Nevada, October 3-6.

1999 Meta-analysis of therapeutic trials. Oral presentation at the Pfizer-FDA Outcomes Research Preceptorship, Pfizer Inc., New York, NY, July 19-20.

1999 Analysis issues in health-related quality of life. Oral (plenary) presentation from break-out session at the 1999 Regulatory Issues in Health Related Quality of Life Assessment: PhRMA/FDA Interactive Workshop, Washington, D.C., March 24-25.

1998 Validation of the behavioural activity rating scale: A novel measure of activity in agitated patients. Poster presentation at the 9th Congress of the Association of European Psychiatrists (AEP), Copenhagen, Denmark, September 20-24.

1998 Viagra® (sildenafil citrate) improves quality of life in erectile dysfunction. Poster presentation at the 106<sup>th</sup> Annual Convention of the American Psychological Association, San Francisco, California, August 14-18.

1998 Evaluating the erectile function domain of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Invited oral presentation at the Eighth Applied Statistics Symposium of the International Chinese Statistical Association, Connecticut College, New London, Connecticut, June 5-7.

1998 Some developments on the International Index of Erectile Function. Oral presentation at the Drug Information Association workshop on Global Statistical Challenges and Strategies in the Pharmaceutical Industry, Hilton Head, South Carolina, March 15-17.

1997 Embedding the regression-discontinuity within the randomized design in pharmaco-economic evaluations. Invited oral presentation at the session on Pharmacoeconomics at the 20th Midwestern Biopharmaceutical Statistics Workshop, American Statistical Association, at Ball State University, Muncie, Indiana, May 19-21.

1995 Statistical and clinical features of cutoff designs. Invited presentation to the New York Chapter of the American Statistical Association, New York, NY, September 14.

1995 Applying the “real-time meta-analysis system” to randomized control trials of congestive heart failure. Oral presentation at the 16th Annual Meeting of the Society for Clinical Trials, Seattle, Washington, April 30-May 3.

1994 Relative efficiency of conventional to cutoff-based randomized clinical trials. Oral presentation at the annual meeting of the American Evaluation Association, Boston, Massachusetts, November 2-5.

1994 An evaluation of large studies and meta-analyses of smaller studies. Oral plenary presentation at the Second International Cochrane Colloquium, Hamilton, Ontario, Canada, October 1-4.

1994 Comparing results from the largest studies with meta-analyses of smaller studies. Oral presentation at the 15th Annual Meeting of the Society for Clinical Trials, Houston, Texas, May 8-11.

1994 Efficacy and safety of anticoagulant and antiplatelet therapy versus anticoagulant therapy after heart valve replacement: A meta-analysis. Paper presentation at the 15th Annual Meeting of the Society for Clinical Trials, Houston, Texas, May 8-11.

1994 Efficacy and safety of different aspirin dosages on vascular diseases: A meta-analysis. Poster presentation at the Meeting of the American Federation for Clinical Research, Baltimore, Maryland, April 29-May 2.

1993 Development of a "Real-Time Meta-Analysis System (RTMAS)" to systematically evaluate efficacy of ambulatory pharmaceuticals. Oral presentation at the Dartmouth-Hitchcock Summer Symposium on Technology Assessment, Lyme, New Hampshire, July 22-23.

1993 An introduction to WESVAR and WESLOG for complex survey data in NIS-2. Oral presentation at the 1993 Summer Research Institute, National Data Archive on Child Abuse & Neglect, Cornell University, Ithaca, New York, July 11-16.

1993 The epidemiology of child sexual abuse and physical abuse: Findings from the second incidence study. Oral presentation at the Summer Research Institute, National Data Archive on Child Abuse & Neglect, Cornell University, Ithaca, New York, July 11-16.

1992 An illustrative statistical analysis of cutoff-based randomized clinical trials. Oral presentation at the 13th Annual Meeting of the Society for Clinical Trials, Philadelphia, Pennsylvania, May 10-13.

1992 A review of the second national incidence and prevalence study of child abuse and neglect. Oral presentation at the Judge Baker Children's Center, Harvard Medical School, Boston, Massachusetts, February 3.

1991 An introduction to cutoff-based randomized clinical trials. Oral presentation at the Harvard School of Public Health, Department of Epidemiology, Boston, Massachusetts, October 23.

1991 Working with the second national incidence and prevalence study of child abuse and neglect. Workshop presentation at a skills workshop at the 9th Annual Conference on Child Abuse & Neglect, Denver, Colorado, September 14.

1991 A simulation study of cutoff-based randomized clinical trials. Seminar presentation at the 15th Meeting of the Upstate New York and Southern Ontario Epidemiology Group, State University of New York Health Science Center, Syracuse, New York, May 10.

1990 Random measurement error in regression-discontinuity designs. Oral presentation at the American Evaluation Association Conference, Washington, D.C., October 18-20.

1990 Power analysis of regression-discontinuity designs. Paper presentation at the American Evaluation Association Conference, Washington, D.C., October 18-20.

1990 Coupling the regression-discontinuity design with the randomized experimental design: Computer simulations from the UCSF cocaine treatment study. Seminar presentation at Cornell University's Epidemiology Forum, Ithaca, New York, March 30.

1990 Coupling outcome pattern matching and program theory with ordinal categorical methods for the m by 2 ordered contingency table. Oral presentation at the Edward F. Kelly Evaluation Conference, Ithaca, New York, February 23.

1989 Introduction to the regression-discontinuity design in psychosocial epidemiology. Seminar presentation at Cornell University's Epidemiology Forum, Ithaca, New York, November 3.

### **Coauthored Presentations Delivered by Collaborators**

2025 Characterizing long COVID symptoms patterns by age: a US prospective study. Di Fusco M, Lupton L, Cappelleri JC, Yehoshua A, Moran MM, Puzniak L, Lopez SMC, Sun X. Poster presentation at the European Respiratory Society (ERS) Congress 2025, Amsterdam, Netherlands, and online, September 27-October 1.

2025 Acute COVID-19 symptoms patterns in younger and older adults: a US nationwide study. Di Fusco M, Lupton L, Moran MM, Cappelleri JC, Puzniak L, Yehoshua A, Lopez SMC, Sun X. Poster presentation at the European Respiratory Society (ERS) Congress 2025, Amsterdam, Netherlands, and online, September 27-October 1.

2025 Psychometric validation and meaningful within-patient change of the FAACT-5IASS in patients with cancer cachexia. Fang J, Roth JA, Harrington MA, Groarke J, Collins SM, Cappelleri JC, Bushmakin A. Poster presented at the Cancer Cachexia Conference 2025, Turin, Italy, September 25-27.

2025 Meaningful within-patient change of PROMIS-Fatigue and PROMIS-Physical Function in patients with cancer cachexia in the phase 2 ponsegronab study. Fang J, Roth JA, Bushmakin A, Harrington MA, Groarke JD, Collins SM, Crawford J, Roeland EJ, Cappelleri JC. Poster presented at the Cancer Cachexia Conference 2025, Turin, Italy, September 25-27.

2025 Understanding gastroenterologist preferences at the time of treatment escalation to first-line advanced therapies in ulcerative colitis: a discrete choice experiment in five European countries. Schreiber S, Walsh A, Hur P, Panattoni L, Hauber B, Gahlon G, Coulter J, Wosik K, Cappelleri JC, Prood N, Guo X, Buisson A. Oral presentation at the Annual Meeting of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), Leipzig, Germany, September 15-20.

2025 Caring for an infant with respiratory syncytial virus affects caregivers' well-being: preliminary findings from a multinational cross-sectional survey. Maculaitis MC, Kopenhafer L, Cappelleri JC, Deese J, Rene C, Pugh SJ, Alexander-Parrish R, Vichnin M, Turiga MF, Chen N, Law AW. Caring for an infant with respiratory syncytial virus affects caregivers' well-being: preliminary findings from a multinational cross-sectional survey. Poster presentation at the 6<sup>th</sup> European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Vaccines, Lisbon, Portugal, September 10-12.

2025 Enhancing cancer clinical trials with patient-reported outcomes: Insights from SISAQOL-IM – Single arm studies. le Cessie S on behalf of SISAQOL-IMI Work Package 3. Oral presentation at the 46<sup>th</sup> Annual Conference at the International Society of Clinical Biostatistics (ICSB), Basel, Switzerland, August 24-28.

2025 Patient-reported outcomes among patients with triple-class refractory multiple myeloma in real-world clinical practice: A prospective, multi-site observational study – Interim Results. Charalampous C, Kumar SK, Parrondo R, Chhabra S, Nagaraj M, Duh MS, Bobbili PJ, Wang A, Chen J, Mohan M, Hlavacek P, Sandin R, Cappelleri JC, Hughes D, Nador G, DiBonaventura M. Podium (oral) presentation at the International Society of Pharmacoepidemiology (ISPE) 41<sup>st</sup> Annual Meeting, Washington, D.C., August 22-26.

2025 Patient-reported outcomes in single-arm trials: recommendations for the design and analysis. Thomassen D, le Cessie S, Roychoudhary S, on behalf of SISAQOL-IMI Work Package 3. Oral presentation at the 2025 Joint Statistical Meetings, Nashville, Tennessee, August 2-7.

2025 The hazards of using hazard ratios in indirect treatment comparisons. Chu H, Jiang Z, Liu J, He W, Cappelleri JC, Roychoudary S, Chen Y). Oral presentation at the 2025 Society for Research Synthesis Methodology Meeting, Madison, Wisconsin, July 8-11.

2025 Statistical journey from latent class to linking: Case study of Long COVID symptom list. Sun X, Cappelleri JC, Di Fusco M. Oral presentation at the 2025 International Conference ICSA Applied Statistics Symposium, Storrs, Connecticut, June 15-18.

2025 Patient perspectives and preferences on advanced treatment administration in ankylosing spondylitis: a cross-sectional study. Deodhar A, Maculaitis MC, Kopenhafer L, Beusterien K, Ling Y-L, Hauber B, Cappelleri JC, Yndestad A, Phillips L, Zayed M. Oral presentation at the European Congress of Rheumatology (EULAR) 2025 Congress, Barcelona, Spain, June 11-14.

2025 SISAQOL-IMI recommendations: Statistical considerations for advancing PRO analysis for cancer clinical trials. Schlichting M, Coens C, Goetghebeur E, Regnault A, Cocks K, Rantell KR, Wintner LM, Giesinger J, Lawrence R, Alexis S on behalf of SISAQOL-IMI Consortium. Poster presentation at the PSI 2025 Conference, London, United Kingdom, June 8-11.

2025 Quantifying patient preferences for bacillus Calmette-Guérin patient (BCG) and PD-(L)1 inhibitors in high-risk non-muscle invasive bladder cancer (NMIBC): A discrete choice experiment. Hallworth P, Eccleston A, Mason B, Hauber B, Bell B, Coulter J, Marin L, Thompson A, Jones J, Chang J, Ayala-Nune L, Brinkmann J, Guest C, Gater A, Koshy A, Cappelleri JC, Chisolm S, Satkunasivam R. Poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 30-June 3.

2025 Amelioration of indirect costs following COVID-19 infection in high-risk US patients treated with nirmatrelvir-ritonavir. Fernandez MM, Brady BL, Evans K, Sidhu GS, Cislo P, Ernst FR, Cappelleri JC, Chaudhary MA, Drabo EF, Mokgokong R. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Association between social vulnerability and long COVID: A nationwide U.S. study among symptomatic outpatients. Manuela Di Fusco, Lupton L, Yehoshua A, Gavaghan M, Puzniak L, Lopex MCL, Cappelleri JC, Sun X. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Symptom burden of acute influenza infection among US adults: An interim analysis of a national prospective study. Hu T, Lupton K, Yehoshua A, Cappelleri JC, Gavaghan M, Welch V, Lopez SMC, Di Fusco M, Sun X. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 An interim analysis of the burden of influenza infection in health-related quality of life and work productivity among adults in the United States. Hu T, Yehoshua A, Cappelleri JC, Gavaghan M, Di Fusco M, Sun X. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Frequency and severity of COVID-19 acute symptoms among symptomatic US adults testing positive for SARS-CoV-2: Early 2024-2025 respiratory season results of a nationwide study. Yehoshua A, Lupton L, Hu T, Cappelleri JC, Gavaghan M, Lopex SMC, Puzniak L, Di Fusco M, Sun X. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Impact of COVID-19 on quality of life and work productivity among symptomatic US adults testing positive for SARS-CoV-2: Interim analysis of a nationwide longitudinal study. Yehoshua A, Hu T, Cappelleri JC, Gavaghan M, Di Fusco M, Sun X. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Di Fusco M, Lupton L, Yehoshua A, Gavaghan MB, Puzniak L, Lopex SMC, Cappelleri JC, Sun X. Disparities in COVID-19 vaccination uptake by social vulnerability index: A US nationwide study. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Burden of COVID-19 on health-related quality of life in immunocompromised adult participants from the EPIC-IC trial. Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Psychometric validation and meaningful within-patient change of the FAACT-5IASS in patients with cancer cachexia. Fang J, Roth JA, Harrington MA, Groarke J, Collins SM, Cappelleri JC, Bushmakin A. Poster presentation at ISPOR 2025, Montreal, Canada, May 13-16.

2025 Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe ulcerative colitis: A discrete choice experiment. Schreiber S, Buisson A, Bewtra M, Hur P, Panattoni L, Hauber B, Land N, Coulter J, Gahlon G, Guo X, Smith CC, Cappelleri J, Wosik K, Maravic MC, Walsh A. Poster presentation at Digestive Disease Week (DDW 2025), San Diego, California, and virtually, May 3-6.

2025 Understanding benefit-risk trade-off differences between advanced therapy naïve and experience patients to informed shared decision making: A discrete choice experiment in the United States and Europe. Schreiber S, Buisson A, Bewtra M, Hur P, Panattoni L, Hauber B, Gahlon G, Coulter J, Smith CC, Guo X, Land N, Wosik K, Cappelleri J, Maravic MC, Walsh A. Poster presentation at Digestive Disease Week (DDW 2025), San Diego, California, and virtually, May 3-6.

2025 Meaningful change in the ability to perform physical activities for patients with cachexia and cancer. Northcott C, Newell A, Hwang S, Coutler J, Kopenhafer L, Santamaria M, Karahanoglu I, Maculaitis M, Cappelleri JC, Beusterien K, Fortune E, Saxton C, Andac-Jones E, Hauber B. Poster presentations at the American Association for Cancer Research Annual Meeting, Chicago, Illinois, April 25-30.

2025 Development of the Hemophilia Life Interference Questionnaire (HLIQ): A tool to evaluate the impact of hemophilia B and its treatment on patient lives. Thakkar S, Booragadda H, Merla V, Mazar I, Cappelleri J, Bushmakin A, Diaz M, Yaworsky A, Turner-Bowker D, Love E. Poster presentation at the World Federation of Hemophilia 2025 Comprehensive Care Summit, Dubai, United Arab Emirates, April 23-25.

2025 Development of the Long COVID/post-acute sequelae of COVID-19 (PASC) patient-reported outcome (PRO) instrument. Chandler D, Tatlock S, Abramoff B, Bramson C, Cappelleri JC, Chohan A, Harrison M, Jamal H, Lusk J, Mazar I, Paredes R, Ustianowski A, Weinstein E, Mokgokong R. Poster presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID 2025), Vienna, Austria, April 11-15.

2025 Work productivity losses after COVID-19 infection among high-risk US patient with or without treatment with nirmatrelvir/ritonavir. Fernandez M, Brady BL, Evans K, Cha-Silva AS, Shah R, Sidhu GS, Cislo P, Ernst PR, Cappelleri JC, Chaudhary MA, Drabo EF, Mokgokong R. Poster presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID 2025), Vienna, Austria, April 11-15.

2025 Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial. Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC. Oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID 2025), Vienna, Austria, April 11-15.

2025 Health-related quality of life, work productivity and activity levels in younger and older adults with acute COVID-19. Di Fusco M, Cappelleri JC, Lupton LL, Moran MM, Puzniak L, Lopez SMC, Gavaghan MB, Yehoshua A, Sun X. Poster presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID 2025), Vienna, Austria, April 11-15.

2025 Time to first and sustained improvement in weekly migraine days among patients receiving preventive treatment with rimegepant 75 mg. Tepper S, Abraham L, Bushmakin AG, Cappelleri JC, Fullerton T, Yang J, Lipton R. Poster presentation for the American Academy of Neurology 2025 Annual Meeting, San Diego, California, April 5-9.

2025 The psychosocial burden of caring for infants with RSV disease among US caregivers. Poster presentation at 13<sup>th</sup> International Respiratory Syncytial Virus (RSV) Symposium, Iguazu Falls, Brazil, March 12-15.

2025 The importance of digital health technology-derived physical activity for adult patients with cancer and cachexia. Poster presentation at International Conference on Frailty and Sarcopenia Research (ICFSR 2025), Toulouse, France, March 12-14.

2025 Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative colitis: A discrete choice experiment. Poster presented at the 20<sup>th</sup> Congress of the European Crohn's and Colitis Organisation (ECCO) – Inflammatory Bowel Diseases 2025, Berlin, Germany, February 19-22.

2025 Health-related quality of life outcomes for marstacimab in participants with severe haemophilia A or moderately severe to severe haemophilia B: Results from the Phase 3 Basis trial. Poster presentation at EAHAD 2025: 8<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Milan, Italy, February 4-7.

2025 Indirect treatment comparison of marstacimab versus emicizumab in haemophilia. A. Poster presentation at EAHAD 2025: 8<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Milan, Italy, February 4-7.

2025 Patient burden and preferences for haemophilia treatments: A multi-country discrete-choice experiment with Hemo-TEM. Poster presentation at the 18<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD 2025), Milan, Italy, February 4-7.

2025 SISAQOL-IMI WP6: Future research. Invited oral presentation at SISAQOL-IMI Closed Meeting, Ghent, Belgium, February 5.

2025 Interpretation of clinically meaningful results. Invited oral presentation at SISAQOL-IMI Public Launch, Ghent, Belgium, and virtual, February 4.

2024 Real-world treatment patterns, resource utilization, and cost of care in Medicare beneficiaries newly diagnosed with acute myeloid leukemia and treated with venetoclax-based regimen. Roth JA, D'Amico P, Purcell S, Donckels E, Cappelleri JC, Ma J, Petrilla A, Kagan J, Yu A, Russell-Smith A. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, December 7-10.

2024 Updated results of a matching-adjusted indirect comparison of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, Leblanc TW, Cappelleri J, Chu Haitao, Nador G, Aydin D, Crus IP, Hlavacek P. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 The impact of multiple myeloma on care partner well-being, work productivity, and resource use in the United States and Western Europe. Annunziata K, Sternbach N, Tanaka H, DiBonaventura M, Cappelleri JC, Watkins J, Hughes D, Meche A, Kim CH, Kennedy T, Scheurer H, LeBlanc TW. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 Patient-reported outcomes among patients with triple-class refractory multiple myeloma in real-world clinical practice: A prospective, multi-site observational study – Interim results. Charalampous C, Kuma SK, Parrondo R, Chhabra S, Nagaraj M, Duh MS, Bobbili PJ, Wang A, Chen J, Mohan M, Hlavacek P, Sandin R, Cappelleri JC, Hughes D, Nador G, DiBonaventura M. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 The effect of elranatamab on patient-reported outcomes in patients with relapsed/refractory multiple myeloma naïve and exposed to B-Cell maturation antigen (BCMA)-directed therapies: Updated follow-up from the MagnetisMM-3 study. Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Cappelleri JC, Conte U. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 Symptomatic Progression Free Survival (SPFS): A new endpoint for multiple myeloma combining patient-reported outcomes (PROs) and progression. Kortüm KM, Theurich S, Farrell J, Cappelleri JC, Ashman O, Neff-Baro S, Gauthier A, Jewiti-Rigondza K, Scheid C. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 Patient and caregiver preferences for hemophilia prophylactic treatments: A discrete choice experiment. Lu H, Whitty J, Gould T, Colavecchia C, Coulter J, Dunn N, Chowdary P, Wilcox LJ, Cappelleri JC, Christopher SA, Sohn A, Hauber B. Poster presentation at the 66<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, and online, December 7-10.

2024 The impact for caring for an infant with respiratory syncytial virus on work-related outcomes: Insights from caregivers recruited from Canada, Germany, Italy, and Netherlands. Chen N, Maculaitis MC, Rene C, Deese J, Atwell J, Atwell J, Vichnin M,

Turiga MF, Cappelleri JC, Kopenhafer L, Law AW. Poster presentation at ISPOR EU, Barcelona, Spain, November 17-20.

2024 Health inequalities exist between the United States and Europe for patients with axial spondyloarthritis. Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling Y-L, Cappelleri JC, Sanches-Riera L, Masri K, Hughes M, Massey N. Poster presentation at ACR Convergence 2024, American College of Rheumatology, Washington, D.C., November 14-19.

2024 Understanding gastroenterologist preferences at the time of treatment escalation to first-line advanced therapies in ulcerative colitis: a discrete choice experiment in five European countries. Schreiber S, Walsh A, Hur P, Panattoni L, Hauber B, Gahlon G, Coulter J, Wosik K, Cappelleri JC, Prood N, Guo X, Buisson A. Poster presentation at the American College of Gastroenterology Annual Meeting (ACG 2024), Philadelphia, Pennsylvania, October 25-30; E-poster at United European Gastroenterology (UEG) Week, Vienna, Austria, October 12-15.

2024 Patient reported outcomes of nirmatrelvir/ritonavir treatment for high-risk, nonhospitalized adults with symptomatic COVID-19. Cha-Silva AS, Coetzer H, Gebo K, Ren J, Amie Scott A, Cappelleri JC, Ansari W, Leister-Tebbe H. Poster presentation at IDWeek 2024, Los Angeles, California, October 16-19, 2024.

2024 Six-month trajectory of symptoms of COVID-19 fatigue by age and BNT162b2 COVID-19 vaccination status: A prospective study among symptomatic US Adults testing positive for SARS-CoV-2 at a national retail pharmacy. Di Fusco M, Berk A, Allen K, Porter T, Alvarez M, Cappelleri JC, Moran MM, Sun X. Poster presentation at IDWeek 2024, Los Angeles, California, October 16-19.

2024 Effectiveness of BNT162b2 COVID-19 vaccination against Long COVID among older adults: A nationwide study. Di Fusco M, Rudolph AE, Lupton L, Cappelleri JC, Yehoshua A, Puzniak L, Lopez SMC, Sun X. Poster presentation at IDWeek 2024, Los Angeles, California, October 16-19.

2024 The economic burden of infant RSV among US caregivers. Maculaitis MC, Rene C, Cappelleri JC, Kopenhafer L, Pugh SJ, Alexander-Parrish R, Deese J, Vichnin M, Turiga MF, Chen N, Atwell J, Law AW. Poster presentation at IDWeek 2024, Los Angeles, California, October 16-19.

2024 Updated results of a matching-adjusted indirect comparison (MAIC) of elranatamab (ELRA) versus teclistamab (TEC) in patients (pts) with triple-class exposed (TCE) refractory (TCR) multiple myeloma (MM). Mol, I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador Gu, Aydin D, Cruz IP, Hlavacek P. Poster presentation at the Academy of Managed Care Pharmacy (AMCP), Las Vegas, Nevada, October 14-17.

2024 Relationship between the Pediatric Outcomes Data Collection Instrument (PODCI) and EQ-5D-3L utility score in Duchenne muscular dystrophy. Posner N, Merla V, Aslam Z, Bushmakin AG, Cappelleri JC. R. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Relationship between the Pediatric Outcomes Data Collection Instrument (PODCI) and North Star Ambulatory Assessment (NSAA). Posner N, Merla V, Aslam Z, Bushmakin AG, Cappelleri JC. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Patterns of disease progression in Duchenne muscular dystrophy: heterogeneous changes in motor function task among patients with similar trajectories over one year. Signorovitch J, Johnson M, Gomez-Lievano A, Akbarnejad H, Ma Y, Posner N, Talaga A, Kane A, Aslam Z, Bhambri R, Dukacz S, Cappelleri JC. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Physician and caregiver concordance in Duchenne muscular dystrophy patients in Europe, Japan, and the United States: a multi-national survey. Strober J, Ishigaki K, Posner N, Cappelleri JC, Talaga A, Dukacz S, Aslam Z, Morton E, Iqbal H, Chatterton E, DeCourcy J. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Real-world symptom progression in Duchenne muscular dystrophy patients in Europe, Japan, and the United States: results from a multi-national survey. Strober J, Ishigaki K, Posner N, Cappelleri JC, Talaga A, Dukacz S, Aslam Z, Morton E, Iqbal H, Chatterton E, DeCourcy J. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Meaningful Within-Patient Change (MWPC) thresholds for North Star Ambulatory Assessment (NSAA) and Modified Pediatric Outcomes Data Collection Instrument (PODCI) in patients with Duchenne Muscular Dystrophy (DMD). Posner N, Bushmakin A, Mazar I, Shen Q, Dukacz S, Ines Mo, Aslam Z, Cappelleri JC. Poster presentation at the 29<sup>th</sup> Annual Congress of the World Muscle Society, Prague, Czechia, October 8-12.

2024 Real-world survey on the treatment patterns and neurologist treatment satisfaction for Duchenne muscular dystrophy patients in Japan. Ishigaki K, Nagano M, Shima D, Posner N, Cappelleri JC, Talaga A, Morton E, Iqbal H, Chatterton E, DeCourcy J. Poster presentation at the Joint Conference of the 22<sup>nd</sup> Annual Meeting of Asian and Oceania Myology Center and the 10<sup>th</sup> Annual Meeting of the Japan Muscle Society (AOMS-JSM 2024), Nara, Japan, September 12-15.

2024 Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments. Le H, Coulter J, Cappelleri JC, Lu H, Quaife M, Meginnis K, Fernandez G, Culver K, Vaghela S, Rifi N, Stinchcombe T. Poster presentation at the International Association for the Study of Lung Cancer World Conference on Lung Cancer 2024, San Diego, CA, September 7-10.

2024 UK and US patient preferences for tyrosine kinase inhibitors in ALK+ advanced non-small cell lung cancer in the first-line setting. anaplastic lymphoma kinase positive advanced non-small cell lung cancer tyrosine kinase inhibitors treatments. Culver K, Montague D, Le H, Coulter J, Cappelleri JC, Lu H, Quaife M, Meginnis K, Fernandez G, Vaghela S, Rifi N, Stinchcombe TE. E-poster presentation at the 2024 World Conference on Lung Cancer, San Diego, California, September 7-10.

2024 Real-world clinical outcomes for Duchenne muscular dystrophy patients in Europe: results from a multi-national survey. Merla V, Posner N, Cappelleri JC, Talaga A, Dukacz S, Aslam Z, Morton E, Chatterton E, Iqbal H, Hatchell N. E-presentation at the 10<sup>th</sup> European Academy of Neurology (EAN) EAN Congress, Helsinki, Finland, June 29 – July 2.

2024 Impact of Duchenne muscular dystrophy on caregiver employment and quality of life: A real-world survey in France, Germany, and Spain. Merla V, Posner N, Cappelleri JC, Talaga A, Dukacz S, Aslam Z, Morton E, Chatterton E, Iqbal H, Hatchell N. E-presentation at the 10<sup>th</sup> European Academy of Neurology (EAN) EAN Congress, Helsinki, Finland, June 29 – July 2.

2024 Flora Dr, Byrd R, Platt D, Hlavacek P, Goldman EH, Cappelleri JC, Kennedy CT, LeBlanc TW. Multiple myeloma experiences and preferences: A qualitative study of patients and care partners. Poster presentation at the European Hematology Association (EHA) 2024, Madrid, Spain, June 13-16.

2024 Updated results of a matching-adjusted indirect comparison of elranatamab versus telistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. E-poster presentation at the European Hematology Association (EHA) 2024 Hybrid Congress, Madrid, Spain, June 13-16.

2024 Efficacy of elranatamab and teclistamab in triple-class exposed/refractory multiple myeloma (TCE/R MM): a matching-adjusted indirect comparison (MAIC). Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Take K, Moribe T, Hlavacek P. Oral presentation at the 2024 Japanese Society of Hematology Annual Meeting, Fukuoka City, Japan, May 31-June 2.

2024 Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapy.” Jairath V,

Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, Bartolome L. Poster presentation at Digestive Disease Week (DDW) 2024, Washington, D.C., May 18-21.

2024 Patient and oncologist preferences for anaplastic lymphoma kinase preferences for anaplastic lymphoma kinase positive advanced non-small cell lung cancer (ALK+aNSCLC) tyrosine kinase inhibitors (TKIs) treatment in the first line (1L) setting. Le H, Coulter J, Cappelleri JC, Lu H, Quaife M, Meginnis K, Fernandez G, Culver K, Vaghela S, Thomaidou D, Thomas StinchcombeT. Poster presentation at ISPOR 2024, Atlanta, Georgia, May 5-8.

2024 Health state transition probabilities for Duchenne muscular dystrophy: Estimation from published data. Signorovitch J, Gomez-Lievano A, Johnson M, Posner N, Merla V, Arkbarnejad H, Ma Y, Dukacz S, Aslam Z, Cislo P, Cappelleri JC. Poster presentation at ISPOR 2024, Atlanta, Georgia, May 5-8.

2024 Impact of COVID-19 vaccination with BNT162b2 on the frequency of acute symptoms among symptomatic US adults testing positive for SARS-CoV-2 at a national retail pharmacy. Di Fusco M, Cappelleri JC, Yehoshua A, Alvarez MB, Allen KE, Porter TM, Berk A, Puzniak Laura Lopez SMC, Sun X. Poster presentation at ISPOR 2024, Atlanta, Georgia, May 5-8.

2024 Role of video versus text information in willingness to be vaccinated for invasive meningococcal disease among US adolescents/young adults and parents. Schley K, Whichello C, Hauber B, Krucien N, Cappelleri JC, Peyrani P, Presa JV, Coulter J, Heidenreich S. Poster presentation at ISPOR 2024, Atlanta, Georgia, May 5-8.

2024 Prediction of long-term factor IX durability among hemophilia B patients treated with fidanacogene elaparovec gene therapy. Morris A, Ortega L, Thakkar S, Wilcox L, Cappelleri JC, Incerti D, Ines M, Deb P, Chhabra A, Vytlacil E, Batt K, Lakdawalla D. Poster presentation at ISPOR 2024, Atlanta, Georgia, May 5-8.

2024 Descriptive analysis of self-reported HRQoL using EQ-5D-5L among symptomatic outpatients with COVID-19 in the US during an Omicron predominant period. Cha-Silva AS, Cappelleri JC, Di Fusco M, Ren J, Allen KE, Puzniak L, Sun X. Poster presentation at the 34<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 27-30.

2024 Clinical efficacy of interventions for adult patients with moderately severe to severe hemophilia B: An indirect treatment comparison with fidancogene elaparovec. Thakkar S, Cappelleri JC, Merla V, Wilcox LJ, Chhabra A, Jin H, Lindsley K, Uyei J. Co-authored abstract accepted as a moderated poster presentation at the World Federation of Hemophilia (WFH) 2024, Madrid, Spain, April 21-24.

2024 Implications of the estimated framework for the imputation and analysis of quality of life in single-arm trials. Thomassen D, Roychoudhury S, Delphin C, Reynders D, Musoro JZ, Sauerbrei W, Goetghebeur E, le Cessie S, on behalf of SISAQO-IMI Work Package 3. Poster presentation at the European Causal Inference Meeting (EUROCIM), Copenhagen, Denmark, April 17-19.

2024 Identifying gaps in knowledge and patient communication among healthcare providers in the United States: Factors associated with increased risk of severe COVID-19 outcomes. Ashkenazy R, Maculaitis MC, Alexander-Parrish R, Rudolph AE, Allen KE, Cha-Silva AS, Kopenhafer L, Ren J, Wiemken TL, Cappelleri JC. Poster presentation at the American Pharmacists Association 2024 Annual Meeting and Exposition, Orlando, Florida, March 22-25.

2024 Relationships among abrocitinib treatment, itch, skin clearance, anxiety, and depression: A mediation modeling analysis. Silverberg JI, Dytoc M, Gooderham MJ, Yosipovitch G, Bushmakin AG, Cappelleri JC, Güler E, Myers DE, Rohr CS. Poster presentation at the American Academy of Dermatology (AAD) Annual Meeting, San Diego, California, March 8-12.

2023-

2024 Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial. Blum JL, Rocque G, Ji Y, Pluard T, Migas J, Lakanpal S, Jepsen, Gauthier E, Montelongo ML, Cappelleri JC, Chen C, Karuturi M, Tripathy D. Encore poster presentation at the 41<sup>st</sup> Annual Miami Breast Cancer Conference, Miami, Florida, March 7-10, 2024; poster presentation at ESMO Breast Cancer, Madrid, Spain, October 20-24, 2023.

2023-

2024 Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trials. Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Chen C, Karuturi MS, Tripathy D. Encore poster presentation at the 41<sup>st</sup> Annual Miami Breast Cancer Conference, Miami, Florida, March 7-10, 2024; poster presentation at the 2023 San Antonio Breast Cancer Symposium, San Antonio, Texas, December 5-9, 2023.

2024 Relationship between North Star Ambulatory Assessment (NSAA) total score and EQ-5D-3L utility scores: Impact of motor function and patient's quality of life. Merla V, Posner N, Cappelleri JC, Bushmakin AG, Xiao S. Poster presentation at the 2024 Muscular

Dystrophy Association (MDA) Clinical & Scientific Conference, Orlando, Florida, March 3-6.

2024 Observational study of tofacitinib in ulcerative colitis in Sweden (ODEN) - Interim analysis of clinical and biomarker data. Nyberg L, Söderling J, Olén O, Strid H, Halfvarson J, Hedin C, Jónsdóttir S, Hjortswang H, Cappelleri JC, Henrohn D, Seddighzadeh M, Marsal J, Grip O. Poster presentation at the European Crohn's and Colitis Organisation (ECCO) 2024 Congress, Stockholm, Sweden, February 21-24.

2024 Observational study of tofacitinib in ulcerative colitis in Sweden (ODEN) - Interim analysis health-related quality of life and fatigue. Nyberg L, Söderling J, Olén O, Strid H, Halfvarson J, Hedin C, Jónsdóttir S, Hjortswang H, Cappelleri JC, Henrohn D, Seddighzadeh M, Marsal J, Grip O. Poster presentation at the European Crohn's and Colitis Organisation (ECCO) 2024 Congress, Stockholm, Sweden, February 21-24.

2024 Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapy. Jairath V, Leahy TP, Potluri R, Wosik K, Gruben D, Cappelleri JC, Bartolome L. Poster presentation at the 19<sup>th</sup> Congress of the European Crohn's and Colitis Organization (ECCO) – Inflammatory Bowel Diseases, Stockholm, Sweden, February 21-24.

2024 Psychometric evaluation of the Haem-A-QoL in adults with haemophilia B. Thakkar S, Kawata AK, Bushmakin AG, Lenderking WR, Cappelleri JC, Ines M, Melin V, Daniele P, Clucas C. Poster presentation at the 17<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Frankfurt, Germany, February 6-9.

2024 The Haemophilia Activities List: Psychometric evaluation in adults with haemophilia B. Thakkar S, Kawata AK, Bushmakin AG, Lenderking WR, Cappelleri JC, Ines M, Melin V, Daniele P, Clucas C. Poster presentation at the 17<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Frankfurt, Germany, February 6-9.

2023 A matching-adjusted indirect comparison of the efficacy of elranatamab and teclistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P. Poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, December 9-12.

2023 Sex difference in perceptions of psoriatic arthritis disease impact, management, and physician interactions: Results from a global patient survey. Eder L, Richette P, Coates L, Azevedo VF, Cappelleri JC, Hoang M, Moser J, Kinch C, Kessouri M. Oral presentation at the 36<sup>th</sup> French Rheumatology Congress, Paris, France, December 10-12.

2023 Validation of Skin Pain Numerical Rating Scale of Pruritus and Symptoms Assessment for atopic dermatitis in adults and adolescents with moderate-to-severe atopic dermatitis. Silverberg JI, Ständer S, Kim BS, Bewley A, Misery L, Vestergaard C, Gooderham MJ, Bushmakin AG, Cappelleri JC, Güler E, Alderfer J, Watkins M, Selfridge A, Myers DE. Poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 10.

2023 A parametric method for unanchored matching-adjusted indirect treatment comparison (MAIC) based on survival outcomes for health economic (HE) models in absence of proportional hazards (PH). Mol I, Liu Y, Hu Y, Hlavacek P, Cappelleri JC, Chu H, Aydin D, Nader G, Heeg B. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Clinical efficacy and safety of interventions for adult patients with moderately severe to severe hemophilia B: A systematic review. Thakkar S, Cappelleri JC, Merla V, Wilcox L, Chhabra A, Jin H, Lindsley k, Uyei J. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Real-world data establishing HCRU and costs for the treatment of patients with intermediate- to high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) utilizing Medicare claims data. Petrilla A, Silverstein A, Bello T, Eccleston A, Chandrasekar S, Chang J, Cappelleri J, Brinkmann J, Schroeder A. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 The impact of Duchenne muscular dystrophy on caregiver employment: A survey in Europe, Japan, and the United States. Strober J, Ishigaki K, Merla V, Posner N, Cappelleri JC, Xiao S, Talaga A, Brunner S, Morton E, Olsen S, De Courcy J. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Healthcare resource utilisation for paediatric and adolescent Duchenne muscular dystrophy patients: analysis of real-world data. Strober J, Ishigaki K, Merla V, Posner N, Cappelleri JC, Xiao S, Talaga A, Brunner S, Halima I, Chatterton E, Hatchell H. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Progressive disease milestones and survival in Duchene Muscular Dystrophy (DMD): A model-based synthesis for extrapolating lifetime treatment effects from clinical trial results. Smith EC, Poser N, Signorovitch J, Johnson M, Merla V, Gomez-Lievano A, Zhang A, Sharma A, Inês M, Cappelleri JC, Cislo P. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Drivers of treatment preferences in high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients: Qualitative interviews to inform a patient-preference study. Mason B, Eccleston A, Gater A, Hauber B, Thompson A, Coulter J, Guy M, Ayala-Nunes L, Brinkmann J, Hallworth P, Cappelleri JC, Bell B, Chang J, Satkunasivam R. Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12-15.

2023 Sex differences in perceptions of psoriatic arthritis disease impact, management, and physician interactions: Results from a global patient survey. Eder L, Richette P, Coates L, Azevedo VF, Cappelleri JC, Hoang M, Moser J, Kessouri M. Poster presentation at ACR Convergence 2023, San Diego, California, November 10-15.

2023 Sample size decisions for discrete choice experiments in pharmaceutical and health care applications. Boeri M, Garczarek U, Krucien N, Vass C, Heindenreich S, Cappelleri JC, Janssen E, Robert V, Saint-hilary G, Mt-Isa S. Oral presentation at the Society for Medical Decision Making 45<sup>th</sup> North America Meeting, Philadelphia, Pennsylvania, October 22-25.

2023 Impact of tofacitinib maintenance therapy on key ulcerative colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies. Dubinsky MC, Gardiner S, Hur P, Guo X, Paulissen J, Cappelleri JC, Bushmakin, Panés J. Poster presentation at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, Vancouver, Canada, October 20-25.

2023 Relationship between Northstar Ambulatory Assessment (NSAA) and EQ-5D-3L utility score: Impact of motor function on patient's quality of life. Posner N, Merla V, Cappelleri JC, Bushmakin AG, Xiao S. Poster presentation at the National Organization for Rare Disorders (NORD) Rare Disease Orphan Products Breakthrough Summit, Washington, DC, October 15-17.

2023 Interpreting the relationships among abrocitinib treatment, itch, skin pain, and health-related quality of life: A mediation modeling analysis of JADE MONO-1 and JADE MONO-2. Silverberg JI, Ständer S, Kim BS, Bewley A, Misery L, Bushmakin AG, Cappelleri JC, Guler E, Alderfer J, Watkins M, Chan G, Myers DE. Poster presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2023. Berlin, Germany, October 11-14.

2023 Efficacy of once-weekly treatment for paediatric growth hormone deficiency: A systematic literature review and indirect treatment comparison. Schaible K, Huelin R, Loftus J, Nijher M, Neupane B, Cappelleri JC, Fahrbach K. Poster presentation at the 61<sup>st</sup> Annual European Society for Paediatric Endocrinology (ESPE) Meeting, The Hague, Netherlands, September 21-23.

2023 Developing recommendations to handle patient reported outcome data in oncology cancer trials: SISAQOL-IMI. le Cessie S, Thomassen D, Goetghebeur E, on behalf of work package 3 of the SISAQOL-IMI consortium. Oral presentation at the International Society of Clinical Biostatistics, Milan, Italy, August 27-31.

2023 Imputation methods for longitudinal patient reported outcomes in the presence of death and other intercurrent events. Thomassen D, Roychoudhury S, Amdal Delphin C, Liu L, Musoro JZ, Sauerbrei W, le Cessie S, Goetghebeur E, on behalf of SISAQOL-IMI Work Package 3. Oral presentation at the International Society of Clinical Biostatistics, Milan, Italy, August 27-31.

2023 Comparing quality of life - while alive - between treatment and (external) controls: methods for real world analysis in clinical trials. Els Goetghebeur E, Reynders D, Thomassen D and le Cessie Sm on behalf of work package 3 of the SISAQOL-IMI consortium. Oral presentation at the International Society of Clinical Biostatistics, Milan, Italy, August 27-31.

2023 Zero-inflated bivariate generalized linear mixed model for meta analysis of double-zero-event study. Li L, Lin L, Cappelleri JC, Chu H, Chen Y. Oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 5-10.

2023 Non-collapsible effect measure can falsely yield small-study effects. Zhang B, Liu Z, Xu J, Tong J, Lin L, Chu H, Cappelleri JC, Chen Y. Oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 5-10.

2023 A review and comparison of arm-based vs. contrast-based network meta-analysis for binary outcomes. Chu H, Lin L, Chen Y, Cappelleri JC. Oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 5-10.

2023 The need for data literacy and data science education in modern society. Gascon G, Pierson S, Wu E, Ravula S, Cappelleri JC, Lum K, Nagaraja C, Paul S, Wallman K. Oral presentation at the Joint Statistical Meetings, Toronto, Canada, August 5-10.

2023 Characterizing the preferences of pregnant people for preventives to protect their infants against respiratory syncytial virus. Beusterien KM, Law A, Maculaitis MC, Will O, Kopenhafer L, Olsen P, Hauber A, Vietri JT, Cappelleri JC, Coulter J, Shea K. Poster presentation at the 2023 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting, Denver, Colorado, July 27-29.

2023 Indirect treatment comparison of elranatamab with belmaf. sele-dex, and real-world physician's choice of treatment in patients with triple-class exposed relapsed/refractory multiple myeloma. Mol I, Hu Y, Cappelleri JC, Chu H, Aydin D, Hlavacek P. Poster

presentation at the European Hematology Association (EHA) 2023 Hybrid Congress, Frankfurt, Germany, and virtual, June 8-15.

2023 Sex differences in perceptions of psoriatic arthritis disease impact, management and physician interaction: results from a global patient survey. Eder L, Richette P, Coates LC, Azevedo V, Cappelleri JC, Hoang M, Moser J, Kinch C, Kessouri M. Oral presentation at the European Congress of Rheumatology (EULAR) 2023, Milan, Italy, May 31-June 3.

2023 Time to improvement of pain, morning stiffness and disease activity in patients with ankylosing spondylitis treated with tofacitinib. Navarro-Compán V, Deodhar A, Bahiri R, Bushmakin A, Cappelleri J, Kinch C, Rammaoui J. Poster presentation at the European Congress of Rheumatology (EULAR) 2023, Milan, Italy, May 31-June 3.

2023 The role of registries in overcoming lack of data in oncology and rare diseases. Ren J, Cappelleri JC. Invited oral presentation at Real-World External Data US, Online Conference, May 23, 2023.

2023 Mason B, Mesana L, Hallworth P, di Pietro A, Randhawa S, Rezai N, Hughes O, Guenzel C, Gater A, Chen K, Clifford M, Hauber B, Marin L, Cappelleri JC. Quantifying patient preferences for targeted therapies in metastatic melanoma: A discrete-choice experiment. Poster presentation at ISPOR 2023, Boston, Massachusetts, May 7-10.

2023 What drives the views of young people (16–23 years) and parents on invasive meningococcal disease and their willingness to vaccinate? Schley K, Heidenreich S, Michaels-Igbokwe C, Whichello C, Venkatraman M, Presa J, Peyrani P, Coulter J, Cappelleri JC, Hauber B. Poster presentation at ISPOR 2023, Boston, Massachusetts, May 7-10.

2023 Some considerations and guidance for analyzing clinically meaningful change using anchor-based method. Ren J, Cappelleri JC, Giesinger JM. Poster presentation at ISPOR 2023, Boston, Massachusetts, May 7-10.

2023 Impact of tofacitinib maintenance therapy on key ulcerative colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies. Dubinsky MC, Gardiner S, Hur P, Guo X, Paulissen J, Cappelleri JC, Bushmakin AG, Panés J. Poster presentation at the 18<sup>th</sup> Congress of European Crohn's and Colitis Organisation (ECCO) 2023, Copenhagen, Denmark, March 1-4, 2023, and at Digestive Disease Week (DDW) 2023, Chicago, Illinois, and virtually, May 6–9, 2023.

2023 US healthcare providers' performance and willingness to recommend novel RSV preventives to protect infants: a discrete choice experiment. Beusterien KM, Law A,

Kopenhafer L, Maculaitis MC, Olsen P, Will O, Hauber B, Vietri JT, Yacisin K, Cappelleri JC, Coulter J, Shea K. Poster presentation at RSVVW '23: A Global Conference on Novel RSV Preventive and Therapeutic Interventions – 7<sup>th</sup> Respiratory Syncytial Virus Foundation (ReSViNET) Conference, Lisbon, Portugal, February 22-24.

2023 Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate-to high-risk non-muscle invasive bladder cancer, 2010-2019. Petrilla AA, Silverstein AR, Eccleston A, Thompson A, Brinkmann J, Bello T, Chang J, Cappelleri JC, Chandrasekar S, Schroeder AL. Poster presentation at the ASCO Genitourinary Cancers Symposium, San Francisco, California, February 16-18.

2023 A comparison of arm-based vs. contrast-based network meta-analysis for binary outcomes. Chu H, Lin L, Wang Z, Chen Y, Cappelleri JC. Oral presentation at the 14<sup>th</sup> International Conference on Health Policy Statistics, Scottsdale, Arizona, January 9-11.

2022-

2023 The role of registries in overcoming lack of data in oncology and rare diseases. Ren J, Cappelleri JC. Invited oral presentation at Real-World External Data US, Online Conference, May 23, 2023; Next Generation Real-World Registries, Online Conference, February 22-23, 2022.

2022 Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib. Gossec L, Celli D, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad, Dina O. Poster presentation at SFR Hybrid Congress, Paris, France, December 11-13.

2022 Examining the relationships among abrocitinib treatment, itch, skin pain, and work and activity impairments in patients with atopic dermatitis: A mediation modeling analysis. Silverberg JI, Ständer S, Thyssen JP, Kim BS, Castro C, Bewley A, Misery L, Bushmakin AG, Cappelleri JC, Guler E, Alderfer J, Watkins M, Chan G, Myers DE. Poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 11.

2022 Examining the relationships among abrocitinib treatment, itch, skin pain, and dermatology-specific quality of life in patients with atopic dermatitis: A mediation modeling analysis. Silverberg JI, Ständer S, Thyssen JP, Kim BS, Castro C, Bewley A, Misery L, Bushmakin AG, Cappelleri JC, Guler E, Alderfer J, Watkins M, Chan G, Myers DE. Oral presentation at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 11.

2022 Systematic literature review of the ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators. Dubinsky M, Rice A, Yarlas A, Hur P, Cappelleri JC,

Kulisek N, Fahrny A, Bushmakin A, Biedermann L. Poster presentation at Advances in Inflammatory Bowel Diseases (AIBD) 2022, Orlando, Florida, December 5-7.

2022 Psychosocial, humanistic, and economic burden of moderate-to-severe atopic dermatitis in China: Analysis of a cross-sectional survey. Zhang J, Deng Y, Pan S, Yue L, Encinas G, Maculaitis MC, Cappelleri JC, DiBonaventura M, Myers DE. Poster presentation at the 18<sup>th</sup> Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology, Shanghai, China, and virtual, November 18-20.

2022 Relationships between work productivity, activity impairment and select patient-reported outcomes in patients with ankylosing spondylitis: A post hoc analysis of two placebo-controlled trials. Magrey M, Wei Cheng-Chung J, Yndestad A, Bushmakin AG, Cappelleri JC, Dina O, Deodhar A. Poster presentation at the American College of Rheumatology (ACR) Convergence 2022, Philadelphia, Pennsylvania, November 10-14.

2022 Evaluating the impact of exact logistic regression on matching adjusted indirect comparisons (MAICs) of treatments between trials: A simulation study. Moradian H, Tremblay G, Senchaudhuri P, Heeg B, Zabriskle BN, Corcovan C, Chu H, Cappelleri JC. Poster presentation at ISPOR Europe 2022, Vienna, Austria, and virtual, November 6-9.

2022 Bayesian hierarchical model-based network met-analysis to overcome survival extrapolation challenges caused by immature data: Application in previously treated metastatic non-small cell lung cancer (NSCLC) PD-L1 > 1%. Heeg B, Verhoek A, Tremblay G, Chu H, Roychoudhury S, Cappelleri J, Harari O, Soltanifer M, Ouwens M. Poster presentation at ISPOR Europe 2022, Vienna, Austria, and virtual, November 6-9.

2022 Generalizing the distribution and dynamics of health outcomes in clinical trials of novel treatments of rare disease for the real-world. Incerti D, Lakdawalla DN, Dorling P, Deb P, Vytlacil E, Morris A, Cappelleri JC. Poster presentation at ISPOR Europe 2022 – 25<sup>th</sup> Annual European Congress, Vienna, Austria, and virtual, November 6-9.

2022 Preferences for a *Clostridioides difficile* vaccine among adults in the United States. Vietri J, Maculaitis MC, Cappelleri JC, Yu H, Kopenhafer L, Yacisin K, Moran MM, Beusterien K. Poster presentation at IDWeek 2022, Washington, DC, October 19-23.

2022 Health disparities, social determinants of health, and emotional impacts in patients with ulcerative colitis: Results from a global ulcerative colitis patient survey. Odufalu F-D, Dubinsky M, Peyrin-Biroulet L, Ylänné K, Sipes A, Cappelleri JC, Russo LJ, Segovia M, Gardiner S, Johnson P, Mulvey A, Panaccione R. Poster presentation at the American College of Gastroenterology Annual Scientific Meeting, Charlotte, North Carolina, and virtual. October 21-26. (Winner of “Outstanding Presenter Award.”)

2022 Direct and indirect effects of tofacitinib on work productivity in patients with ulcerative colitis: A mediation analysis between work productivity and the Mayo score. Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J. Poster presentation at the American College of Gastroenterology Annual Scientific Meeting, Charlotte, North Carolina, and virtual. October 21-26.

2022 Indirect effects of tofacitinib on work productivity in patients with ulcerative colitis: A mediation analysis between work productivity and the Inflammatory Bowel Disease Questionnaire. Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J. Poster presentation at the American College of Gastroenterology Annual Scientific Meeting, Charlotte, North Carolina, and virtual. October 21-26.

2022 Relationship between disease severity as assessed by the Mayo score and work productivity in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction and maintenance studies. Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J. Poster presentations at the United European Gastroenterology (UEG) Week 2022, Vienna, Austria, and virtual, October 8-11.

2022 Relationship between health-related quality of life and work productivity in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction and maintenance studies. Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J. Poster presentations at the United European Gastroenterology (UEG) Week 2022, Vienna, Austria, and virtual, October 8-11, at the American College of Gastroenterology Annual Scientific Meeting, Charlotte, North Carolina, and virtual. October 21-26. (Winner of “Outstanding Presenter Award.”)

2022 The impact of the COVID-19 pandemic on patients with ulcerative colitis: results from a global UC Narrative survey. Peyrin-Biroulet L, Yläne K, Sipes A, Segovia M, Gardiner S, Cappelleri JC, Mulvey A, Panaccione R. Poster presentation at the United European Gastroenterology (UEG) Week 2022, Vienna, Austria, and virtual, October 8-11.

2022 Real-world quality of life (QoL) in patients with HR+/HER2 – advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS. Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier

E, Wang Y, Montelongo M, Cappelleri JC, Karuturi MS, Tripathy D. Poster presentation at the European Society for Medical Oncology (ESMO) Congress 2022, Paris, France, September 9-13.

2022 Preferences for topical treatment in patients with mild-to-moderate atopic dermatitis. Feldman SR, Thyssen JP, Marco Boeri M, Gerber R, Neary MP, Cha A, Hauber B, Cappelleri JC, Xenakis J, Leach C, Zeichner J. E-poster presentation at the 31<sup>st</sup> European Academy of Dermatology and Venereology (EADV) Congress, Milan, Italy, and online, September 8-10.

2022 Developing international standards in the analysis of patient reported outcomes in cancer clinical trials: methodological issues and STRATOS engagement in the European IMI-SISAQOL project. le Cessie S, Liu L, Thomassen D, Goethgebeur E on behalf of work package 3 of SISAQOL. Oral presentation at the 43<sup>rd</sup> Annual Conference of the International Society of Clinical Biostatisticians, STRATOS (STRengthening Analytical Thinking for Observational Studies) Mini-Symposium, Newcastle, United Kingdom, and virtual, August 21-25.

2022 Humanistic, economic, and psychosocial burden of moderate-to-severe atopic dermatitis in Taiwan: Cross-sectional survey analysis. Chu C-Y, Kuo E, Wee Ja, Yue L, Encinas GA, Maculaitis MC, Cappelleri JC, Myers DE, DiBonaventura M. Poster presentation at the Taiwanese Association for Psoriasis and Skin Immunology (TAPSI) Annual Conference, Taiwan, June 25-26.

2022 Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib. Gossec L, Celli D, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Oluwaseyi D. Poster tour and presentation at the Annual European Congress of Rheumatology EULAR 2022, Copenhagen, Denmark, and virtual. June 1-4.

2022 Patient preferences for ulcerative colitis treatment in the Middle East region: Results from a discrete choice experiment. AlHarbi O, Farsakh NA, Al-Awadhi S, Al-Taweel T, Mikhail I, Batwa F, Bedran K, Balkan D, Cappelleri JC, Boeri M, Habjoka S, Mosli M. Poster presentation at Digestive Disease Week (DDW) 2022, San Diego, California, and virtual, May 21-24.

2022 The burden of high-risk non-muscle invasive bladder cancer among patients treated with Bacillus Calmette-Guerin. Kopenhafer L, Chang J, Thompson A, Sikirica S, Masters ET, Cappelleri JC, Peck EY, Maculaitis MC. Poster presentation at ISPOR 2022, Washington, D.C., and virtual, May 15-18.

2022 Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with an unmeasured

confounder: A simulation study. Ren J, Cislo P, Cappelleri JC, Hlavacek P, DiBonaventura M. Podium presentation at ISPOR 2022, Washington, D.C., and virtual, May 15-18.

2022 Humanistic, economic, and psychosocial burden in adults with moderate-to-severe atopic dermatitis in Brazil: Analysis of a cross-sectional survey. Pires M, Maculaitis MC, Cappelleri JC, Seugling F, Encinas GA, Myers DE, DiBonaventura M. E-poster presentation at Reunión Anual de Dermatólogos Latinoamericanos (RADLA) 2022 Virtual Congress, May 5-8.

2022 Patient experience and unmet needs in high-risk non-muscle invasive bladder cancer. Kopenhafer, L, Sikirica S, Masters ET, Cappelleri JC, Peck EY, Maculaitis MC. Poster presentation at the Academy of Managed Care Pharmacy (AMCP) 2022, Chicago, Illinois, March 29-April 1.

2022 Gooderham MJ, Lebwohl MG, Simpson EL, Wollenberg A, Bushmakin AG, Cappelleri JC, DiBonaventura M, Rojo R, Watkins M, Valdez H, Myers DE. Time to improvement in daily signs and symptoms associated with atopic dermatitis (AD) in patients with moderate-to-severe AD in pooled monotherapy studies of abrocitinib. Poster and oral presentations at the American Academy of Dermatology (AAD) 2022 Annual Meeting, Boston, Massachusetts, March 25-29.

2022 Design and analysis of externally controlled studies. Ren J, Cappelleri JC. Invited oral presentation at the PROMETRIKA Webinar Series: Keys to a Successful Natural History Study – A Statistical Problem At Its Core. January 27.

2021 Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS. Karuturi M, Rocque GB, Cappelleri JC, Blum J, McCune S, Bijoy Telivala B, Kurian S, Anderson D, Pluard T, Migas J, Wang Y, Montelongo MZ, Tripathy D. Poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS) – 44<sup>th</sup> Annual Meeting, San Antonio, Texas, December 7–10.

2021 Relationship between dermatologic and health-related quality of life in patients with psoriatic arthritis: post hoc analysis of two Phase 3 studies. Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch. Poster presentation at the American College of Rheumatology (ACR) 2021 Virtual Annual Meeting. November 3-10.

2021 Examining the relationship between treatment and pain and physical function outcomes in patients with osteoarthritis: a mediation modeling approach. Abraham L, Dworkin RH, Turk DC, Markman JD, Williams DA, Bushmakin AG, Hall JA, Semel DC,

Cappelleri JC, Yang R. Poster presentation at the American College of Rheumatology (ACR) 2021 Virtual Annual Meeting. November 3-10.

2021 Novel and existing flexible survival methods for network meta-analyses. Heeg B, Garcia A, van Beekhuizen S, Verboek A, Roychoudhury S, Cappelleri JC, Postma MJ, Ouwens MJNM. Podium presentation at Virtual ISPOR Europe 2021, December 1-3.

2021 Network meta-interpolation: A fast novel NMA approach accounting for effect modification. Heeg B, Garcia A, van Beekhulzen S, Verhoek A, Roychoudhury S, Cappelleri JC, Postma MJ, Ouwens MJNM. Poster presentation at Virtual ISPOR Europe 2021, December 1-3.

2021 Pre/perimenopausal (Premeno) women receiving palbociclib (PAL) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER 2-) advanced breast cancer (ABC) in a real-world setting: Treatment patterns for POLARIS. Karuturi MS, Garrett A, Blum JL, Andersen J, Jepsen E, Pluard T, Stanton T, Manning K, Cappelleri JC, Wang Y, Tripathy D. Encore poster presentation at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021 Virtual Conference, October 18-21.

2021 Characteristics and real world treatment history of patients treated with tofacitinib for ulcerative colitis in Europe. Armuzzi A, Hart A, Sharma PP, Hoskin B, Woolcott J, Mammar N, Hennessy F, Cappelleri JC, Milligan G, Dignass A. Poster presentation at the United European Gastroenterology Week Virtual – 29<sup>th</sup> Annual Congress, October 3-5.

2021 Treatment satisfaction with medications prescribed for osteoarthritis: Cross-sectional surveys with patients and physicians in the United States. Schnitzer TJ, Robinson RL, Jackson J, Tive L, Jackson J, Berry M, Barlow S, Viktrup L. Poster presentation at the American Academy of Family Physicians 2021 Annual Meeting – Family Medicine Experience, Anaheim, California, September 28-October 2.

2021 Meaningful within-patient change for patient-reported outcome measures: Model-based approach versus cumulative distribution functions. Ren J, Bushmakin A, Cislo P, Cappelleri JC. Poster presentation at the 40<sup>th</sup> Annual American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop (Virtual), September 21-24.

2021 Treatment patterns in Black and Indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2- negative (HER 2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results. Rocque GB, Blum J, Montero A, Sonnier S, McCune S, Gallagher C, Pluard T, Cappelleri JC, Drucker M, Wang Y, Tripathy D. E-poster

presentation at the 46<sup>th</sup> Congress of the European Society for Medical Oncology Congress – ESMO 2021 (Virtual), September 16-21.

2021 Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC). Ajmera M, Chang J, Hitchens A, Kearney M, Esterberg E, Kim R, Cappelleri JC, Devgan G, Costa N, Candrilli S. E-poster presentation at the 46<sup>th</sup> Congress of the European Society for Medical Oncology Congress – ESMO 2021 (Virtual), September 16-21.

2021 Examining the relationships between treatment and pain and physical function outcomes in patients with osteoarthritis: A mediation modeling approach. Abraham L, Dworkin RH, Turk DC, Markman JD, Williams DA, Bushmakin AG, Hall JA, Semel DC, Cappelleri JC, Yang R. Poster presentation at WCO-IOF-ESCEO (World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases) 2021 Virtual Congress, August 26-28.

2021 Meaningful improvements in WOMAC pain and physical function in three phase 3 trials of tanezumab in patients with moderate-to-severe osteoarthritis: A responder analysis. Conaghan PC, Dworkin RH, Schnitzer TJ, Berenbaum F, Yang R, Bushmakin AG, Cappelleri JC, Brown MT, Viktrup L, Abraham L. Oral presentation and poster presentation at WCO-IOF-ESCEO (World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases) 2021 Virtual Congress, August 26-28.

2021 Handling multiple imputation in Wilcoxon signed-rank test: A case study applied to a haemophilia clinical trial. Hwang E, Cappelleri J, Roychoudhury R, Meyer D. Speed presentation at the 2021 Joint Statistical Meetings Virtual Conference, August 8-12.

2021 Matching-adjusted indirect comparison of crisaborole ointment 2% vs topical calcineurin inhibitors in the treatment of patients with mild-to-moderate atopic dermatitis. Thom H, Cheng V, Keeney E, Eceleston A, Zang C, Cappelleri JC, Cha A, Neary MP. E-poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, Madrid, Spain (digital) and Kraskow, Poland (hybrid), July 10-12.

2021 Longitudinal patient pathways in atopic dermatitis: a retrospective population-based cohort study in Swedish routine clinical care. von Kobyletzki L, Ballardini N, Neregård P, Neary MP, Ortsäter G, Lindberg I, Geale K, Dun AR, Henrohn D, De Geer A, Cha A, Cappelleri JC, Romero W, Thyssen JP. E-poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, Madrid, Spain (digital) and Kraskow, Poland (hybrid), July 10-12.

2021 Comorbidities in Adult Atopic Dermatitis: A Retrospective Population-Based Matched Cohort Study in Sweden. Thyssen JP, Henrohn, Neary MP, Geale K, Dun AR, Ortsäter

G, Lindberg I, Neregård P, De Geer A, Cha A, Cappelleri JC, Romero W, von Kobyletzki L. E-poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, Madrid, Spain (digital) and Kraskow, Poland (hybrid), July 10-12.

2021 Novel and existing time-to-event extrapolation techniques for network meta-analyses: Recommendations for health technology assessments. Heeg B, Garcia A, van Beekhuizen S, Verhoek A, van Oostrum I, Roychoudhury S, Cappelleri JC, Postma MJ, Ouwens MJNM. Poster presentation at 2021 Virtual Annual Meeting of the Society for Research Synthesis Methods, June 29-July 1.

2021 Adjusting global survival to make results more relevant and generalizable to local markets. Cislo PR, Ren J, Cappelleri JC. Invited oral presentation at the virtual seminar “Precision & Innovative Medicine and Health Technology Assessment,” co-hosted by the Basel Biometric Society and the European Federation of Statisticians in the Pharmaceutical Industry, June 28.

2021 Interpreting the relationship between pruritus, function and quality of life in patients with moderate-to-severe atopic dermatitis: A post hoc analysis of JADE MONO-1 and MONO-2. Gooderham MJ, Yosipovitch G, Ständer S, Fonacier L, Szepietowski JC, Deleuran M, Girolomoni G, Bushmakin AG, Cappelleri JC, Watkins M, Feeney C, Valdez H, Rojo R, DiBonaventura M, Myers DE. Oral presentation and poster presentation at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, June 13.

2021 Psychometric evaluation of Functional Assessment of Chronic Illness Therapy – Fatigue in patients with active ankylosing spondylitis. Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, Cappelleri JC, Navarro-Compán. Oral presentation at EULAR (European Alliance of Associations for Rheumatology) 2021 - Annual European (Virtual) Congress of Rheumatology, June 2-5.

2021 Real-world effectiveness of systemic therapies for atopic dermatitis (AD) in the United States: Analysis of a retrospective claims database. DiBonaventura M, Lafeuille M-H, Emond B, Duh MS, Fakih I, Yin N, Myers De, Feeney C, Cappelleri JC, Wu JJ. Encore poster presentation at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, June 13. Poster presentation at American Academy of Allergy, Asthma & Immunology – 77<sup>th</sup> Annual (Virtual) Meeting, February 26-March 1.

2021 Real-world effectiveness of systemic therapies for atopic dermatitis in the United States: Retrospective analysis of a US claims database. DiBonaventura M, Lafeuille M-H, Emond B, Duh MS, Fail I, Ying N, Myers DE, Feeney C, Cappelleri JC, Wu JJ. Poster presentation at the San Diego Dermatology Symposium 2021 Virtual Conference, June 11-13

2021 Overall, complete, and stringent complete response rates and minimal residual disease as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. Daniele P, Mamolo C Cappelleri JC, Bell T, Neuhof A, Tremblay G, Musat M, Forsythe A. E-poster presentation at the European Hematology Association (EHA) 2021 Virtual Congress, June 9-17.

2021 Overall and complete response rates as potential surrogates for overall survival in relapsed refractory multiple myeloma. Daniele P, Mamolo C Cappelleri JC, Bell T, Neuhof A, Tremblay G, Musat M, Forsythe A. E-poster presentation at the European Hematology Association (EHA) 2021 Virtual Congress, June 9-17.

2021 The patient experience of acute lymphoblastic leukemia and its treatment: A social media review. Morrison R, Sikirica S, Crawford R, Cappelleri JC, Russell-Smith TA, Shah R, Chadwick H, Doward L. E-poster presentation at the European Hematology Association (EHA) 2021 Virtual Congress, June 9-17.

2021 Quantifying patient preference for tyrosine kinase inhibitors in chronic myeloid leukemia: A discrete-choice experiment. Mason B, Russell-Smith A, Hallworth P, Gater A, Sikirica S, Gardner T, Anand J, Hughes O, Mamolo C, Cappelleri JC. Poster presentation at the European Hematology Association 2021 Virtual Congress, June 9-17.

2021 Real-world quality of life (QoL) in black indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from POLARIS. Rocque GB, Blum J, Montero A, Karuturi MS, Manning K, Shabazz L, Gallagher C, Zuberi L, Cappelleri JC, Drucker M, Wang Y, Tripathy D. Poster presentation at the American Society of Clinical Oncology (ASCO) 57<sup>th</sup> Annual Meeting (Virtual), June 4-8.

2021 Effect of tofacitinib on patient-reported outcomes in patients with acute ankylosing spondylitis: results from a Phase 3 trial. Navarro-Compán V, Cheng-Chung Wei J, Filip van den Bosch F, Marina Magrey M, Lisy Wang L, Dona Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Poster presentation at EULAR 2021: The Annual European Congress of Rheumatology, Paris, France, June 2-5.

2021 Responsiveness and responder definitions for the NCCN/FACT Bladder Symptom Index (NFBISI-18) in individuals with locally advanced or metastatic urothelial cancer (UC). Peipert JC, Chang J, Di Pietro A, Cislo P, Cappelleri JC, Cell D. Poster presentation at Virtual ISPOR 2021, May 17-20.

2021 Direct Healthcare Cost of Atopic Dermatitis in the Swedish Population. Lindberg I, De Geer, Ortsäter G, Dun AR, Geale K, Thyssen JP, Von Kobyletzki L, Metsini A, Henrohn

D' Neregård P, Cha A, Cappelleri JC, Romero W, Neary MP. E-poster presentation at the 2021 Society for Investigative Dermatology Virtual Meeting, May 3-8.

2021 Physicians' perspectives on surgical procedures related to osteoarthritis in the United States. Robinson RL, Abdeen A, Jackson J, Cappelleri JC, Hall J, Tive L, Bushmakin AG, Schepman P, Berry M. Poster presentation at the 2021 Osteoarthritis Research Society International (OARSI) Virtual World Congress, April 29-May 3.

2021 Treatment satisfaction with medications prescribed for osteoarthritis: Cross-sectional surveys with patients and physicians in the US. Schnitzer TJ, Robinson RL, Jackson J, Cappelleri JC, Tive L, Bushmakin AG, Jackson J, Berry M, Barlow S, Viktrup L. Poster presentation at the 2021 Osteoarthritis Research Society International (OARSI) Virtual World Congress, April 29-May 3.

2021 Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD). Yosipovitch, G, Deleuran M, Su J, Fonacier L, Bushmakin AG, Cappelleri JC, Feeney C, Thorpe, A, Rojo R, Valdez H, Myers DE. Poster presentation at the 2021 American Academy of Dermatology Association Virtual Meeting Experience, April 23-25.

2021 Interpreting the relationship between pruritus, sleep, and work productivity: Results from JADE MONO-2. Gooderam MJ, Ständer S, Szepietowski JC, Girolomini G, Bushmakin AG, Cappelleri JC, Biswas P, Feeney C, Chan G, DiBonaventura M, Myers DE. Poster presentation at the 2021 American Academy of Dermatology Association Virtual Meeting Experience, April 23-25

2021 Comparative efficacy and safety of systemic therapies used in adult and adolescent moderate-to-severe atopic dermatitis (AD): A systematic literature review and network meta-analysis (NMA). Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Poster presentation at the 2021 American Academy of Dermatology Association Virtual Meeting Experience, April 23-25.

2021 Patient and caregiver perspectives on treatment attributes for atopic dermatitis. Zeichner J, Feldman SR, Ervin C, Crawford R, Evans E, Zielinski MA, Cappelleri JC, DiBonaventura M, Takeya L, Myers DE. Poster presentation at the 2021 American Academy of Dermatology Association Virtual Meeting Experience, April 23-25.

2021 Changes in the WOMAC domains are associated with clinically important changes in functional health and well-being: pooled analysis of 4 tanezumab Phase 3 trials. Dworkin RH, Turk DC, Williams DA, Bushmakin AG, Abraham L, Hall JA, Semel DC,

Cappelleri JC, Yang R. Poster presentation at the Society of General Internal Medicine's 2021 Virtual Annual Meeting, April 20-23.

2021 Reliability, validity, and clinically important differences (CIDs) on the NCCN/FACT Bladder Symptoms Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC). Peipert Devin J, Chang J, Li S, DiPietro A, Cislo P, Cappelleri JC, Celli D. Poster presentation at 2021 Genitourinary Cancers Virtual Symposium, February 11-12.

2021 Pruritus, sleep, and productivity: A post hoc analysis of abrocitinib versus placebo in patients with moderate-to-severe atopic dermatitis (AD) from JADE MONO-2. Yosipovitch G, Fonacier L, Ständer S, Su J, Gooderham MJ, Szepietowski JC, Deleurun M, Girolomoni G, Biswas P, C Feeney C, Valdez H, Rojo R, Thorpe A, Chan G, JC Cappelleri JC, DiBonaventura M, Myers DE. Poster presentation at the American Academy of Allergy, Asthma & Immunology – 77<sup>th</sup> Annual (Virtual) Meeting, February 26-March 1.

2021 Comparative effectiveness of crizotinib versus entrectinib in ROS1-positive non-small cell lung cancer using clinical trial and real-world data. Groff M, Tremblay G, Iadeluca L, Wilner K, Wiltshire R, Bartolome L, Usuri T, Cappelleri JC, Camidge DS. Poster presentation at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer, Singapore, Worldwide Virtual Event, January 28-31.

2020 Evaluating the severity of atopic dermatitis in children and adults: Mapping of Investigator's Static Global Assessment to Eczema Area and Severity Index in Phase 3 studies of crisaborole, 2%. Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger T. Poster presentation at the Third Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 13-14.

2020 Examining the relationships among abrocitinib monotherapy, pruritus severity, and skin clearance in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-1 and JADE MONO-2. Simpson EL, Yosipovitch G, Ständer S, Silverberg JI, Thyssen JP, Kwatra SG, Luger T, Guttmann-Yassky E, Tom WL, Bushmakin AG, Cappelleri JC, Chan G, Feeney C, Yin N, Valdez H, DiBonaventura M, Myers DE. Poster presentation at the Third Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 13-14.

2020 Economic impact of abrocitinib monotherapy and combined therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE. Gooderham MJ, Chu C-Y, Rojo R, Valdez V, Biswas P, Cameron MC, Feeney C, Encinas GA, Peeples-Lamirande K, Cappelleri JC, Myers DE, DiBonaventura

M. Oral presentation at the Third Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 13-14.

2020 Characteristics of patients treated with tofacitinib for ulcerative colitis in the real world: Findings from a large US claims database. Chiorean M, PP Sharma, Chastek B, Salese L, Bell EJ, Peterson-Brandt, Cappelleri JC, Guo X, Khan N. Poster presentation at Advances in Inflammatory Bowel Diseases: 2020 Vision for the Next Decade Virtual Conference, December 9-12.

2020 Pre/perimenopausal women receiving palbociclib for hormone receipt positive (HR) / human epidermal growth factor receptor 2 – negative (HER2-) advanced breast cancer (ABC) in a real-world setting: Treatment patterns from POLARIS. Karuturi MS, Garrett A, Blum JL, Andersen J, Jepsen E, Pluard T, Stanton T, Manning K, Dighe F, Cappelleri JC, Beery F, Wang Y, Tripathy D. Poster presentation at the San Antonio Breast Cancer Virtual Symposium, 43<sup>rd</sup> Annual Meeting, December 8-11.

2020 Impact of COVID-19 on study sites: Survey analysis from the noninterventional POLARIS study. Tripathy D, Blum JL, Rocque G, Cuevas JD, Specht J, Corso S, Francis JE, Mendez S, Pope V, Cappelleri JC, Wang Y. Oral presentation at the San Antonio Breast Cancer Virtual Symposium, 43<sup>rd</sup> Annual Meeting, December 8-11.

2020 Comparative effectiveness of glasdegib or venetoclax in combination with low dose cytarabine using simulated treatment comparisons. Tremblay G, Daniele P, Dolph M, Bell TJ, Chan G, Brown A, Cappelleri JC. Oral presentation at 62<sup>nd</sup> American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8.

2020 Osteoarthritis patient hopes and satisfaction with prescription NSAIDS and opioid. Conaghan PG, Abraham L, Viktrup L, Cappelleri JC, Beck C, Bushmakin AG, Jackson J, Berry M, Jackson J. Poster presentation at Virtual ISPOR Europe, November 16-19.

2020 A comparison of characteristics of patients with osteoarthritis of the hip or knee who are willing or not to undergo total joint replacement survey. Conaghan PG, Abraham L, Viktrup L, Cappelleri JC, Beck C, Bushmakin AG, Jackson J, Berry M, Jackson J. Poster presentation at Virtual ISPOR Europe, November 16-19.

2020 Evaluating the severity of atopic dermatitis (AD) in children and adults mapping of Investigator's Static Global Assessment (ISGA) to Eczema Area and Severity Index (EASI) in phase 3 studies of crisaborole, 2%. Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger T). Poster presentation at Virtual ISPOR Europe 2020, November 16-19.

2020 Meaningful within-patient change in WOMAC domains in patients with moderate-to-severe osteoarthritis. Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L. Poster presentation at the

American College of Rheumatology Convergence 2020: The ACR's All-Virtual Annual Scientific Meeting, November 5-9.

2020 Itch as the major mediator of the effect of tofacitinib in health-related quality of life in PsA: a mediation analysis. Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Poster presentation at the American College of Rheumatology Convergence 2020: The ACR's All-Virtual Annual Meeting, November 5-9.

2020 Treatment patterns for moderate-to-severe atopic dermatitis among patients in Europe. DiBonaventura M, Anderson P, Piercy J, Massey L, Cappelleri JC, Llamado LJ, Feeney V. E-poster presentation at the European Academy of Dermatology and Venereology 29<sup>th</sup> (Virtual) Congress, October 28-November 1.

2020 The relationship between pruritus, sleep disruption, and quality of life (QoL) among patients with moderate-to-severe atopic dermatitis (AD) in Europe. DiBonaventura M, Anderson P, Piercy J, Massey L, Cappelleri JC, Llamado LJ, Feeney C. E-poster presentation at the European Academy of Dermatology and Venereology 29<sup>th</sup> (Virtual) Congress, October 28-November 1.

2020 Quantifying patient preferences for systematic atopic dermatitis treatments using a discrete choice experiment. Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, DiBonaventura M. E-poster presentation at the European Academy of Dermatology and Venereology 29<sup>th</sup> (Virtual) Congress, October 28-November 1.

2020 Itch as the major mediator of the effect of tofacitinib in health-related quality of life in PsA: a mediation analysis. Merola JF, Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Yosipovitch G. E-poster presentation at the European Academy of Dermatology and Venereology 29<sup>th</sup> (Virtual) Congress, October 28-November 1.

2020 Relationship between Investigator's Static Global Assessment (ISGA) and Patient-Oriented Eczema Measure (POEM) in children aged 3 to <24 months with atopic dermatitis from the CARE 1 study. Eichenfield LF, Simpson EL, Zaenglein AL, Fiorillo L, Ramien ML, Bushmakin AG, Cappelleri JC, Takiya LN, Zang C, Werth JL, Myers DE. Poster presentation at the Pediatric Dermatology Research Alliance – 2020 Annual Virtual Conference, October 22-23.

2020 Concern about addiction is associated with lower quality of life in patient with osteoarthritis: An observational data analysis. Garrison LP, Schepman P, Bushmakin AB, Robinson RL, Tive L, Hall J, Dzingina M, Jackson J, Berry M, Cappelleri JC. Poster presentation at the PAINWeek 2020 Virtual National Conference, September 8-12..

2020 The comparative effectiveness of glasdegib combined with low-dose cytarabine versus azacytidine among newly-diagnosed acute myeloid leukemia patients who are ineligible for intensive chemotherapy. van Beckhuizen S, Hu Y, Gezin A, Heeg B, Bell T, Charaan M, Brown A, Chan G, Cappelleri JC. E-poster presentation at the Virtual Edition of the 25<sup>th</sup> Congress of the European Hematology Association, June 11-14.

2020 The impact of osteoarthritis disease activity on healthcare resource use: Analysis of real-world European data. Conaghan PG, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck C, Bushmakin AG, Hatchell N, Clayton E, Jackson J. Poster presentation at the EULAR 2020 Virtual E-Congress, June 3-6.

2020 Understanding current prescription drug treatment paradigms for patients with osteoarthritis. Conaghan PG, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck C, A Bushmakin A, Hatchell N, Clayton E, Jackson J. Oral presentation at the EULAR 2020 Virtual E-Congress, June 3-6.

2020 How does OA pain impact function, mobility and requirement for help in daily activities in European patients? Conaghan PG, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck C, A Bushmakin A, Hatchell N, Clayton E, Jackson J. Poster presentation at the EULAR 2020 Virtual E-Congress, June 3-6.

2020 Patient journey to diagnosis, treatment patterns, and quality of life in patients with Ankylosing Spondylitis across Central Eastern Europe and the United States. Korotaeva T, Dina O, Holdsworth E, Fallon L, Milligan G, Meakin S, Wang L, Vasilescu R, Cappelleri JC, Deodhar A. Poster presentation at the EULAR 2020 Virtual E-Congress, June 3-6.

2020 Exploring heterogeneity in preferences for attributes of pharmaceutical treatments for osteoarthritis and chronic low back pain in the United States: A latent class approach. Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Klein K, Walsh DA, Turk D. Podium presentation at Virtual ISPOR 2020, May 18-20.

2020 Design of study to assess impact of electronic chronic pain questions on patient-reported outcomes and healthcare utilization in a United States general practice setting. Shah V, Lamerato L, Abraham L, Cappelleri JC, DeLor B, Ellsworth S, Hegeman-Dingle R, Park P. Poster presentation at Virtual ISPOR 2020, May 16-20.

2020 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies. Colombel J-F, Bushmakin AG, Cappelleri JC, Kulisek N, Santana GO, Lawendy N,

Ponce de Leon D, Lakatos PL. Poster presentation at Digestive Disease Week, Chicago, Illinois, May 2-5.

2020 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical program. Dubinsky MC, Bushmakin AG, Cappelleri JC, Woolcott J, Sharma P, Maller E, Salese L, Armuzzi A. Poster presentation at Digestive Disease Week 2020, Chicago, Illinois, May 2-5.

2020 Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: Analysis of a retrospective claims database. Eichenfield LF, DiBonaventura M, Xenako J, Lafeuille M-H, Sheng Du M, Fakih I, Levenberg M, Cappelleri JC, Sikirica V. Poster presentation at the Academy of Managed Care Pharmacy Virtual Learning Event, Houston, Texas, April 21-24.

2020 Providing evidence to support clinical endpoints from mobile sensor data in drug labelling and regulatory decision-making – report from the DIA Study Endpoints Community. Walton MK, Cappelleri JC, Byrom B, Goldsack JC, Eremenco S, Harris D, Potero E, Patel N, Flood E, Daumer M. Oral presentation at the 7<sup>th</sup> Winter Symposium of the Human Motion Project, Munich, Germany, March 4.

2020 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with Ulcerative Colitis in the tofacitinib OCTAVE Phase 3 induction studies Colombel J-F, Bushmakin AG, Cappelleri JC, Kulisek N, Santana GO, Lawendy N, Ponce de Leon D, Lakatos PL. Poster presentation at the 15<sup>th</sup> Congress of the European Crohn's and Colitis Organisation (ECCO), Vienna, Austria, February 12-15.

2020 The concordance of Short Form-36 Health Survey with Mayo scores in the tofacitinib ulcerative colitis clinical programme. Dubinsky MC, Bushmakin AG, Cappelleri JC, Woolcott J, Sharma P, Maller E, Salese L, Armuzzi A. Poster presentation at the 15<sup>th</sup> Congress of the European Crohn's and Colitis Organisation (ECCO), Vienna, Austria, February 12-15.

2019 Quality of life in patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings. Rocque G, Blum JL, Montero A, Nakhoul I, Kurian S, Frank RC, Telivala B, Ajmera M, Coblenz D, Cappelleri JC, Want Y, Tripathy D. Poster-discussion style “Spotlight Discussion” at the 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-14.

2019 Quality-adjusted survival for low-dose cytarabine (LDAC) versus glasdegib+LDAC among newly diagnosed acute myeloid leukemia patients who are not candidates for intensive chemotherapy: A Q-TWiST analysis. Kwon Y, Bell TJ, Solem C, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang C, Cortes JE. Poster presentation at the 61<sup>st</sup>

American Society of Hematology Annual Meeting and Exposition, Orlando, Florida, December 7-10.

2019 Living with ulcerative colitis in Japan: Biologic persistence and healthcare resource utilization. Bargo D, Tritton T, Cappelleri JC, Modesto I, DiBonaventura M, Smith T, Tsuchiya T, Gardiner S, Blackburn S, Kobayashi T. Poster presentation at Japan Digest Disease Week 2019, Kobe, Japan, November 21-24.

2019 Pruritus outcomes with crisaborole by baseline atopic dermatitis severity in pediatric patients. Yosipovitch G, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Stein Gold LF. Encore poster presentation at the American Society of Health-System Pharmacists – 54<sup>th</sup> Midyear Clinical Meeting, Las Vegas, Nevada, December 8-12; poster presentation at the Society of Dermatology Physician Assistants – 17<sup>th</sup> Annual Fall Conference, Scottsdale, Arizona, November 21-24.

2019 The relationship between pruritus, sleep disruption, and quality of life among patients with moderate-to-severe atopic dermatitis. DiBonaventura M, Anderson P, De Villareal J, Bell D, Cappelleri JC, Feeney C. Oral presentation at the 10<sup>th</sup> World Congress on Itch, Sydney, Australia, November 17-19.

2019 Pruritus outcome with crisaborole by baseline atopic dermatitis (AD) severity. Yosipovitch G, M Kalabis M, C Zang C, B Vlahos B, P Sanders P, DE Myers DE, AG Bushmakin AG, JC Cappelleri JC, Stein Gold LF. Poster presentation by the 10<sup>th</sup> World Congress on Itch, Sydney, Australia, November 17-19.

2019 What are the prescribing trends and satisfaction levels with analgesics for osteoarthritis as reported by US rheumatologists, orthopaedic surgeons, and primary care physicians? Schnitzer T, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Williams N, Hubanova P, Jackson J. Poster presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 Relationships between Psoriatic Arthritis Disease Activity Score and patient-reported outcomes in patients with psoriatic arthritis: Post hoc analysis of two phase 3 studies. Coates LC, Bushmakin AG, FitzGerald O, Gladman D, Fallon L, Cappelleri JC, Hsu M-A, Helliwell PS. Poster presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 Patient preferences for attributes of treatments for chronic pain associated with osteoarthritis pain and chronic low back pain that differentiate nerve-growth factor inhibitors, nonsteroidal anti-inflammatory drugs, and opioids in the United States: A discrete-choice experiment. Turk DC, Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Walsh DA. Oral presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 Persistence with etanercept in patients with ankylosing spondylitis or psoriatic arthritis in Germany: A real-world analysis. Baraliakos X, Poddubnyy D, Behrens F, Curiale C, Tarallo M, Behmer O, Hudson N, Gray C, Cappelleri JC. Poster presentation at the 2019 American College of Rheumatology / Association of Rheumatology Professionals Annual Meeting, Atlanta, Georgia, November 8-13.

2019 The economic and patient burden of mild-to-moderate atopic dermatitis in pediatric patients in Sweden. Ortsäter G, Geali K, Dun AR, Cappelleri JC, Cha A, Romero W, Neary M. Poster presentation at ISPOR Europe 2019, Copenhagen, Denmark, November 2-6.

2019 Persistence and healthcare resource use (HCRU) in patients initiating etanercept treatment for ankylosing spondylitis (AS) or psoriatic arthritis (PsA) in Germany: A real-world analysis. Baraliakos X, Poddubnyy D, Behrens F, Curiale C, Tarallo M, Hernandez AC, Behmer O, Hudson N, Gray C, Cappelleri JC. Poster presentation at ISPOR Europe 2019, Copenhagen, Denmark, November 2-6.

2019 A systematic literature review and network meta-analysis (NMA) of crisaborole 2% ointment for the treatment of mild-to-moderate atopic dermatitis (AD). Fahrbach K, Tarpey J, Bergrath E, Hughes R, Cha A, Gerber R, Cappelleri JC. Poster presentation at ISPOR Europe 2019, Copenhagen, Denmark, November 2-6.

2019 Exploring heterogeneity in preferences for attributes of pharmaceutical treatments for osteoarthritis and chronic low back pain in the United Kingdom: A latent class approach. Boeri M, Abraham L, Hauber B, Atkinson J, Bushmakin AG, Cappelleri JC, Russo L, Viktrup L, Walsh DA, Turk D. Podium presentation at ISPOR Europe 2019, Copenhagen, Denmark, November 2-6.

2019 Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab and vedolizumab for the treatment of moderate to severe ulcerative colitis in Germany. Quon P, Sardesai A, Milev S, DiBonaventura M, Cappelleri JC, Kissner A, Modesto I, Dietz L, Dignass A, Bargi D. Poster presentation at ISPOR Europe 2019, Copenhagen, Denmark, November 2-6.

2019 Adult patients with mild or moderate atopic dermatitis are significantly impacted by their condition: Results from a real-world study in the United States. Silverberg JI, Anderson P, Cappelleri JC, Piercy J, Moon R, Tallman AM, Bell D, Levenberg M, Myers DE, Gerber RA. Poster presentation for Academy of Managed Care Pharmacy Nexus, National Harbor, Maryland, October 29-November 1.

2019 Item-level improvements in Inflammatory Bowel Disease Questionnaire scores in patients with ulcerative colitis treated with tofacitinib induction therapy. Dubinsky MC, DiBonaventura MD, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panés J. Poster presentation at the 27th United European Gastroenterology Week, Barcelona, Spain, October 19-23; poster presentation at the American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, October 25-30.

2019 Does scrolling affect measurement equivalence of electronic patient-reported outcomes? Results of a quantitative equivalence study. Shahraz S, Pham TP, Gibson M, De La Cruz M, Baara M, Karnik S, Dell C, Pease S, Nigam S, Cappelleri JC, Markedian J, Lipset C, Zornow P, Lee J, Byrom B. Oral presentation at the 26<sup>th</sup> Annual Conference of International Society for Quality of Life Research, San Diego, California, October 20-23.

2019 Living with ulcerative in Germany: Estimating the frequency and extent of dose escalations among patients with moderate to severe ulcerative colitis. Dignass A, Waller J, Cappelleri JC, Modesto I, Kissner A, Dietz L, DiBonaventura M, Wood R, Bargo D. Poster presentation at the 27th United European Gastroenterology Week, Barcelona, Spain, October 19-23.

2019 Living with ulcerative in Germany: Exploring concomitant steroid and immunosuppressant use among patients with moderate to severe ulcerative colitis. Dignass A, Waller J, Cappelleri JC, Modesto I, Kissner A, Dietz L, DiBonaventura M, Wood R, Bargo D. Poster presentation at the 27th United European Gastroenterology Week, Barcelona, Spain, October 19-23.

2019 Etanercept persistence in juvenile idiopathic arthritis up to adult care in patients in Germany. Minden K, Horneff G, Blum A, Curiale C, Tarallo M, Hudson N, Gray C, Cappelleri JC, Daly Hernandez AC. Poster presentation at the Paediatric and Adolescent Rheumatology Conference, Birmingham, United Kingdom, October 8-9.

2019 Measures of functional status in adults aged >= 70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS. Karuturi MS, Blum J, Wallmark J, McCune S, Lakhanpal S, Telivala B, Salkeni M, Tsai, Rakowski MT, Bardia A, Cappelleri JC, Richardson E, Wang Y, Tripathy D. Poster presentation at ESMO (European Society for Medical Oncology) 2019 Congress, Barcelona, Spain, September 27-October 1.

2019 Understanding palbociclib practice patterns in a real-world setting. Rocque G, Blum JL, Montero A, Wilks S, Anderson D, Diab S, Migas J, Nakhoul I, Spell D, Sleckman B, Cappelleri JC, Wang Y, Tripathy D. Poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Quality Care Symposium, San Diego, California, September 6-7.

2019 The impact of osteoarthritis disease severity on current healthcare resource utilization in the European Union – Results from a real-world study. Conaghan P, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck, C, Bushmakin AG, Williams N, Mellor J, Jackson J. Poster presentation at the 11<sup>th</sup> Congress of the European Pain Federation, Valencia, Spain, September 4-7.

2019 Current treatment patterns among patients in Europe with chronic low back pain: Analysis of real-world data. Conaghan P, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck C, Bushmakin A, Jackson J, Husbands J, Golden K. Poster presentation at the 11<sup>th</sup> Congress of the European Pain Federation, Valencia, Spain, September 4-7.

2019 Current treatment patterns among European patients with osteoarthritis: analysis of a real-world dataset. Conaghan P, Abraham L, Graham-Clarke P, Viktrup L, Cappelleri JC, Beck C, Bushmakin A, Williams N, Mellor J, Jackson J. Poster presentation at the 11<sup>th</sup> Congress of the European Pain Federation, Valencia, Spain, September 4-7.

2019 What matters most in the diagnosis and monitoring of osteoarthritis by physician specialty. Nalamachu S, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Jackson J. Poster presentation at the PAINWeek 2019 Conference, Las Vegas, Nevada, September 3-7.

2019 Measuring the severity of osteoarthritis: Do patients and physicians agree? Robinson RL, Bruemmer, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Jackson J, Kroenke K. Poster presentation at the PAINWeek 2019 Conference, Las Vegas, Nevada, September 3-7.

2019 Opioid use for the treatment of osteoarthritis among primary care physicians, rheumatologists, and orthopedic surgeons. Schnitzer TO, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Jackson J. Poster presentation at the PAINWeek 2019 Conference, Las Vegas, Nevada, September 3-7.

2019 Time to health-related quality of life improvement in the Phase 3 BFORE trial: First line bosutinib vs. imatinib in chronic phase chronic myeloid leukemia. Brümmendorf TH, Bushmakin AG, Cappelleri JC, Reisman A, Viqueira A, Mamolo C, Isfort S. Poster presentation at the 24<sup>th</sup> Congress of the European Hematology

Association, Amsterdam, The Netherlands, June 13-16.

2019 Using indirect number needed to treat (NNT) in oncology comparative effective research: The case of glasdegib + low-dose cytarabine (GLAS+LDAC) vs azacytidine (AZA) or decitabine (DE) among acute myeloid leukemia (AML) patients ineligible to receive intensive chemotherapy. Tremblay G, Westley T, Garib SA, Bell T, Cappelleri JC, Chan G, Forsythe A. Poster presentation at the 24<sup>th</sup> Congress of the European Hematology Association, Amsterdam, The Netherlands, June 13-16.

2019 Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation. Taylor PC, Mease PJ, Bushmakin AG, Cappelleri JC, Fleischmann R, Fallon L, Woolcott J, Ogdie A, Azevedo VF, de Vlam K. Poster presentation at the European Congress of Rheumatology Annual Meeting, Madrid, Spain, June 12-15.

2019 Pruritus outcomes crisaborole ointment, 2%, by baseline atopic dermatitis severity. Yosipovitch G, Olivadoti M, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Stein Gold LF. Poster presentation at the 32<sup>nd</sup> Annual Eastern Allergy Conference, Palm Beach, Florida, May 30-June2; Israel Society of Dermatology and Venereology 40<sup>th</sup> Annual Meeting, Eilat, Israel, May 15-17; and Winter Clinical Dermatology Conference, Kauai, Hawaii, January 18-23.

2019 Impact of psoriatic arthritis from the patient's perspective in the context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An online global survey. Coates LC, Orbai A-M, Azevedo VF, Cappelleri JC, Moser J, Lippe R, Eder L, Richette P, Weng MY, Queiro Silva R, Fallon L. Poster presentations at la Sociedad Española de Reumatología – XLV Congreso Nacional, Valencia, Spain, May 21-24, 2019; Pan American League of Associations for Rheumatology Congress, Quito, Ecuador, April 27-30.

2019 An appraisal of Real-World Evidence (RWE) in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACS). Deitelzweig S, Cichewicz W, Di Fusco M, Kang A, Russ C, Snook K, Bergrath E, Earley A, Cappelleri JC. Poster presentation at the 2019 Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22.

2019 Psychometric evaluation and score interpretation of the NCCN-FACT Ovarian Symptoms Index-18 in patients with advanced ovarian cancer: Real-world evidence. Trigg A, Kelly M, Iadeluca L, Chang J, Moreno-Koehler A, Yaworsky A, Krohe M, Rider A, Cappelleri JC, Cella D, Cocks K. Poster presentation at the 2019 Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22.

2019 Perceived disease severity and treatment satisfaction among patients with ulcerative colitis in the United States. DiBonaventura M, Bargo D, Lucas J, Bluff D, Hoskin B, Cappelleri JC, Kayhan C, Salese L. Poster presentation at DDW 2019: Digestive Disease Week, San Diego, California, May 18-21.

2019 Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: Data from the OCTAVE program. Dubinsky MC, Bushmakin AG, DiBonaventura M, Cappelleri JC, Salese L, Maller ES, Armuzzi A. Poster presentation at DDW 2019: Digestive Disease Week, San Diego, California, May 18-21.

2019 Measuring the mediating effects of Mayo score components for tofacitinib in disease-specific quality of life in ulcerative colitis: Data from the OCTAVE program. Dubinsky MC, Bushmakin AG, DiBonaventura M, Cappelleri JC, Salese L, Maller ES, Armuzzi A. Poster presentation at DDW 2019: Digestive Disease Week, San Diego, California, May 18-21.

2019 The effect of crisaborole ointment, 2%, on pruritus in patients with atopic dermatitis (AD): An extended analysis. Yosipovitch G, Simpson E, Tan H, Gerber RA, Luger T, Ständer S, Wynnis T, Cappelleri JC, Bushmakin AG, Ports WC, Tallman AM. Oral presentation at the Israel Society of Dermatology and Venereology 40<sup>th</sup> Annual Meeting, Eilat, Israel, May 15-17.

2019 Assessing the burden of chronic pain in osteoarthritis and chronic back pain when untreated and treated with prescription medications. Haswell H, Conaghan PG, Coates GL, Clewes C, Howland S, Doane MJ, Jaffe DH, Dragon E, Abraham L, Viktrup L, Bushmakin AG, Cappelleri JC. Poster presentation at the British Pain Society Annual Scientific Meeting 2019, London, England, May 1-3.

2019 Patient perception of psoratic arthritis treatment and communication with physicians in Australia: Results from a patient survey. Lim I, Steinberg K, Cappelleri JC, Ng H, Witcombe D, Fallon L. Poster presentation at the 21<sup>st</sup> Congress of the Asian Pacific League of Associations for Rheumatology (in conjunction with the Australian Rheumatology Association), Brisbane, Australia, April 8-11.

2019 Impact of pain severity among patients with osteoarthritis on healthcare use in the United States. Robinson RL, Bobula J, Cappelleri JC, Bushmakin AG, Tive L, Viktrup L, Mellor J, Williams N, Hubanova P, Jackson J. Poster presentation at the 2019 American Pain Society Scientific Meeting, Milwaukee, Wisconsin, April 3-6.

2019 Indirect comparative effectiveness of treatments for older acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy (NIC): Combination glasdegib + low-dose

cytarabine (GLAS+LDAC) vs. decitabine or venetoclax+LDAC. Tremblay G, Westley T, Bell TJ, Cappelleri JC, Chan G, Hearnden J, Forsythe A. Poster presentation at the 59<sup>th</sup> Annual Scientific Meeting of the British Society of Haematology, Glasgow, Scotland, April 1-3.

2019 Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy (daunorubicin and cytarabine) for first-line treatment of acute myeloid leukemia. Mokgokong R, Mamolo C, Cappelleri JC, Knight C, Brockbank J, Cawson M, Palaka A, Cataigne S. Poster presentation at the 59<sup>th</sup> Annual Scientific Meeting of the British Society of Haematology, Glasgow, Scotland, April 1-3.

2019 Modeling the costs and outcomes associated with treatment sequences, with and without tofacitinib, for psoriatic arthritis in the United States. Bungey G, Chang-Douglass S, Hsu M-A, Cappelleri JC, Young P, Woolcott J. Poster presentation at the Academy of Managed Care Annual Meeting, San Diego, California, March 25-28.

2019 Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: Data from the OCTAVE program. Dubinsky M, Bushmakin AG, DiBonaventura M, Cappelleri JC, Salese L, Maller ES, Armuzzi A. Poster presentation at the 14<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, March 6-9.

2019 Perceived disease severity and treatment satisfaction among patients with ulcerative colitis in Europe. Armuzzi A, Tarallo M, Bargo D, Lucas J, Bluff D, Hoskin B, Salese L, Cappelleri JC, Kayhan C, DiBonaventura M. Poster presentation at the 14<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, March 6-9.

2019 Living with ulcerative colitis in Germany: Quantifying the socioeconomic impact of moderate to severe ulcerative colitis. Dignass A, Waller J, Cappelleri JC, Salese L, Kissner A, Dietz L, DiBonaventura M, Wood R, Bargo B. Poster presentation at the 14<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, March 6-9.

2019 Measuring the mediating effects of Mayo score components for tofacitinib on disease-specific quality of life in ulcerative colitis: Data from the OCTAVE program. Dubinsky M, Bushmakin AG, DiBonaventura M, Cappelleri JC, Salese L, Maller E, Armuzzi A. Poster presentation at the 14<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, March 6-9.

2019 Living with ulcerative colitis in Germany: Quantifying the healthcare resource utilization and direct healthcare costs associated with the treatment of moderate to severe ulcerative colitis in Germany. Dignass A, Waller J, Cappelleri JC, Salese L, Kissner A, Dietz A,

Dietz L, DiBonaventura M, Wood R, Bargo D. Poster presentation at the 14<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, March 6-9.

2018 The association between corticosteroid exposure and long-term clinical and economic outcomes among patients diagnosed with ulcerative colitis. DiBonaventura M, Yeaw J, Jiang M, Cappelleri JC, Dekoven M, Singh E, Salese L. Poster presentation at the 2018 Advances in Inflammatory Bowel Diseases Conference, Orlando, Florida, December 12-15. (Selected for poster award.)

2018 Patient and physician preferences for ulcerative colitis treatments in the United States. Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin D. Abstract accepted for poster presentation at the 2018 Advances in Inflammatory Bowel Diseases: Multidisciplinary Approaches to IBD Patient-Centered Care Conference, Orlando, Florida, December 13-15. (Selected for Best Poster Award – earned a poster of distinction award and best abstract award.)

2018 Patient perception of medical care for psoriatic arthritis in North America and Europe: Results from a Patient Survey. Richette P, Coates LC, Azevedo VF, Cappelleri JC, Moser J, Lippe R, Lim I, Eder L, Weng MY, Silva RQ, Fallon L, Kessouri M. Poster presentation at the 31<sup>st</sup> French Rheumatology Congress, Paris, France, December 9-11.

2018 Patient-perceived involvement in disease management drives patient-physician alignment in satisfaction with disease control in psoriatic arthritis. Gossec L, Orbai AM, Lobosco S, Moon R, Massey O, Piercy J, Cappelleri JC, Fallon L, Young P, Romero AB, Hsu MA. Poster presentation at the 31<sup>st</sup> French Rheumatology Congress, Paris, France, December 9-11.

2018 Impact of psoriatic arthritis from the patient's perspective in the context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An online global survey. Coates LC, Orbai A-M, Azevedo VF, Cappelleri JC, Moser J, Lippe R, Lim I, Eder L, Richette P, Weng MY, Silva RQ, Fallon L. Poster presentation at the 31<sup>st</sup> French Rheumatology Congress, Paris, France, December 9-11.

2018 Adult patients experiencing mild or moderate atopic dermatitis are significantly impacted by their condition: results from a real-world study in the United States. Myers DE, Silverberg JI, Anderson P, Cappelleri JC, Piercy J, Moon R, Tallman AM, Bell D, Levenberg M, Gerber RA. Poster (encore) presentation at the American Society of Health System Pharmacists Midyear Meeting and Expo, Anaheim, California, December 2-6.

2018 Comparative effectiveness of combination glasdegib + low-dose cytarabine (GLAS+LDAC) vs. combination venetoclax + low-dose cytarabine (VEN+LDAC) among older acute myeloid leukemia (AML) patients ineligible for intensive

chemotherapy (NIC): Indirect treatment comparison (ITC) methods. Westley T, Forsythe A, Bell TJ, Cappelleri JC, Chan G, Tremblay G. Poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting & Exposition, San Diego, California, December 1-4.

2018 Clinical responses of glasdegib plus low-dose ara-c, azacitidine, and decitabine among acute myeloid leukemia (AML) patients ineligible to receive intensive chemotherapy: Comparative effectiveness using indirect treatment comparison (ITC) methods. Westley T, Forsythe A, Bell TJ, Cappelleri JC, Tremblay G, Chan G. Poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting & Exposition, San Diego, California, December 1-4.

2018 Impact of diarrhea on health-related quality of life: Analysis of the Phase 3 BFORE trial of bosutinib vs. imatinib for new diagnosed chronic phase chronic myeloid leukemia. Brümmendorf TH, Mamolo C, Reisman A, Bushmakin AG, Cappelleri JC, Crescenzo R, DeAnnuntis L, Viquiera A, Cortes JE. Poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting & Exposition, San Diego, California, December 1-4.

2018 Comparison of cure rates between gemtuzumab ozogamicin plus standard of care chemotherapy vs. standard of care alone in patients with newly diagnosed acute myeloid leukemia. Muresan B, Mamolo C, Cappelleri JC, Mokgokong R, Palaka A, Hills R, Latimer N, Soikkeli F, Heeg B. Abstract accepted for poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting and Exposition, San Diego, California, December 1-4.

2018 Impact of diarrhea on health-related quality of life: Analysis of the Phase 3 BFORE trial of bosutinib vs. imatinib for new diagnosed chronic phase chronic myeloid leukemia. Brümmendorf TM, Mamolo CM, Reisman A, Bushmakin AG, Cappelleri JC, Crescenzo RJ, DeAnnuntis L, Viquieras A, Cortes JE. Poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting & Exposition, San Diego, California, December 1-4.

2018 An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Muresan B, Mamolo C, Cappelleri JC, Crescenzo R, Leip E, Viquiera A, Heeg B. Poster presentation at the 60<sup>th</sup> American Society of Hematology Annual Meeting & Exposition, San Diego, California, December 1-4.

2018 Examining the relationship between Investigator's Static Global Assessment and quality of life: 2 phase 3 studies of the phosphodietrase 4 inhibitor crisaborole ointment, 2%, in patients 2 years and older with mild to moderate atopic dermatitis. Gerber RA, Bushmakin AG, Cappelleri JC, Tallman AM, Ports WC. Poster (encore) presentation at the 2018 Dermatology Update Fall Meeting, Montreal, Canada, November 15-17; ePoster

presentation at the European Academy of Dermatology and Venereology Annual Meeting, Paris, France, September 12-16.

2018 Health-related quality of life in patients with advanced (stage II-IV) ovarian cancer resistant or refractory to frontline platinum-based therapy. Byrne K, Moon R, Chang J, Higson O, Doherty JP, Cappelleri JC. Poster presentation at the 21<sup>st</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR Europe 2018), Barcelona, Spain, November 10-14.

2018 Real-world treatment patterns of patients with advanced (stage II-IV) ovarian cancer classified as resistant or refractory to frontline platinum-based therapy. Byrne K, Moon R, Chang J, Hubanova P, Doherty JP, Cappelleri JC. Poster presentation at the 21<sup>st</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR Europe 2018), Barcelona, Spain, November 10-14.

2018 An economic evaluation of tofacitinib for the treatment of moderate-to-severely active ulcerative colitis: Modeling the cost of treatment strategies in the United States. Milev S, DiBonaventura M, Quon P, Goh JW, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. Poster presentation at the Academy of Managed Care Pharmacy Nexus 2018, Orlando, Florida, October 22-25. Selected for bronze ribbon.

2018 A link between quality of patient-rheumatologist communication and patient healthcare needs in psoriatic arthritis: An online survey of US-based patients and rheumatologists. Orbai A-M, Coates LC, Azevedo VF, Garg A, Majjhoo A, Griffiths CEM, Young P, Cappelleri JC, Moser J, Fallon L. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24.

2018 Modeling the costs and outcome associated with treatment sequences, with and without tofacitinib, for moderately to severely active psoriatic arthritis in the US. Bungey G, Chang-Douglass S, Hsu M-A, Cappelleri JC, Young P, Woolcott J. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24.

2018 Impact of psoriatic arthritis from the patient's perspective in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire: An online global survey. Coates LC, Orbai A-M, Azevedo VF, Cappelleri JC, Moser J, Lippe R, Lim I, Eder L, Richette P, Weng M, Silva RQ, Fallon L. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24.

2018 Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib. de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Mease PJ, Fleischmann

R, Taylor PC, Azevedo VF, Fallon L, Maniccia A, Woolcott J. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24.

2018 Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis. Ogdie A, de Vlam K, Bushmakin AG, Cappelleri JC, Mease PJ, Fleischmann R, Taylor PC, Azevedo VF, Fallon L, Maniccia A, Woolcott J. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24.

2018 Facilitating shared decision making on psoriatic arthritis : Factors influencing patient preference for treatment mode of administration. Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Poster presentation at the American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting, Chicago, Illinois, October 19-24, 2018.

2018 Treatment patterns among patients with moderate-to-severe ulcerative colitis in Western Europe. Armuzzi A, Tarallo M, DiBonaventura M, Bargo D, Lucas J, Bluff D, Hoskin B, Salese L, Cappelleri JC, Gigante G. Oral presentation at the United European Gastroenterology Week – 26<sup>th</sup> Annual Conference, Vienna, Austria, October 20-24; poster presentation at the American College of Gastroenterology, Philadelphia, Pennsylvania, October 5-10.

2018 The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in Europe. Armuzzi A, Tarallo M, DiBonaventura M, Bargo D, Lucas J, Bluff D, Hoskin B, Salese L, Cappelleri JC, Gigante G. Oral presentation at the United European Gastroenterology Week – 26<sup>th</sup> Annual Conference, Vienna, Austria, October 20-24, selected as a poster of excellence; poster presentation at the American College of Gastroenterology, Philadelphia, Pennsylvania, October 5-10.

2018 Efficacy of tofacitinib and biologics as induction and maintenance therapy for moderately-to-severely active ulcerative colitis: A systematic review and meta-analysis. Rubin DT, Ashaye AO, Zhang Y, Fahrbach K, Kayhan C, Lohan C, Cappelleri JC, DiBonaventura M. Poster presentation at the United European Gastroenterology Week – 26<sup>th</sup> Annual Conference, Vienna, Austria, October 20-24.

2018 First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer - A prospective, multicenter noninterventional study. Blum JL, McCune S, Salkeni MA, Anderson DM, Migas JJ, Lakhapal S, Patel K, Bardia A, Rocque G, Wang J, Cappelleri JC, Comstock

G, Wang Y, Tripathy D. Poster presentation at the European Society for Medical Oncology 2018 Annual Meeting, Munich, Germany, October 19-23.

2018 Efficacy of tofacitinib and biologics as induction and maintenance therapy for moderately-to-severely active ulcerative colitis: a systematic review and network meta-analysis. Rubin DT, Ashaye AO, Zhang Y, Fahrbach K, Freitag A, Kayhan C, Lohan C, Cappelleri JC, DiBonaventura M. Poster presentation at the American College of Gastroenterology, Philadelphia, Pennsylvania, October 5-10. (Recognized as a “Presidential Poster” for high quality, novel, unique, and interesting research, an honor bestowed upon < 5% of research submissions each year.)

2018 Examining molecular response and quality of life in chronic phase chronic myeloid leukemia in the Bosutinib BFORE trial. Brümmendorf TH, Bushmakin AG, Cappelleri JC, Crescenzo R, Reisman A, Mamolo C. Oral presentation at the 37<sup>th</sup> World Congress of the International Society of Hematology, Vancouver, Canada, September 13-16.

2018 Evaluation of treatment effects on the Investigator’s Static Global Assessment: longitudinal analysis of 2 phase 3 studies of the phosphodiesterase 4 inhibitor crisaborole ointment, 2%, in patients 2 years and older with mild to moderate atopic dermatitis. Cappelleri JC, Gerber RA, Bushmakin AG, Tallman AM, Ports WC. Oral presentation at the European Academy of Dermatology and Venereology Annual Meeting, Paris, France, September 12-16.

2018 Adult patients experiencing mild or moderate atopic dermatitis are significantly impacted by their condition: results from a real-world study in the United States. Silverberg JI, Anderson P, Cappelleri JC, Piercy J, Moon R, Tallman AM, Bell D, Levenberg M, Myers DE, Gerber RA. ePoster presentation at the European Academy of Dermatology and Venereology Annual Meeting, Paris, France, September 12-16.

2018 Impact of mild or moderate atopic dermatitis on adult patients: results from a real-world study in 3 European countries. Egeberg A, Anderson P, Cappelleri JC, Piercy J, Moon R, Tallman AM, Bell D, Aikman L, Myers DE, Gerber RA. ePoster presentation at the European Academy of Dermatology and Venereology Annual Meeting, Paris, France, September 12-16.

2018 Relationship among treatment, pruritus, Investigator’s Static Global Assessment, and quality of life: mediation modeling using 2 phase 3 studies of the phosphodiesterase 4 inhibitor crisaborole ointment, 2%, in patients 2 years and older with mild to moderate atopic dermatitis. Bushmakin AG, Cappelleri JC, Gerber RA, Tallman AM, Ports WC. ePoster presentation at the European Academy of Dermatology and Venereology Annual Meeting, Paris, France, September 12-16.

2018 Healthcare resource use by disease severity for patients with osteoarthritis in the United States using Adelphi Osteoarthritis Disease Specific Programme. Robinson RL, Bobula J, Cappelleri JC, Bushmakin A, Tive L, Viktrup L, Mellor J, Jackson J. Poster presentation at PAINWeek 2018, Las Vegas, Nevada, September 4-8.

2018 Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: a mediation analysis. Simpson E, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Wynn T, Ports WC, Tallman AM, Tan H, Gerber RA. Poster presentation at 100th Annual Meeting of the Swiss Society for Dermatology and Venereology, Ecublens, Switzerland, August 30-September 1.

2018 Relationship between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom W, Ports WC, Tallman AM, Tan H, Gerber RA. Poster presentation at the 100<sup>th</sup> Annual Meeting of the Swiss Society for Dermatology and Venereology, Ecublens, Switzerland, August 30-September 1.

2018 Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: a mediation analysis. Simpson E, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Tom W, Ports WC, Tallman AM, Tan H, Gerber RA. Poster presentation at the 100<sup>th</sup> Annual Meeting of the Swiss Society for Dermatology and Venereology, Ecublens, Switzerland, August 30-September 1.

2018 A link between quality of patient-physician communication and patient healthcare needs in PsA. Orbai A-M, Coates L, Azevedo VF, Garg A, Majjhoo A, Griffith CEM, Young P, Cappelleri JC, Moser J, Fallon L. Poster presentation at the International Federation of Psoriasis Association - 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, June 27-30.

2018 Assessing the burden of treated and untreated chronic low back pain in Europe. Doane MJ, Jaffe, Dragon E, Abraham L, Viktrup L, Bushmakin AG, Cappelleri JC. Poster presentation at the Annual European Congress of Rheumatology, Amsterdam, The Netherlands, June 13-16.

2018 Assessing the burden of treated and untreated osteoarthritis pain in Europe. Doane MJ, Jaffe, Dragon E, Abraham L, Viktrup L, Bushmakin AG, Cappelleri JC. Poster presentation at the Annual European Congress of Rheumatology, Amsterdam, The Netherlands, June 13-16.

2018 Treatment patterns in psoriatic arthritis in US and Europe: Results from a real-world international survey. Orbai A-M, Gossec L, Lobosco S, Moon R, Massey O, Piercy J, Cappelleri JC, Fallon L, Young P, Romero AB, Hsu M-A. Poster presentation at the Annual European Congress of Rheumatology, Amsterdam, The Netherlands, June 13-16.

2018 Patient-perceived involvement in disease management drives patient-physician alignment in satisfaction with disease control in psoriatic arthritis. Gossec L, Orbai A-M, Lobosco S, Moon R, Massey O, Piercy J, Cappelleri JC, Fallon L, Young P, Romero AB, Hsu M-A. Poster presentation at the Annual European Congress of Rheumatology, Amsterdam, The Netherlands, June 13-16.

2018 Network meta-analysis of tofacitinib vs bDMARDs or apremilast for the treatment of TNF inhibitor-naïve patients with psoriatic arthritis. Gladman DD, Orbai A-M, Gomez-Reino J, Chang-Douglass S, Leoncini E, Burton HE, Kanik KS, Hendrikx T, Cappelleri JC, Hsu M-A. Poster presentation at the Annual European Congress of Rheumatology, Amsterdam, The Netherlands, June 13-16.

2018 Evaluating different indirect treatment comparison approaches: A case study in acute myeloid leukemia patients ineligible to receive intensive chemotherapy. Tremblay G, Westley T, Arondekar B, Cappelleri J, Chan Geoffrey, Fortsythe A, Briggs A. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 23<sup>rd</sup> International Meeting, Baltimore, Maryland, May 19-23.

2018 Effects of the oral Janus Kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD). Simpson E, Wollenberg A, Bissonnette R, Zhang JI, Papacharalambous J, Zhu L, Zhang W, Beebe JS, Vincent M, Peeva E, Bushmakin AG, Cappelleri JC, Chen L. Poster presentation at the 7<sup>th</sup> International Investigative Dermatology Meeting, Orlando, Florida, May 16-19.

2018 Prevalence of alopecia areata in the United States from a large cross-sectional survey. Mostaghimi A, Benigno M, Udall M, Anastassopoulos KP, Cappelleri JC, Daniel S, Wahl PM, Chander P, Lapthorn J, Chen L, Peeva E. Poster presentation at the 2018 International Investigative Dermatology Meeting, Orlando, Florida, May 16-19.

2018 Pharmacotherapeutic treatment paradigms of osteoarthritis in the United States. Mychaskiw MA, Abraham L, Cappelleri JC, Bushmakin A, Tive L, Viktup L, Williams N, Mellor J, Jackson J. Poster presentation at the 2018 World Congress on Osteoarthritis, Liverpool, United Kingdom, April 26-29, 2018.

2018 Validation of the Pruritus and Symptoms Assessment for atopic dermatitis in adults with moderate to severe atopic dermatitis. Lebwohl MG, Simpson EL, Bushmakin AG, Cappelleri JC, Gooderham MJ, Wollenberg A, Hall R, Gater A, Wells JR, Papacharalambous J, Hsu M-A, Tallman AM, Peeva E, Zhang W. Poster presentation at the 10<sup>th</sup> Georg Rajka International Symposium on Atopic Dermatitis, Utrecht, The Netherlands, April 11-13.

2018 Relationship between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom W, Ports W, Tallman A, Tang H, Gerber RA. E-poster presentation at the 2018 Annual Meeting of the American Academy of Dermatology, San Diego, California, February 16-20.

2017 Comparative efficacy and safety of gemtuzumab ozogamicin (GO) plus daunorubicin-cytarabine combination and comparators as induction therapy for newly diagnosed acute myeloid leukemia: a systematic review and network meta-analysis. Ashaye AO, Khankhel Z, Xu Y, Fahrbach K, Mokgokong R, Orme M, Lang K, Cappelleri JC, Mamolo C. Poster presentation at the 59<sup>th</sup> American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 9-12.

2017 Indirect treatment comparison (ITC) of inotuzumab ozogamicin (InO) and blinatumomab (Blin) for relapsed or refractory (RR) acute lymphoblastic leukemia (ALL). Stelljes M, Su Y, Fahrbach K, Vandendries E, Page V, Onyekwere U, Wang Y, Cappelleri JC, Proskorovsky. Poster presentation at the 59<sup>th</sup> American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 9-12.

2017 Treatment of relapsed or refractory lymphoblastic leukemia in real-world US practices. LeBlanc TW, Su Y, Hayes KC, Fielding R, Benigno M, Cappelleri JC. Poster presentation at the 59<sup>th</sup> American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 9-12.

2017 POLARIS: palbociclib in hormone receptor-positive advanced breast cancer: a prospective multicenter noninterventional study. Tripathy D, Bardia A, Rocque G, Blum JL, Wilks ST, Lakhapal S, Migas JL, Cappelleri JC, Smith JP, Comstock G, Wang Y. Poster presentation at the 40<sup>th</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 5-9.

2017 Axitinib and cabozantinib in the treatment of sunitinib-refractory patients with metastatic renal cell carcinoma (mRCC): Results of matching indirect treatment comparison (MAIC) analysis of AXIS and METEOR trials. Proskorovsky I, Benedit A, Négrier S, Cappelleri JC, Bargo D, Desai J, Larkin J. Oral and poster presentations at the Sixteenth International Kidney Cancer Symposium. Miami, Florida, November 3-4.

2017 Important group differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in patients with metastatic renal cell carcinoma. Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, Arondekar B, Bushmakin AG. Poster presentation at the 20<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, Scotland, November 4-8.

2017 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: Results from 2 Phase 3 studies. Strand V, de Vlam K, Covarrubias-Cobos JA, Mease P, Gladman D, Hendrikx T, Kudlacz E, Graham D, Wu J, Cappelleri JC, Hsu M-A. Poster presentation at the 2017 Annual Meeting of the American College of Rheumatology, San Diego, California, November 3–8.

2017 Patient preference associated with the use of treatments for psoriatic arthritis: Results of a conjoint analysis. Xu Y, Sudharshan L, Hsu M-A, Koenig A, Cappelleri JC, Liu W, Smith TW, Pasquale M. Poster presentation at the 2017 Annual Meeting of the American College of Rheumatology, San Diego, California, November 3–8.

2017 Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: A mediation analysis. Simpson E, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Wynn T, Ports WC, Tallman AM, Tan H, Gerber RA. Poster presentation at the 36<sup>th</sup> Anniversary Fall Clinical Dermatology Conference, Las Vegas, Nevada, October 12-15.

2017 Validation of the severity pruritus scale (SPS) for the assessment of pruritus in atopic dermatitis. Yosipovitch G, Simpson E, Bushmakin AG, Cappelleri JC, Luger T, Ständer S, Wynn T, Benjamin K, Ports W, Tallman A, Tan H, Gerber RA. Poster presentation at the 36<sup>th</sup> Anniversary Fall Clinical Dermatology Conference, Las Vegas, Nevada, October 12-15.

2017 The effect of crisaborole ointment on pruritus subjects with atopic dermatitis (AD): An extended analysis. Yosipovitch G, Simpson E, Luger T, Tan H, Gerber RA, Luger T, Ständer S, Wynn T, Cappelleri JC, Bushmakin AG, Ports WC, Tallman A. Poster presentation at the 36<sup>th</sup> Anniversary Fall Clinical Dermatology Conference, Las Vegas, Nevada, October 12-15.

2017 Treatment patterns and outcomes among platinum-refractory/resistant ovarian cancer patients. Parikh R, Kurosky S, Udall M, Chang J, Cappelleri JC, Doherty J, Kaye JA. Poster presentation at Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, Pennsylvania, October 1-4.

2017 Epidemiology of physician diagnosed neuropathic pain in Brazil. Udall M, Kudel I, Cappelleri JC, Sadosky A, Concialdo K, Parsons B, Hlavacek P, Hopps M, Salomon P, DiBonaventura M, Clark M, Garcia JB. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 6<sup>th</sup> Latin America Conference, São Paulo, Brazil, September 15-17.

2017 Comparative efficacy and safety of tofacitinib and biologics as induction therapy for moderately-to-severely active ulcerative colitis: A systematic review and network meta-analysis. Rubin DT, Ashaye AO, Zhang Y, Xu Y, Fahrbach K, Chen LA, Manuchehri A, Kayhand C, Woolcott J, Cappelleri JC, Healey P. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22<sup>nd</sup> Annual International Meeting, Boston, Massachusetts, May 20-24.

2017 A systematic review of the Inflammatory Bowel Disease Questionnaire for measuring health-related quality of life in patients with ulcerative colitis. Yarlas A, Sands B, Rubin D, Lindsay J, Panés J, Vermiere S, Chen LA, Bayliss M, Maher S, Bushmakin A, Cappelleri JC, Su C, Kayham C, Healey P. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22<sup>nd</sup> Annual International Meeting, Boston, Massachusetts, May 20-24.

2017 Real-world study on treatment patterns and dose titration of pregabalin for neuropathic pain. Yeh Y, Ling YL, Shelbaya A, Lyndon G, Cappelleri JC, Varvara R, Gao X. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22<sup>nd</sup> Annual International Meeting, Boston, Massachusetts, May 20-24.

2017 Estimating health state utilities for patients with acute myeloid leukemia. Castejón N, Cappelleri JC, Cuervo J, Lang K, Mehta P, Mokgokong R, Mamolo C. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22<sup>nd</sup> Annual International Meeting, Boston, Massachusetts, May 20-24.

2017 Characteristics of patients with neuropathic pain screened by the painDETECT and diagnosed by physician exam. Kudel I, Hopps M, Cappelleri JC, Sadosky A, Concialdi K, Liebert R, Parsons B, Hlavacek P, Alexander AH, DiBonaventura M, Markman JD, Farrar JT, Stacey BR. Poster presentation at the 36<sup>th</sup> Annual Scientific Meeting of the American Pain Society, Pittsburgh, Pennsylvania, May 17-20.

2017 The SF-36 Health Survey distinguishes disease burden on functioning and well-being between patients with active vs. inactive ulcerative colitis. Rubin D, Panés J, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Poster presentation at Digestive Disease Week, Chicago, Illinois, May 6-9.

2017 A systematic review of the SF-36 Health Survey for measuring health-related quality of life in patients with ulcerative colitis. Chen LA, Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Manuchehri A, Healey P. Poster presentation at Digestive Disease Week, Chicago, Illinois, May 6-9.

2017 Evaluation of pain interference, pain severity, and fatigue in fibromyalgia patients taking opioids and pregabalin: Responder analysis using area under the curve. Davis F, Gostin

M, Roberts BA, Risko R, Cappelleri JC, Sadosky A. Poster presentation at the American Academy of Pain Medicine 2017 Annual Meeting, Orlando, Florida, March 15-19.

2017 Text messaging to improve outcomes in patients with painful diabetic peripheral neuropathy. Masi C, Bauer V, Wang C-H, Goodman N, Craig T, Glosner S, Juhn M, Cappelleri JC, Sadosky A, Cooley C, Lapin B. Poster presentation at the 2017 Society of General Internal Medicine Annual Meeting, Washington, D.C., April 19-22; oral presentation at Evanston Hospital, Evanston, Illinois, February 16.

2017 Assessing atopic dermatitis symptoms in adolescents and adults: Development of a patient-reported symptom diary. Hall R, Gater A, Wells J, Chen L, Papacharalambous J, Cappelleri JC, Hsu M-A. E-Poster presentation at the 2017 American Academy of Dermatology Annual Meeting, Orlando, Florida, March 3-7.

2017 The SF-36 Health Survey distinguishes disease burden on functioning and well-being between patients with active vs. inactive ulcerative colitis. Rubin DT, Panés J, Linsday JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Poster presentation at the 12<sup>th</sup> Congress of the European Crohn's and Colitis Organisation (ECCO), Barcelona, Spain, February 15-18.

2017 Evaluating patient preference for haemophilia A treatment. Schulz M, Cordo A, Tolley C, Staunton H, Brohan E, Spurden D, Cicchetti MJ, Cappelleri JC. Poster presentation at the 10<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Paris, France, February 1-3.

2016 Matching-adjusted indirect treatment comparison of bosutinib, dasatinib, nilotinib and ponatinib on survival for second line chronic phase chronic myeloid leukemia patients. Muresan B, Mamolo C, Cappelleri JC, Shapiro M, Crescenzo R, Su Y, Heeg B. Poster presentation at the American Society of Hematology 58<sup>th</sup> Annual Meeting and Exposition, San Diego, California, December 3-6.

2016 Patient-reported outcomes from a global Phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard of care chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Shapiro M, Cappelleri JC, Marks DI. Poster presentation at the American Society of Hematology 58<sup>th</sup> Annual Meeting and Exposition, San Diego, California, December 3-6; Kantarjian HM, Su Y, Bhattacharyya H, Yan E, Shapiro M, Cappelleri JC. Poster presentations at the American Society of Clinical Oncology (ASCO), Chicago, Illinois, June 3-7, and also at the European Hematology Association 2016 Congress, Copenhagen, Denmark, June 9-12.

2016 The four stages of fibromyalgia: Potential for more precise treatment options. Davis F, Gostine M, Roberts BA, Risko R, Cappelleri JC, Clair A, Sadosky A. Poster presentation at the 2016 ACR/ARHP Annual Meeting, Washington, D.C., November 11-16. (ACR=American College of Rheumatology; ARHP=Association of Rheumatology Health Professionals).

2016 Timing of adverse events (AEs) in sunitinib (SU) treated patients with metastatic renal cell carcinoma (mRCC) and implications for a 2/1 schedule. Lee J, Benedict A, Cappelleri JC, Sandin R, Ramaswamy K. Poster presentation at the 15<sup>th</sup> International Kidney Cancer Symposium, Miami, Florida. November 4-5.

2016 Axitinib (axi) and everolimus (eve) in the treatment of sunitinib-refractory (su-r) patients with metastatic renal cell carcinoma (mRCC): Results of a matching adjustment indirect comparison (MAIC) and simulated treatment comparison (STC). Proskorovosky I, Benedict A, sn S, Bargo Da, Sandin R, Ramaswamy K, Desai J, Cappelleri JC, Larkin J. Poster presentation at the 15<sup>th</sup> International Kidney Cancer Symposium, Miami, Florida. November 4-5.

2016 Further validation of the HaemoPREF in a real-world setting. Tolley C, Staunton H, Brohan E, Spurden D, Cicchetti M, Cappelleri JC. Poster presentation at the 19<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Vienna, Austria, October 29-November 2.

2016 Sunitinib dosing schedules in the management of metastatic renal cell carcinoma: A meta-analysis. Abogunrin S, Ashaye AO, Fahrbach K, Cappelleri JC, Sandin R, Ramaswamy K. Poster presentation at the 19<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Vienna, Austria, October 29-November 2.

2016 A systematic review of the SF-36<sup>®</sup> Health Survey for measuring health-related quality of life in patients with ulcerative colitis . Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Poster presentation at the 19<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Vienna, Austria, October 29-November 2.

2016 Text messaging to improve outcomes in patients with painful diabetic peripheral neuropathy (pDPN). Bauer V, Goodman N, Lapin B, Cooley C, Craig T, Glosner S, Juhn M, Cappelleri JC, Sadosky AB, Masi C. Poster presentation at the 2016 Midwest Regional Meeting of the Society of General Internal Medicine, Cleveland, Ohio, September 22-23.

2016 The economic burden of fibromyalgia in Japan. Lee LK, Ebata N, Hlavacek P, DiBonaventura M, Cappelleri JC, Sadosky A. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 7<sup>th</sup> Asia-Pacific Conference, Sunte City, Singapore, September 3-6. (Award finalist)

2016 Impact and perspectives of painful diabetic peripheral neuropathy in a United States multicultural population. Alexander AH, Cappelleri JC, M Eichholz, Hlavacek P, Parsons B, Sadosky A, Tuchman MM. Poster presentation at the 76<sup>th</sup> Scientific Session of the American Diabetes Association, New Orleans, Louisiana, June 10-14.

2016 Evolution of biologic treatment, satisfaction with control of disease, and patient-reported outcomes in European patients with psoriatic arthritis: A real-world study. Lucas J, Wood R, Piercy J, Cappelleri JC, Koa B, Chhabra A, Vasilescu R, Hsu M-A. Abstract in Annals of Rheumatic Disease at the Annual European Congress of Rheumatology (EULAR), London, United Kingdom, June 8-11.

2016 Measurement properties of painDETECT: Rasch analysis of responses from community-dwelling population of persons with neuropathic pain. Packham T, Cappelleri JC, Sadosky A, Brunner F, MacDermid J. Poster presentation at the 37<sup>th</sup> Annual Scientific Program of the Canadian Pain Society, Vancouver, Canada, May 24-27.

2016 Clinical and economic burden of early versus late initiation of branded celecoxib among patients with osteoarthritis. Shelbaya A, Solem CT, Walker C, Wan Y, Johnson C, Cappelleri JC. Poster presentation at the 21<sup>st</sup> Annual International Meeting of the International Society for Pharmacoeconomics & Outcomes Research, Washington, DC, May 21-25.

2016 The economic burden of fibromyalgia in Japan. Lee LK, Ebata N, Hlavacek P, DiBonaventura M, Cappelleri JC, Sadosky A. E-poster presentation at the 8<sup>th</sup> World Congress of the World Institute of Pain, New York, NY, May 20-23.

2016 The prevalence of broad neuropathic pain in the United States: Results from a multi-channel general population health survey. DiBonaventura M, Sadosky A, Concialdi K, Kudel I, Parsons B, Cappelleri JC, Hlavacek P, Alexander AH, Stacey B, Markman JD, Farrar JT. Poster presentation at the 35<sup>th</sup> Annual Scientific Meeting of the American Pain Society, Austin, Texas, May 11-14.

2016 Characteristics associated with non-diagnosed neuropathic pain in the United States. Hopps M, DiBonaventura M, Kudel I, Concialdi K, Sadosky A, Parsons B, Cappelleri JC, Hlavacek P, Alexander AH, Stacey B, Farrar JT, Markman J. Poster presentation at the 35<sup>th</sup> Annual Scientific Meeting of the American Pain Society, Austin, Texas, May 11-14.

2016 Text messaging to improve diabetes outcomes in patients with painful diabetes peripheral neuropathy: Preliminary findings from a pragmatic pilot study. Bauer V, Goodman N, Lapin B, Cooley C, Craig T, Glosner S, Juhn M, Cappelleri JC, Masi C. Poster presentation at the Northshore Research Institute, Evanston, Illinois, April 27.

2016 Treatment patterns, healthcare resource utilization, and costs associated with psoriatic arthritis among Humana commercial and Medicare member populations. Mease P, Schwab P, Dinh H, Sheer R, Cappelleri JC, Bananis E, Harnett J, Hsu M-A. Poster presentation at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, California, April 19-22. (AMCP = Academy of Managed Care Pharmacy).

2015 Simplified interpretation of the erectile function domain of the International Index of Erectile Function. Cappelleri JC, Tseng L-J, Luo X, Stecher V, Lue T. Podium presentation at the 21<sup>st</sup> Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Las Vegas, Nevada, November 19-22. Awarded among the 12 best abstracts of all abstracts submitted to conference.

2015 Validation of the Overactive Bladder Questionnaire (OAB-Q; 1-Week Recall) in medically complex elderly adults with overactive bladder. Barsdorf AI, Carlsson M, Bushmakin AG, Quinn S, Cappelleri JC, Pleil A. Poster presentation at the International Society for Pharmacoeconomics & Outcomes Research 18<sup>th</sup> Annual European Congress, Milan, Italy, November 7-11.

2015 Disease burden, outcomes and costs among adults admitted to hospital in the United Kingdom (UK) due to plaque or erythrodermic psoriasis. Schaefer C, Mamolo C, Cappelleri JC, Le C, Daniel S, Griffiths CEM. Poster presentation at the International Society for Pharmacoeconomics & Outcomes Research 18<sup>th</sup> Annual European Congress, Milan, Italy, November 7-11.

2015 Measures of health-related quality of life in psoriatic arthritis: are they sensitive to both joint and skin aspects? Ndosi M, Hsu M-A, Cappelleri JC, Jones H, Chhabra A, Hellawell PS. Poster presentation at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, San Francisco, California, November 6-11.

2015 Rasch analysis of the Hospital Anxiety and Depression Scale in psoriatic arthritis: Results from the PRESTA study. Ndosi M, Hsu M-A, Cappelleri JC, Jones H, Chhabra A, Hellawell PS. Poster presentation at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, San Francisco, California, November 6-11.

2015 Assessing alternative selection criteria for fibromyalgia patients within a multicenter chronic pain claims database. Gostine M, Davis F, Roberts B, Risko R, Cappelleri JC, Asmus M, Clair A, Sadosky A. Oral presentation at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, San Francisco, California, November 6-11.

2015 Clinical characteristics of fibromyalgia in a chronic pain population. Gostine M, Davis F, Roberts B, Risko R, Cappelleri JC, Asmus M, Clair A, Sadosky A. Poster presentation at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, San Francisco, California, November 6-11.

2015 Mapping average pain severity to painDETECT symptoms. Sadosky A, Koduru V, Bienen EJ, Cappelleri JC. Poster presentation at the America Academy of Pain Medicine's 32<sup>nd</sup> Annual Meeting, Palm Spring, California, February 18-21.

2015 Comparison of tofacitinib with other systematic agents for treatment of moderate to severe plaque psoriasis: a network meta-analysis. Baker WL, Sobieraj DM, Kohn C, Coleman CI, Mamolo C, Cappelleri JC. E-Poster presentation at the 24<sup>th</sup> European Academy of Dermatology and Venereology Congress, Copenhagen, Denmark, October 7-11.

2015 Prevalence of self-reported chronic pain in primary care. Asmus MJ, Mulhem E, Hillenberg JB, Donevan S, Krichbaum D, Whipple S, Cappelleri JC, Hegeman-Dingle R, Coyne K, Currie B, Sadosky A. Poster presentation at the American Academy of Pain Management, 26<sup>th</sup> Annual Clinical Meeting, Washington, DC, September 17-20.

2015 Psychometric validation of the Electronic Chronic pain Questions (eCPQ) in a primary care setting. Coyne K, Currie B, Donevan S, Asmus MJ, Krichbaum D, Cappelleri JC, Hegeman-Dingle R, Burbridge C, Mulhem E, Hillenberg JB. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Characterizing neuropathic pain profiles: Enriching interpretation of painDETECT Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Economic impact of adherence to pain treatment guidelines in chronic pain patients. Margolis J, Princic N, Smith DS, Abraham L, Cappelleri JC, Shah SN, Park PW. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Development of a novel algorithm to determine adherence to treatment guidelines for chronic pain conditions. Margolis J, Princic N, Smith DS, Abraham L, Cappelleri JC, Shah SN, Park PW. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Patient characteristics and health resource utilization of a chronic pain population within an integrated healthcare system. Romanelli RJ, Shah SN, Ikeda L, Lynch B., Craig TL, Cappelleri JC, Ishisaka D. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Acute pain management due to sprains, strains and contusions in the Medicare population. Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale M. Poster presentation at PAINWeek 2015, Las Vegas, Nevada, September 8-12.

2015 Frequency and prevalence of flares in psoriasis: Results of the Adelphi Real World Psoriasis Disease Specific Programme in the United States. Mamolo C, Lucas J, Wood R, Cappelleri JC, Piercy J, Mallbris L, Hsu M-A. E-Poster presentation at the American Academy of Dermatology Summer Meeting, New York, NY, August 19-23; poster presentation at the International Federation of Psoriasis Associations – 4<sup>th</sup> Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, July 8-11.

2015 Understanding patient preferences associated with the use of therapies for rheumatoid arthritis: Results of a conjoint analysis. Saverno K, Louder A, Singh A, Cappelleri JC, Aten A, Koenig A, Pasquale M. Poster presentation at the 8<sup>th</sup> Annual Rheumatology Nurses Society Annual Conference, Orlando, Florida, August 6-8.

2015 Burden of flares on patients with moderate to severe psoriasis: Results of the Adelphi Real World Psoriasis Disease Specific Programme in the United States. Hsu M-A, Lucas J, Wood R, Cappelleri JC, Piercy J, Mallbris L, Mamolo C. Poster presentation at the American Academy of Dermatology Summer Meeting, New York, NY, August 19-23; poster presentation at the International Federation of Psoriasis Associations – 4<sup>th</sup> Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, July 8-11.

2015 Treatment patterns, clinical outcomes, and patient-reported outcomes among adults admitted to hospital in the United Kingdom (UK) due to plaque or erythrodermic psoriasis. Schaefer C, Mamolo C, Cappelleri JC, Le C, Daniel S, Mallbris L. Poster presentation at the International Federation of Psoriasis Associations – 4<sup>th</sup> Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, July 8-11.

2015 Rasch analysis of the Health Assessment Questionnaire Disability Index in psoriatic arthritis. Ndosi M, Hsu M-A, Cappelleri JC, Jones H, Chhabra A, Helliwell P. Poster presentation at the International Federation of Psoriasis Associations – 4<sup>th</sup> Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, July 8-11.

2015 Rasch analysis of the Psoriatic Arthritis Quality of Life and Dermatology Life Quality Index measures in psoriatic arthritis. Ndosi M, Hsu M-A, Cappelleri JC, Jones H,

Chhabra A, Helliwell P. Poster presentation at the International Federation of Psoriasis Associations – 4<sup>th</sup> Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, July 8-11.

2015 Comparative analysis of the effectiveness of anti-TNF therapies in non-radiographic axial spondyloarthritis using novel statistical techniques. Benedict A, Ishak J, Gal P, Proskorovsky I, Cappelleri JC, Everiss T, Jones H, Hughes R, Jenkins A. Poster presentation at the European League Against Rheumatism Conference, Rome, Italy, June 10-13.

2015 Multisite prospective observation study of fibromyalgia patients in the US. Schaefer C, Adams E, Udall M, Masters ET, Mann RM, Daniel S, McElroy H, Cappelleri JC, Clair A, Hopps M, Staud R, Mease P, Silverman S. Poster presentation at the European League Against Rheumatism Conference, Rome, Italy, June 10-13.

2015 Validation of the Physician Global Assessment: Confirmation with Phase 3 clinical trials. Callis-Duffin K, Bushmakin AG, Mallbris L, Mamolo C, Cappelleri JC. Oral presentation at the 23<sup>rd</sup> World Congress of Dermatology, Vancouver, Canada, June 8-13.

2015 Clinically meaningful improvement in pruritus with tofacitinib: Results from a Phase 3 program. Mamolo C, Luger T, Cappelleri JC, Bushmakin AG, Mallbris L. Poster presentation at the 23<sup>rd</sup> World Congress of Dermatology, Vancouver, Canada, June 8-13.

2015 Treatment adherence and generic switch evaluation of Celebrex in patients with osteoarthritis using a retrospective claims database. Ji X, Liu S, Solem CT, Cappelleri JC, Gao X, Stephens J. Poster presentation at the 20<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20.

2015 Trends associated with implementing and lifting a step therapy policy for the Humana Medicare population: an interrupted time series analysis. Null KD, Moll K, Cappelleri JC, Sadosky A, Parsons B, Pasquale MK. Poster presentation at the 20<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20.

2015 Drivers of healthcare resource utilization and factors associated with increased resource use in patients with fibromyalgia: An evaluation using electronic medical records. Margolis J, Masters ET, Cappelleri JC, Smith D, Faulkner S, Thomson E. Poster presentation at the 20<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, May 16-20.

2015 Healthcare costs of postherpetic neuralgia (PHN) and fibromyalgia (FM) in patients adherent and non-adherent to pain management guidelines. Abraham L, Cappelleri JC, Margolis J, Princic N, Shad S, Park PW. Poster presentation at the 5<sup>th</sup> International Congress on Neuropathic Pain (NeuPSIG 2015), Nice, France, May 14-17.

2015 Transitions among chronic pain and fibromyalgia patients: Results from a two-year observational fibromyalgia study in the United States. Adams EH, McElroy HM, Udall M, Masters ET, Mann R, Schaefer C, Cappelleri JC, Clair AG, Hopps M, Daniel S, Mease P, Silverman S, Staud R. Poster presentation at the 34<sup>th</sup> Annual Scientific Meeting of the American Pain Society, Palm Springs, California, May 13-16.

2015 Patient preferences associated with therapies for rheumatoid arthritis among Humana Medicare members: A conjoint analysis. Louder AM, Singh A, Cappelleri JC, Koenig A, Aten A, Saverno KJ, Pasquale MK. Poster presentation at the Academy of Managed Care Pharmacy's (AMCP) 27<sup>th</sup> Annual Meeting & Expo, San Diego, California, April 7-10.

2015 The association of low back pain and health status, work productivity, and healthcare resource use in Japan. Sadosky A, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K. Poster presentation at the Academy of Pain Medicine's 31<sup>st</sup> Annual Meeting, National Harbor, Maryland, March 19-22.

2012

2015 Methods for responder analysis of patient-reported outcomes. Barsdorf AI, Zou K, Carlsson MM, Cappelleri JC. Poster presentation at the 11<sup>th</sup> International Conference on Health Policy Statistics, Providence, Rhode Island, October 7-9, 2015; poster presentation at the Joint Statistical Meetings, San Diego, California, July 28-August 2, 2012 (third-place winner for best poster from the Biopharmaceutical Section of the American Statistical Association).

2014 Examination of patients newly diagnosed with fibromyalgia: Use of guidelines-recommended therapies and opioids in clinical practice. Shah SN, Masters ET, Cappelleri JC, Clair A, Halpern R, Blauer-Peterson C, Van Voorhis D. Oral presentation at the American College of Rheumatology/Association of Arthritis Health Professionals 2014 Annual Meeting, Boston, Massachusetts, November 14-19.

2014 Understanding patient preferences associated with the use of therapies for rheumatoid arthritis. Louder A, Saverno K, Singh A, Cappelleri JC, Aten A, Koenig A, Pasquale M. Poster presentation at the American College of Rheumatology/Association of Rheumatology Health Professionals 2014 Annual Meeting, Boston, Massachusetts, November 14-19.

2014 The first step to improve patients' health care is to know what to improve: Demonstrating the use of "Group Concept Mapping" as a novel way to develop a patient-centered disease model and enrich content validity. Willgoss T, Humphrey L, Cappelleri JC, Symonds T. Workshop presentation at the 17<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Amsterdam, The Netherlands, November 8-12.

2014 Group concept mapping: A novel, patient-centered, mixed methods approach to identifying relevant concepts for patient-reported outcome measures and facilitating participant agreement. Willgoss TG, Kane M, Humphrey L, Huffman M, Symonds T, Cappelleri JC. Oral plenary presentation at the International Society of Quality of Life Research 21<sup>st</sup> Annual Conference, Berlin, Germany, October 15-18.

2014 Most bothersome symptom in women with vulvar-vaginal atrophy as a moderator of treatment effects. Pinkerton JV, Bushmakin AG, Abraham L, Cappelleri JC, Komm B. Oral presentation at the 25<sup>th</sup> Annual Meeting of the North American Menopause Society. Washington, D.C., October 15-18.

2014 Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Abraham L, Bushmakin AB, Cappelleri JC, Pinkerton JV, Komm B. Oral presentation at the 25<sup>th</sup> Annual Meeting of the North American Menopause Society, Washington, D.C., October 15-18.

2014 Impact of switching from pregabalin to generic gabapentin in a novel pharmacy benefit design. Odell K, Sadosky A, Martin C, Bancroft T, Halpern R, Cappelleri JC. Poster presentation at the Academy of Managed Care Pharmacy's 2014 Nexus Meeting, Boston, Massachusetts, October 7-10.

2014 Comparison of medical and pharmacy costs between adherence and non-adherence to pain management guidelines for patients with painful diabetic peripheral neuropathy. Shah SN, Cappelleri SN, Park PW, Princic N, Margolis JM. Poster presentation at the Academy of Managed Care Pharmacy's 2014 Nexus Meeting, Boston, Massachusetts, October 7-10.

2014 Evaluation of a cost-reduction pharmacy benefit program on pregabalin utilization and costs in a commercially insured health plan population. Sadosky A, Martin C, Bancroft T, Odell K, Halpern R, Cappelleri JC. Poster presentation at the Academy of Managed Care Pharmacy's 2014 Nexus Meeting, Boston, Massachusetts, October 7-10.

2014 Treatment patterns in newly diagnosed fibromyalgia patients. Shah SN, Masters ET, Cappelleri JC, Clair A, Halpern R, Blauer-Peterson C, Van Voorhus D. Poster

presentation at the American Academy of Pain Management 25<sup>th</sup> Annual Clinical Meeting, Phoenix, Arizona, September 18-21.

2014 Mapping painDETECT classification to EuroQoL health status. Cappelleri JC, Koduru V, Biennen EJ, Sadosky. Poster presentation at the American Academy of Pain Management 25<sup>th</sup> Annual Clinical Meeting, Phoenix, Arizona, September 18-21.

2014 Measurement of painDETECT in neuropathic pain conditions. Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. Poster presentation at the American Academy of Pain Management 25<sup>th</sup> Annual Clinical Meeting, Phoenix, Arizona, September 18-21.

2014 Potential drug-drug interactions and opioid use among painful diabetic peripheral neuropathy Medicare members newly started on pregabalin or duloxetine. Ten Eyck L, Sadosky A, Ellis P, Cappelleri JC, Parsons B, Mudumby P, Ndehi L, Suehs B. Poster presentation at the American Diabetes Association's 74<sup>th</sup> Scientific Sessions, San Francisco, California, June 13-17.

2014 Meta-analysis and systematic reviews in comparative effectiveness research. Cappelleri JC, Jansen JP. 4-hour short course at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Network meta-analysis. Jansen JP, Cappelleri JC. 4-hour short course at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Multivariate meta-analysis: Use and applications. Snedecor SJ, Wan Y, Cappelleri JC, Stevens JW. 1-hour workshop at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Patient-reported outcomes (PROs) – Use in electronic medical records (EMR) and implications for comparative effectiveness research (CER). Symonds T, Reeve BB, Cappelleri JC, Katzen I. 1-hour workshop at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Measurement properties of painDETECT by severity of neuropathic pain. Cappelleri JC, Parliyan A, Koduru V, Sadosky A. Poster presentation at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Mixed methods for the development of clinical outcome assessments (COAs): Exploring further possibilities for mixed data collection and analysis. Willgoss TG, Humphrey L, Symonds T, Cappelleri JC. Poster presentation at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Prior authorization on the treatment of patients with fibromyalgia or painful diabetic peripheral neuropathy. Placzak H, Masters ET, Gu T, Cappelleri JC, Wasser T, Clair A, Cook J, Eisenberg DF. Poster presentation at the 19<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research., Montreal, Canada, May 31-June 4.

2014 Psychometric properties of the SF-12, Penn Shoulder Score, and VAS-Pain for rotator cuff retears . Menon J, Cappelleri JC, Mardekian J, Vendetti NJ, Mychaskiw M, Thomas J III. Poster presentation at the 61<sup>st</sup> Annual Meeting of the American College of Sports Medicine, Orlando, Florida, May 27-31.

2014 Potential drug-drug interactions and opioid use among Medicare members with fibromyalgia and newly initiated on pregabalin or duloxetine. Sadosky A, Ellis J, Ten Eyck L, Cappelleri JC, Parson B, Mudumby P, Brown C, Suehs B. Poster presentation at the 33<sup>rd</sup> Annual Scientific Meeting of the American Pain Society, Tampa, Florida, April 30-May 3.

2014 An Internet-based study characterizing the association between pain severity and the burden of fibromyalgia in the US. Schaefer C, Masters ET, Mann R, Cappelleri JC, Daniel S, Adams EH, Zlateva G, McElroy H, Chandran AB, Assaf AR, McNett M, Mease P, Silverman S, Staud R. Poster presentation at the Society of General Internal Medicine 37<sup>th</sup> Annual Meeting, Denver, Colorado, April 24-27.

2014 Economic burden of chronic widespread pain and fibromyalgia in the US. Schaefer C, Masters ET, Mann R, Cappelleri JC, Daniel S, Adams EH, Zlateva G, McElroy H, Chandran AB, Assaf AR, McNett M, Mease P, Silverman S, Staud R. Poster presentation at the Society of General Internal Medicine 37<sup>th</sup> Annual Meeting, Denver, Colorado, April 24-27.

2014 HAEMOPREF: A novel questionnaire for evaluating patient perception and preference for haemophilia A treatment. Teal S, Brohan E, Marshall C, Tolley C, Schulz M, Westfeld M, Cappelleri JC. Poster presentation at the 7<sup>th</sup> Annual Congress of the European Association for Haemophilia and Allied Disorders, Brussels, Belgium, February 26-28.

2014 Tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes. Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Digital

oral poster presentation at the 9<sup>th</sup> Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, February 20-23.

2013 Determining the magnitude of a detectable and a relevant treatment benefit in aesthetic medicine using a photoguide and the internet. Pleil AM, Bushmakin AG, Shields A, Jensen J, Cappelleri JC. Poster presentation at the 16<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, November 2-6.

2013 Item refinement and psychometric testing of a novel survey for evaluating patient perception and preference for haemophilia A treatment. Teal S, Brohan E, Hettema Y, Humphrey L, Willgoss T, Hudgens S, Westfeld M, Cappelleri JC. Poster presentation at the 16<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, November 2-6.

2013 Confirmatory factor analysis and evaluation of clinically important differences in menopause-specific quality of life associated with bazeodoxifene/conjugated estrogens in a vulvar/vaginal atrophy population. Abraham L, Bushmakin AG, Pinkerton JV, Cappelleri JC, Mirkin S. Poster presentation at the 16<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, November 2-6.

2013 Rationale for initiating and switching biologic therapy in patients with rheumatoid arthritis (RA); Results of a European chart review study. Emery P, Solem CT, Macahilig CP, Corman S, Majer IM, McGuire M, Cappelleri JC, Tarallo M. Poster presentation at the 16<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, November 2-6.

2013 Improvement in disease activity scores associated with early versus late initiation of biologic therapy in patients with rheumatoid arthritis (RA): Results of a European chart review study. Emery P, Solem CT, Macahilig CP, Majer IM, Stephens JM, Cappelleri JC, Tarallo M. Poster presentation at the 16<sup>th</sup> Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, November 2-6.

2013 Comparative burden of chronic widespread pain and fibromyalgia in the US population. Schaefer C, Mann R, Masters ET, Cappelleri JC, Daniel S, Zlateva G, McElroy H, Chandran AB, Adams EH, Assaf AR, McNett M, Mease P, Silverman S, Staud R. Oral presentation at the 2013 Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, San Diego, California, October 25-30.

2013 A population-based survey and physician assessment of the characteristics and prevalence of fibromyalgia. Adams EH, Daniel S, Chandran AB, McElroy H, Schaefer C, Mann R, Zlateva G, Cappelleri JC, Masters ET, Assaf AR, McNett M, Silverman S, Mease P, Staud R. Poster presentation at the 2013 Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, San Diego, California, October 25-30.

2013 Documentation of fibromyalgia in electronic medical records. Masters ET, Shah SN, Cappelleri JC, Udall M, Velentgas P, Su Zhaohui, Swenson A, Greenacre A, Bryant A. Poster presentation at the 24<sup>th</sup> Annual Clinical Meeting of the American Academy of Pain Management, Orlando, Florida, September 26-29.

2013 Pregabalin prior authorization and medication interactions. Johnston SS, Sadosky A, Cappelleri JC, Johnson BH, Shrady G, Silverman SL. Poster presentation at the American Academy of Pain Management 24<sup>th</sup> Annual Clinical Meeting, Orlando, Florida, September 26-29, 2013.

2013 Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: A systematic review. Coleman CI, Cappelleri JC, Baker WL, Phung OJ, White CM, Sobieraj DM. Oral presentation at the 8<sup>th</sup> Annual Meeting of the Society for Research Synthesis Methods, Brown University, Providence, Rhode Island, June 26-28.

2013 Systematic review of pharmacologic therapies for neuropathic pain associated with stroke, HIV, trauma, and multiple sclerosis. Sudharshan L, Snedecor SJ, Cappelleri JC, Sadosky A, Desai P, Jalundhwali Y, Botteman M. Poster presentation at the 18<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-23.

2013 Systematic review and meta-analysis of pharmacological therapies for pain associated with post-herpetic neuralgia. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, Botteman M. Poster presentation at the 32<sup>nd</sup> Annual Scientific Meeting of the American Pain Society, New Orleans, Louisiana, May 8-11, 2013.

2013 An indirect comparison of clinical success of antimicrobial agents for confirmed methicillin-resistant staphylococcus aureus (MRSA) complicated skin and soft tissue infections (CSSTI). Bassetti M, Patel D, Chuang L-H, Charbonneau C, Simoneau D, Baillon-Plot N, Stephens J, Treur M, Cappelleri J, Haider S, Nathwani D. Podium presentation at the 26<sup>th</sup> European Congress on Surgical Infections, Prague, Czech Republic, May 8-11.

2013 Burden-of-illness on moderate-to-severe psoriasis subjects seeking treatment: An overall descriptive assessment. Schaefer C, Mamolo C, Cappelleri JC, Cole J, Gunther S, Fowler J, Johnson S. Poster presentation at the International Investigative Dermatology 2013, Edinburgh, Scotland, May 8-11.

2013 High compliance but low persistency after one year with systemic and biologic treatments for psoriasis in Sweden. Svedbom A, Mamolo C, Dalen J, Cappelleri JC, Petersson IF, Stahle M. Poster presentation at the International Investigative Dermatology 2013, Edinburgh, Scotland, May 8-11.

2013 Impact of physician specialty on classification of physician-perceived patient severity for patients with osteoarthritis. Bailey J, Hawker G, Wood R, Cappelleri J, Higgins V, Joyce N, Hsu M-A. Poster presentation at the 2013 World Congress on Osteoarthritis, Philadelphia, Pennsylvania, April 18-23.

2012 Surgical management of Dupuytren's disease in Europe: Focus on referral patterns, procedures, and resource utilization in Nordic region. Dahlin LB, Leclercq C, Bainbridge C, Szczypa PP, Cappelleri JC, Guérin D, Gerber RA. Oral presentation at the Annual General Meeting of the Swedish Society of Medicine, Stockholm, Sweden, November 28-30.

2012 Healthcare resource utilization and costs of spinal cord injury with neuropathic pain in a Medical population. Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC. E-poster presentation at the 11<sup>th</sup> Annual Pain Medicine Meeting, Miami, Florida, November 15-18.

2012 Prevalence of potential drug-drug and drug-condition interactions in fibromyalgia patients newly-initiating pregabalin or duloxetine. Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Silverman SL. Poster presentation at the 2012 American College of Rheumatology/Association of Rheumatology Health Professionals, Washington, D.C., November 9-14.

2012 Factors associated with gastroprotective agent use and adherence among adults with arthritis taking NSAIDS in the United States. Joshi AV, Margolis MK, Cappelleri JC, Hsieh R, Essex MN, Park PW, Coyne KS. Poster presentation at the American College of Gastroenterology 77<sup>th</sup> Annual Scientific Meeting and Postgraduate Course, Las Vegas, Nevada, October 19-24.

2012 Impact of step-therapy policy restriction for pregabalin on healthcare utilization and expenditures in a commercial population. Louder AM, Udall M, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Poster presentation at the Academy of Managed Care Pharmacy 2012 Education Conference, Cincinnati, Ohio, October 3-5.

2012 Sunitinib dosing schedule and data collection timepoints: Impact on quality of life outcomes in metastatic renal cell carcinoma. Bushmakin AG, Cappelleri JC, Kortytowsky B, Sandin R, Matczak E, Cella D. Poster presentation at the Conference of the European Society for Medical Oncology, Vienna, Austria , September 28-October 8.

2012 Systematic review and meta-analysis of pharmacologic therapies for painful diabetic peripheral neuropathy. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehata S, Botteman M. Poster presentation at the American Academy of Pain Management, Phoenix, Arizona, September 20-23. (Winner of Blue Ribbon.)

2012 Systematic review of pharmacologic therapies for neuropathic pain associated with spinal cord injury. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundwala Y, Botteman M. Poster presentation at the American Academy of Pain Management, Phoenix, Arizona, September 20-23.

2012 Medicaid costs for neuropathic pain in spinal cord injury. Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC. Poster presentation at the American Academy of Pain Management, Phoenix, Arizona, September 20-23.

2012 Economic burden of spinal cord injury with neuropathic management. Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC. Poster presentation at the American Academy of Pain Management, Phoenix, Arizona, September 20-23.

2012 Initial use of pregabalin in patients with neuropathic pain following spinal cord injury. Gore M, Finnerup NB, Sadosky A, Cappelleri JC, Mardekian J, Tai K-S, McMahon S, Nieshoff E. Poster presentation at the 2012 Annual Meeting of the Academy of Spinal Cord Injury Professionals, Las Vega, Nevada, September 3-5.

2012 Dupuytren's disease in Nordic and other European regions: A patient chart review. Dahlin LB, Bainbridge C, Dias J, Szczyga PP, Cappelleri JC, Guérin D, Gerber RA. Oral presentation at the 24<sup>th</sup> Scandinavian Hand Society Meeting, Copenhagen, Denmark, August 30-September 1.

2012 Time-to-event modeling of successful intercourse in a sildenafil trial. Cappelleri JC, Bushmakin AG, Stecher VJ, Symonds T. Podium presentation at the World Meeting on Sexual Medicine, Chicago, IL, August 26-30.

2012 Treatment preferences for Dupuytren's contracture, a discrete choice experiment. Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, Sianos G, Anthony I, Cappelleri JC, Szczyga P, van Hout BA. Poster presentation at the Federation of European Societies for Surgery of the Hand 2012, Antwerp, Belgium, June 20-23.

2012 Direct and indirect effects of collagenase Clostridium histolyticum (CCH) treatment in patients with Dupuytren's contracture. Warwick D, Wilbrand S, Bushmakin AG, Cappelleri JC, Gerber RA, Hurley D, Szczyga PP. Oral presentation at the Federation of European Societies for Surgery of the Hand – XVII Congress, Antwerp, Belgium, June 20-23.

2012 Meta-analysis of joint structural deterioration over time in minimally treated rheumatoid arthritis patients. Jansen JP, Vieira MC, Bradley JD, Cappelleri JC, Zwillich SH, Wallenstein GV. Poster presentation at the European League Against Rheumatism 2012, Berlin, Germany, June 6-9.

2012 Using discrete choice experiments (DCE) to estimate preference-based utilities for Dupuytren's contracture (DC). Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, Sianos G, Anthony I, Cappelleri JC, Szczyga P, van Hout BA. Poster presentation at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, D.C., June 2-6.

2012 The impact of reducing dosing frequency of oral therapies on adherence, compliance, and cost for acute and chronic illnesses: A meta-analysis. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson A. Poster presentation at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, D.C., June 2-6.

2012 Prevalence of gastroprotective agent use among adults with arthritis taking NSAIDS. Coyne, KS, Margolis MK, Cappelleri JC, Hsieh R, Essex MN, Park PW, Joshi AV. Poster presentation at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, D.C., June 2-6.

2012 Association between restrictions on celecoxib use and healthcare utilization and costs in Medicare beneficiaries with arthritis. Durden E, Maiese BA, Essex MN, Cappelleri JC, Joshi AV. Poster presentation at the 17<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, D.C., June 2-6.

2012 Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC). Celli D, Davis MP, Bushmakin AG, Cappelleri JC, Hahn EA, Korytowsky B, Bhattacharayya H, Sandin R, Beaumont JL, Matczak E, Motzer RJ. Poster presentation at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 1-5.

2012 Surgical management of Dupuytren's disease in Europe: referral patterns, procedures, and resource utilization. Leclercq C, Dahlin LB, Bainbridge C, Szczyga PP, Cappelleri

JC, Guérin D, Gerber RA. Poster presentation at the European Federation of National Associations of Orthopaedics and Traumatology – 13<sup>th</sup> Annual Congress, Berlin, Germany, May 23-26.

2012 Surgical management of Dupuytren's disease in Germany and 11 other countries: results from a surgeon survey and patient chart review. Dahlin LB, Bainbridge C, Szczypa PP, Cappelleri JC, Guérin D, Gerber RA. Poster presentation at the European Federation of National Associations of Orthopaedics and Traumatology – 13<sup>th</sup> Annual Congress, Berlin, Germany, May 23-26.

2012 Healthcare resource utilization and economic impact of a  $\geq 2$  g/dL decrease in hemoglobin after NSAID treatment in osteoarthritis patients. Goldstein J, Luo X, Cappelleri J, Sands G. Oral presentation at Digestive Disease Week 2012. San Diego, California, May 19-22.

2012 Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of non-vertebral fractures in a high-risk postmenopausal osteoporosis population. Ellis A, Jansen J, Luo X, Cappelleri JC, Chines A, Sutradhar S, Reginster J-Y. Oral presentation at the European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Bordeaux, France, March 21-24.

2012 The burden of multiple comorbidities in subjects with neuropathic pain. Langley PC, Carroll D, van Litsenburg C, Cappelleri JC. Poster presentation at the 6<sup>th</sup> World Congress of the World Institute of Pain, Miami Beach, Florida, February 4-6.

2011 Differences in surgical management of Dupuytren's disease in Sweden and 11 other European countries: Results from a survey and patient chart review. Dahlin LB, Bainbridge C, Szczypa P, Cappelleri JC, Guérin D, Gerber RA. Oral presentation at the Annual General Meeting of the Swedish Society Of Medicine, Stockholm, Sweden, November 30-December 2.

2011 Understanding the relationship between erection and satisfaction in erectile dysfunction treatment: An application of a longitudinal mediation model. Bushmakin AG, Cappelleri JC, Symonds T, Stecher VJ. Poster presentation at the Sexual Medicine Society of North American 17<sup>th</sup> Annual Fall Scientific Meeting, Las Vegas, Nevada, November 10-13.

2011 Using a Weibull parametric model for failure-time data to assess progression-free survival as a surrogate endpoint for overall survival in a trial of patients with metastatic renal cell carcinoma. Négrier S, Bushmakin AG, Cappelleri JC, Charbonneau C, Sandin R, Michaelson MD, Figlin RA, Motzer RJ. Poster presentation at the 14<sup>th</sup> Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research, Madrid, Spain, November 5-8.

2011 Safety of biologic treatments for moderate to severe plaque psoriasis: a systematic review, basic meta-analysis, and Bayesian mixed treatment comparison. Baker EL, Coleman CI, Reinhart KM, Phung OJ, Ashave A, Kugelman K, Chen W, White CM, Mather J, Mamolo CM, Cappelleri JC, Baker WL. Poster presentation at the American College of Clinical Pharmacy Annual Meeting, Pittsburgh, Pennsylvania, October 16-19.

2011 Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Sherrill B, Akhras K, Kaye J, Sandin R, Cappelleri JC, Heyes A, Chen C. Poster presentation at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27.

2011 Network meta-analysis of second and third-line treatments on overall response and overall survival with metastatic non-small cell lung cancer. Bianic F, Despiegel N, Cure S, Campbell J, Wang Z, Cappelleri JC, Govidan R. Poster presentation at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27.

2011 Assessment of progression-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma. Négrier S, Bushmakin AG, Cappelleri JC, Charbonneau C, Sandin R, Michaelson MD, Figlin RA, Motzer RJ. Poster presentation at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27.

2011 Comparison of health-related quality of life in patients reporting the same adverse event fatigue on different treatments. Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Sandin R, Négrier S, Michaelson MD, Davis MP, Motzer RJ. Poster presentation at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27.

2011 Association of patient-reported osteoarthritis severity with other patient-reported outcomes in the European clinical setting. Bushmakin AG, Cappelleri JC, Taylor-Stokes G, Sayers J, Sadosky A, Carroll D, Gosden T, Emery P. Poster presentation at the 2011 World Congress on Osteoarthritis, San Diego, CA, September 15-18.

2011 The costs associated with sleep difficulties among fibromyalgia patients. Wagner J-S, DiBonaventura M, Chandran A, Cappelleri JC. Poster presentation at WASM 2011: World Association of Sleep Medicine, 4<sup>th</sup> International World Sleep Congress, Quebec City, Canada, September 10-15.

2011 The association of sleep difficulties with health-related quality of life among fibromyalgia patients. Wagner J-S, DiBonaventura M, Chandran A, Cappelleri JC. Poster presentation at SLEEP 2011: The 25<sup>th</sup> Anniversary Meeting of the Associated Professional Sleep Societies, LLC, Minneapolis, Minnesota, June 1-15.

2011 Direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance. Pinkerton JV, Bushmakin AG, Racketa J, Cappelleri JC, Chines AA, Mirken S. Oral presentation delivered at the 13<sup>th</sup> World Congress on Menopause, Rome, Italy, June 8-11.

2011 Current trends in the surgical management of Dupuytren's disease in Europe: An analysis of patient charts. Bainbridge C, Dahlin L, Szczyga PP, Cappelleri JC, Guérin D, Gerber RA. Poster presentation at the 12<sup>th</sup> Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Copenhagen, Denmark, June 1-4. (Winner of the Jacques Duparc Award.)

2011 Current trends in the surgical management of Dupuytren's disease in Europe: The surgeon's perspective. Dahlin LB, Bainbridge C, Szczyga PP, Cappelleri JC, Guérin D, Gerber RA. Podium presentation at the 12<sup>th</sup> Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Copenhagen, Denmark, June 1-4.

2011 Characteristics of patients with self-reported severe osteoarthritis in the European Union. Wang S, Sadosky A, Bushmakin AG, Cappelleri JC, Taylor-Stokes G, Sayers J, Carroll D, Gosden T, Emery P. Poster presentation at the 2011 Annual Meeting of the European League Against Rheumatism, London, United Kingdom, May 25-28.

2011 Surgical management of Dupuytrens disease across 12 European countries: An analysis of patient charts. Dias J, Leclercq C, Dahlin LB, Bainbridge C, Szczyga PP, Cappelleri JC, Kyriazis Y, Gerber RA. Oral presentation at the 16<sup>th</sup> Congress of the European Societies for Surgery of the Hand/EUROHAND, Oslo, Norway, May 25-28.

2011 All-cause and disease-related health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin versus duloxetine. Sanchez RJ, Burke JP, Joshi AV, Cattaneo MJ, Cappelleri JC, Kulakodlu M, Halpern R. Poster presentation at the American Pain Society 30<sup>th</sup> Annual Scientific Meeting, May 19-21, Austin, Texas.

2011 All-cause and fibromyalgia-related health care costs in fibromyalgia patients prescribed pregabalin versus duloxetine. Sanchez RJ, Burke JP, Joshi AV, Cattaneo MJ, Cappelleri JC, Kulakodlu M, Halpern R. Poster presentation at the American Pain Society 30<sup>th</sup> Annual Scientific Meeting, May 19-21, Austin, Texas.

2011 Significant impact of symptom severity on health status with fibromyalgia. Luo X, Cappelleri JC, Chandran A. Poster presentation at the American Pain Society 30<sup>th</sup> Annual Scientific Meeting, Austin, Texas, May 19-21.

2011 Network meta-analysis for health technology assessment. Cappelleri J, Fletcher C, Jones B, Lawton A, Lane P, Moneuse P, Roger J, Tate H. Invited seminar at the 34<sup>th</sup> Statisticians in the Pharmaceutical Industry (PSI) conference, Gloucestershire, United Kingdom, May 15-18.

2011 Design and execution of a meta-meta-analysis. Lane P, Higgins J, Whitehead A, Lewis S, Anagnostelis B, Cappelleri JC, Anzures-Cabrera J, Hewson N, Baker N, Moneuse P, Hollis S, Haughe S. Invited oral presentation at the 34<sup>th</sup> Statisticians in the Pharmaceutical Industry (PSI) conference, Gloucestershire, United Kingdom, May 15-18.

2011 Efficacy of biologic treatments for moderate-to-severe plaque psoriasis: A systematic review and meta-analyses. Baker EL, Coleman CI, Reinhart KM, Phung OJ, Ashave A, Kugelman K, Chen W, White CM, Mather J, Mamolo CM, Cappelleri JC, Baker WL. Oral presentation at the 8<sup>th</sup> European Academy of Dermatology and Venereology Spring Symposium, Carlsbad, Czech Republic, April 14-17.

2011 Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. Kleinman NL, Sanchez RJ, Beren I, Lynch WD, Cappelleri JC, Joshi AV. Poster presentation at the 27<sup>th</sup> Annual Meeting of the American Academy of Pain Medicine, National Harbor, Maryland, March 24-27.

2011 All-cause and fibromyalgia-related healthcare costs in fibromyalgia patients prescribed pregabalin versus duloxetine. Burke JP, Sanchez R, Joshi AV, Cattaneo MJ, Cappelleri JC, Kulakodlu M, Halper R. Poster presentation at the American Academy of Pain Medicine Annual Meeting, National Harbor, MD, March 24-27.

2011 The burden of fibromyalgia: Assessment of health status using the EuroQoL (EQ-5D) in patients with fibromyalgia relative to other conditions. Luo X, Cappelleri JC, Chandran A. Poster presentation at the 27<sup>th</sup> Annual Meeting of the American Academy of Pain Medicine, National Harbor, Maryland, March 24-27.

2011 An evaluation of the effect of CP-690,550, an oral Janus kinase inhibitor, on pruritus in patients with plaque psoriasis. Mamolo C, Bushmakin AG, Cappelleri JC, Harness J, Stewart M, Tan H. Poster presentation at the 69<sup>th</sup> Annual Meeting of the American Academy of Dermatology, New Orleans, Louisiana, February 4-8.

2011 The itch severity item: Mediation modeling and measurement characteristics from a phase 2b trial of CP-690,550, on oral Janus kinase inhibitor, in patients with plaque psoriasis. Mamolo C, Bushmakin AG, Cappelleri JC, Harness J, Stewart M, Tan H. Poster presentation at the 69<sup>th</sup> Annual Meeting of the American Academy of Dermatology, New Orleans, Louisiana, February 4-8.

2010 The URAM (Unité Rhumatologique des Affections de la Main) scale: Development and validation of a tool to assess Dupuytren's disease-specific disability. Beaudreuil J, Allard A, Zerkak D, Gerber RA, Cappelleri JC, Quintero N, Lasbleiz S, Bernabe B, Orcel P, Bardin T. Oral presentation at the 23<sup>rd</sup> Congress of the French Society of Rheumatology, Paris, France, November 28-December 1.

2010 To what extent does sildenafil affect satisfaction via improved erections? Sotomayor M, Cappelleri JC, Bushmakin AG, Mould J, Gomez-Palacio R, Abreu P, Velasco C. Poster presentation at the Annual Meeting of the Mexican Society of Urology, Cancun, Mexico, November 9-13.

2010 Physical functioning, 6-Minute walk distance, and pulmonary vascular resistance in adult patients with pulmonary arterial hypertension treated with sildenafil: Examining the distributions of outcomes. Quazi K, Cappelleri JC, Mychaskiw MA, Hwang L-J, Mardekian J. Poster presentation at the American College of Chest Physicians – CHEST 2010, Vancouver, Canada, October 30-November 4.

2010 Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Louder AM, Joshi AV, Ball At, Cappelleri JC, Deminski MC, Sanchez RJ. Poster presentation at the Academy of Managed Care Pharmacy's Fall Educational Conference, St. Louis, Missouri, October 13-16, 2010.

2010 Baseline quality of life as a prognostic tool of median survival in patients receiving sunitinib for metastatic renal cell carcinoma. Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Michaelson MD, Motzer RJ. Poster presentation at the 35<sup>th</sup> Annual European Society for Medical Oncology Congress, Milan, Italy, October 8-12, 2010.

2010 Clinically important difference and severity classification for range of motion in patients with Dupuytren's contracture: Results from a phase 3 trial of collagenase clostridium histolyticum. Gerber RA, Bushmakin AG, Cappelleri JC, Hellio Le Graverand M-P. Oral presentation at the Federation of European Societies for Surgery of the Hand XV Congress, Bucharest, Romania, June 23-26.

2010 A structured literature review on the efficacy and safety of fasciectomy and fasciotomy procedures for Dupuytren's contracture in Europe. Crean S, Gerber RA, Hellio Le Graverand M-P, Cappelleri JC. Poster presentation at the Federation of European Societies for Surgery of the Hand XV Congress, Bucharest, Romania, June 23-26.

2010 Can patient-reported kidney-cancer-specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott

P, Kim S, Stadler WM, Rini B. Poster presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 4-8.

2010 Linking changes in pain severity to changes in other patient-reported outcomes in patients with posttraumatic peripheral neuropathic pain treated with pregabalin. Serpell M, Van Seventer R, Bach F, Morlion BJ, Zlateva G, Bushmakin AG, Cappelleri JC, Nimour M. Poster presentation at the Third International Congress on Neuropathic Pain, Athens, Greece, May 27-30.

2010 How has meta-analysis been changing? Lane P, Higgins J, Whitehead A, Anagnostelis B, Cappelleri J, Anzures-Cabrera, Hewson N, Baker N, Moneuse P, Hollis S, Haugie S, Lewis S. Invited oral presentation at the 10<sup>th</sup> Annual Statisticians in the Pharmaceutical Industry (PSI) Conference, Manchester, England, May 16-19.

2010 Good research practices for comparative effectiveness research and use of indirect treatment comparisons in health care decisions. Fleurence R, Jansen J, Hoaglin D, Boersma C, Cappelleri J, Devine B, Hawkins N, Itzler R, Thompson D. Invited oral brief to Board of Directors at the 15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, Georgia, May 15-19.

2010 Assessment of measurement properties of peak VO<sub>2</sub> in children with pulmonary arterial hypertension. Cappelleri JC, Hwang L-J, Layton G, Mardekian J, Richardson H, Mychaskiw MA. Poster presentation at the 106<sup>th</sup> American Thoracic Society International Conference, New Orleans, Louisiana, May 14-19.

2010 The incremental and extended impact of painful diabetic peripheral neuropathy on health outcomes over time. DiBonaventura MD, Cappelleri JC, Joshi AV. Poster presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2010 The impact of pain severity on healthcare resource use and associated direct costs in patients with painful diabetic peripheral neuropathy. DiBonaventura MD, Cappelleri JC, Joshi AV. Poster presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2010 The relationship between pain severity and health-related quality of life, work productivity, and associated indirect costs in patients with painful diabetic peripheral neuropathy. DiBonaventura MD, Cappelleri JC, Joshi AV. Poster presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2010 Relationship of disease severity in osteoarthritis with pain, function, and work productivity. Sadosky AB, Bushmakin AG, Cappelleri JC, Lionberger DR. Poster

presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2010 Health status and disease severity in osteoarthritis. Sadosky AB, Bushmakin AG, Cappelleri JC, Lionberger DR. Poster presentation at the American Pain Society's 29<sup>th</sup> Annual Scientific Meeting, Baltimore, Maryland, May 6-8.

2009 Interrelationships of sildenafil treatment effects on the physiological and psychological aspects of erectile dysfunction: The role of performance anxiety. Berner MM, Althof SE, Goldstein I, Claes HIM, Cappelleri JC, Bushmakin AG, Symonds T, Schnetzler G. Poster presentation at the 12<sup>th</sup> Congress of the European Society for Sexual Medicine Meeting, Lyon, France, November 15-18.

2009 Sildenafil treatment affects erection maintenance directly and indirectly via erection hardness. Claes HIM, Goldstein I, Althof SE, Berner MM, Cappelleri JC, Bushmakin AG, Symonds T, Schnetzler G. Poster presentation at the 12<sup>th</sup> Congress of the European Society for Sexual Medicine Meeting, Lyon, France, November 15-18.

2009 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with meta-static renal cell carcinoma (mRCC). Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Poster presentation at the joint 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20-24; the 8<sup>th</sup> International Kidney Cancer Symposium, Chicago, Illinois, September 25-26; and the International Society for Pharmacoeconomics and Outcomes Research 12<sup>th</sup> Annual European Congress, Paris, France, October 24-27.

2009 Effect of blood loss on physical functioning: Pooled analysis of patients with osteoarthritis or rheumatoid arthritis. Strand V, Luo X, Bushmakin Ag, Cappelleri JC, Assaf AR, Cuffel B, Sands G. Poster presentation at the 2009 Annual Scientific Meeting of the American College of Rheumatology, Philadelphia, Pennsylvania, October 16-21.

2009 Health-related quality of life with sunitinib as maintenance therapy following carboplatin and paclitaxel treatment for locally advanced or metastatic non-small cell lung cancer. Page R, Blais N, Torigoe Y, Mundayat R, Ball G, Cappelleri JC, Kim ST, Chao R, Goss G. Poster presentation at the joint 15<sup>th</sup> Congress of the European Cancer Organization and 34<sup>th</sup> Congress of the European Society for Medical Oncology, Berlin, Germany, September 20-24.

2009 Health-related quality of life (HRQOL) with sunitinib (SU) as maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). Blais N, Torigoe Y,

Luo Y, Wei G, Cappelleri JC, Kim ST, Chao R, Goss G. Poster presentation at the 13<sup>th</sup> World Conference on Lung Cancer, San Francisco, California, July 31-August 4.

2009 Quality of life with sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma: Final results. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Poster presentation at the 45<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 29-June 2.

2009 Integrating ePRO and EDC – Challenges and lessons learned. Invited panelist at the Center for Business Intelligence's 4<sup>th</sup> Forum on Patient Reported Outcomes (PRO), Alexandria, Virginia, May 27-28.

2009 Type 1 error control using law of iterated logarithm in cumulative meta-analysis. Hu M, Lan KKG, Cappelleri JC. Oral presentation at the 32<sup>nd</sup> Annual Midwest Biopharmaceutical Statistics Workshop, Muncie, Indiana, May 18-20.

2009 Changes in health-related quality of life with smoking cessation treatment. Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG. Poster presentation at the joint conference of the Society for Research on Nicotine and Tobacco (SRNT) and SRNT-Europe, Dublin, Ireland, April 27-30.

2009 Health-related quality of life in patients with metastatic renal cell carcinoma from a phase III trial of sunitinib versus interferon-alfa. Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Li JZ, Kim ST, Motzer RJ. Poster presentation at the 14 Congress of the European Association of Hospital Pharmacists, Barcelona, Spain, March 25-27.

2009 Clinical importance of differences in the Fibromyalgia Impact Questionnaire. Bennett R, Cappelleri J, Bushmakin A, Sadosky A, Zlateva G. Poster presentation at the 5<sup>th</sup> World Congress of the World Institute of Pain, New York, NY, March 13-16.

2008 Relationship between erection hardness and confidence in men with erectile dysfunction treated with sildenafil citrate. Berner M, Althof SE, Goldstein I, Cappelleri JC, Bushmakin AG, Symonds T, Schnetzler G. Moderated poster presentation at the Joint Congress of the European and International Societies for Sexual Medicine, Brussels, Belgium, December 7-11.

2008 An updated geographic subpopulation analysis of health-related quality of life (HRQOL) in patients with metastatic renal cell carcinoma (MRCC) enrolled in a phase III trial of sunitinib versus interferon-alfa. Cella D, Bushmakin AG, Cappelleri JC, Li J, Kim ST, Motzer RT, Charbonneau C. Poster presentation at the 11<sup>th</sup> Annual European Congress, Athens, Greece, November 8-11.

2008 Direct and indirect treatment effect on sleep disturbance in generalized anxiety disorder: a statistical mediation model analysis. Bollu V, Cappelleri JC, Bushmakin AG, Mychaskiw MA, Feltner D. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 11<sup>th</sup> Annual European Congress, Athens, Greece, November 8-11.

2008 Psychometric evaluation of the Medical Outcomes Study Sleep Scale in patients with generalized anxiety disorder. Bollu V, Bushmakin AG, Cappelleri JC. Poster presentation at the 15<sup>th</sup> Annual Congress of the International Society for Quality of Life Research, Montevideo, Uruguay, October 22-25.

2008 Health-related quality of life (HRQOL) in metastatic renal cell carcinoma (mRCC) in patients receiving sunitinib (SU) or interferon-alfa (IFN- $\alpha$ ) in a randomized phase III trial: Updated geographic analysis. Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Li JZ, Kim ST, Motzer RJ. Poster presentation at the 33<sup>rd</sup> European Society for Medical Oncology Congress, Stockholm, Sweden, September 12-16, 2008.

2008 Analysis and interpretation of results based on patient reported outcomes. Sloan J, Erickson P, Dueck A, Cappelleri J, Li T. Invited oral presentation at the Center for Business Intelligence's 2<sup>nd</sup> Forum on Patient Reported Outcomes (PRO), Philadelphia, Pennsylvania, May 21-22.

2008 A comprehensive paradigm to estimate minimally clinically important difference (MCID). Treglia M, Mancuso JY, Cappelleri JC, Bushmakin A, Pitman V. Poster presentation at the 13<sup>th</sup> Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7.

2008 Discovering the structure of the Power of Food Scale (PFS) in obese patients. Cappelleri JC, Bushmakin A, Gerber RA, Leidy NK, Sexton C, Karlsson J, Lowe MR. Poster presentation at the 13<sup>th</sup> Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7.

2008 Psychometric analysis of the Three-factor Eating Questionnaire (TFEQ): Results from a large diverse sample of obese and non-obese subjects. Cappelleri JC, Bushmakin A, Gerber RA, Leidy NK, Sexton C, Lowe MR, Karlsson J. Poster presentation at the 13<sup>th</sup> Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7.

2007 Relationship of the erection hardness score to successful sexual intercourse. Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. Moderated poster

presentation at the Sexual Medicine Society of North America, Chicago, Illinois, December 6-9.

2007 Relationship between successful sexual intercourse and the erection hardness score. Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. Poster presentation at the European Society of Sexual Medicine, Lisbon, Portugal, November 25-28, 2007.

2007 The impact of sunitinib malate on the pain relief response rate in patients with advanced gastrointestinal stromal tumor. Charbonneau C, Mardekian J, Chambers R, Cappelleri J, Li J, Demitri G. Poster presentation at the 13th Annual Connective Tissue Oncology Society Meeting, Seattle, Washington, November 1-3.

2007 Use of erection hardness score in clinical practice: relationship to successful sexual intercourse. Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. Invited oral presentation at the American Urological Association's Western Section, Scottsdale, Arizona, October 28-November 1.

2007 Weight loss response at 6 months can be predicted at 1 and 3 months. Mancuso J, Cappelleri J, Digenio A, Gerber R, Moritz W, Dvorak R. Poster presentation at the Annual Meeting of NASSO, The Obesity Society, New Orleans, Louisiana, October 20-24.

2007 Health-related quality of life and kidney cancer-related symptoms in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib versus interferon-alfa: Results for the European and US subsample analyses in a randomized multinational phase III trial. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ. Poster presentation at the 14<sup>th</sup> Meeting of the European Association for Cancer Research, Barcelona, Spain, September 23-27; 6<sup>th</sup> International Kidney Cancer Symposium, Chicago, Illinois, October 12-13; 10<sup>th</sup> Annual European International Society for Pharmacoeconomics and Outcomes Research Congress, Dublin, Ireland, October 20-23; 1<sup>st</sup> Europe Multidisciplinary Meeting on Urological Cancers (EMUC) Congress, Barcelona, Spain, November 2.

2007 Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib vs. interferon-alfa (IFN- $\alpha$ ). Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Michaelson MD, Motzer RJ. Poster presentation at the 43<sup>rd</sup> Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 1-5.

2007 Effect of sildenafil on erectile function and depression: Meta-analysis of randomized, double-blind, placebo-controlled studies in men with erectile dysfunction and treated or

untreated depression. Cappelleri JC, Nurnberg HG, Siegel RL. Podium presentation at the the 160<sup>th</sup> Annual Meeting of the American Psychiatric Association, San Diego, California, May 19-24.

2007 Hypertension may not influence cardiovascular benefits of statin therapy: Results from a meta-regression analysis of 69,984 patients. Messerli FH, Pinto L, Tang S, Thakker KM, Cappelleri JC, Dubois R. Poster presentation at the 12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 19-23.

2007 Health-related quality of life in patients with metastatic renal cell carcinoma treated with axitinib (AG-013736). Trask PC, Bushmakin AG, Cappelleri JC, Kim S, Bycott P, Liau KF. Poster presentation at the 12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 19-23.

2007 Effects of sunitinib versus interferon-alfa on health-related quality of life in patients with metastatic renal cell carcinoma (mRCC). Cella D, Li JZ, Cappelleri JC, Bushmakin A, Kim ST, Chen I, Motzer RJ. Oral presentation at the 22<sup>nd</sup> Annual European Association of Urology Congress, Berlin, Germany, March 21-24.

2007 Effect of varenicline and bupropion on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. West R, Baker CL, Cappelleri JC, Bushmakin A. Poster presentation at the 13<sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco, Austin, Texas, February 21-24. Poster presentation at the UK National Smoking Cessation Conference, London, England, June 14-15.

2007 Type 1 error control in cumulative meta-analysis. Hu M, Lan KKG, Cappelleri JC. Oral presentation at Tufts-New England Medical Center, Boston, Massachusetts, January 31.

2006 Improved depression severity by sildenafil treatment of erectile dysfunction associated with treated or untreated major depressive disorder. Nurnberg GH, Siegel RL, Cappelleri JC. Moderated presentation at the Sexual Medicine Society of North America Fall Meeting, Las Vegas, Nevada, November 2-5.

2006 Impact of five different methods of delivering a non-pharmacological weight loss program on health related quality of life in patients on sibutramine. Bollu V, Cappelleri JC, Bury-Maynard D, Gerber R, Digineo AG, Moritz W, Dvorak R. Poster presentation at the North American Association for the Study of Obesity 2006 Annual Scientific Meeting, Boston, Massachusetts, October 20-24. Also presented as a poster presentation at the 9<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 16-19, 2004.

2006 Relationship between weight loss expectations and actual weight loss in a randomized 6-month weight loss study. Bollu V, Cappelleri JC, Bury-Maynard D, Gerber R, Dagineo AG, Moritz W, Dvorak R. Poster presentation at the North American Association for the Study of Obesity 2006 Annual Scientific Meeting, Boston, an Association for the Study of Obesity 2006 Annual Scientific Meeting, Boston, Massachusetts, October 20-24.

2006 How cognitive function affects activities of daily living in patients with Alzheimer's Disease. Treglia M, Bushmakin A, Siddiqi S, Cappelleri JC. Poster presentation at the 22<sup>nd</sup> Conference of Alzheimer's Disease International, Berlin, Germany, October 12-14. Also presented as a poster presentation at the 9<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 16-19, 2004.

2006 A comparison of two confidence interval approaches on the dependability coefficient in a two-factor crossed design. Cappelleri JC, Ting N. Oral presentation at the Joint Statistical Meetings, Seattle, Washington, August 6-10.

2006 Does the presence of hypertension affect cardiovascular benefits of statin therapy? Results from a meta-regression analysis of 69,984 patients. Messerli FH, Pinto L, Tang S, Thakker KM, Cappelleri JC, Sichrovsky T, Dubois R. Poster presentation delivered at the 55<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 11-14; oral presentation delivered at the Sixteenth European Society of Hypertension, Madrid, Spain, June 12-15, 2006.

2006 Mayo Clinic/FDA Patient-reported Outcomes Consensus Meeting Group. Five invited oral plenary presentations and draft manuscripts on conceptual issues; instrument selection; development issues; validation; and analysis, interpretation and reporting of results presented at the Mayo Clinic/FDA meeting on the FDA Guidance on Patient Reported Outcomes, Chantilly, Virginia, February 23-25.

2005 The International Index of Erectile Function (IIEF): an industry-based, brief sexual scale. Rosen RC, Cappelleri JC. Invited oral and paper presentation delivered at the European Medicines Agency Workshop, London, England, October 21.

2005 Establishing a minimally important difference in 6-minute walk distance and SF-36 among patients with pulmonary arterial hypertension. Gilbert C, Brown, MCJ, Cappelleri JC, Parpia T, and McKenna SP on behalf of the SUPER-1 Study group. Poster presentation delivered at the Annual Congress of the American College of Chest Physicians, Montreal, Canada, October 29-November 3.

2005 Reliability, validity, and responsiveness of the QIDS-SR-16 daily version. Lenderking WR, Hu M, Cappelleri JC, Rush AJ. Poster presentation at the 12th Annual Meeting of the International Society for Quality of Life Research, San Francisco, California, October 19-22.

2005 Development and evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A) scale for measurement of onset of symptom relieve in patients with GAD. Williams V, Morlock R, Fehnel S, Wills M, Hill C, Barrows S, Cappelleri JC, Feltner D. Poster presentation at the 12<sup>th</sup> Annual Meeting of the International Society for Quality of Life Research, San Francisco, California, October 19-22.

2005 Perioperative myocardial ischemic injury: Incidence and resource utilization in prospective clinical trial. Mackey WC, Fleisher LA, Haider S, Sheikh S, Cappelleri JC, Lee WC, Wang Q, Stephens J. Oral presentation at 2005 Annual Meeting of the New England Society for Vascular Surgery, Stowe, Vermont, September 16-18.

2005 Evaluating the sample invariance property of the standard error of measurement. Ghosh S, Cappelleri J, Bushmakin A, Lenderking WR. Oral presentation at the Joint Statistical Meetings, Minneapolis, Minnesota, August 7-11.

2005 Near normalization of erectile function and improvement of psychosocial quality of life in men with erectile dysfunction treated with sildenafil citrate. Stecher VJ, Levinson IP, Cappelleri JC, Siegel RL, Tseng L-J. Poster presentation at the 100<sup>th</sup> Annual Meeting of the American Urological Association, San Antonio, Texas, May 21-26.

2005 Linking changes in visual functioning according to changes in visual acuity among patients with age-related macular degeneration. Pleil AM, Cappelleri JC, Thompson JR, Getter CA, Li SC, Coleman R, Chikkala S, Knur K, Reichel MB, Wolf S. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 1-5.

2005 Cross-sectional and longitudinal assessments of the 25-item National Eye Institute Visual Function Questionnaire in patients with age-related macular degeneration. Reichel MB, Wolf S, Cappelleri JC, Thompson JR, Getter CA, Li SC, Coleman R, Chikkala S, Knur K, Pleil AM. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 1-5.

2005 Self-esteem and erectile function after 9 months of sildenafil citrate treatment. Althof SE, O'Leary MP, Cappelleri JC, Siegel RL, Crowley AR, Harnett J, Tseng L-J. Collins S. Poster presentation at the 30<sup>th</sup> Annual Conference of the American Society of Andrology, Seattle, Washington, April 2-5, 2005.

2005 Evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A) Questionnaire in patients with generalized anxiety disorder. Morlock R, Williams V, Feltner D, Cappelleri JC, Brock J, Endicott J. Poster presentation at the 25<sup>th</sup> Annual Conference of the American Disorders Association of America, Seattle, Washington, March 17-20. Poster presentation at the 158<sup>th</sup> Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26.

2005 Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): A new instrument to assess the onset of efficacy in Generalized Anxiety Disorder (GAD). Feltner D, Harness J, Brock J, Sambunaris A, Cappelleri J, Morlock R. Poster presentation at the 25<sup>th</sup> Annual Conference of the American Disorders Association of America, Seattle, Washington, March 17-20.

2004 Using a pattern mixture model to understand the impact of nonrandom missing data in health-related quality of life among patients undergoing non-cardiac vascular surgery. Lee WC, Cappelleri JC, Haider S, Sheikh S, Gold K, Stephens J. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 7<sup>th</sup> Annual European Congress, Hamburg, Germany, October 24-26.

2004 Relationship between erectile functioning and psychosocial functioning following treatment with Viagra® (sildenafil citrate): Results from an international, multicenter, randomized, double-blind, placebo-controlled trial. Glina S, Cappelleri JC, Duttagupta S, Sherman N, Stecher VJ, Siegel R, Tseng L-J. Podium presentation at the 11<sup>th</sup> World Congress of the International Society for Sexual and Impotence Research, Buenos Aires, Argentina, October 17-21.

2004 Relationship between erectile functioning and psychosocial functioning following treatment with Viagra® (sildenafil citrate): Results from an international trial. Takei M, Takamoto H, Glina S, Cappelleri JC, Duttagupta S, Sherman N, Stecher VJ, Siegel R, Tseng L-J. Poster presentation at the 11<sup>th</sup> Annual Meeting of the International Society for Quality of Life Research, Hong Kong, China, October 16-19.

2004 Assessing self-esteem, confidence, and relationships in men with erectile dysfunction treated with Viagra® (sildenafil citrate): Results from an international, multicenter, double-blind, placebo-controlled trial. King R, Glina S, Cappelleri JC, Duttagupta S, Sherman N, Stecher VJ, Siegel R, Tseng L-J. Moderated poster presentation at the Société Internationale d'Urologie. Honolulu, Hawaii, October 3-7.

2004 Daily measurement detects an earlier onset antidepressant effect. Lenderking WR, Hu M, Tennen H, Cappelleri JC, Petrie CD. Oral presentation at the International Society for Quality of Life Research 2004 Symposium, Boston, MA, June 27-29.

2004 Applying the Rasch model to enhance interpretation of the National Eye Institute Visual Functioning Questionnaire. Thompson JR, Cappelleri JC. Poster presentation at the Drug Information Association/National Cancer Institute conference on “Advances in Health Outcomes Measurement: Exploring the Current State and the Future Applications of Item Response Theory, Item Banks, and Computer-adaptive Testing,” Bethesda, Maryland, June 24-25.

2004 Relationship between erectile functioning and psychosocial functioning following treatment with sildenafil citrate: Results from a multicenter, double-blind, placebo-controlled trial. Forest C, Althof SE, O’Leary M, Cappelleri JC. Poster presentation at the 32<sup>nd</sup> Annual Conference of the American Academy of Physician Assistants, Las Vegas, Nevada, June 1-6.

2004 Health status in high-risk patients undergoing noncardiac vascular surgery in the United States. Sheikh S, Haider S, Cappelleri JC, Lee WC, Gold K, Stephens J, Fleisher LA. Poster presentation at the 9<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 16-19.

2004 Comparing psychometric properties of self-versus interviewer-rated instruments used in clinical trials for patients with anxiety disorders. Lau DT, Cappelleri JC, Morlock R, Feltner D. Poster presentation at the 9<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 16-19.

2004 A meta-analysis of three-day azithromycin therapy versus longer courses of comparator antibiotics in acute sinusitis. Harnett J, Enuha S, Xuan J, Cappelleri JC. Poster presentation at the 9<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 16-19.

2004 Assessing onset of symptom relief in patients with generalized anxiety disorder. Morlock R, Feltner D, Fehnel S, Williams V, Cappelleri J, Harness J, Kavoussi R, Endicott J. Poster presentation at the 157<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, New York, May 1-6, and at the 24<sup>th</sup> Annual Conference of the Anxiety Disorders Association of America, Miami, Florida, March 11-14.

2004 Assessing self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil citrate: Results from an international, multicenter, double-blind placebo-controlled trial. Stecher VJ, Glina S, Cappelleri JC, Duttagupta S, Sherman N, Siegel R, Tseng L-J. Poster presentation at the 157<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, New York, May 1-6.

2004 US double-blind, placebo-controlled trial assessing self-esteem, confidence, and relationships in men with erectile dysfunction treated with sildenafil citrate. Althof SE, Cappelleri JC, Duttagupta S, Sherman N, Siegel R, Crowley AR, Tseng L-J. Poster presentation at the 157<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, New York, May 1-6.

2004 Quality of life in patients with occult choroidal neovascularisation: A three-year longitudinal study. Gäßler P, Pleul C, Reichel C, Knur K, Nestler A, Lustig S, Cappelleri JC, Wolf S, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 Health-related quality of life compared with visual function and lesion size in patients with age-related macular degeneration. Knur KK, Gäßler P, Lustig S, Cappelleri JC, Wolf S, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 Age-related macular degeneration and health care resource utilization in a one-year longitudinal study. Pleul C, Gäßler P, Lustig S, Cappelleri JC, Wolf S, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 Quality of life in patients with age-related macular degeneration: A prospective study. Knur KK, Reichel MB, Gäßler P, Pleul C, Getter C, Lustig S, Cappelleri JC, Wolf S. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 An interpretation of quality of life based on binocular visual acuity in German patients with age-related macular degeneration. Pleil AM, Cappelleri JC, Chisholm JA, Getter CA, Lustig SP, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 Validity and reliability of the German version of the 25-item National Eye Institute Visual Function Questionnaire in patients with age-related macular degeneration. Lustig SP, Cappelleri JC, Chisholm JA, Getter CA, Pleil AM, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25-29.

2004 Responsiveness of the Self-Esteem And Relationship questionnaire in men with erectile dysfunction treated with Viagra® (sildenafil citrate): Results from an international, double-blind, placebo-controlled trial. Glina S, Cappelleri JC, Duttagupta S, Sherman N, Stecher VJ, Siegel R, Tseng L-J. Poster presentation at the European Association of Urology, 19<sup>th</sup> Annual Congress, Vienna, Austria, March 24-27.

2003 Health-related quality of life compared with visual function and lesion size in patients with age-related macular degeneration. Knur KK, Reichel MB, Gäßler P, Lustig S, Cappelleri JC, Wolf S. Poster presentation at the European Association for Vision and Eye Research, Alicante, Spain, October 8-11.

2003 Health-care resource utilization in patients with age-related macular degeneration in a one-year longitudinal study. Pleul C, Reichel MB, Gäßler P, Lustig S, Cappelleri JC, Wolf S. Poster presentation at the European Association for Vision and Eye Research, Alicante, Spain, October 8-11.

2003 Relationship of satisfactory sexual intercourse and psychosocial factors following Viagra® (sildenafil citrate) treatment in men with erectile dysfunction. Althof SE, Cappelleri JC, Duttagupta S, Stecher V. Poster presentation at the International Consultation on Erectile and Sexual Dysfunctions, Paris, France, June 28-July 1.

2003 Assessing behavioral functioning in Alzheimer's disease: Benchmarking with the BEHAVE-AD-FW. Treglia M, Clouse B, Cappelleri JC. Poster presentation at the 8<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 18-21.

2003 Long-term treatment satisfaction with inhaled insulin (Exubera®) and improved glycemic control in patients with type 1 and type 2 diabetes. Rosenstock J, Cappelleri JC, Nadkarni S, Petrie CD, Gerber RA. Poster presentation at the Twelfth Annual Meeting of the American Association of Clinical Endocrinologists, San Diego, California, May 14-18.

2003 A two year longitudinal study of quality of life in patients with occult choroidal neovascularisation. Gäßler P, Pleul C, Nössler N, Knur K, Nestler A, Lustig S, Cappelleri J, Wolf S, Reichel MB. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 4-May 9.

2003 Health-related quality of life measured by the NEI-VFQ in 300 patients with age-related macular degeneration. Reichel MB, Knur K, , Pleul C, Reichel CM, Nestler A, Lustig S, Cappelleri J, Wolf S. Poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 4-May 9.

2003 Confidence intervals on intraclass correlation coefficients in a balanced two-factor random design. Gilder K, Ting N, Cappelleri JC, Hanamura RC. Oral presentation at the First Annual Connecticut ASA Statistics Mini-Conference, Stamford, Connecticut, May 3.

2003 Assessing responsiveness of the Self-Esteem And Relationship (SEAR) questionnaire in men with erectile dysfunction treated with sildenafil citrate. O'Leary M, Cappelleri JC, Shpilsky AB, Duttagupta S, Siegel R, Althof SE. Poster presentation at the American Urological Association Annual Meeting, Chicago, Illinois, April 26-May 1.

2003 A modified large sample approach to approximate interval estimation for a certain intraclass correlation coefficient. Cappelleri JC, Ting N. Oral presentation at the San Diego chapter of the American Statistical Association, San Diego, California, April 17.

2002-3 Assessing clinical significance for QOL measures in oncology research. Berzon R, Sloan J, Varricchio C. Oral presentation at the Canadian Association for Psychosocial Oncology/6<sup>th</sup> World Congress of Psycho-Oncology, Banff, Alberta, Canada, April 23-27, 2003; Frost M, Osoba D, Sloan J, Berzon R. Oral presentation at the 38<sup>th</sup> Annual Meeting of the Drug Information Association, Chicago, Illinois, June 16-20, 2002.

2002 Self-esteem in patients with erectile dysfunction: An important but overlooked parameter in measuring treatment effectiveness. Bell S, Cappelleri JC, Duttagupta S. Poster presentation at the Fourth Annual Drug Information Association Workshop on Pharmaceutical Outcomes Research, Newport, Rhode Island, October 16-18.

2002 Balancing compliance, patient satisfaction and improved glycaemic control in patients with type 1 and type 2 diabetes: Long-term studies with inhaled insulin (Exubera<sup>®</sup>). Rosenstock J, Cappelleri JC, Nadkarni S, Petrie CD, Gerber RA. Poster presentation at the 38<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes, Budapest, Hungary, September 1-5.

2002 Development and validation of Self-Esteem/Overall Relationship Questionnaire (SEORQ) in erectile dysfunction. Cappelleri JC, Bell SS, Stecher V, Diuguid C, Duttagupta S, Sweeney M, Quirk F. Poster presentation at the 18<sup>th</sup> International Conference on Pharmacoepidemiology, Edinburgh, Scotland, August 18-21.

2002 Assessing the clinical significance of single items relative to summated scores. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C, for the Clinical Significance Consensus Meeting Group. Poster presentation at the American Society of Clinical Oncology, Orlando, Florida, May 18-21.

2002 A 12 month longitudinal study of health related quality of life in patients with occult choroidal neovascularisation. Reichel MB, Gäbler P, Nössler N, Pleul C, Nestler A, Reichel C, Lustig S, Cappelleri J, Wolf S. Oral presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 5-May 10.

2001 Relacion entre la mayor satisfaccion del paciente con insulina inhalada y un mejor control glicemico en pacientes con diabetes tipo 1 o tipo 2. Rosenstock J, Cefalu W, Skyler J, Gerber RA, Cappelleri JC, Nadkarni S, Petrie CD, Kourides IA. Poster presentation at the XI Congreso Asociacion Latinoamericana de Diabetes (ALAD), Uruguay, November 11-15;

Improved patient satisfaction is associated with inhaled insulin and improved glycemic control: Results from two multi-center randomized controlled trials. Cappelleri JC, Gerber RA, Rosenstock J, Nadkarni S, Petrie CD, Kourides IA. Poster presentation at the American Diabetes Association's 61<sup>st</sup> Scientific Sessions. Philadelphia, Pennsylvania, June 22-26.

2000-1 The WOMAC discriminates between patients with mild and severe osteoarthritis. Lustig SP, Shaw AR, Cappelleri JC, Vazquez-Abad M-D. Poster presentations at  
 64<sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology and  
 35<sup>th</sup> Annual Scientific Meeting of the Association of Rheumatology  
 Health Professionals, Philadelphia, Pennsylvania, October 28-November 2, 2000.  
 3<sup>rd</sup> Annual Drug Information Association (DIA) Workshop on Pharmaceutical  
 Outcomes Research, Savannah, Georgia, April 22-24, 2001.

2000 Differences in information processing speed deficits between subtypes of multiple sclerosis. Snyder PJ, Cappelleri JC, Archibald CJ, Fisk JD. Poster presentation at the 30<sup>th</sup> Annual Meeting of the Society for Neuroscience, New Orleans, Louisiana, November 4-9.

2000 Relationship between changes in joint space width (JSW) and C-reactive protein (CRP), clinical assessments, and health-related quality of life (HRQoL) instruments in mild/moderate osteoarthritis (OA). Woodworth TG, Mackillop N, Edwards M, Vazquez-Abad M-D, Shaw AR, Cappelleri JC, Ting N, Buckland-Wright C, Lustig S. Poster presentation at the 64<sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology and 35<sup>th</sup> Annual Scientific Meeting of the Association of Rheumatology Health Professionals, Philadelphia, Pennsylvania, October 28-November 2.

2000 Improved patient satisfaction with inhaled insulin in subjects with type 2 diabetes mellitus: Results from a multicenter randomized controlled trial. Cappelleri JC, Gerber RA, Bell-Farrow AD, English JS, Agramonte RF, Kourides IA. Poster presentation at the American Diabetes Association's 60<sup>th</sup> Scientific Sessions, San Antonio, Texas, June 9-13.

2000 Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: Results from a multicenter extension trial. Gerber RA, Cappelleri JC, Bell-Farrow AD, English JS, Agramonte RF, Gelfand RA. Poster presentation at the American Diabetes Association's 60<sup>th</sup> Scientific Sessions, San Antonio, Texas, June 9-13.

2000 Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. Snyder PJ, Cappelleri JC. Poster presentation at the Eleventh Annual Meeting of Theoretical & Experimental Neuropsychology (Tennet XI), Université du Québec à Montréal, Montréal, Canada, June 15-17.

1999 A diagnostic evaluation of the erectile function domain of the International Index of Erectile Function (IIEF). Sweeney M, Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Poster presentation at the First International Consultation on Erectile Dysfunction, Paris, France, July 1-3.

1999 Subanalysis of the efficacy of Viagra® (sildenafil citrate) in the treatment of mild erectile dysfunction. Stecher V, Sweeney M, Cappelleri JC, Smith MD. Poster presentation at the First International Consultation on Erectile Dysfunction, Paris, France, July 1-3. Poster presentation at the V Congreso de la Sociedad Latino Americana Para El Estudio de la Impotencia (SLAI), Acapulco, Mexico, October 7-10.

1999 Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus: Results from a multicenter randomized controlled trial. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA, Chandler LP, Gorkin L. Oral presentation at the 59<sup>th</sup> Annual Scientific Meeting of the American Diabetes Association, San Diego, California, June 19-22.

1998 Constructing and evaluating the “Sexual Health Inventory for Men: IIEF-5” as a diagnostic tool for erectile dysfunction. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña, B. Oral presentations at  
 8th World Meeting for Impotence Research, Amsterdam, Holland, August 25-28.  
 4th Asian Congress in Urology, Singapore, September 17-20 (with Y. Kimoto).

1998 Validation of the behavioural activity rating scale: A novel measure of activity in agitated patients. Swift RH, Harrigan EP, Cappelleri J, Kramer D, Chandler LP. Poster presentations at  
 11<sup>th</sup> European College of Psychopharmacology (ECNP), Paris, France, October 31-November 4.  
 21st Collegium Internationale Neuro-Psychopharmacologicum (CINP) Glasgow, Scotland, July 12-16.

151st Annual Meeting of the American Psychiatric Association (APA)  
Toronto, Canada, May 30-June 4.

1998 Weight gain associated with conventional and newer antipsychotics: A meta-analysis.  
Allison DB, Mentore JL, Heo M, Weiden P, Cappelleri J, Chandler LP.  
Poster presentations at  
151st Annual Meeting of the American Psychiatric Association (APA)  
Toronto, Canada, May 30-June 4.

9th Congress of the Association of European Psychiatrists (AEP)  
Copenhagen, Denmark, September 20-24.

1998 Issues in comparisons between meta-analyses and large trials. Ioannidis, JPA, Cappelleri, JC, Lau, J. Oral presentation at the 19<sup>th</sup> Annual Meeting at the Society for Clinical Trials, Atlanta, Georgia, May 17-20.

1997 Interaction of epidemic and individual heterogeneity on target populations of clinical trials. Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Poster presentation at the Second Joint Society for Clinical Trials and International Society for Clinical Biostatistics, Boston, Massachusetts, July 6-10.

1997 An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. Invited oral presentation at the International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Washington, D.C., December 5-7.

1990 Cutoff assignment strategies for enhancing randomized clinical trials (RCTs). Trochim WMK, Cappelleri JC. Oral presentation at the Annual Conference of the American Evaluation Association, Washington, D.C., October 18-20.

1990 Why Stanley and Robinson are wrong again about the regression-discontinuity design. Trochim WMK, Cappelleri JC. Oral presentation at the Annual Conference of the American Evaluation Association, Washington, D.C., October 18-20.

**Other Professional Contributions (Selective)**

Member, Board of Dean's Advisors, Harvard University, Harvard T.H. Chan School of Public Health, 2025-2028.

Elected Member, The Academy of Public Health, 2025.

Working Group Member, ISPOR HEOR Certificate Program, 2025.

Member of the Harvard Committee on University Resources (COUR), 2020-2025.

Chair. Standardizing patient-reported outcome in oncology: Improving cancer care through patient experience. Joint Statistical Meetings, Nashville, Tennessee, August 2-7, 2025.

Organizer. Recent developments and insights in vaccine research: Empowering the patient experience through statistical science. 2025 International Chinese Statistical Association (ICSA) Applied Statistics Symposium, Storrs, Connecticut, June 15-18, 2025.

Organizer. Developments and insights in gene therapy research: Empowering drug development through statistical science. 2025 International Chinese Statistical Association (ICSA) Applied Statistics Symposium, Storrs, Connecticut, June 15-18, 2025.

Chair. Emerging topics of lifetime data analysis in biopharmaceutics and causal inference. 2025 Lifetime Data Science Conference, Brooklyn, New York, May 28-30, 2025

Featured in and provided commentary on “A Conversation with Dr. David Salsburg” (Bar H and Ting N, *Journal of Data Science* 23(1):70-89, 2025). <https://ids-online.org/journal/JDS/article/1405/info>.

Member of the Scientific Program Committee, International Chinese Statistical Association (ICSA) 2025 Applied Statistics Symposium, Storrs, Connecticut, June 15-18, 2025.

Member of the Health Technology Assessment Scientific Working Group (HTA SWG) (October 2024 to present). American Statistical Association, Biopharmaceutical Section.

Co-chair (July 1, 2023 – June 30, 2026). ISPOR Health Science and Policy Council, Task Force Review Committee.

Pfizer Project Lead (January 1, 2021 – June 30, 2025). Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life endpoints – Innovative Medicines Initiatives (SISAQOL-IMI).

Co-lead for Work Package on Clinically Meaningful Change and Member of the Steering Committee (May 1, 2024 – June 30, 2025). Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life endpoints – Innovative Medicines Initiatives (SISAQOL-IMI).

Member of the Advisory Board (2022 – present). National Cancer Institute, Office of the Patient-Centered Outcomes Research.

Vice President of Healthcare Industrial Liaison (2020 – present). DahShu, East Coast Chapter.

Member of the POLARIS Steering Committee (2018 – present). **Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: A Multi-Center Prospective Non-Interventional Study.**

Member of Leadership Group (2017 – present). International Society for Health Economics and Outcomes Research (ISPOR), Statistical Methods in Health Economics and Outcomes Research, Special Interest Group.

Member (2017 – present). Study Endpoints Community and Statistics Community, Drug Information Association.

Member (2017 – present). the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Statistical Methods in HEOR Special Interest Group.

Member (2014 – present). International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Short Course Development & Quality Assurance Committee.

Member (2017 – 2024). American Statistical Association, External Nominations and Awards Committee.

Member of the Steering Committee. The 30<sup>h</sup> Pfizer/ASA/UConn Distinguished Statistician Colloquium, Storrs, Connecticut, October 2, 2024.

Chair and co-organizer. Advances in multi-state model application in clinical trials. Joint Statistical Meetings, Portland, Oregon, August 3-8, 2024.

Executive Committee Board Member (2019 – 2024), New York City Metropolitan Chapter, American Statistical Association.

Past President (June 1, 2022 – May 31, 2024), New England Statistical Society.

Member (2022 – June 30, 2023). ISPOR Health Science Policy Council, Task Force Review Committee.

Moderator. Perspectives from clinicians, academic trial groups, industry groups, patient groups about sustainability of SISAQOL-IMI recommendations. SISAQOL-IMI Internal General Assembly (Virtual), December 6, 2023.

Co-organizer. An emerging trend in oncology: Global initiatives incorporating patient-reported outcomes. American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Rockville, Maryland, September 27-29, 2023.

Chair. Innovative research synthesis methods. Joint Statistical Meetings, Toronto, Canada, August 5-10, 2023.

Chair. Real-world evidence and randomized clinical trials: from best practices to application. International Chinese Statistical Association (ICSA) 2023 Applied Statistics Symposium, Ann Arbor, Michigan, June 11-14, 2023.

Co-organizer and chairperson. Advances in dosing finding method for non-oncology. Dose Finding and Other Topics in Drug Development Honoring Dr. Naitee Ting's 70<sup>th</sup> Birthday, Storrs, CT, and virtual, June 7-9, 2023.

Organizer and Moderator. "Causality inference with observation data," by Guido W. Imbens, winner of the 2021 Nobel Memorial Prize in Economic Sciences, at the 2023 Annual Symposium on Risk and Opportunities of AI in Pharmaceutical Medicine: AI and Causality, Portland, Maine, and virtual, June 5, 2023.

Member (2018 – 2023). American Statistical Association, Scientific and Public Affairs Advisory Committee.

Member of the Steering and Advisory Committee. American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Rockville, Maryland, September 27-29, 2023.

Co-chair of the Program Committee. Dose finding in drug development in honor of Naitee Ting's 70<sup>th</sup> birthday, Storrs, Connecticut, June 8-9, 2023.

Co-organizer and chairperson. Taking patient-centered outcomes from data to impact. Invited session at the 14<sup>th</sup> International Conference on Health Policy Statistics, Scottsdale, Arizona, January 9-11, 2023.

Member of the Scientific Organization Committee. 14<sup>th</sup> International Conference on Health Policy Statistics, Scottsdale, Arizona, January 9-11, 2023.

Chair of the Chernoff Excellence in Statistics Award (June 1, 2017 – June 1, 2022). New England Statistical Society.

Member (2022). Award of Merit Committee, Harvard T.H. Chan School of Public Health.

Advisory Member of the Biostatistics Working Group (September 2020 – 2022). Indiana University School of Public Health – Bloomington, Indiana.

Participant in an online 3-round survey (Delphi method). Develop SPIRIT and CONSORT extensions for factorial trials: Reporting Factorial Trial (RAFT) Study, 2022.

Organizer and Moderator. “Causality in data science,” by Guido Imbens, winner of the 2021 Nobel Memorial Prize in Economic Sciences, Pfizer Inc (virtual), October 18, 2022.

Moderator. Souring on SUCRAs: When treatment ranking goes wrong. ISPOR Educational Webinar, October 5, 2022.

Organizer and Moderator. Shared parameter mixed-effects location scale models for intensive longitudinal data, by Donald Hedeker. Virtual seminar sponsored by the American Statistical Association, New York City Metro Area Chapter, September 16, 2022.

President (June 1, 2020 – May 31, 2022), New England Statistical Society.

Chairperson. Rise to the occasion to meet pandemic: Perspectives on COVID-19 vaccine development. 35<sup>th</sup> New England Statistics Symposium, Storrs, Connecticut, and virtual, May 22-25, 2022.

Co-chair. Statements by WP 3 in single-arm cancer clinical trials. SISAQOL-IMI Consensus Meeting #2 (virtual), March 16-17, 2022.

Co-moderator. Methodological work for cancer RCTs (work package 2) and Feasibility of developing recommendation for non-RCTs (work package 3). SISAQOL-IMI: Interim general assembly meeting # 1 (virtual), November 8, 2021.

Discussion Leader. Tips on how to conduct a successful interview. Roundtable luncheon at the 40<sup>th</sup> Annual American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop (virtual), September 21-24, 2021.

Member of the Organizing Steering Committee and the Short Course Committee. American Statistical Association Biopharmaceutical Section Regulatory-Industry Statistics Virtual Workshop, September 21-24, 2021.

Invited guest and panelist. ICSA general member meeting, awards ceremony and social activities. 30<sup>th</sup> Annual International Chinese Statistical Association (ICSA) Applied Statistics Symposium (Virtual), September 12-15, 2021.

Judge. Statistical approaches in text analysis. Joint Statistical Meetings (Virtual), August 7-12, 2021.

Chair. Scientific and Public Affairs Advisory Committee (SPAAC) Statistical Significance Speed Session II. Joint Statistical Meetings (Virtual), August 7-12, 2021.

Featured (with Daniel O'Connor) and interviewed by Richard Zink in Episode 91 of the Biopharmaceutical Section podcast of the American Statistical Association to discuss the benefits and challenges in using patient-reported outcomes and how to appropriately define clinically meaningful change: listen [here](#). Distributed on August 1, 2021.

Co-moderator. Presentation of cross-cutting work packages. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life endpoints – Innovative Medicines Initiatives (SISAQOL-IMI): Virtual Kick-off Meeting (General Meeting # 1), May 17-18, 2021.

Alumni interviewer for admissions to Harvard College (2014-2020, 2023-2025).

Co-organizer. Methods to evaluate and correct for bias in patient-reported outcomes in clinical trials: Advancing the validity of patient-centric drug development. Invited session at the Joint Statistical Meetings Virtual Conference, August 2-6, 2020.

President-elect (June 1, 2018 – May 31, 2020), New England Statistical Society.

Reviewer and beta tester. nQuery 8 – versions 8.4 and 8.5 (Statistical Solutions, 2019).

Member of the Organizational Committee. American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 23-25, 2019.

Organizer. Advances in clinical outcome assessments. Invited session at the Joint Statistical Meetings, Denver, Colorado, July 27-August 1, 2019.

Discussion Leader. Tips for interviewing well. Roundtable discussion at the Joint Statistical Meeting, Washington, D.C., August 6-11, 2022; Eastern North America Region of the International Biometric Society, Philadelphia, Pennsylvania, March 24-27, 2019.

Co-organizer and panelist. Advancing clinical trial design and analysis with patient and regulatory input. Fifth Drug Information Association (DIA) Webinar on Getting the Questions Right Series, November 13, 2018.

Vice President for Strategies & Development (June 1, 2017 – May 31, 2018). New England Statistical Society.

Vice president (2015 – 2018). Executive Committee, New York City Metropolitan Chapter, American Statistical Association.

Delphi Panelist. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO Extension (Calvert et al. JAMA 2018; 483-494).

Chairperson. Meta-analysis and systematic review. 2018 International Conference on Health Policy Statistics, Charleston, South Carolina, January 10-12, 2018.

Member of Fundraising Committee. 12<sup>th</sup> International Conference on Health Policy Statistics, Charleston, South Carolina, January 10-12, 2018.

Co-chairperson. eCOA/ePRO 2017 Summit: Develop technology-driven partnerships that revolutionize patient engagement and data management and ensure effective clinical trials, Philadelphia, Pennsylvania, December 13-14, 2017.

Member of the Industry Special Interest Group of the International Society for Quality of Life Research, 2017.

Organizer. Patient-reported outcomes: Measurement, implementation and interpretation. Short course at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 25-27, 2017.

Organizer. Advances in handling non-proportional hazard issues under different clinical settings. Parallel session at the American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Washington, D.C., September 25-27, 2017.

Organizer and chairperson. Using patient-reported outcomes to capture symptomatic adverse events in cancer clinical trials: Challenges and opportunities. Joint Statistical Meetings, Baltimore, Maryland, July 29-August 2, 2017.

Member (2016 – 2017). Standards & Best Practices Committee of the International Society of Quality of Life Research.

Member of the Award Selection Committee for the Lester R. Curtin Award, a travel award for the 2017 Conference of Statistical Practice, American Statistical Association. December 2016.

Co-chairperson and roundtable discussion leader. eCOA/cPRO 2016 Summit: Electronic clinical outcome assessment and electronic patient reported outcome summit, Philadelphia, Pennsylvania, December 13-14, 2016.

Reviewer and beta tester. LogXact 11.1 (Cytel; Cambridge, MA, 2016).

Member (2010 – 2016). Comparative Effectiveness Research Task Force Leadership Group (ISPOR), 2010-2016.

Host/Speaker. Navigating the long and winding road to validly interpreting patient-reported outcomes. Joint Statistical Meetings, Health Policy Statistics Session Roundtable Discussion, Chicago, Illinois, July 30-August 4, 2016.

Consultant. American Statistical Association DataFest, Middletown, Connecticut (hosted by Wesleyan University), April 8-10, 2016.

Past Chair (2016), Chair (2015) and Chair-Elect (2014). Executive Committee, Health Policy Statistics Section, American Statistical Association.

Consultant. Web-based software for the regression-discontinuity design. Grant awarded in 2015-2016 by the Institute of Education Sciences.

Instructor for independent study course on patient-reported outcomes. Riddhi Doshi (doctoral student, University of Connecticut, Health Science Center, Fall 2015).

Thesis or graduate co-advisor. Samiran Ghosh (University of Connecticut, 2006) for PhD in statistics; Fang Reng (University of Connecticut, 2004) for MS in statistics; Kye Gilder (University of Rhode Island, 2003) for PhD in statistics; Mark Unruh (Tufts University, 2002) for MS in clinical and translational science; and Suzanne Vogel (Yale University, 2000) for MPH in epidemiology.

Member of Leadership Council (2015 – 2016). RSQUAREedge.

Chairperson. Pharmaceutical applications (invited session). 29<sup>th</sup> New England Statistics Symposium, Storrs, Connecticut, April 24-25, 2015.

Member of the Advisory Committee. 11<sup>th</sup> International Conference on Health Policy Statistics, Providence, Rhode Island, October 7-9, 2015.

Judge (2014 – 2015). Student paper competition for 2014 and 2015 Joint Statistical Meetings, sponsored by the Health Policy Statistics Section of the American Statistical Association.

Organizer. Patient-reported outcomes: Measurement, implementation and interpretation. Invited short course at ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, D.C., September 22-24, 2014.

Nominator. Nominated a colleague who became a Fellow of the American Statistical Association in 2014.

Member of the ISPOR Patient-Reported Outcomes (PRO) Review Group, 2013-2015.

Reviewer and beta tester. StatXact 10 and LogXact 10 (Cytel; Cambridge, MA, 2013).

Member of the Advisory Committee. 10<sup>th</sup> International Conference on Health Policy Statistics, Chicago, Illinois, October 9-11, 2013.

Chairperson. Statistical methods for longitudinal studies. Joint Statistical Meetings, Montreal, Canada, August 3-8, 2013.

Moderator. Assessing the evidence for the health care decision maker. Invited plenary session of the 18<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, Louisiana, May 18-22, 2013.

Contributor and Coauthor. Statistics helps to systematically synthesize evidence: Meta-analysis is informative! One of the Stats Bubbles in Statistics 2013 (International Year of Statistics: A Celebration of the Contributions of the Statistical Sciences to Society). Selected as one of the one-page Statistical Significance papers that the American Statistical Association uses for Congress and others.

Consultant. Report from the Quantitative Research Panel. Patient-Reported Outcome (PRO) Consortium, Critical Path Institute, Coordinating Committee Meeting. Silver Spring, Maryland, April 5, 2012.

Chairperson and Reviewer. Patient-Centered Outcomes Research Institute (PCORI) grant applications (pilot research projects) for the study section on patient-oriented outcomes instruments. Washington, D.C., February 22, 2012.

Stakeholder. Treatment effect heterogeneity in clinical trials. Grant awarded in 2012 by the Patient-Centered Outcomes Research Institute (PCORI).

Chairperson. Database and simulation-based methods for decision making. 9<sup>th</sup> International Conference on Health Policy Statistics, Cleveland, Ohio, October 5-7, 2011.

Chairperson. Longitudinal data. Eastern North American Region of the International Biometric Society 2011 Spring Meeting, Miami, Florida, March 20-23, 2011.

Co-organizer. Statistical issues in comparative effectiveness research. The Second International Symposium for Biopharmaceutical Statistics: Bridging Drug Development from Research to Marketing, Berlin, Germany, March 1-March 3, 2011.

Chairperson. Database and simulation-based methods for decision making. 9<sup>th</sup> International Conference on Health Policy Statistics, Cleveland, Ohio, October 5-7, 2011.

Member of the Advisory Committee. 9<sup>th</sup> International Conference on Health Policy Statistics, Cleveland, Ohio, October 5-7, 2011.

Member (2011). Drug Information Association Comparative Effectiveness Scientific Working Group.

Member (2019 – 2011). Health Technology Assessment Special Interest Group, Statisticians in the Pharmaceutical Industry.

Moderator. Conducting and interpreting indirect treatment comparison and network meta-analysis: Learning the basics. 13<sup>th</sup> European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Prague, Czech Republic, November 6-9, 2010.

Chairperson and co-organizer. Heterogeneity in treatment response: What it is, why it's important and how to find it. ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, D.C., September 20-22, 2010.

Member of the Organizing Committee. ASA Biopharmaceutical Section FDA-Industry Statistics Workshop, Washington, D.C., September 20-22, 2010.

Chairperson. Innovative methods for cost and cost-effectiveness analysis, Joint Statistical Meetings, Vancouver, Canada, August 1-5, 2010.

Chairperson. Contributed paper session. 24<sup>th</sup> New England Statistics Symposium, Cambridge, Massachusetts, April 16-17, 2010.

Judge. American Statistical Association – Section on Health Policy Statistics, Long-term Excellence Award and Mid-career Award, Washington, D.C., January 20-22, 2010.

Chairperson. Multiple-treatment meta-analysis for promoting comparative effectiveness research. 8<sup>th</sup> International Conference on Health Policy Statistics, Washington, D.C., January 20-22, 2010.

Member of the Advisory Committee. 8<sup>th</sup> International Conference on Health Policy Statistics, Washington, D.C., January 20-22, 2010.

Member, Leadership Team, Indirect Treatment Comparisons Task Force (2009 – 2010). Good Research Practices Task Force for Comparative Effectiveness Research, International Society for Pharmacoeconomics and Outcomes Research.

Member (2009 – 2011). Meta-Analysis Expert Group, Statisticians in the Pharmaceutical Industry.

Member of the Scientific Advisory Committee. Third Asia-Pacific Forum on Andrology, Nanjing, China, October 10-13, 2009.

Chairperson. So you want to be an expert witness, Joint Statistical Meetings, Washington, D.C., August 1-6, 2009.

Chairperson. Innovative designs in clinical studies and related topics. First International Symposium on Biopharmaceutical Statistics, Shanghai, China, June 30-July 2, 2008.

Chairperson. Statistical estimation. International Indian Statistical Association Conference, Storrs, Connecticut, May 22-25, 2008.

Program advisor. Center for Business Intelligence's 2<sup>nd</sup> Forum on Patient Reported Outcomes (PRO), Philadelphia, Pennsylvania, May 21-22, 2008.

Invited moderator. Interpreting and reporting results based on patient reported outcomes. Center for Business Intelligence's 2<sup>nd</sup> Forum on Patient Reported Outcomes (PRO), Philadelphia, Pennsylvania, May 21-22, 2008.

Co-organizer and co-chair of entire conference and Member of the Scientific Planning Committee. 7<sup>th</sup> International Conference on Health Policy Statistics: Methodological Issues in Health Services and Outcomes Research, Philadelphia, Pennsylvania, January 17-18, 2008.

Chairperson. Meta-Analysis. 7<sup>th</sup> International Conference on Health Policy Statistics: Methodological Issues in Health Services and Outcomes Research, Philadelphia, Pennsylvania, January 17-18, 2008.

Member, Executive Committee, Health Policy Statistics Section, American Statistical Association, 2006-2008.

Health Outcomes Committee, Pharmaceutical Research and Manufacturers of America (PhRMA), Technical advisor (ad hoc). Health Outcomes Committee, 1999-2006.

Organizer of contributed session. Advances in confidence intervals on variance components. Joint Statistical Meetings, Seattle, Washington, August 6-10, 2006.

Member (2006-2011). Committee on Outreach Education, American Statistical Association.

Course Faculty. Mayo Clinic College of Medicine. FDA Guidance on Patient Reported: Discussion, Dissemination, and Operationalization, Chantilly, Virginia, February 23-25, 2006.

Organizer and chairperson of invited session. Developments in meta-analysis. 15<sup>th</sup> Annual Applied Statistics Symposium of the International Chinese Statistical Association, Storrs, Connecticut, June 14-17, 2006.

Chairperson of invited session. Predicting high-cost users of medical care and persistence of high expenditures over time. 6<sup>th</sup> International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Boston, Massachusetts, October 28-30, 2005.

Member of Scientific Planning Committee. 6<sup>th</sup> International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Boston, Massachusetts, October 28-30, 2005.

Host/Organizer. Longitudinal research: Current status and future prospects. Two-hour workshop by Judith Singer and John Willett, Groton, CT, August 26, 2005.

Host/Speaker. Longitudinal data: Basic concepts. Joint Statistical Meetings, Health Policy Statistics Session Roundtable Luncheon, Minneapolis, Minnesota, August 7-11, 2005.

Workshop leader. Use pharmacoeconomics and patient reported outcomes (PROs) to demonstrate product value in Phase IV studies. Invited workshop presentation at the Center for Business Intelligence's 5<sup>th</sup> Annual Forum on Phase IV Clinical Trials, Philadelphia, Pennsylvania, September 20-21, 2004.

Chairperson of invited session. Advanced statistical analysis I. International Society for Quality of Life Research 2004 Symposium - Stating the art: Advancing outcomes research methodology and clinical applications, Boston, Massachusetts, June 27-29, 2004.

Statistical consultant and member of scientific advisory board (2004 – 2006). Child and Adolescent Trauma Treatments and Services Project (CATS). Led and managed by the New York State Office of Mental Health.

Organizer of invited session. Advances in meta-analysis. Joint Statistical Meetings, Toronto, Canada, August 8-12, 2004.

Host/Speaker. Generalizability theory. Joint Statistical Meetings, Health Policy Statistics Session Roundtable Luncheon, Toronto, Canada, August 8-12, 2004.

Staff representative. Joint Council of Sections/Council of Chapters Information Booth, Joint Statistical Meetings, Toronto, Canada, August 8-12, 2004.

Reviewer of abstracts. International Society for Quality of Life Research 2004 Symposium - Stating the art: Advancing outcomes research methodology and clinical applications, Boston, Massachusetts, June 27-29, 2004.

Member of the ISOQOL Scientific Program Committee. Stating the art: Advancing outcomes research methodology and clinical applications, International Society for Quality of Life Research 2004 Symposium, Boston, Massachusetts, June 27-29, 2004.

Reviewer of abstracts. International Society for Pharmacoeconomics and Outcomes Research 9<sup>th</sup> Annual International Meeting, Arlington, Virginia, May 16-19, 2004.

Representative to the Council of Sections (2002 – 2004). Executive Committee, Health Policy Statistics Section, American Statistical Association.

Chairperson. Quality of life and measurement. International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Chicago, Illinois, October 17-19, 2003.

Pfizer representative. Support for student travel at the 2003 International Conference on Health Policy Research, Chicago, Illinois, October 17-19, 2003.

Course Faculty. Mayo Clinic College of Medicine. Quality of Life III: Translating the Science of QOL Assessment into Clinical Practice, Scottsdale, Arizona, October 2-4, 2003.

Reviewer of abstracts. Tenth Annual Meeting of the International Society for Quality of Life Research, Prague, Czech Republic, November 12-15, 2003.

Host/Speaker. Methods to explain clinical significance of health status measures. Joint Statistical Meetings, Health Policy Statistics Session Roundtable Luncheon, San Francisco, California, August 3-7, 2003.

Judge. Poster session. Eight Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 18-21, 2003.

Moderator. Contributed podium presentations on cardiovascular disease. Eight Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 18-21, 2003.

Chairperson. Paper session on clinical significance. Ninth Annual Conference of the International Society for Quality of Life Research, Orlando, Florida, October 30-November 2, 2002.

Judge of the Early Career Investigator Best Poster Awards. Ninth Annual Conference of the International Society for Quality of Life Research, Orlando, Florida, October 30-November 2, 2002.

Member of the ISOQOL Scientific Program Committee. Ninth Annual Conference of the International Society for Quality of Life Research, Orlando, Florida, October 30-November 2, 2002.

Health Outcomes Committee, Pharmaceutical Research and Manufacturers of America (PhRMA), Technical advisor (ad hoc). Health Outcomes Committee, 1999-2006.

Staff representative. Joint Council of Sections/Council of Chapters Information Booth, Joint Statistical Meetings, New York, NY, August 11-15, 2002.

Organizer of roundtables. American Statistical Association, Biopharmaceutical Section, Joint Statistical Meetings, New York, NY, August 11-15, 2002.

Member. Organizing Committee of the Mathematical Sciences Research Institute's Symposium and Workshop: Statistical Challenges for Meta-analysis of Medical and Health-policy Data, Berkeley, California, May 9-11, 2002.

Reviewer of abstracts. Seventh Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 19-22, 2002.

Coordinator. Submitted listing calendar events of 1<sup>st</sup> (2000), 2<sup>nd</sup> (2001), 3<sup>rd</sup> (2002), 4<sup>th</sup> (2003), 5<sup>th</sup> (2004), and 6<sup>th</sup> (2005) Kitasato University-Harvard School of Public Health Symposium in Amstat News.

Course Faculty. Mayo Clinic College of Medicine. Assessing Clinical Significance for Quality of Life Measures in Oncology Research: State-of-the-Science, Rochester, Minnesota, April 5-6, 2002.

Thesis or graduate co-advisor. Samiran Ghosh (University of Connecticut, 2006); Fang Reng (University of Connecticut, 2004); Kye Gilder (University of Rhode Island, 2003); Mark Unruh (Tufts University, 2002); and Suzanne Vogel (Yale University, 2000).

Chairperson. Risk adjustment and provider profiling. International Conference on Health Policy Research: Methodological Issues in Health Services and Outcomes Research, Boston, Massachusetts, December 7-9, 2001.

Reviewer of abstracts. Eighth Annual Conference of the International Society for Quality of Life Research, Amsterdam, The Netherlands, November 7-10, 2001.

Moderator/Organizer. Frontiers in meta-analysis. Sixth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 20-23, 2001.

Host/Speaker. Analyzing resources and cost data from randomized trials. Joint Statistical Meetings, Biopharmaceutical Session Roundtable Luncheon, Indianapolis, Indiana, August 13-17, 2000.

Organizer of invited session. Methodological issues in meta-analysis. Joint Statistical Meetings, Indianapolis, Indiana, August 13-17, 2000.

Reviewer. LogXact 4 for Windows: Logistic Regression Software Featuring Exact methods (Cambridge, MA: Cytel Software Corporation, 2000), by Cyrus Mehta and Nitin Patel.

Reviewer. Comprehensive Meta-analysis: A Computer Program for Research Synthesis (Englewood, NJ: Biostat, 1999), by Michael Borenstein and Hannah Rothstein.

Reviewer. SOLAST™ 2.0 for Missing Data (Cork, Ireland: Statistical Solutions Ltd., 1999).

Chairperson. Analysis issues in health-related quality of life. 1999 Regulatory Issues in Health Related Quality of Life Assessment (PhRMA/FDA Workshop), Washington, D.C., March 24-25, 1999.

Reviewer and beta tester, Comprehensive Meta Analysis: A computer program for research synthesis (Michael Borenstein, Hannah Rothstein; Englewood, New Jersey: Biostat, Inc., 1999)

Chairperson/Organizer of invited session. Outcomes research issues in Alzheimer's disease. PhRMA Biostatistics and Clinical Data Management 1998 Annual Workshop: Opportunity and Challenges for Industry and FDA, Bethesda, Maryland, November 9-11, 1998.

Chairperson/Organizer of invited session. Eighth Applied Statistics Symposium of the International Chinese Statistical Association, Connecticut College, New London, Connecticut, June 5-7, 1998.

Chairperson/Organizer of invited session. Randomized controlled trials and outcomes research. Drug Information Association meeting on Global Statistical Challenges and Strategies in the Pharmaceutical Industry, Hilton Head, South Carolina, March 15-17, 1998.

Pfizer representative. Honorary dinner committee representing Pfizer at Rise to the Occasion, a fundraising gala to raise research funds for the American Paralysis Association, Hartford, Connecticut, May 2, 1998.